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Abstract 
 
Background 
Otosclerosis is a common form of conductive and mixed hearing loss in Caucasian 
populations, with an estimated prevalence of 0.3-0.4%. Since 1998, eight loci have been 
mapped to otosclerosis in families with apparent autosomal dominant (AD) otosclerosis 
but none of the causative genes have been identified. 
Objective 
As no otosclerosis gene has yet been identified, the main objective of this thesis was to 
identify otosclerosis-disease causing genes by studying Newfoundland (NL) families. 
Methods 
Families with familial otosclerosis were identified and chracterized clinically. Those 
which fit the diagnostic criteria for otosclerosis were recurited for this study. Molecular 
genetic analyses of these families were carried out by genotyping, haplotyping, Sanger 
sequencing of candidate genes in linked regions and exome sequencing.  
Results  
One Family (2081) was solved through identification of a pathogenic variant 
(FOXL1c.976_990hetdel) in the FOXL1 gene at chromosome (Chr) 16q that was present 
in all affected individuals. The 15 base pair (bp) deletion was also identified in a second 
family from Ontario (ON) and the possible pathways involving FOXL1 in the 
pathogenesis of otosclerosis were suggested. In the second otosclerosis family, three 
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candidate variants were identified through exome sequencing of the candidate regions 
under a dominant model.  
Conclusion  
I have identified the first otosclerosis gene, FOXL1, a transcription factor involved in the 
disease pathogenicity. I also identified three possible candidate mutations for a second 
otosclerosis family. This finding will have a major impact on molecular genetic studies of 
other otosclerosis families and it will allows for genetic counselling and the possibility for 
gene therapies in the future.  
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Chapter 1: General introduction  
1.1 Purpose of the study and significance 
Hearing loss is the most common sensory defect worldwide. It has a severe effect on 
language acquisition and the learning process when it develops early in life and affects 
the social well being and career goals of affected individuals when it developes later in 
life. Otosclerosis is the most common cause of progressive conductive and mixed hearing 
loss in the Caucasian population. Otosclerosis is a complex condition that can be treated 
surgically (a stapedectomy) but this can be challenging in some cases. Stapedectomy can 
in some cases treat the conductive component of hearing loss but in others, unsuccessful 
surgery can worsen the hearing loss. Identification of the relevant otosclerosis gene in a 
particular family can help with screening family members leading to early diagnosis and 
provision of an appropriate hearing aid. Providing genetic diagnosis allows accurate 
genetic counselling, and carrier testing for relatives. Also genetic diagnosis may have a 
role for planning in therapies such as a cochlear implant. Identifying mutations that cause 
otosclerosis can also help to understand the molecular mechanism underlying the 
development of otosclerosis and to elucidate the pathways involved in disease 
development, which ultimately may provide new knowledge for drug therapies. 
Development of a drug therapy for otosclerosis would be beneficial due to the risks 
associated with surgery, occasionally resulting in further hearing loss. Many genetic 
studies have been carried out to identify the genetic cause of otosclerosis in familial and 
sporadic cases. To date, eight loci have been mapped for otosclerosis and none of the 
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causative genes had been identified when this study began.  The ultimate goal of this 
thesis was to identify otosclerosis genes that segregate in Newfoundland families.  
1.2 Anatomy and function of the ear 
The ear is divided into three parts: outer ear, middle ear and inner ear. The outer ear 
consists of the pinna and the auditory canal. The auditory canal captures sound and passes 
it to the tympanic membrane. The middle ear consists of the tympanic membrane and 
three small ossicle bones (ossicular chain): malleus (hammer), incus (anvil) and stapes 
(stirrup). The stapes is attached to the oval window of the inner ear and is characterized 
by its free movement, which is important for the transmission of sound from the middle 
ear into the inner ear (Figure 1.1). The inner ear consists of the membranous labyrinth 
that is embedded in the bony labyrinth located within the temporal bone. The inner ear is 
divided into the semicircular canal, vestibule, and the snail shaped cochlea. The cochlea is 
divided into three compartments, the scala vestibule, and scala tympani that are filled 
with perilymph and scala media (vascularise) that is filled with endolymph.  The most 
important scala is the scala media, which contains the organ of Corti 
1
. The organ of Corti 
consists of one row of inner hair cells (IHC), which are responsible for the transmission 
of hearing signals into the brain, and three rows of outer hair cells (OHC). The tectorial 
membrane is located on top of the organ of Corti and is made up of a massive 
extracellular matrix. It helps deflection of the stereocilia of the hair cells, which is 
important for the mechano-electrical transduction of sound signals 
2
.    
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Figure 1.1: Structure of the ear  
Ear consists of outer, middle, and inner ear compartments. The outer ear consists of the pinna and 
external auditory canal. The middle ear consists of three ossicles, the malleus, incus and stapes 
bones which is attached to the oval window. The tympanic member is suited between the external 
and middle ear. The inner ear consists of the semicircular canals, cochlea and round window. The 
Eustachian tube is connected to the tympanic cavity where the three middle bones are located. 
This Figure is taken from reference 3 
3
.   
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1.3 How sound is transmitted 
Sound travels from the outer ear to the middle ear through the external auditory canal. 
In the middle ear, sound vibrates the three middle ear bones, is transmitted into the 
cochlea, and moves the fluid in the three scala
4
. Sound traveling fluid in the cochlear 
compartments leads to movement of the basilar membrane, which activates the sensory 
cells (OHC and IHC) to convert the mechanical signals into electrical signals. When 
sound is transmitted into the cochlea, the fluid in the scala media and the tectorial 
membrane on top of the hair cells move, and the stereocilia are deflected which opens the 
gate of the ion channels that are located at the stereocilia tips. Opening the gate of these 
ion channels leads to flow of potassium ions from the potassium-rich endolymph into the 
hair cells causing depolarization of the cells. As a result of cell depolarization, the 
voltage-gated calcium channels on the IHC open causing a calcium influx, which triggers 
the release of neurotransmitters in the auditory nerve
5
. 
 
 
 
 
 
 
 
 
 
 
 
5 
1.4 Hearing loss 
1.4.1 Classification of hearing loss 
  Hearing loss is classified based on phenotype presented by the patient. Hearing 
loss is divided into syndromic hearing loss (SHL) and non-syndromic hearing loss 
(NSHL).  SHL is accompanied by extra-auditory clinical symptoms. It is estimated that 
about 30 % of all hearing loss is SHL and this is mostly caused by mutations in single 
genes. NSHL is isolated and accounts for about 70 % of the genetic forms of hearing 
loss
6
. Hearing loss is divided into categories based on the onset of the hearing loss, 
severity and configuration of the loss. 
Hearing loss is classified as pre-lingual or post-lingual based on age of onset of 
the hearing loss. Pre-lingual hearing loss manifests before speech development. It is 
important to keep in mind that all congenital (present at birth) hearing loss is pre-lingual, 
but not all pre-lingual hearing loss is congenital. Post-lingual hearing loss develops after 
speech acquisition.   
Hearing loss is classified into conductive hearing loss, SNHL and auditory 
neuropathy. SNHL results from abnormal function of the inner ear, which transforms 
sound waves to electrical impulses into the auditory cortex. This type of hearing loss is 
usually permanent and has no medical or surgical treatment. Conductive hearing loss 
develops as a result of an obstruction that interferes with the conduction of sound from 
the external and middle ear canal into the inner ear (e.g. wax in the external ear canal, 
perforation of the ear drum, fluid or infections in the middle ear or fixation of the ossicles 
to the oval window in otosclerosis). This type of hearing loss is often medically or 
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surgically treatable. Mixed hearing loss, which is a combination of conductive and 
sensorineural hearing loss and central auditory dysfunction that results from damage at 
the level of the cranial nerve, brain stem, or cerebral cortex are, another types of hearing 
loss
7,8
. These types of hearing loss are defined by measuring the hearing threshold 
(measured by decibel (dB)) across several frequencies (measured by hertz (Hz)). Pure 
Tone audiometry (PTA) is the standard technique for measuring the hearing threshold and 
it is represented on a chart called audiogram (Figure 1.2). It records the air conduction 
signals and bone conduction signals on the audiogram. Air conduction measures how 
much of the sound travels through the external and middle ear into the cochlea and then to 
the brain. Bone conduction measures how well sound travels through the bone to the 
cochlea, bypassing the middle and external ear. Examples of presentation of conductive 
and SNHL on audiogram are shown in Figures (1.2, 1.3 and 1.4)8.  
 The degree of hearing loss is measured by PTA and classified according to 
severity of the loss as shown in Table 1.2. Another classification based on the shape of 
the air conduction audiogram across different frequencies as shown in Table 1.2. This 
classification is helpful, in some cases, in identifying the underlying aetiologies. For 
example, mutation in TECTA gene cause cookie-bite configuration.  
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Figure 1.2: Pure tone audiogram showing air conduction 
  Pure tone audiogram from a case with conductive hearing loss. X- axis =frequency; y-axis 
=intensity). X=air conduction; ☐=bone conduction. 250-500 Hz are low-pitched frequencies. 
2000-8000 Hz are high-pitched frequencies. The audiogram shows differences between air and 
bone conduction, which is knownas air bone gap (ABG). This figure is taken from reference 8 
8
.  
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Figure 1.3: Pure tone audiogram showing SNHL 
Pure tone audiogram from a case with SNHL.  X- axis =frequency; y-axis =intensity; X=air 
conduction; ☐=bone conduction. 250-500 Hz are low-pitched frequencies and 2000-8000 Hz are 
high-pitched frequencies. The audiogram shows no difference in the ABG and drop in all 
frequencies. This figure is taken from reference 8
8
.  
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Figure 1.4: Pure tone audiogram showing mixed hearing loss 
Pure tone audiogram shows a case mixed hearing loss. X axis =frequency; y-axis =intensity). 
X=air conduction; ☐=bone conduction. 250-500 Hz are low-pitched frequenciesand 2000-8000 
Hz are high-pitched frequencies. The audiogram shows both a difference in the ABG and a drop 
in high frequency. This figure is taken from reference 8 
8
.  
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Table 1.1: Types of hearing loss based on severity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pure tone average (dB) Degree of Hearing Loss (Hz) 
>15 Normal 
16-25 Slight 
26-40 Mild 
41-55 Moderate 
56-70 Moderately severe 
71-90 Severe 
≥ 90 Profound 
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Table 1.2: Types of hearing loss based on configuration 
 
 
 
 
 
 
 
   
  Based on mode of inheritance, hearing loss is classified into dominant, recessive, X 
linked and mitochondrial. To date, 137 loci and 71 genes have been identified for NSHL 
9
 
All loci associated with hearing loss have been designated as DFN, with a further letter 
determing the mode of inheritance. DFNA is the designation for AD inheritance, DFNB 
for autosomal recessive (AR), and DFNX for X-linked. Other classifications include 
OTSC for otosclerosis and recently DFNM for modifiers and AUNA for auditory 
neuropathy. There is no current designation for hearing loss caused by mitochondrial 
mutation. The numbers following the identified loci represent the chronological order at 
which each locus was identified; for example, DFNA1 represents the first locus to be 
identified for AD hearing loss.  
Term Description 
Flat Hearing loss across all frequencies 
 Sloping (high frequencies) Hearing loss affects high frequencies 
Rising (low frequencies) Hearing loss affects lower frequencies 
Notch (Carhart, cookie-bite) Sharply drop at one frequency 
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1.5 Gene discovery in non-syndromic hearing loss using families  
1.5.1 Ascertainment of families 
 The first step in the genetic study of hearing loss in families is to construct a 
pedigree for the family of interest, define the clinical phenotype, and determine the 
pattern of inheritance.  Carefully and correctly determining the clinical phenotype of all 
family members is an important step in order to succeed in gene discovery. Ascertainment 
of a family for a study usually starts with the proband, which is the first person (i.e. Index 
case) that participates in the study.  In order to identify the clinical phenotype in a family, 
there needs to be a complete family history, prenatal and postnatal medical history for the 
proband and the proband’s family. In the family history, it is important to determine for 
all the relatives the age of onset of the hearing loss and their relationship in order to 
determine the mode of inheritance when the full pedigree is constructed.  Establishing a 
history of consanguinity is imperative in families with hearing loss because this suggests 
a recessive mode of inheritance.  
Exclusion of syndromic form of hearing loss is important in apparently isolated 
hearing loss cases. This requires a physical examination, which includes an eye 
examination to identify, for example Usher syndrome, which is characterized by both 
retinitis pigmentosa and hearing loss. Physical examination by a clinical geneticist to 
identify any dysmorphic features is also required. In cases with a history of renal or 
thyroid functional abnormalities, laboratory investigation should be carried. For example, 
the thyroid function test should be ordered to determine the possibility of Pendred 
syndrome.  
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Determining the mode of inheritance is an important step in studying the genetics 
of hearing loss.  Hearing loss can be developed as result of an inherited mutation or de 
novo mutation. De novo mutation is present in one family member as a result of a 
mutation in a germ cell (sperm or ovum) of one of the parents. De novo mutations have 
been reported as causative mutations in hearing loss; for example, an R75W de novo 
mutation in GJB2 (gap junction protein BETA 2) gene was identified in a sporadic case 
of isolated profound hearing loss
10
. 
The inherited form of the hearing loss is transmitted in many ways, including AD, 
AR,  X-linked, and mitochondrial inheritance
11
. AD inheritance passes from generation to 
generation in a vertical pattern. Only one mutated allele is needed to develop the 
phenotype. In this case, the offspring have a 50 % chance of inheriting the mutated allele 
and being affected. In the AR mode of inheritance, two mutated alleles are needed to 
develop hearing loss. AR hearing loss is characterized by horizontal transmission; both 
parents are carriers of a mutated allele, and each offspring has a 25 % chance of inheriting 
both mutated alleles and developing hearing loss. A history of consanguinity suggests that 
it is likely that hearing loss in a family segregates in an AR pattern. In isolated 
populations, and when the phenotype is relatively common, the recessive disease may be 
seen in successive generations (pseudo-dominant inheritance) resulting from marriage of 
an affected individual with another gene carrier. AR hearing loss accounts for about 80 % 
of the cases of hereditary hearing loss and the most common gene that causes AR 
deafness is GJB2. AD hearing loss accounts for about 20% of hereditary hearing loss 
cases
12
. 
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X-linked inheritance involves genes on the X-chromosome. Males inherit their X 
chromosome from the mother and their Y chromosome from their father (no male to male 
transmission). All daughters of an affected father are carriers and transmit the disease 
gene to 50 % of their childern. The most characteristic features of X-linked inheritance 
are that (i) the males are severely affected and (ii) they develop the disease early in life as 
they have only one copy of the X chromosome. Females with an X-linked phenotype 
show a wide range of clinical severity, which has been explained by varying degrees of 
X-inactivation. X-inactivation is a phenomenon that occurs during early embryogenesis in 
females. One X chromosome, either paternal or maternal, is inactivated to create balance 
in gene dosage between males and females
13
. The X-inactivation process occurs 
randomly; half of the female cells silence the X chromosome inherited from the father 
and the other half silence the X-chromosome inherited from the mother. If the disease 
gene is located on the X chromosome inherited from the father, the other copy of the X 
chromosome inherited from the mother will still be active and produce normal protein. In 
some cases, this process is not random and one of the chromosomes, paternal or maternal, 
gets inactivated completely. This phenomenon is known as Skewed X-inactivation
14,15
. In 
this case, if the disease gene is located on the inactive chromosome, the female will not 
develop hearing loss. On the other hand, if the disease gene is located on the active 
chromosome, severe phenotype will develope as result. 
 In addition to the main modes of inheritance, there are two other modes of 
inheritance depending on the gender of the carrier. Y-inheritance is characterized by male 
to male transmission. To date, there are no hearing loss diseases linked to the Y-
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chromosome. Mitochondrial inheritance is another mode of inheritance. Since 
mitochondrial DNA is transmitted from the mother, every child has 50 % chance of 
inheriting the disease gene. X-linked and mitochondrial hearing loss make up the 
remaining percentage (about 5 %) of hearing loss 
16
. It is estimated that about 50 % of all 
hearing loss has a genetic basis (a monogenic condition)
17
. To date, 71 genes have been 
identified where mutations cause hearing loss 
12
. 
1.5.2 Complications of family ascertainment 
1.5.2.1  Penetrance 
Penetrance is mainly a feature of dominantly inheritance genetic disorders. 
Penetrance is defined as the probability of patients to express the phenotype when they 
have inherited a disease mutation. Penetrance can be 100%, which means that every 
person with the mutation will express the phenotype. For example, the missense mutation 
c.2005 C>T in exon 8 of Wolframin (WFS1) gene causes low frequency non-syndromic 
sensorineural hearing loss (LFSNHL) and is 100 % penetrant; every individual with this 
mutation develops low frequency hearing loss 
18,19
.  One hundred percent penetrant 
conditions are relatively rare and reduced penetrance is more common. For example, if 25 
% of those with a mutation express the phenotype, the penetrance is said to be 25 % and 
this trait shows incomplete penetrance. AD inherited traits could be mistaken as recessive 
inheritance if a person who has a disease causing mutation is non-penetrant. 
Age-related penetrance describes a situation when phenotypes are not clinically 
detected until adulthood, or have a variable age of onset. The genotype is constant but the 
phenotype can express at a later age. For example, Huntington’s disease is an AD trait 
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characterized by late onset neurological deterioration and it is one of the most well known 
examples of a dominant trait of age-related penetrance. Affected individuals may show 
clinical symptoms at any age from childhood to old age but individuals usually present 
between the ages of 35 and 45 years. Full penetrance may not be seen until age 65 or 
later
19,20
.  Age-related penetrance is well documented in hearing loss and it complicates 
the diagnosis in some time
21
. For example, age related penetrance of some manifestation 
of syndromic hearing loss could obscure the difference between syndromic and 
nonsyndromic hearing loss.  For example, Pendered (PS) syndrome and non syndromic 
hearing loss with enlargement of vestibular aqueduct (EVA) are similar in the 
presentation of hearing loss and the presence of EVA. The difference between both 
disease is the development of goiter in the PS. Age related penetrance of the goiter 
phenotype can complicated in the diagnosis. Further family history and laboratory/clinical 
examinations are important for clear diagnosis
22
. 
1.5.2.2  Variable expression 
Variable expression is defined as difference in the degree of phenotype expression 
caused by a mutation in a gene. For example, neurofibromatosis type 2 (NF2) is an AD 
disease caused by mutations in the neurofibromin gene and it is characterized by 
progressive hearing loss, Café-au-lait (coffee with cream-colored) spots on the skin, 
cataract, neurological and skeletal problems
19,23
. The range of the expressivity of these 
manifestations is variable. Patients may exhibit a range of symptoms ranging from 
freckles and pale brown palm to severely disfiguring neurofibromatosis over their body. 
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The variability in the expression of the full manifestation of a disease obscures the 
diagnosis and lead to misdiagnosis of the condition.   
1.5.2.3  Phenocopy 
A phenocopy is referred to an affected individual who had developed the same 
phenotype segregating in the family due to a different etiology
24
. For example, in genetic 
studies, a phencopy is defined as an individual marked as being affected however the 
underlying etiology is different from the other affected individuals in the family. 
 In many cases, the phenocopies are caused by environmental factors rather than 
genetic factors but in fact can be due to either
25
. Phenocopies can prove problematic in 
gene hunting studies. They are an example of heterogeneity within a pedigree that 
weakens the LOD scores by creating false recombinants. The phenocopy phenomenon is 
common in genetic studies of hearing loss primarily because the hearing loss is common. 
For example, genetic analysis of the DFNA15 kindred identified a linked region on Chr5 
that was inherited by all affected in the family except one affected member. Close 
examination of this person found that their hearing loss was different from that seen in 
other affected family members and mutational analysis of the POU4F3 gene revealed that 
this family member did not have the POUF4F3 mutation associated with the hearing loss 
in other members of the family
26
. Another study carried by Abdelfatah et al has identified 
a novel in-frame deletion in KCNQ4 (DFNA2A) in 10/23 deaf relatives. Further 
examination of audio profiles of the non-deletion carriers deaf relatives revealed different 
audiometric profiles from that of the deletion-carriers, which most likely represents 
phenocopies
27
.  
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1.5.3 Genetic analysis of the families  
      There are several approaches to genetically analyzing families with hereditary 
disorders and I am going to discuss those used in this thesis.  
1.5.3.1  Exclusion of known loci or genes 
Exclusion of previously mapped loci for a certain disease is considered an important 
step that can save time and money and help to find the causative gene. However, this 
procedure can be lengthy and impractical when the disease is common, when it has been 
mapped to many regions in the genome, or is caused by many genes, as exemplified by 
hearing loss.  
In AR hearing loss, there are 76 mapped loci with 39 cloned genes, with the most 
common mutated locus being DFNB2 (GJB2). The most effective way to study AR 
hearing loss is to screen for the most commonly mutated genes first. In AD hearing loss 
where 54 loci have been mapped and 25 genes cloned, classifying hearing loss based on 
audio profiles provides success in identifying causative genes
27,28
.  AudioGene is a tool 
which can provide a list of genes predicted to cause AD hearing loss based on patient 
audio profiles
29
. Typical audio profiles of patients with mutations in 16 known AD loci 
have been identified. In X-linked hearing loss, there are only 5 loci with 3 cloned genes. 
The lower number of these loci makes them more practical to screen individually
30
.   
1.5.3.2 Candidate gene and genome-wide association approches 
Candidate gene (CG) and genome-wide association  (GWA) studies are methods 
aimed to uncover the genetic aetiology of complex diseases by demostrating an 
association between genotype and disase susceptibility across one or more markers using 
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cohorts of case and control (affected cases and unaffected controls)
31
. For each 
association study, two cohorts have to be carefully designed with clear phenotype of the 
cases and exclusion criteria for the control. The primary cohort used for an association 
study is called a discovery cohort and the secondary cohort that is used for replication and 
validation of the primary results is called a replication cohort.  
The main difference between CG and GWA studies is that CG examines 
association based on candidate genes, while GWAs examine the whole genome for an 
association. Both techniques show ability to identify susceptibility genes, with some 
advantage for each one over the other
32,33
. CGs lack the ability to identify novel 
succeptibility genes due to limitations in choosing candidate genes, but mange to provide 
a high statistical power. On the other hand, GWA studies are capable of identify a novel 
suceptibility genes, but their statistical capibilities of lowe power. The statistical power of 
the GWAs is increased when millions of the single nucletoid polymorphism (SNP) are 
used. 
 GWA studies have many limitations interfere with their success. Of these 
limitation, lack of the proper defined case control cohort, especially in complex diseases 
with no clear phenotype (many manifestation). Insufficient sample size, population 
stratification and massive number of statistical tests, which increase the possibility of 
false positive, are other limitations encounter in GWAS. The major obstacle facing the 
GWAs is the reproducibility. Failure to replicate the results of an association studies in 
another population, leading to doubt in the accuracy of the finding. This failure can be 
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result of poor definition of the phenotype used in the association studies or difficulty in 
attributing genotypes
34
.     
1.5.3.3  Genome-wide linkage analysis 
Multiplex families with strong pedigree structures and with genomic DNA 
available from two or more generations are suitable for genome-wide linkage analysis. 
Genomic DNA from available individuals (including affected and unaffected) is 
genotyped with polymorphic markers that span each of the 22 human autosomes. Each 
marker has a specific variation called allele. There are two types of markers that have 
been used for genome-wide scans; microsatellite markers and SNPs. Microsatellite 
markers are characterized by repetitive sequences that vary in length between individuals. 
These microsatellite markers are mainly informative because they are poly-allelic and 
result in informative genotypes
35
. SNPs are bi-allelic, giving limited genotype variability 
but they are more frequent and highly distributed in the genome
36
.  
An informative marker is defined as a marker that has a high heterozygosity rate 
in a population. In other words, informative markers are markers that give a heterozygous 
genotype (two different alleles). The degree of informativeness of a marker is measured 
by how many alleles it gives at a certain locus within a family. The main aim of using 
informative markers is to obtain informative genotype (i.e. two different alleles) and 
therefore, informative offspring.  For example, if both parents are homozygous at the 
marker locus (i.e. one allele), none of the offspring are informative; if both parents are 
heterozygous for the same alleles at the same locus, half of the offspring are informative. 
On the other hand, if both parents are heterozygous for different alleles at the same locus 
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(i.e. four different alleles), all offspring are informative (Figure 1.5).  In most cases, 
genotypes for a single DNA maker are not informative, but because DNA tends to be 
inherited in large segments (haplotypes), looking at genotypes for several markers across 
the DNA region can be very informative. Haplotypes, which are groups of alleles that are 
inherited together from a single parent, have a great role in pedigree analysis. Pedigree 
analysis contributes significantly in the field of genetics by playing an important role in 
the identification of disease-genes. 
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Figure 1.5:  Degree of informativeness of markers within a pedigree 
An example of marker informativeness within a pedigree. Parents and all offspring are 
homozygous for marker 1 locus. For marker 2 locus, parents and 50 % of the offspring are 
heterozygous for the same allele. Each parent inherited a different allele at marker 3 locus and 
alloffspring are heterozygous. A1, A2, A3 and A4 are alleles. Both markers 2 and 3 are examples 
of an informative markers in this family, however marker 1 is not informative. 
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The main goal of performing genome-wide genotyping in a family with a certain 
disease is to identify a specific region in the genome that is shared by affected relatives, 
but not shared by unaffected relatives, which gives a rough location of the disease gene. 
Identifying of this specific region in the genome requires identifying genetic 
recombination within the family. Recombination is a process in which paternal and 
maternal chromosomes exchange parts. Recombination occurs in the germline cells and 
passed down from generation to generation. Recombination commonly occurs between 
largely distant markers. If the markers are very close together, recombination is less 
likely.  
Mapping a disease gene requires measuring the recombination fraction (). The 
recombination fraction measures the distance between genotyped markers and the 
likelihood of a crossover event to occur between two markers. The closer the markers, the 
less likely that a recombination can occur so they tend to segregate together
37
. If markers 
are tightly linked and no recombination occurs, the recombination fraction is 0. If markers 
can separate from each other by a crossover, the recombination fraction will have a value 
range from 0 to 0.5. In other words, if two markers are not close, the frequency of 
recombination will be 50 % (half of the offspring will be recombinant) and if these two 
markers are close, the frequency of recombination will be less than 50 %. The frequency 
of recombination is equal to the number of recombinant offspring divided by the total 
numbers of offspring.  Loci/markers are unlinked if they are located on different 
chromosomes or lie far apart on the same chromosome. Conversely, they are linked if 
they are located close to each other
38
. The frequency of the recombination is an important 
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point in haplotype analysis within pedigrees. The less recombination detected, the more 
accurate the haplotypes. To construct haplotypes from the genotype data, all possible 
distinct haplotype possibilities have to considered and haplotypes with least 
recombination are chosen
39
.  In some situations, even using the rule of least number of 
recombination, the numbers of recombinant haplotypes are still higher than the expected. 
It has been reported that the rate of recombination is variable across the genome which 
can explain the high rate of recombination in some regions of the genome, especially the 
telomeric end of chromosomes
40
.   
Linkage analysis is a statistical method that measures how likely the phenotype in 
question is linked to a certain region in the genome. There are two types of linkage 
analysis: parametric and non-parametric. In parametric linkage analysis, all parameters 
have to be defined such as the mode of inheritance, allele frequency, penetrance, and the 
phenocopy rate. In contrast, non-parametric linkage analysis does not require defined 
parameters and is based on identifying identical-by-descent (IBD) alleles that are shared 
between affected individuals in a pedigree
41
. In non-parametric linkage analysis, two 
likelihoods are considered: i) The likelihood that the phenotype segregating in the family 
is due to genetic linkage between loci, and ii) the likelihood that the phenotype 
segregating in the family is not a result of linkage between markers (θ=0.5). The ratio 
between these two likelihoods gives the odds of linkage versus no linkage. The logarithm 
of the odds ratio is the LOD score (Z). The LOD score is calculated at different θ ratios 
for each marker. A LOD score of 3 is the threshold for accepting linkage. A LOD score 
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below or equal to -2 is considered a minimal threshold for linkage exclusion. LOD scores 
above 1 are considered suggestive of linkage. 
 Once the linked region has been determined, the boundaries of this region represent 
the disease interval. Usually the identified region is large because the markers used for 
whole genome genotyping are widely spread across the genome. In order to decrease the 
size of the linked region, markers (SNPs or microsatellite markers) that are spaced close 
to each other across the linked region are genotyped in all available relatives. Close 
spacing of genotyped markers helps to identify any critical recombination that reduces the 
genetic interval. The newly minimized region is called candidate region. Decreasing the 
size of the linked region, decreases the number of genes needed to be screened
42
.  
1.5.3.4 Positional candidate gene sequencing  
All annotated genes within the disease candidate region are called positional 
candidate genes.  It is important to examine all the annotated genes in the critical region. 
All positional genes in a candidate region are candidate genes and they have to be 
screened because there are many genes in the genome of unknown function and 
expression. We can prioritize some genes to be screened first based on their expression 
profile or involvement in a relevant pathway. In hearing loss, genes that are expressed in 
the ear would be prioritized. Hearing loss is divided into many types and for each type, 
certain genes would be prioritized. Thus, genes that are expressed in the cochlea, hair 
cells, tectorial membrane, or any part of the inner ear would be prioritized for the SNHL.  
Similarly, genes that are expressed in the bone of the ear, or have a role in inflammation 
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or the immune system, would be a good candidate for conductive hearing loss caused by 
overgrowth of the bone cells (otosclerosis).  
 In the past decade, Sanger sequencing has been the gold standard method for 
screening genes. The Sanger sequencing technique is very suitable for detecting small 
mutations, including point mutations, and small insertions and deletions (indels)
43
 
44
. 
Traditionally, Sanger sequencing was utilized to find mutations in the coding region of a 
gene along within intron-exon boundaries.  
1.5.3.5 Mutation identification and validation 
In gene screening, a screening panel is designed using genomic DNA from a small 
number of confirmed clinically affected family members and unaffected family members 
who do not have the phenotype. A mutation screening panel is a quick screening tool for 
candidate genes. It is then sequenced for the positional candidate genes in the region of 
interest. Variants that are present in affected members but absent in unaffected members 
are designated for follow up.  Frequency of the candidate variants can be primarily 
determined through SNP database (dbSNP) and the 1000 genomes project
45,46
.  Rare 
variants are more likely to be pathogenic but with the development of next generation 
sequencing techniques (NGS) to sequence the genomes of many individuals, dbSNP and 
the 1000 Genomes Project databases have been hugely expanded with variants of 
unknown frequency or low frequency (less than 1 %)
45,46
. For known variants, minor 
allele frequency (MAF) of each variant is listed in dbSNP. MAF refers to the frequency 
of least common allele in certain population. Variants that are in dbSNP/1000 Genomes 
Project database with a low MAF are candidates for follow-up. 
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There are many types of variants that can be identified through Sanger sequencing. 
These variants include missense mutations, silent variants, splicing variants, deletions and 
insertions. Variants located in highly conserved coding regions and/or causing dramatic 
changes in amino acids (e.g.: hydrophilic to hydrophobic) are more likely to be 
pathogenic. Intronic variants could affect the donor and acceptor splice site. They also 
can affect branch points, Intronic Splicing Enhancers (ISE) and Intronic Splicing 
Silencers (ISS). Not only intronic variants are candidates for aberrant splicing defects, but 
synonymous (silent) and benign missense variants are also possible candidates for 
splicing because they could affect Exonic Splicing Enhancers (ESE) and Exonic Splicing 
Silencers (ESS). Consequently, they can enhance or supress the accurate splicing of the 
pre-mRNA. Variants within these sequences could affect the splicing efficiency at the 
splice donor/acceptor and could activate cryptic donor/acceptor sites. Variants within the 
ESE and ESS motifs could be predicted as silent or benign missense variants at the 
protein level, which do not affect the protein drastically. Unfortunately, despite 
preditctions that these variants are benign, functional assessment is necessary to rule out 
whether there are major drastic effects on RNA splicing that could not be predicted using 
prediction programs. Hence, silent variants and missense mutations that are predicted to 
be benign should be checked for possible splicing effect using a variety of splicing 
prediction programs. 
Different bioinformatics analysis prediction programs are available to help predict the 
outcome of nucleotide change on protein and also predicted for possible splice site at the 
variation position. Two of these prediction programs, Sorting Intolerant From Tolerant 
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(SIFT)
47
,  and PolyPhen-2
48
 are used for  missense mutations prediction. Human Splicing 
Finder (HSF), MaxEntScan, NNSPLICE, GeneSplicer, SpliceSiteFinder (SSF) and other 
known constitutive signals splice prediction tools are used for predicting the effect of the 
splice site mutations on the splicing efficiency
49-55
.  
The SIFT prediction program is based on measuring the degree of conservation of an 
amino acid residues across closely related sequence through searching for the protein 
sequence homology to the protein of interest. Substitutions with scores less than 0.05 are 
predicted to be deleterious by SIFT. The Polyphen program predicts the possible impact 
of an amino acid change on the physiochemical properties of the protein product. The 
effect of amino acid substitutions is categorized by Polyphen according to the following 
scores: scores of 0.00–0.99 are classified as benign, 1.00–1.24 as borderline, 1.25–1.19 as 
potentially damaging, 1.50–1.99 as possibly damaging, and ≥2 as damaging56.  
Splicing prediction programs are aimed to assess if the identified variants are located 
within putative donor and acceptor splice site, branch points and cis-acting elements ESE, 
ESS, ISE and ISS. The splicing prediction programs use algorithms to calculate the 
consensus values of potential splice sites and search for branch points and each program 
has a particular score value as follows: SSF [0-10, HSF [0-100], MaxEntScan [0-12], 
NNSPLICE [0-1], GeneSplicer [0-15]. The scores calculated by these programs give an 
indication of the possible splicing effect of the mutation based on the measured 
differences in the scores between the wild and mutant forms. The higher the difference in 
the score between the wild and mutant forms, the more likely the prediction is true.  
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 By using previously listed prediction program, variants with deleterious effect on the 
protein level as well as variants that affect splice site will be of interest. Not to mention, 
deletion and insertion (indel) variants are highly candidate variants. There are no 
available programs to predict the effect of indel variants on the protein level. Sequencing 
analysis produce a huge number of interesting variants. In order to determine which one 
of these variants is the disease causing variant, segregation analysis of these variants 
across large family and determine the allele frequency of candidate variants in ethnically 
matched population will help in identifying mutation causing disease.  Also, identifying 
additional families with the same mutation, or with different mutations within the same 
gene, and performing functional studies in order to show pathogenicity, are important 
steps to validate potentially interesting findings.   
Variants are shared across families in two ways: 1) In case of a founder mutation, 
families inherit variants that are identical by descent (IBD) and this variant is placed on a 
founder haplotype. Founder haplotypes are segments of chromosomes shared by several 
individuals from the founder population and inherited from a shared ancestor; 2) In case 
of a recurrent mutation, families inherit the same variant but this variant occurs at distinct 
haplotype, identical by state (IBS). In other words, IBD alleles refer to alleles that are 
identical copies of ancestral allele.  IBS refers to alleles that are the same due to 
coincidental co-occurrence of these alleles and not driven from a known common 
ancestor. 
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1.5.3.6  Next generation sequencing 
Exploring the sequence of the human genome is essential for genetic studies. In the 
last decade, Sanger sequencing has provided great genetic information for many diseases. 
The limitations of Sanger sequencing regarding throughput, speed and genome coverage, 
have prevented scientists from obtaining the required genetic information in a reasonable 
time and has led to the development and adoption of a new technology. NGS is a new 
genomic technique, which sequences the whole genome in parallel with a very rapid 
throughput
57
.  The development of NGS, especially exome sequencing, has made a huge 
impact to the field.  Exome sequencing sequences all the coding regions of the genome 
(~1 % of the genome) excluding the intronic and intragenic regions
58
. Exome sequencing 
has proven utility in the discovery of a variety of disease gene mutations, including those 
for infantile hepatopathy
59
, non-small cell lung carcinoma
60
, and inflammatory bowel 
disease
61
. In the last few years, there are many competitive platforms with the same 
principle; procedure and different technologies were released.  The principle behind NGS 
is based on sequencing a small fragment of DNA and identifies the base of each fragment 
from analyzing the signal released from each fragment. This procedure is applied to 
millions of fragments and produces hundreds of gigabase of data in a single run. 
Fragmentation of genomic DNA (gDNA) into a library of small fragments is 
consideredthe first step of NGS process. The constructed library is further enriched and 
sequenced in millions of reactions. The sequenced stretch of bases, called reads, is then 
realigned to a reference sequence. The final output of the sequence is a full set of aligned 
reads that cover each chromosome in the sequenced sample. The output of the NGS is 
hugely increased in the last few years from one gigabase (Gb) in 2007 to terabase in 
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2011
62
 . The huge improvement in the sequencing output allowed researchers to move 
with their study forward. With the decreased cost of NGS, researchers can now sequence 
many samples in a single run. The differences between platforms are based on technology 
under the reaction, run time, read length/coverage and throughput per run. Of these 
factors, the depths of coverage and uniform distribution of reads are critical to achieve the 
maximum sequencing efficiency.  For example, the Illumina sequencing platform uses 
bridge amplification technique to amplify the target library and to perform a library 
cluster. Sequencing technology used by Illumina platform is sequencing by synthesis that 
produces a fluorescent signal from incorporation of fluorescent-labeled nucleotides into 
the newly synthesized strand
63
.  
Analysis of NGS data requires many steps beginning with mapping of the raw data to 
a reference sequence, This is followed by extensive use of a wide variety of 
bioinformatics tools, such as software for variant calling in the detection of SNPs and 
indels
64
.  As a significantly large amount of data is provided by one NGS run, it is 
advantageous to sequence large numbers of well defined affected and unaffected family 
members which will significantly help reduce the number of potentially causative 
variants. 
First, variants present in the unaffected exomes, as well as common variants with high 
frequencies from SNP/ 1000 genome database, and the exome variant server are 
removed
46
. Only novel variants and variants with low frequencies are included for further 
analyses which are subsequently filtered based on pathogenicity effects, i.e., nonsense, 
missense mutations, or potential splice variants. Validation and segregation analysis of 
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these potential pathogenic variants involves Sanger sequencing using all available 
members of the study family. The use of NGS technology reduces processing time while 
increasing data output. However, due to the huge amount of data produced, analysis 
requires a high powered computer system
65
. The combined use of NGS and Sanger 
sequencing technologies provides powerful tool in gene discovery studies. 
1.6 Otosclerosis  
1.6.1  Overview 
Otosclerosis is the most common cause of progressive conductive and mixed 
hearing loss
66
 
67
.  It is thought that otosclerosis develops as a result of abnormalities in 
bone remodeling in the endochondral layer of the otic capsule. Abnormalities in bone 
remodeling in the otic capsule leads to development of sclerotic foci and the footplate of 
the stapes bone is the common site affected
68
. The development onset of sclerotic foci 
ranges between the third and sixth decade, and although the effect can be unilateral, 80 % 
of those with otosclerosis have both ears affected
69
. 
Otosclerosis is classified into clinical otosclerosis and histological otosclerosis. 
Clinical otosclerosis is characterized by conductive hearing loss which develops as a 
result of fixation of the stapes bone to the oval window by sclerotic foci. In addition to 
conductive loss, a SNHL component may develop later. SNHL is present as a first sign in 
10 % of cases
70
. In contrast, histological otosclerosis is a type of otosclerosis discovered 
through post-mortem examination of the temporal bones of people with no proclaimed 
hearing loss but with an identified otosclerotic lesion. In Caucasian population, clinical 
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otosclerosis has a mean prevalence of 0.3-0.4 % 
71
 while histological otosclerosis has a 
mean prevalence of 3.5-4.5% in the same population
70,72
. 
Conductive hearing loss but not residual SNHL is treatable with great success by 
stapedectomy surgery
73
. The cause of the SNHL component is unknown, though it may 
be a consequence of abnormal remodelling of the bony labyrinth which lies in close 
proximity to the cochlea, and damage due to lysosomal enzyme release
74
 
75
. Another 
explanation for SNHL is hyalinization of the spiral ligament caused by adjacent 
otosclerosis foci
75,76
.  
Ethnicity is considered an important factor in the prevalence of otosclerosis. For 
example, the prevalence of clinical otosclerosis in Japanese and Chinese populations is 
similar and is estimated to be half as common in these populations as in Caucasian 
populations
77
 
78
. While these prevalence studies provide an estimation of the disease 
frequency in a certain population, the small number of participants and lack of clinical 
data can give a biased interpretation of results. Most of previous studies carried to 
estimate the percentage of histological otosclerosis was of high-risk bias. This high risk 
bias arose from including all specimens with otosclerotic temporal bone, without 
distinction. Of these specimens collection, about 15 % showed evidence of stapes 
fixation
70
. These selections bias the actual estimation and can overestimate the 
histological prevalence. On the other hand, studies carried by Declau et al and 
Schuknecht et al, were based on using unselected series of temporal bone and exclusion 
of all specimen with evidence of stapes fixation. The prevalence estimate of histological 
otosclerosis by their studies was lower than the previous reported studies. It ranged 
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between 2.5% and 4.4% by Declau et al and Schuknect et al respectively
70
.The 
prevalence of otosclerosis in the NL population is not known and as immigrants from 
England and Ireland settled NL originally, we can speculate that the prevalence of 
otosclerosis in NL may be similar to that of other Caucasian populations especially, North 
European. Developing a study that can estimates the actual prevalence of otosclerois in 
NL population will be of great help in genetic studies of otosclerosis.  
Otosclerosis is considered a non-syndromic form of conductive hearing loss.  
Syndromic forms of conductive hearing loss that affect bone remodelling, include 
osteogenesis imperfecta (OI), and congenital stapes fixation. OI is a condition 
characterized by bone fragility and is associated with conductive hearing loss similar to 
otosclerosis
19,79
.  Approximately 90 % of OI cases are caused by mutations in COL1A1 or 
COL1A2 genes that encode alpha 1 and alpha 2 chains of type I collagen. The 
histopathological changes in the ears of OI patients are very similar to those observed in 
otosclerosis patients, and nearly half of all individuals with OI develop conductive 
hearing loss occurring in the second and third decade
80,81
.  
Congenital stapes fixation is a non-progressive condition that occurs in the first 
decade along with other skeletal manifestations, such as proximal symphalangism 
(SYM1), multiple synostoses syndrome (SYNS1) and stapes ankylosis with broad thumb 
and toes. It is caused by mutations in the NOG gene
82
. Previous genetic studies in 
otosclerosis have screened COL1A1, COL1A2 and NOG genes in families with isolated 
otosclerosis, but no mutations have so far been identified
83
 
84-90
. 
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1.6.2 Bone remodeling and otic capsule 
The otic capsule is trilaminar with a middle endochondral layer.  The main 
characteristic feature of the endochondral layer of the otic capsule is that bone 
ossification is completed after the first year of life. Once it calcifies, the bone in the otic 
capsule undergoes very slow bone remodeling each year
91
. In comparison, the rate of 
bone remodeling for most of the human skeleton is high. The difference in the rates is 
thought to be due to the production of osteoprotegerin (OPG) by the cochlea, which 
antagonizes the RANKL ligand (activation of bone remodeling) and maintains the static 
state of otic capsule bone
92
. 
Sclerotic lesions (foci) develope as a result of imbalance of bone remodelling in the 
otic capsule. Bone remodeling is a normal physiological process that is controlled by both 
osteoclasts (bone resorbing cells) and osteoblasts (bone forming cells). Human skeleton 
integrity depends on the balance between bone resorption by osteoclasts and bone 
formation by osteoblasts
93
. A detailed knowledge about osteoclasts and 
osteoclastogenesis helps to understand how otosclerosis develops. Osteoclastogenesis is a 
process that produces osteoclasts. Osteoclastogenesis is initiated by mononuclear cells, 
and requires expression of macrophage-colony stimulating factor (M-CSF), 
Osteoprotegrin (OPG) and other transcription factors. In the presence of receptor activator 
of nuclear factor kappa-B ligand (RANKL), produced by osteoblasts, Osteoclasts undergo 
differentiation after binding the RANKL ligand to the RANK receptor on the immature 
osteoclast (Figure1.6). The expression of many factors is required for osteoclast 
maturation including the nuclear factor of activated T cells, calcineurin dependent 1 
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(NFAT-c1); microphthalmia-associated transcription factor (MITF); and AP-1 
transcription factor c-fos expression
94
. The lysosomal enzymes required for bone 
resorption are secreted by the mature active multinucleated giant osteoclasts. New bone 
matrix is deposited by osteoblasts in the site where bone destruction by osteoclasts 
occurs. Pre-osteoblasts are differentiated from mesenchymal stem cells (MSC) in the 
presence of runt-related 2 (RUNX2), distal-less homeo box-5 (DLX5) and MSH 
homeobox-like 2 (MSX2) transcription factors, as well as glucocorticosteroids, 
parathormone (PTH), vitamin D (1,25-(OH)2D), prostaglandins (PGE2), 
lipopolysaccharides (LPS), histamine and pro-inflammatory cytokines: interleukins (IL-1 
and IL-11) and tumor necrosis factor alpha (TNF-α) 97. Collagen type1, osteoclastin, and 
alkaline phosphates are secreted into the matrix by mature osteoblasts. Some of the 
osteoblast cells turn into osteocytes which function to maintain the mineralization of the 
bone
95
 
96
. 
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Figure 1.6: Pathways involved in bone remodeling 
Osteoclast and osteoblast cells with RANKL ligand on the surface of the osteoblasts. Osteoclasts 
carry the RANKL receptors. Upon binding the RANKL ligand to the RANKL receptor, pre-
osteoclasts undergo maturation and develop into mature osteoclasts.  mRANKL = membrane-
bound RANKL; sRANKL = Soluble form of RANKL. This figure is taken from reference 97
97
. 
 
 
 
 
 
monocyte/macrophage cell line 
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1.6.3 History and stages of otosclerosis 
In humans, otic capsule calcification is complete by the first year of life and there 
is no activity of osteoblasts and osteoclasts detected in the otic capsule at the adult age
98
. 
In otosclerosis, osteoclast cells resorb the endochondral bone of the otic capsule followed 
by deposition of new bone by osteoblasts, which results in a poorly organized region that 
doesn’t resemble the normal structure of an otic capsule. Otosclerosis pathology runs in 
two stages: i) active stage (otospongiosis) which is characterized by hypercellurity where 
osteoclasts and osteoblasts can be seen in large numbers with fewer collagen fibers in the 
extracellular matrix, and wide pseudovascular space “Swiss cheese” pattern (Figure 1.7) 
104; ii) inactive stage (sclerosis) which is characterized by hypocellularity and abundant 
deposition of new, woven bone, which increases thickness of the stapes bone footplate. 
Otosclerosis foci can become inactive at any time but also can become reactivated at any 
time.  Both active and inactive otosclerosis foci can be seen in histological specimens 
from an otosclerotic region
99
. The active area in the otic capsule appears as hypodense 
regions surrounding the inner ear on a CT-scan. In later stage of otosclerosis, this active 
region is replaced by fibrous tissue and forms a dense sclerotic bone
100
.  
Valsalva was the first to report otosclerotic lesions in 1741
101
 but it was Politzer 
who, in 1894, identified otosclerosis as a common cause of hearing loss
102
.  In 1912, 
Seibenmann first described the active form of otosclerosis (otospongiosis) as 
characterized by a high vascularized region in the otic capsule with activated 
macrophages and osteoclasts
103
. 
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Figure 1.7: Histological findings in different stages of otosclerosis 
 Different histological stages of otosclerosis. (a) Active stage with hypercellularity and increased 
number of osteoclasts and osteoblasts at the anterior pole (AP) of the stapes bone. Arrow points to 
the wide pseudovascular spaces “Swiss cheese” pattern. (b) Inactive otosclerosis foci at the AP of 
stapes bone with hypocellularity, hypovascularity and woven bone (line). (c) Advanced stage of 
otosclerosis with intense eosinophilic staining. (d) Sclerosis, hypocellularity, hypovascularity and 
increased thickness of the stapes footplate pointed by black arrow. (e) Histological image of 
normal stapes. PP: posterior pole; AC: anterior crus; PC; posterior crus; FP: footplate. This figure 
is taken from reference104
104
.  
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1.6.4 Diagnosis of otosclerosis 
Commonly, patients with otosclerosis present with slowly progressive hearing loss 
in their 20s or 30s. In some cases, associated symptoms are reported including vertigo or 
dizziness, otorrhea and tinnitus. The most definitive diagnosis of otosclerosis is actual 
visualization of the stapes fixation during the stapedectomy surgery
105
. Pre-operative 
diagnosis of otosclerosis is based on audiological evaluation of the hearing loss. The main 
aim of the audiological tests is to establish the conductive component of the hearing loss. 
In addition to audiological evaluation, visualization of the tympanic membrane (TM) by 
otomicroscopy is essential in otosclerosis diagnosis. In majority of patients, TM appears 
normal. In 10% of cases, red hue may be seen in area with hypervascularity in the active 
phase of otosclerosis (Schwartz sign)
106
.  
  The audiological evaluation is based on pure tone audiometry, tympanometry, 
and acoustic reflexes, which are the most important tests to diagnosis otosclerosis and 
arranging for further treatment. Tympanometry is appreciated in otosclerosis, especially 
in the advanced stage as it measures the compliance of the TM. In the early stage of 
otosclerosis, the middle ear pressure is not changeable and therefore, the peak of the 
tympanogram is always in the normal range. The compliance of the tympanic membrane 
is reduced and results in drop of the height of the peak as otosclerosis progresses.  
 Acoustic reflex is helpful in diagnosis of otosclerosis as it measures the change in 
the compliance of the middle ear in response to sound stimuli. Change in the compliance 
of the middle ear is caused by contraction of stapedius muscles, stiffness of the ossicular 
chain and lead to decrease the sound transmission to the vestibule.  Acoustic reflex is able 
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to detect otosclerosis in early stage, even before the conductive component, by the 
characteristic diphasic reflex pattern. Also, it detects the progression of otosclerosis over 
time by its characteristic pattern.  As otosclerosis progresses, the acoustic reflex is 
reduced followed by elevation of ipsilateral (same ear) then contralateral (opposite ear) 
threshold and ended by absence of reflexes.  
Pure tone audiometry measures the air and bone conduction, either masked ar 
unmasked. The masking technique, which is occupying the untested ear with sound, is 
used to ensure that the result obtained is true for the tested ear. Normal or low thresholds 
of bone conduction with a higher threshold of air conduction suggests a conductive 
hearing loss. Conductive hearing loss is diagnosed when ABG is greater than 10 dB 
(Figure 1.8A).  Pure tone audiometry has a better chracterization of the severity of 
otosclerosis. The first chracteristic audiometric sign of otosclerosis is a decrease in air 
conduction in the low frequency and is referred to as “stiffness tilt”. It is believed that it is 
caused by a decrease in the compliance secondary to stapes fixation. The Carhart notch, 
the chracteristic audiologic sign of otosclerosis, is chracterized by a decrease in the bone 
conduction thresholds at different frequencies, especially 2000Hz (Figure 1.8A). It is 
belived that it appears as a result of distraction of the normal ossicular resonance by 
stapes fixation, and is not a true representation of the cochlear dyfunction. In other words, 
the drop in the high frequencies is not caused by a dysfunction of the cochlea, but is the 
result of change in the compliance of the middle ear caused by stapes fixation. This 
hypothesis is supported by the fact that the Carhart notch disappears after stapedectomy.  
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In spite of the superiority of pure tone audiometry over tympanometry and 
acoustic reflexes in detecting disease progression, the measurement of pure-tone air and 
bone conduction thresholds has a limitation based on individual variations of test 
sensitivity. The variation in the test sensitivity emerges from the difference between the 
energy delivered by a vibrator for obtaining bone conduction thresholds, which is much 
greater in magnituide, and that required by headphones to deliver stimuli for air 
conduction threshold. It is important to apply masking technique to remove contribution 
of the untested ear. A combination of pure tone audiometry, acoustic reflex and 
tymapnometry is important for accurate pre-operative diagnosis of otosclerosis
106
.  
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Figure  1.8: Audiogram profile of an otosclerosis patient 
(a) Audiogram of a patient with late stage of otosclerosis showing a difference in the ABG.  Rt 
ear = O, Lt ear =X, bone conduction Rt ear = [, bone conduction Lt ear =]. Characteristic Carhart 
notch denoted by an arrow. (b) Low frequency loss observed in a patient with early stage of 
otosclerosis. This loss is known as "Stiffness tilt" and is denoted by an arrow. The audiograms 
presented below are taken from original audiograms of one of the family probands studied in this 
thesis.  
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1.6.5 Genetic cause of otosclerosis 
The cause for the development of sclerotic foci in the ear is unknown, though 
genetic factors were suggested in conjunction with the first description of familial 
conductive hearing loss in 1841
107
. Albrecht recognized AD inheritance of otosclerosis in 
1922, and low penetrance (40 %) of otosclerosis was reported by Larson and Morrison in 
1960 and 1967 respectively
108
 
109
 
110
. The most compelling evidence supporting 
underlying genetic factors in otosclerosis emerged in 1966 from studies of concordant 
monozygotic twins
111,112
. The most prevalent mode of inheritance is the dominant mode 
as  suggested in previous studies
113,
 
114,
 
86,
 
87,88,
 
115,
 
90
. However, Bauer and Stain suggest a 
recessive mode of inheritance based on a study of 94 families with otosclerosis 
members
116
. This work has been criticized by Morrison, who claim that the data in the 
study lack adequate diagnostic criteria and risks the possibility of including members with 
other cause of hearing loss
110
. A digenic mode of inheritance was suggested by one study, 
while X-linked inheritance was proposed by another
117
. No mitochondrial mode of 
inheritance was suggested for otosclerosis transmission.  
Previous genetic studies of familial form of otosclerosis have been carried out 
through traditional linkage analysis. The aim of these studies was to map the otosclerosis 
segregating in families to a region in the genome and to identify the causative mutation. 
To date, a literature search reveals a total of eight AD loci (OTSC1, OTSC2, OTSC3, 
OTSC4, OTSC5, OTSC7, OTSC8 and OTSC10) that have been mapped, originally in eight 
large, unrelated families with different ethnic origins (Table 1.3). However, not a single 
gene has been identified since the first OTSC locus was mapped sixteen years ago
113,
 
114,
 
86,
 
87,88,
 
115,
 
90
. 
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Table 1.3: Currently mapped AD otosclerosis loci and their respective genomic 
location 
 
 
 
 
 
 
Locus 
name  
Locus  
Ch. 
Country of the 
original families 
Subsequent families 
mapped to the same locus 
Citation  
OTSC1 15q25-q26 India  
113
 
OTSC2 7q34-q36 Belgium  
114
 
OTSC3 6p21.3-22.3 Cyprus Tunisian Families (n=2)  
86
  
118
 
OTSC4 16q22.1q23.1 Israel  
87
 
OTSC5 3q22-24 Dutch  
88
 
OTSC6 Reserved   
OTSC7 6q13-16.1 Greek Dutch Family 
115
 
OTSC8 9p13.1-9q21 Tunisia  
90
 
OTSC9 Reserved   
OTSC10  1q41-44 Dutch   
80
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The first advance in our understanding of the genetic aetiology of otosclerosis using 
traditional linkage analysis was reported in 1998, through the identification of a locus 
(OTSC1) on Chr15 which co-segregated with otosclerosis in a large family from India. 
This family included five of 16 affected relatives with surgically confirmed otosclerosis, 
and other siblings who had conductive hearing loss. Tomek et al, 1998 genotyped 160 
polymorphic markers evenly dispersed across the human genome. Analysis yielded a 
single locus on Chr15q25-26 (OTSC1) that generated a logarithm of odds (LOD) score of 
3.4. Construction of disease-associated haplotypes identified a minimal critical region of 
14.3 cM containing 33 candidate genes
113
. 
 The second otosclerosis gene was mapped several years later in a 4 generation 
Belgian family with AD otosclerosis, including 10 family members with surgically 
confirmed otosclerosis. Multipoint linkage analysis of 391 genotyped markers yielded 
positive LOD scores for five candidate regions. With additional genotyping across the 
five  regions, there was suggestive linkage to the Chr 7q34-36 region and extension of the 
haplotype identified the OTSC2 critical region containing 152 genes
114
. In 2002, a 
genome-wide study on a large Cypriot family segregating otosclerosis identified OTSC3 
at Chr 6p21.3 after excluding linkage to OTSC1 and OTSC2 loci
86
. The OTSC3 locus 
overlaps with the HLA region on 6p21.3-22.3 and contains 488 genes. More recently, two 
unrelated Tunisian families with AD otosclerosis were identified in which haplotype 
segregation was consistent with linkage to OTSC3 and haplotype sharing suggested a 
common ancestor and single founder mutation
118
.   
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 In 2006, an independent lab mapped OTSC4 in a five generation Israeli family of 
Yemenite Jewish origin with AD otosclerosis and 12 affected people. After excluding 
OTSC1-3, a genome-wide scan using 400 microsatellite markers were carried out and 
positive LOD scores at three loci were identified. Additional genotyping in each of the 
three candidate regions showed that two of them no longer supported linkage. However, 
the third locus on Chr16q21-23.2 gave a LOD score greater than 3
87
. The fifth locus, 
OTSC5, at 3q22-24 was mapped in a four generation Dutch family with AD otosclerosis 
after linkage exclusion to previous OTSC1, OTSC2, OTSC3 and OTSC4 loci
88
. The sixth 
locus, OTSC6, has been reserved but its location in the genome has not been published
12
. 
The seventh locus, OTSC7, was mapped to Chr 6q13-16.1 in a Greek family, in a 
genomic region spanning 66 genes. A subsequent Dutch family was identified with 
suggestive linkage to this locus. All genes (KCNQ5, C6orf148, LOC653194, EIF3S6P1, 
DPPA5, ECAT1, LOC441161, RPL39P3, DDX43, C6orf150, MTO1, EEF1A1, SCL17A5 
and CD109) in the overlap region between the Greek and Dutch families were sequenced, 
but no mutations were found
115
. The OTSC7 authors suggest that either the families have 
independent loci or that the mutation is in a regulatory region so that deep sequencing of 
the region is required to solve it. This region is the first of the otosclerosis candidate 
regions to have the coding regions of all annotated genes sequenced. 
The next locus (OTSC8) was mapped to the pericentric region of Chr 9 with a 
minimal critical region of 34.16 Mb. OTSC8 was mapped in another Tunisian family with 
seven affected individuals, using genome wide scan after linkage exclusion to previously 
mapped OTSC1, OTSC2, OTSC3, OTSC4, OTSC5 and OTSC7 loci, and three candidate 
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genes (COL1A1, COL1A2 and NOG)
90
. Recently, two additional loci have been added to 
the list of mapped otosclerosis loci. The first locus has been reserved for OTSC9 but its 
location in the genome has not been published. The second locus (OTSC10) has been 
mapped to a region on Chr1q41-44 with a maximum LOD score of 3.3. This was 
confirmed in a large Dutch family after excluding linkage to the previously mapped 
OTSC1, OTSC2, OTSC3, OTSC4, OTSC5, OTSC7, and OTSC8 loci 
12,84
.  
Many association studies have been carried out to in search of association between 
candidate genes, genome–wide SNPs and otosclerosis. Association studies between each 
of COL1A1 and COL1A2 and otosclerosis were conducted previously due to similarities 
in the hearing loss profile and bone pathology between OI caused by mutations in 
COL1A1 and COL1A2 genes, and otosclerosis
119
. Significant associations between 
COL1A1 and otosclerosis were reported by McKenna et al. (2004), and validated in 
American and German, but not in Spanish groups
120
 
121
. The association between 
COL1A1 and otosclerosis was further supported in a study by Schrauwen et al who 
employed a large Belgian-Duch cohort of case and controls
122
. No association between 
the COL1A2 gene and otosclerosis were found but targeted deletion of COL1A2 in a 
mouse was found to cause development of mild hearing loss and thickness in the stapes 
footplate
119,
 
121
. Several other genes have been implicated as a result of association 
studies. Transforming growth factor beta 1 (TGF-β1) is one important factor in bone 
remodeling and it helps initiation of embryogenesis of the otic capsule
123
. Most recently, 
a case-control association study on transforming growth factor beta 1 (TGF-β1) in a large 
Belgian–Dutch kindred identified a SNP (rs1800472; c.788C>T, p.T263I) that showed a 
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significant signal at the T allele and which was found to be underrepresented in 
otosclerosis patients and therefore, thought to be protective
124
. Genetic association with 
13 candidate genes including additional members of the TGF-β1 pathway (BMP2 and 
BMP4) was carried out in the same population used for detection of the TGF-β1 
association. Two SNPs in BMP2 and BMP4 have shown association with otosclerosis 
cases
125
. In addition to candidate gene approach, a GWA study carried by Schrauwen et al 
identified seven SNPs in the RELN gene in which six were highly associated with 
otosclerosis in 694 unrelated cases from Belgian-Dutch population with otosclerosis
126
.  
All previous association studies excluding that of Morrison et al were conducted by 
the same group using the same Belgian-Dutch case-control cohort population to detect an 
association. The cohort consisted of 694 cases of which 97.8 % (n=679) were diagnosed 
with otosclerosis based on surgical confirmation and a similar number (n = 694) of 
unrelated controls. Case and control cohorts were sex, age, and ethnically-matched. Of 
the 1388 subjects, only 302 cases and 302 controls were involved in the primary analysis 
(discovery cohort). The remaining cases and controls were used for secondary analysis 
(replication cohort). The sample size of the discovery cohort is considered small for an 
association study, especially for GWA studies. The control cohort was also randomly 
chosen from a DNA bank with no phenotypic characterization that could affect the 
statistical power of the studies. On the other hand, some of this finding was replicated in 
different populations. For example, the association between otosclerosis and RELN gene 
was subsequently replicated in French and Tunisian cohorts
127
.  The replication cohorts of 
these studies were small in size and lacked the phenotypic assessment of the unaffected 
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controls. All previously listed association studies have bias regarding the sample size and 
phenotypic characterization of the control cohort which lower the statistical power. 
Therefore, designing an association study with large sample size and proper phenotypic 
evaluation of the unaffected cohort will help in identifying a high quality association with 
low risk bias. 
 Despite efforts to identify the genetic factors involved in the disease 
pathogenicity, the disease pathophysiology remains poorly understood. Otosclerosis is 
genetically heterogeneous, as demonstrated by genetic mapping studies in multiplex 
families with an AD form of the disease. These families provide the most promise for 
elucidating the mechanism of this common bone remodeling disorder, yet they are very 
rare. The rarity of families with AD otosclerosis and the large size of the disease intervals 
(large number of candidate genes) are obstacles to success in identifying otosclerosis 
genes. The aim of this thesis was to identify causative gene for otosclerosis segregating in 
NL families.  
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1.7  Founder population  
A founder population forms from the migration of a small group to a new area that 
remains isolated. The new population grows from this small group, which eventually 
creates a population with less genetic variation than that of the source populations
128
. The 
founder effect is potentially increased by the restriction of mating between different 
groups due to religion, culture, tradition, language and geographic isolation within the 
new population
129
. Founder populations increase the likelihood of identifying genes that 
cause genetic disease. There are many isolated populations that have helped in the 
discovery of novel mutations that cause hearing loss. For example, the Ashkenazi Jews 
population has been an isolated group in Europe for over a thousand years. The c.167delT 
mutation in GJB2 was highly prevalent in this population
130
. Population genetic isolates 
are a great source for identifying some of the genetic aetiology of hearing loss
131,
 
132,
 
133
. 
1.8 The NL population   
NL is a Canadian province which includes the island of Newfoundland, which has 
many distinct genetic isolates, especially in outport communities. In NL, the majority of 
original settlers were from southwest England (Protestant), and southern Ireland (Roman 
Catholic) who settled along the coastal regions of the island for fishing purposes. Despite 
a lack of further immigration, the NL population increased from 19,000 to 550,000 
between 1830 and early 1980s, due to large family sizes.  In the mid-20th century, the 
average sib-ship size was still more than eight 
134
.  Religious  differences between the 
original Protestant and Catholic settlers, and geographical distance between communities 
led to the formation of multiple founder clusters around  the island
135
. 
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1.8.1 Gene discovery from the NL population 
NL population  has shown to be suitable for gene discovery and NL families were 
studied to find genes for hereditary hearing loss. For example, a mutation in the 
(Wolframin) WFS1 gene that causes low-frequency hearing loss was identified using NL 
families. This gene  was previously known to cause AR Wolframin syndrome
21
. 
Identification of the WFS1 gene helped to identify more than 12 additional  families with 
AD low frequency hearing loss with WFS1 causal variants
136,137
. The second family that 
helped to find  novel mutations for hearing loss in the TMPRSS3 gene was a family from 
the south coast which presented with AR  non-syndromic hearing loss. Two mutations in 
TMPRSS3, c.207delC and 782+3delGAG,  were identified through the candidate gene 
approach. People with hearing loss were found to be homozygous for c.207delC or 
compound heterozygous for c.207delC and c.782+3delGAG 
138
. A third Newfoundland 
family with AR, congenital profound, non-syndromic hearing loss had a role in the 
genetic identification of a novel mutation c.1583T>A in PCDH13
139
.   Recently, two 
studies were carried out on larger extended families from NL and identified two causative 
genes. The first study was carried out on a multiplex family from NL and identified a 
novel in-frame deletion in KCNQ4 gene
27
. The second study was carried out on an 
extended family from NL segregating X-linked hearing loss and identified a novel point 
deletion (c.99delC) in the SMPX gene that cause a frameshift and a premature stop
140
. 
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1.9 Hypothesis and objectives 
Previous genetic studies of otosclerosis mapped ten otosclerois loci to distinct 
regions in the genome. In spite of that, non of the causative genes for otosclerosis were 
identified. NL is a great source for genetic studies, it has shown a great success 
previously and many hearing loss genes were identified using large extended families 
from this population. Gene screening methods have been hugely improved with the 
development of NGS, aiming to sequence the whole genome in short period and provide 
answers for many disease causation. With the great progress in the new genetic 
techonologies and availabilty of great foundation of multiplex families with founder 
orgin, I hypothesised that the first otosclerosis gene can be identified in this thesis.  
Objectives 
1. Examine two NL families with confirmed otosclerosis for genetic linkage to eight 
published loci and three candidate genes (COL1A1, COL1A2 and NOG gene);  
2. Based on evidence collected from objective 1, linked regions will be fine mapped 
and genes within candidate regions will be sequence by combination of 
conventional Sanger sequencing and NGS.   
3. Perform genome-wide linkage analysis for families that have been excluded from 
linkage to previously mapped loci, to identify a new region and subsequently 
causative gene using the same technologies mentioned in objective 2.  
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2 Chapter 2 
 
 
 
 
 
 
 
Test for linkage of NL Families to published OTSC loci and 
associated candidate genes 
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2.1 Introduction 
To date, eight loci have been mapped to the otosclerosis phenotype. Also, three 
genes (COL1A1, COL1A2 and NOG) were checked for linkage to otosclerosis in previous 
studies (Table 1.1, page 20). To determine if otosclerosis in the NL probands was due to 
mutations at previously mapped/candidate genes, I used a directed approach that included 
genotyping for polymorphic markers within each of the published OTSC critical intervals, 
developed haplotypes at each OTSC locus, and/or did linkage analysis. Also, in this 
Chapter, I narrowed down the size of the OTSC4 disease interval and sequenced 
functional candidate genes within the minimized region. 
2.2  Subjects and methods 
2.2.1  Working definition of clinical otosclerosis 
   Based on available otosclerosis diagnostic evaluation in the literature and in 
consultation with our clinical hearing scientist (Dr. Susan Stanton) and team audiologist 
(Anne Griffin), it was decided that a graded system could be useful in the context of 
familial otosclerosis. For each family member, a clinical diagnosis of otosclerosis was 
only assigned if the clinical presentation met the minimal diagnostic criteria as described 
below.  
Diagnostic criteria classified as follows: 
 Grade 1 =Otosclerosis definite: (diagnoses by surgical confirmation)  
Direct stapes fixation in the middle/inner ear at surgery.  
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Grade 2 = Otosclerosis probable: (clinical diagnosis by otolaryngology) 
 Diagnosis based on clinical evidence. The following evidence from clinical assessment 
provides well-substantiated reasons to suspect otosclerosis: 
1. Audiogram with conductive component > 10 dB after 2 or more tests and at least one 
of the following criteria: 
 Absent stapedial reflexes of affected ear ipsilateral (same ear) and contralateral 
(opposite ear), not explained by other types of middle ear dysfunction or solely by 
degree of hearing loss  
 Schwarz sign on otoscopy 
 Carhart’s Notch on audiogram 
 Low compliance of tympanic membrane on tympanogram 
Each family member was required to meet minimal diagnostic criteria to be diagnosed 
as affected. Due to the variable age of onset of otosclerosis, family members who 
were at least 60 years old and had a normal hearing threshold were considered 
unaffected (normal). 
Hearing loss uncategorized: 
Diagnosis of hearing loss uncategorized was assigned based on the absence of any of the 
previously listed criteria.  
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2.2.2  Study population 
The recruitment of otosclerosis probands was done by contacting ear nose and 
throat (ENT) Doctors, distributing posters and circulation of a monthly magazine that was 
sent to recruited members and their families. Each recruited member had to complete a 
medical questionnaire that listed questions to cover all possible medical conditions that 
could help in hearing loss diagnosis (Appendix1).  
  Genomic DNA from nine NL probands (index cases) with otosclerosis was 
available. Two probands were from multiplex families (2081 and 2114) and as genomic 
DNA of affected and unaffected relatives was readily obtained I started my analysis on 
these families first. Informed consent was obtained according to the ethical standards of 
the research. Of the remaining seven families, only the proband was recruited to the 
study. As we only had one proband for each of the seven otosclerosis families, these were 
used to narrow down linked regions, but not to test linkage. Ethics board of Memorial 
University (#01.186), and the Research Proposals Approval Committee (RPAC) of 
Eastern Health, St. John’s, NL, and Canada. 
2.2.3 Genotypes and haplotypes for Families 2081 and 2114 
 Genomic DNA was extracted from peripheral leukocytes of all participants 
according to a standard method (Appendix 2). Genotyping of the microsatellite markers 
that spanned the critical intervals of the eight published OTSC loci and of the three 
candidate genes is shown in Table 2.1.  All markers were labelled with blue florescent 
dye (6-FAM). DNA amplification PCR was done on the ABI GeneAmp 9700 
thermocycler using a touchdown program (Appendices 3 and 4). After amplification, 0.5 
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ul of the PCR product was added to 0.5 ul of GeneScan™ LIZ ® size standard and 9 ul of 
Hi-Di Formamide as described in Appendix 5.   PCR products were size fractionated on 
an ABI PRISM model 3130xl analyzer and alleles were determined using Gene Mapper 
version 4 software. All reagents and software were purchased from Applied Biosystems / 
Life Technology. All data were independently analyzed (by me and a Research Assistant; 
Dante Galutria) and the results compared. Primer sequences of the microsatellite markers 
used in this study are given in Appendix 6. Progeny (v.7) software was used to draw 
pedigrees. Haplotypes were built manually for the genotyped subjects according to “least 
recombination rules”. For Family 2081, genomic DNA(s) from seven relatives were 
genotyped for all the markers. The seven  relatives represented four affected members 
with grade I otosclerosis (PIDs III-4, III-5, III-8, and III-11), one affected member with 
grade II otosclerosis (PID IV-5), one relative with no history of hearing loss (PID IV-10) 
and one relative with a history of uncategorized hearing loss (PID IV-9).  
For Family 2114, three of four affected with grade I otosclerosis and one sibling 
with no history of hearing loss (PID III-6) were genotyped for all markers. To check for 
possible linkage of Family 2114 to OTSC2 and COL1A2 loci and to determine the 
maternal and paternal haplotypes, other relatives from Family 2114 (PIDs II-5, II-6, III-4 
and III-5) were genotyped with microsatellite markers that spanned OTSC2, and 
COL1A2. To test for segregation and fine map the OTSC4 haplotype, 15 extra DNA 
samples from Family 2081 (PIDs III-1, III-2, III-6, III-7, III-9, III-12, III-13, III-14, III-
15, III-16 IV-1, IV-2, IV3, IV6 and IV12) and DNA samples from seven unrelated 
otosclerosis probands, were genotyped with the markers that spanned OTSC4. 
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Table 2.1: Microsatellite markers used for genotyping 
Table listed microsatellite markers genotyped within the critical regions of the 8 published OTSC 
loci and within the vicinity of 3 otosclerosis associated genes (COL1A1, COL1A2 and NOG). 
Boundaries markers (Bolded) were taken from the original published papers. Size of each region 
is listed in Mb. 
Locus 
Designation  
Location 
Chr 
Size of the 
locus 
Mb 
Markers Genotyped 
OTSC1 15q25-q26 
 
14.5  D15S127, D15S652, D15S649, D15S1004, 
D15S157, D15S657  
OTSC2 7q34-q36 
 
16  D7S495, D7S684, D7S2202, D7S2513, 
D7S676, D7S1798, D7S2442, D7S2426, 
D7S1827 
OTSC3 
 
6p21.3-22.3 
 
17.4  GAAT3A06, D6S1660, D6S1545, D6S464, 
D6S273 D6S1568, D6S291, D6S1602, 
D6S1680 
OTSC4 16q22.1q23.1 10  D16S3107, D16S3025, D16S3095, D16S752, 
D16S3106, D16S3139 D16S3018, D16S3115, 
D16S3097 
OTSC5 3q22-24 
 
15.5  D3S1292, D3S3641, D3S1576, D3S3586, 
D3S3694, D3S1593, D3S3627, D3S1744  
OTSC7 6q13-16.1 
 
13.4  D6S467, D6S280, D6S1596, D6S456, 
D6S1589, D6S460 D6S1652, D6S1595 
D6S1613, D6S450  
OTSC8 9p13.1-9q21 
 
34.6  D9S970, D9S1844, D9S1862, D9S1879, 
D9S166, D9S1799 
OTSC10  1q41-44 26.1  D1S2621, D1S439, D1S2800 and D1S2811 
COL1A1 17q21.31  - D17S797, D17S1795, D17S941, D17S809, 
D17S788  
COL1A2 7q21.1  - D7S644, D7S657, D7S2430, D7S821, D7S651  
NOG 17q24.31  - D17S790, D17S1607, D17S1606, D17S1161  
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2.2.4 Sequencing genes within the candidate region 
The UCSC Genome Browser homepage
141
 and the March 2006 assembly (NCBI 
build 36.1) were used to identify the genomic interval of each candidate region and to 
identify functional candidate genes
142
. Priority screening of the positional candidate genes 
was based on gene function, expression and plausible role in the pathogenesis of 
otosclerosis (e.g., expression in connective tissue, immune system, bone and involvement 
in bone remodeling). In this Chapter, a total of 12 genes within the minimized OTSC4 
were bidirectional sequenced. Primers sequences for the eleven genes are listed in 
Appendix 7. 
 (i) Primer design and reaction amplification  
For each candidate gene, the genomic structure and alternative splice forms were 
determined and primer sets for all coding exons and intron-exon boundaries were 
designed using Primer3
143
. In order to determine the optimal amplification conditions for 
these primer sets, trial PCRs were performed. Each primer was tested using two different 
reaction cocktails; one with betaine and the other without betaine. Betaine acts as an 
enhancer and helps in the amplification, especially in regions of high GC content 
144
. 
Three test DNA samples and one water control was used for each trial. Amplification 
reactions were run first using the touch down 54 (TD54) program (Appendices 3 and 4). 
PCR products from both reactions were separated and visualized on a 1 % agarose gel 
made with 1X TBE (Tris/ Borate/EDTA) buffer, and 5 ul of ethidium bromide or SYBER 
safe (from a stock solution of 10 mg/ml) per 100 ml of gel solution for a final 
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concentration of 0.5 ug/ml.  For each reaction, 5 ul of PCR product and 1ul of 
bromophenol blue/xylene-cyanol dye were added to each well. A 100 bp ladder (from 
Invitrogen/ Life technologies) was used for determing amplicon size and the banding 
pattern was visualized with UV light using the Kodak Molecular Imaging System. The 
PCR products were purified using sephacryl HR300 (Amersham Biosciences) and 
MultiScreen HTS filter plates (Milipore Corporation). Purified PCR products were then 
bidirectionaly (forward and reverse) sequenced using Big Dye Terminator V3.1 cycle 
sequencing kit on an ABI PRISM 3130XL DNA Analyzer, as described in Appendices 8, 
9 and 10.  
(ii) Mutation screening panel 
The mutation screening panel included two members who inherited the presumed 
disease haplotype (PIDs III-4 and III-8), two members who did not, (PIDs III-9 and IV-
12) and one water control.  The panel was screened for the following functional genes: 
ZNF19, ZNF23, COG4, DDX19B, DHX38, DDX19A, PMBP1 and ZFHX3. Another panel 
included three members with the presumed disease haplotype (PIDs III-5, III-11, and IV-
1), one unaffected member (PID IV-5), and one water control. This panel was screened 
for the following functional genes: CABL2, IL34, SF3B3 and WWP2.  
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(iii)  Allele frequency  
As each positional candidate gene was sequenced, the allele frequencies of the 
variants that segregated with the disease haplotype in the screening panel were checked. It 
is important to determine the allele frequency of the clinical otosclerosis before starting 
variant analysis. Usually frequency of the disease allele is estimated from the disease 
prevalence in a given population. Clinical otosclerosis has a mean prevalence of 0.5 % in 
the Caucasian population. Taking this number into consideration, we expect the allele 
frequency of otosclerosis causative variants (heterozygous variants under dominant mode 
of inheritance and homozygous variants under recessive mode of inheritance) would be 
0.5 % in the general population.  
As we do not have an estimation of the prevalence of otosclerosis in the NL 
population we set an allele frequency of ≤ 2 % as a cut-off for variant analysis. Therefore, 
variants with frequencies of 2 % or less were subject to further analysis. Allele 
frequencies of the previously annotated variants were determined using the SNP/1000 
database and allele frequencies of novel variants were determined using NL population 
controls which were obtained through random digit phone dialing, as part of a large 
colorectal cancer study. In the SNP/1000 genome database, allele frequencies of variants 
were listed for different populations. In this study the European population was used as 
reference population for allele frequency. For each variant, the sample size of the 
population controls analysed for this variant is provided and the allele frequency is given 
as a percentage of the variant positive alleles. For example, if an allele has a frequency of 
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45 % and the tested samples were 120 samples (240 alleles) that mean that allele was 
identified in 54 subjects (108 allaes) out of total 120 samples ((240 alleles).  
(IV) Bioinformatics analysis  
The pathogenicity of variants with an allele frequency of 2 % or less was checked 
using bioinformatic prediction programs. The effect of the missense mutations was 
predicted using SIFT  
47
and PolyPhen-2
48
. Human Splicing Finder (HSF), MaxEntScan, 
GeneSplicer and Known constitutive signals, were used as splice prediction tools for 
splice site mutations. Conservation of the amino acid residue across species for the 
variant of interest was determined using Clustal W and WebLogo
145
 . The effect of the 
insertion and deletion variants was assessed experimentally in Chapter 2. 
         (V) Segregation analysis 
Variants predicted to have a deleterious effect on the RNA and translated proteins 
were checked for segregation using all available DNA in the family being studied.  
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(VI) Allele frequency in NL population 
Allele frequency of variants that fully segregated with the disease in the family of 
the study was estimated using NL population controls
146
. A summary of the variant 
analysis steps is illustrated in Figure 2.1. 
 
 
Figure 2.1 : Flowchart shows filtration steps of variants detected in affected 
members under a dominant mode of inheritance 
Figure shows various allele frequencies of identified variants which were determined using 
publicly available SNP database and 1000 genomes. Pathogenicity of missense mutations was 
evaluated using SIFT and Polyphen prediction programs. Three splicing prediction programs 
(MaxEntScan, NNSPLICE, and GeneSplicer) were used for splice site prediction. 
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2.2.5 Functional assay  
2.2.5.1 Reverse transriptase (RT) PCR 
  To  test the effect of an insertion variant on the mRNA, total RNA was extracted 
from Epstein-Barr virus-transformed lymphocytes from three insertion carriers (PID III-4, 
III-5 and III-8). RNA was isolated using Trizol reagent (Applied Biosystems / Life 
Techonologies) and was followed by treatment with TURBO DNA-free DNase treatment 
(Ambion® / Life Technologies). RNA(s) were evaluated and quantified using a 2100 
Bioanalyzer (Agilent Technologies) and  samples with a RNA value greater than 8.5 were 
used.  Complementary DNA (cDNA) synthesis was performed using a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) and Reverse transcriptase PCR 
was carried using primers surrounding the c.10557-10558 het insGGG in the ZFHX3 
gene. Amplification reaction was carried out for all the reactions by the ABI PCR 
GeneAmp 9700 thermocycler. Primers were amplified using the TD 54 program 
(Appendices 1 and 2) and the size fragmented on 1 % agarose gel stained with SYBER 
safe to confirm amplification. 
2.2.6   Two-point linkage analysis  
For Family 2081, a two point LOD score was calculated at three microsatellite 
markers for each locus. The LOD score was calculated using MLINK, version 5.1
147
. To 
run MLINK program, two files were required; a pedigree file and a data file. The 
pedigree file included the affection status for each subject expressed in numbers; number 
1 indicated unaffected, number 2 affected and 0 unknown (e.g. for a subject who has not 
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been examined). Also, the pedigree file included the gender code expressed as a number. 
For example, male =1 and female=2. The data file contained the genotype information of 
each marker for each subject. After loading this information into the MLINK program, 
the LOD scores were generated in a file called outfile data. AD with 99 % penetrance was 
assumed. Gene frequency was set at 0.001 and the LOD score was calculated at different 
recombination fraction (θ) frequencies ranging from 0.000 to 0.5000.  
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2.3 Results 
2.3.1 Pedigree structure and clinical analysis  
2.3.1.1 Pedigree structure of Family 2081 
   Family 2081 is a multiplex family with affected relatives spanning three 
generations where diagnosis of otosclerosis has been confirmed in both genders (Figure 
2.2).  A case of non-paternity in this family was identified as a result of haplotype 
analysis and therefore, for ethical reasons, we decided to neutralize the gender symbols in 
this family.  The proband is PID III-8 and the proband’s sibship consists of six cases of 
otosclerosis out of a total of 12 offspring (6/12). One of the proband’s parents, PIDII-4, 
has a history of hearing loss and one sibling of PID II-4 also has hearing loss, although 
there are not confirmed cases of otosclerosis from the parental side of PID II-4. The 
proband’s parent, PID II-4, is deceased and no further information is available from that 
side of the family.  The other parent, PID II-3, is from a sib ship of six: four of the 
siblings (4/6) also have hearing loss. There is a confirmed case of otosclerosis, from 
subject PID II-3 side, who is the proband’s cousin, PID IV-1. It is evident from the 
pedigree structure that otosclerosis is transmitted in a vertical pattern across generation II, 
III and IV. However, there is no clear evidence of X-linked inheritance. For example, the 
otosclerosis phenotype is similar in both males and females, as males do not appear to be 
more severely affected or have earlier onset. As well, if the father is the putative gene 
carrier, then there are documented cases of male-to-male transmission. Therefore, 
otosclerosis in Family 2081 appears to be inherited as an AD trait and either of the 
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proband’s parents (PID II-3 or II-4) could be the putative gene carrier. In addition to the 
dominant inheritance, pseudodominant inheritance could not be excluded because both 
parents have a history of hearing loss within the context of the genetically isolated 
population of NL. 
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Figure 2.2 Partial pedigree of NL Family 2081 segregating AD otosclerosis 
Figure 2.2 shows that the five generation family 2081 segregates AD otosclerosis. Genders are unidentified  in this pedigree for 
confidential reason. The arrow is points to the proband. Roman numerials on the left side of the pedigree indicate numbers of generations. 
The blue solid symbol refers to otosclerosis grade I. Half blue and white symbol refers to hearing loss grade II. Half black and white symbol 
refer to hearing loss, uncategorized. Circle =female, square =male. Crossed symbol indicates deceased subject. 
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2.3.1.2 Clinical analysis of Family 2081 
All the clinical reports were interpreted with the help of Anne Griffin and Dr Sue 
Stanton. The proband (PID III-8) presented at age 25 with conductive loss in the right ear, 
with only a slight low frequency dip in the left (Figure 2.3.A). Audiological tests were 
further analysed due to availability of pre and post audiological tests for both ears. At age 
51, hearing loss, mostly conductive, was evident in both ears which had advanced to 
moderately severe in the left to severe levels in the right. The bone conduction thresholds 
showed a dip in the mid frequencies, known as the “Carhart’s notch”, often seen in 
patients with otosclerosis (Figure 2.3.B).  After right stapedectomy, there was a 
significant improvement in the right ear and the two audiograms (post-right and pre-left 
stapedectomy) showed near complete resolution of the air bone gap (Figures 2.3.C and 
2.3.D). After the left stapedectomy, both ears showed only a borderline-mild 
sensorineural loss throughout mid and low frequencies. In the high frequencies, the 
remaining hearing loss is greater (Figures 2.3.E and 2.3.F). At age 51, prior to both 
stapedectomies (Figure 2.3A), there was profound hearing loss at 8000 Hz in both ears 
and this did not improve at all after surgery. This could be due to otosclerosis in the 
cochlea just on the other side of the round window, which would affect high frequency 
responses the most.  
The diagnosis of otosclerosis in this family was based on grading scales.  Seven 
affected subjects in this family (PIDs III-4, III-5, III-8, III-11, III-13, III-16 and IV-1) 
were classified as grade I. Subject IV-5 was diagnosed with otosclerosis as grade II based 
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on the hearing profile, which is conductive loss with a large ABG, and the absence of a 
stapedial reflex with low compliance of the tympanic membrane. Family member IV-5 
had developed mild to moderate left and moderate to moderately severe right conductive 
loss by age 36. Otosclerosis presented as conductive hearing loss in 7 members (PIDs III-
4, III-8, III-11, III-13, IV-1, and III-16) and as a pure SNHL in one member (PID III-5).  
Family history indicated that the age of onset in the proband and five siblings 
(PIDs III-4, III-5, III-11, III-13, III-16 and IV-5) with confirmed otosclerosis ranges 
between mid-teens to early twenties. Audiograms of the three affected siblings (III-11, 
III- 13 and III-16) closely resemble the proband’s progression of loss, successful 
resolution of most conductive loss through stapedectomy in one or both ears and overall 
good hearing stability post-surgery. Family member (PID IV-5) who presented with 
hearing loss by mid-teens had a scheduled stapedectomy at 17 years. This subject had a 
complicated history with cholesteatoma in addition to the otosclerosis, which aggravated 
the degree of hearing loss. PID IV-5 received a radical tympanomastoidectomy as a 
treatment for the cholesteatoma and stapedectomy surgery was postponed until recovery 
from the tympanomastoidectomy surgery. Cholesteatoma is a pocket formed in the 
eardrum as result of negative pressure behind the eardrum caused by improper opening of 
the Eustachian tube. Similar to the skin tissue, dead skin cells slough off and fill the sac. 
Excess cell accumulation leads to expansion of the sac and in untreated cases, perforation 
of the middle ear could occur. Usually cholesteatoma is associated with conductive 
hearing loss, similar to otosclerosis, and treated by tympanomastoidectomy. 
Cholesteatoma, in some cases, is misdiagnosed as otosclerosis. Surgical exploration of the 
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middle ear is one way to differentiate between both conditions as stapes fixation is the 
definitive diagnosis of otosclerosis 
148
. Family member PID III-4 appears to have similar 
early progression of conductive loss as the proband, but stapedectomy of the right ear at 
age 36 years was unsuccessful. Significant all frequency sensorineural loss developed 
along with conductive loss resulting in severe to profound mixed loss with 50 dB air bone 
gap bilaterally. At age 75 implantation of a vibrant sound bridge was also unsuccessful 
and the patient subsequently received a cochlear implant.  
Family member PID III-5 reported hearing loss onset by the mid-teens but 
significantly differs from other affected subjects in that hearing loss was dominantly 
sensorineural from the start. Bilateral stapedectomies were carried out, but they were not 
successful. Hearing aids helped initially but were no longer effective once hearing loss 
developed to a profound degree bilaterally: cochlear implantation on the right was very 
successful. Family member IV-3 at age forty-eight showed only mild left high frequency 
sensorineural hearing loss which would appear consistent with noise damage incurred 
from a history of right handed shooting during hunting. Family member IV-10 at age 
thirty shows no hearing loss in either ear. Family members PID III-9, III-14 and IV-9 
have history of uncategorized hearing loss. Family member PID III-7 has no history of 
hearing loss at 70 years old (no audiological reports were available for this subject). 
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Figure 2.3: Serial audiograms for the proband of Family 2081  
Figure 2.3 shows an audiogram series for Family 2081 proband. Audiogram a indicates a 
conductive hearing loss bilaterally at age 25 years, progressing to a mixed hearing loss with a 
significant conductive component bilaterally at age 51 (Audiogram b).  The improvement in post-
operative hearing thresholds following right (Audiogram c) and then left ear stapedectomy 
(Audiogram d) indicates a successful reduction of the conductive component bilaterally as a result 
of stapes surgery. Serial audiograms at age 56 (Audiogram e) and 63 years (Audiogram f) show 
stable post-operative hearing.  The arrow points to Carhart notch. O = Air conduction Rt ear, X = 
Air conduction Lt ear, ] = Masked bone conduction Lt ear, [ = Masked bone conduction Rt ear, < 
= Unmasked bone conduction Rt ear, < = Unmasked bone conduction Lt ear. Δ = Masked air 
conduction Rt ear, ☐ = Masked air conduction Lt ear. 
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2.3.1.3 Pedigree structure of Family 2114 
Family 2114 is a multiplex family (Figure 2.4). The proband is PID III-1 and the 
proband’s sibship consists of five cases of otosclerosis out of nine offspring (5/9). There 
is a presumed AD mode of inheritance with a history of hearing loss on the proband’s 
mother’s side. The proband’s mother (PID II-2) and mother’s sister (PID II-6) also have 
hearing loss, although not confirmed cases of otosclerosis. However the mother and three 
of her nine siblings are deceased and no further information is available. Although the 
father (PID II-1) did not have a history of hearing loss, less is known about his side of the 
family. Despite the fact that there are no cases of male to male transmission, the 
phenotype is similar across both genders so there is little evidence to support X-linked 
inheritance. Putting all of this information together, otosclerosis in Family 2114 appears 
to be inherited as an AD trait with the proband’s mother the putative gene carrier. 
However, because we only have clinical information available on the proband’s 
generation, we cannot rule out a recessive mode of inheritance, especially 
pseudodominance given the isolated NL population.
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Figure 2.4 Partial pedigree of NL Family 2114 segregating AD otosclerosis 
Figure 2.4 shows that four generation family 2114 pedigree segregates otosclerosis. Arrow is pointing to the proband of  Family 2114. 
Roman numerials on the left side of the pedigree indicate the generation. Blue solid symbol refers to otosclerosis grade I. Half blue and 
white symbol refers to hearing loss grade II. Half black and white symbol refers to hearing loss, uncategorized. Crossed symbol indicates 
decessed subject. Circle =female, Square =male 
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2.3.1.4 Clinical analysis of Family 2114 
All the clinical reports were interpreted with the help of Anne Griffin and Dr Sue 
Stanton. The proband of Family 2114 (PID III-1, Figure 2.4) was a 42 old female, at the 
time of diagnosis, with severe hearing loss due to otosclerosis in both ears. Based on 
information taken from the medical questionnaire, she had experienced hearing loss as a 
teenager. An audiogram performed at the age of forty two showed that the proband’s 
hearing loss is mostly conductive, with borderline cochlear (sensorineural) loss, which is 
often seen with otosclerosis (Figure 2.5.A).  The proband underwent surgery at the age of 
42. After undergoing stapedectomy of the right ear, hearing improved and the ABG was 
mainly resolved. However, some hearing loss remains, especially in the low frequencies 
in the right ear (Figure 2.5.B). The proband also underwent stapedectomy of her left ear at 
age 44, and hearing showed great improvement throughout all frequencies with only a 
mild sensorineural loss remaining in the mid to high frequencies (Figure 2.5.C). At age 
51, the proband’s left low and mid frequencies were good but left high frequencies 
showed moderate loss at 2000 Hz to moderately severe at 4000 Hz and 8000Hz, likely 
due to cochlear loss from otosclerosis on the cochlear side of the round window (Figure 
2.5.D).  
 Otosclerosis in the five affected siblings in this family was diagnosed based on 
surgical visualization of stapes fixation (grade 1).  Hearing loss in this family started in 
the teens in PIDs III-1, III-2, III-4, III-5, and around adulthood in PID III-7 (based on 
medical questionnaire, as no early audiograms were available). The conductive loss in all 
the family members was restored after stapedectomy surgery. The unaffected family 
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member PID III-6 has been signed as unaffected based on audiological report of no 
hearing loss at later age (approximately 55 years old). 
Figure 2.5: Serial audiograms for the proband of Family 2114  
Figure 2.5 shows an audiograms series for the Family 2114 proband. Audiogram a indicates a 
conductive hearing loss bilaterally at age 42 years with borderline sensorineural loss. Audiogram 
b indicates the improvement in post-operative hearing thresholds following right and then both 
ear stapedectomy (Audiogram c).  Audiogram d indicates a successful reduction of the conductive 
component bilaterally as a result of stapes surgery with remaining left SNHL. O = Air conduction 
Rt ear, X = Air conduction Lt ear, ] = Masked bone conduction Lt ear, [ = Masked bone 
conduction Rt ear, < = Unmasked bone conduction Rt ear, < = Unmasked bone conduction Lt ear. 
Δ = Masked air conduction Rt ear, ☐ = Masked air conduction Lt ear. 
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2.3.1.5  Proband of the Family 2194  
The proband of Family 2194 presented with hearing loss as a teenager (based on 
medical questionnaire) (Figure 2.6). Her audiological report stated that middle ear 
examination showed bilateral absence of acoustic reflex, which is consistent with the 
grade II diagnosis. The proband’s mother was diagnosed with otosclerosis based on 
surgical confirmation of otosclerosis (grade I) of the left ear and conductive hearing loss 
with absence of acoustic reflex (grade II) in the right ear. Otosclerosis in this family 
seems to be inherited in an AD model with the proband’s mother presumed to be the gene 
carrier. The proband is the only member of this family recruited to this study. 
2.3.1.6  Proband of the Family 2197 
 The proband of this Family was diagnosed with otosclerosis based on surgical 
confirmation of otosclerosis (grade I) (Figure 2.6). Only the proband of this family was 
diagnosed with otosclerosis. Multiple family members were reported to have hearing loss, 
but no clinical information or DNA was collected. 
2.3.1.7  Proband of the Family 2203 
Hearing loss in the proband of Family 2203 was recorded by the second decade from 
the medical questionnaire (Figure 2.6). She was diagnosed with otosclerosis based on 
visual confirmation during surgery (grade I). Bilateral conductive components of the loss 
were resolved by bilateral stapedectomy, which improved her hearing acuity. Multiple 
subjects with uncategorized hearing loss were recognized in this family but no clinical 
information or DNAs were collected.  
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2.3.1.8 Proband of the Family 2066 
  The proband of this Family expressed difficulty in hearing at age 16 (based on 
medical questionnaire) (Figure 2.6). The proband was diagnosed with otosclerosis based 
on surgical confirmation (grade 1). Four siblings (three deceased) of the proband were 
diagnosed as grade II otosclerosis. Both proband’s parents have history of uncategorized 
hearing loss. There are multiple subjects across generations III and IV with uncategorized 
hearing loss. Only the proband of this family was included in the study. 
2.3.1.9  Proband of the the Family 2126 
  Hearing loss in the Family 2126 proband started bilaterally as mild to moderate 
conductive loss in her early twenties, which progressed to profound mixed loss. The 
diagnosis of otosclerosis was based on surgical confirmation (grade1) (Figure 2.6). 
Several subjects with uncategorized hearing loss were noticed in the family pedigree but 
clinical information and DNA were not collected.  
2.3.1.10 Proband of the Family 2200 
  The proband of Family 2200 complained of hearing loss since age 12 (based on 
medical questionnaire) (Figure 2.6). Diagnosis of otosclerosis was based on surgical 
confirmation (grade 1). The hearing loss did not improve after unsuccessful stapedectomy 
surgery. The mother of the proband had many relatives with uncategorized hearing loss. 
Only the proband in this family was recruited to the study. 
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2.3.1.11  Proband of the Family 2209 
 The proband of Family 2209 expressed hearing loss during adulthood. The 
proband was diagnosed with otosclerosis based on surgical confirmation (grade 1) (Figure 
2.6). Otosclerosis in this family seems to be inherited in a dominant mode with the 
proband’s father presumed to be the disease carrier, as he has been diagnosed with grade 
II otosclerosis. One of the proband’s siblings was diagnosed with grade I otosclerosis and 
another sibling and aunt were diagnosed with grade II otosclerosis. We were unable to 
recruit other family members in this study and so only the proband is included. 
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Figure 2.6: Pedigrees of Families 2149, 2203, 2066, 2197, 2126, 2209 and 2200  
 Arrows point to the proband of each family. Roman numerials on the left side of the pedigree indicate the generation. Blue solid symbol 
refers to otosclerosis grade I. Half blue and white symbol refers to hearing loss grade II. Half black and white symbol refers to hearing 
loss, uncategorized. Crossed symbol indicates decessed subject. Circle =female, Square =male.
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2.3.2 Test for linkage to published otosclerosis loci  
2.3.2.1  Exclusion of  Family 2081 to previously mapped loci and genes 
Genetic analysis of Family 2081 was carried out by genotyping four grade I 
affected members with otosclerosis (PIDs III-4, III-5, III-8, and III-11), one grade II 
affected family member (PID IV-5), one relative with no history of hearing loss (PID IV-
10) and one relative with history of uncategorized hearing loss (PID IV-9) with 
polymorphic markers that span the eight previously published loci and three associated 
genes. Haplotypes were constructed across each locus. The mode of inheritance of 
otosclerosis in this family is presumed to be AD with PID II-3 or PIDII-4 thought to be 
disease carriers. A single disease haplotype shared by grade I affected siblings PIDs III-4, 
III-5, III-8, III-11 was expected under a dominant mode of inheritance.  
Affected siblings did not share a disease haplotype at OTSC1, OTSC2, OTSC3, 
OTSC5, OTSC7, OTSC8, or OTSC10 loci nor at the three candidate genes (COL1A1, 
COL1A2 or NOG) loci. The four affected siblings with grade I otosclerosis shared a 
presumed disease (yellow) haplotype across OTSC4. Below are descriptions of each locus 
and how the exclusion or inclusion decision was made.  
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OTSC1 
OTSC1 is the first identified otosclerosis locus in 1998. It spans about 14.5 cM at 
Chr15q25-q26. For Family 2081, genomic DNA was available for seven relatives in 
generations III and IV (haplotypes in generation II are inferred). Six microsatellite 
markers were used for genotyping across this locus. All the markers were fully 
informative except D15S157, which was homozygous for the same allele in six out of 
seven genotyped relatives. Four distinct parental haplotypes (red, yellow, light green and 
blue) were created using the six informative markers (Figure 2.7). Using the rule of least 
number of recombinations, one recombinant haplotype on Chr15q was identified in the 
proband (PID III-8). All four relatives with grade I otosclerosis inherited different 
haplotypes, as we can distinguish between the four parental haplotypes at the OTSC1 
locus. For example, the proband’s sibling PID III-4 inherited the red and yellow 
haplotypes. On the other hand, the proband’s sibling PID III-5 inherited the light green 
and blue haplotypes. This locus was ruled out because the four siblings with the grade I 
otosclerosis did not share a disease haplotype across OTSC1.   
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Figure 2.7: Partial pedigree of Family 2081 showing OTSC1 haplotypes  
 No shared haplotype was detected between affected members. Family proband is PID III-8. 
Roman numerials on the left side of the pedigree indicate the generation. Blue solid symbol refers 
to otosclerosis grade I. Half blue and white symbol refers to hearing loss grade II. Half black and 
white symbol refers to hearing loss, uncategorized. Crossed symbol indicates deceased subject. 
Circle =female, Square =male. Allele sizes are given in base pairs and alleles in the brackets are 
inferred. 
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OTSC2 
OTSC2 is the second identified locus in 2001. It spans about 16 cM interval at Chr7q34-
q36. Nine fully informative microsatellite markers were used for genotyping at this locus. 
Four distinct parental haplotypes (red, yellow, blue and green) were created (parental 
haplotypes were inferred and no recombinations invoked) (Figure 2.8). All four relatives 
with grade1 otosclerosis inherited different haplotypes at the OTSC2 locus. For example, 
the proband PID III-8 inherited the red and blue parental haplotypes. On the other hand, 
proband’s sibling PID III-11 inherited the green and yellow haplotypes. Also, the three 
affected family members (PID III-5, III-8 and IV-5) inherited the parental red haplotype, 
but the remaining two affected members (PID III-4 and III-11) did not.  Affected siblings 
did not share a disease haplotype across OTSC2, therefore, linkage of Family 2081 to this 
locus was ruled out. 
  
 
 
 
 
 
 
 
 
 
 
88 
Figure 2.8: Partial pedigree of Family 2081 showing OTSC2 haplotypes 
 No shared haplotype was detected between affected members. Family proband is PID III-8. 
Roman numerials on the left side of the pedigree indicate the  generation. Blue solid symbol 
refers to otosclerosis grade I. Half blue and white symbol refers to hearing loss grade II. Half 
black and white symbol refers to hearing loss, uncategorized. Crossed symbol indicates decessed 
subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in the 
brackets are inferred. 
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OTSC3 
OTSC3 is the third identified locus in 2002. It spans 17.4 cM interval at Chr 6p21.3-22.3. 
Nine microsatellite markers were used for genotyping at this locus and four distinct 
parental haplotypes (red, blue, light green and yellow) were created (Figure 2.9). Using 
the rule of least number of recombinations, one recombination was detected between 
D6S273 and D6S1568 in the proband sibling (PID III-4). Comparing haplotypes between 
the four affected siblings showed that they inherited different haplotypes. For example, 
the family proband PID III-8 inherited the blue and red parental haplotypes. On the other 
hand, the proband sibling PID III-5 inherited the light green and yellow haplotypes. Also, 
only three (PID III-4, III-5 and IV-5) out of five affected members inherited the parental 
yellow haplotype. The four affected siblings in Family 2081did not share a disease 
haplotype across OTSC3 and they were therefore excluded from linkage to this locus. 
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Figure 2.9: Partial pedigree of Family 2081 showing OTSC3 haplotypes 
Affected members did not share a single haplotype. The family proband is PID III-8 Roman 
numerials on the left side of the pedigree indicate the generation. The blue solid symbol refers to 
otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black 
and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates deceased 
subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in the 
brackets are inferred. 
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OTSC4  
OTSC4, the fourth locus, was mapped in 2006. It spans a 9-10 Mb region at Chr16q22.1-
q23.Ten microsatellite markers genotyped for this locus resulted in four distinct parental 
haplotypes (purple, light green, yellow and red). Parental haplotypes were inferred and no 
recombination was invoked (Figure 2.10). Comparing OTSC4 haplotypes across the four 
grade I affected siblings showed that they shared a yellow haplotype across OTSC4. This 
locus was then subjected to further fine mapping analysis. 
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Figure 2.10: Partial pedigree of Family 2081 showing OTSC4 haplotypes 
 Affected siblings in generation III share a yellow haplotype. The family proband is PID III-8. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
the brackets are inferred. 
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OTSC5 
OTSC5, the fifth locus, was mapped in 2004. It spans a 15.5 Mb region at Chr 3q22-q24. 
Eight informative microsatellite markers were used for genotyping at this locus and four 
distinct parental haplotypes (red, blue, dark green and yellow) were created (Figure 2.11).   
Using the rule of least number of recombinations, one recombination between D3S3694 
and D3S1593 was identified in the Family member PID III-11 which was passed down to 
the family member PID IV-10. The four affected siblings inherited different haplotype.  
For example, the proband PID III-8, inherited the yellow and blue haplotypes, while the 
proband’s sibling PID III-4, inherited the dark green and red haplotype. The grade I 
affected siblings did not share a disease haplotype across this locus, and therefore, it was 
excluded from linkage. 
. 
 
 
 
 
 
 
 
 
 
 
 
94 
Figure 2.11: Partial pedigree of Family 2081 showing OTSC5 haplotypes 
No shared haplotype was detected between affected members. The family proband is PID III-8. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
the brackets are inferred. 
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OTSC7 
OTSC7, the seventh locus, was mapped in 2007. It spans a 13.47 Mb region at Chr 6 q13-
16. Fourteen markers were genotyped for this locus and four distinct parental haplotypes 
(red, light green, blue and yellow) were created (Figure 2.12).  Using the rule of least 
number of recombinations, one recombination between D6S467 and D6S280 was 
identified in PID III-11 and passed to PID IV-9.  The four affected siblings inherited 
different haplotypes. For example, the proband PID III-8 inherited the blue and red 
haplotypes, while the proband’s sibling PID III-5 inherited the light green and the yellow 
haplotypes. The three affected family members (PID III-4, III-5, and IV-5) inherited the 
yellow parental haplotype, affected member (PID III-11) inherited a large portion of the 
yellow haplotype and a small portion of the blue haplotype in a recombination but the 
proband (PID III-8) did not. As the four affected siblings with grade I otosclerosis did not 
share a disease haplotype across this region, OTSC7 was excluded from linkage to the 
otosclerosis segregating in Family 2081.  
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Figure 2.12: Partial pedigree of Family 2081 showing OTSC7 haplotypes 
Affected members did not share a disease haplotype. The family proband is PID III-8. Roman 
numerials on the left side of the pedigree indicate the generation. The blue solid symbol refers to 
otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black 
and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a deceased 
subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in the 
brackets are inferred. 
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OTSC8  
OTSC8, the eighth
 
locus, was mapped in 2008. It spans a 34.16 Mb region at Chr 9p13.1-
9q21. Seven microsatellite markers were genotyped at this locus and four distinct parental 
haplotypes (red, blue, dark green and yellow) were created with no recombinations 
detected (Figure 2.13). At this locus, three affected siblings (PIDs III-4, III-5, III-8 and 
IV-5) inherited the parental green haplotype but not the fourth affected sibling, PID III-
11.  Also, the three affected siblings, PIDs III-5, III-8 and III-11, inherited the yellow 
haplotype but not the affected sibling, PID III-4. As there was no shared disease 
haplotype identified among the four grade1 affected siblings this locus was excluded from 
linkage to otosclerosis segregating in Family 2081.  
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Figure 2.13 Partial pedigree of Family 2081 showing OTSC8 haplotypes 
No shared haplotype was detected between affected members. The Family proband is PID III-8. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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OTSC10 
OTSC10 is the most recently mapped locus (2010). It spans a 26.1 Mb region at Chr1q41-
44. Three markers were genotyped for this locus. D1S2621, D1S2811 and D15S2800 
were homozygous for the same allele in five of seven genotyped relatives. PID III-4, III-
5, III-8, III-11, IV-5, IV-9 and IV-10 were genotyped for these markers and four distinct 
parental haplotypes (blue, red, dark green and yellow) were created (Figure 2.14A). It is 
obvious that the yellow and blue haplotypes have the same allele calls for the genotyping 
using the three markers. In order to phase each of the yellow and the blue haplotypes, two 
spouses PIDs III-6 and III-12 were genotyped for the three markers.  
Genotyping of PID III-6 helped to confirm the yellow haplotype of PID III-5 as it 
showed that the yellow haplotype of PID IV-5 was inherited from PID III-5 (Figure 2.14 
B). In the case of the PID III-11, III-12, IV-9 and IV-10, it was not possible to 
differentiate between the yellow and the blue haplotypes as PID III-11 inherited both 
haplotypes (yellow and blue) and the offspring PID IV-9 and IV-10 inherited either the 
blue or the yellow haplotype. Genotyping of PID III-12 gave two distinct haplotypes 
(brown and light blue). Interestingly, the light blue haplotype was similar to the blue/ 
yellow haplotype of PID III-11. This result suggested that the yellow, blue, and light blue 
haplotypes are probably copies of a common haplotype in the NL population and it would 
not be a good candidate for being presumed as a disease haplotype. Even if we considered 
either haplotype (yellow or blue) as a disease haplotype, the four affected siblings did not 
share the yellow/ blue haplotypes. For example, the proband, PID III-8, inherited the red 
and dark green haplotypes, while the proband’s sibling, PID III-4, inherited the blue and 
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yellow haplotypes. Also, it was noticed that the four affected family members, PID III-4, 
III-5, III-11 and IV-5, inherited the yellow haplotype but the proband did not. In 
summary, affected siblings of Family 2081 did not share a single haplotype across 
OTSC10 and therefore this locus was excluded from linkage. 
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Figure 2.14: Partial pedigree of Family 2081 showing OTSC10 haplotypes 
The family proband is PID III-8. (a) Segregation of OTSC10 in the core Family 2081. (b) Two 
spouses (III-6 and III12) are included in the analysis. Roman numerials on the left side of the 
pedigree indicate the generation. The blue solid symbol refers to otosclerosis grade I. The half 
blue and white symbol refers to hearing loss grade II. The half black and white symbol refers to 
hearing loss, uncategorized. The crossed symbol indicates a deceased subject. Circle =female, 
Square =male. Allele sizes are given in base pairs and alleles in brackets are inferred. 
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COL1A1  
COL1A1, one of the candidate genes for otosclerosis, is a large gene containing 51 exons  
located at Chr17q21.31. Five microsatellite markers that covered the region surrounding 
the COL1A1 were genotyped and four distinct parental haplotypes (blue, red, dark green 
and yellow) were constructed (Figure 2.15). COL1A1 is located between D17S1795 and 
D17S941. All four affected siblings inherited different haplotypes across this region. For 
example, the proband, PID III-8, inherited the blue and dark green haplotypes, as did PID 
III-5 whereas, the proband’s sibling, PID III-4, inherited the yellow and red haplotypes. 
Also, the four affected siblings, PID III-5, III-8, III-11 and IV-5, inherited the parental 
dark green haplotype, whereas the affected member, PID III-4, did not.  As the four 
affected siblings did not share a single haplotype across COL1A1, linkage of this gene to 
otosclerosis segregating in Family 2081was ruled out. 
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Figure 2.15: Partial pedigree of Family 2081 showing COL1A1 haplotypes 
No shared region across COL1A1 among affected members. The family proband is PID III-8. The 
arrow points to the location of the COL1A1 gene within the 17q haplotype. Roman numerials on 
the left side of the pedigree indicate the generation. The blue solid symbol refers to otosclerosis 
grade I. The half blue and white symbol refers to hearing loss grade II. The half black and white 
symbol refers to hearing loss, uncategorized. The crossed symbol indicates a deceased subject. 
Circle =female, Square =male. Allele sizes are given in base pairs and alleles in brackets are 
inferred. 
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COL1A2 
COL1A2, another candidate gene for otosclerosis, is a large gene containing 52 exons 
located at Chr7q21.1. Five microsatellite markers covering the region surrounding 
COL1A2 were used for genotyping and four distinct parental haplotypes (red, yellow, 
light green and blue) were constructed (Figure 2.16A). Using the rule of least number of 
recombinations, a recombination between D16S2430 and D16S821 in PID III-4, and a 
second recombination between D7S657 and D16S2430 in PID III-8 was detected.  The 
four-affected siblings, PIDs II-4, III-5, III 8 and III-11, shared a portion of the yellow 
haplotype between two markers (D7S657 and D7S821) where the COL1A2 gene is 
located. 
To validate this result, one unaffected family member PID III-7, unaffected 
spouse PID III-6, one family member with uncharacterized hearing loss PID III-9, and 
one family member with grade I otosclerosis PID III-13, were genotyped with the five 
markers that cover the COL1A2 gene. Haplotype construction determined that PID III-13 
inherited the parental red and blue haplotypes and did not share the yellow haplotype with 
the other four affected siblings (Figure 2.16B). This excluded linkage of Family 2081 to 
COL1A2. 
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Figure 2.16: Partial pedigree of Family 2081 showing COL1A2 haplotypes 
 Upper panel shows segregation of COL1A2 haplotypes in eight members. The lower panel shows 
segregation of COL1A2 haplotypes within the extended pedigree. The affected member (PID III-
13) who did not inherit the yellow haplotype is circled. The arrow points to the location of the 
COL1A2 gene within the 7q haplotype. The family proband is PID III-8. Roman numerials on the 
left side of the pedigree indicate the generation. The blue solid symbol refers to otosclerosis grade 
I. The half blue and white symbol refers to hearing loss grade II. The half black and white symbol 
refers to hearing loss, uncategorized. The crossed symbol indicates deceased subject. Circle 
=female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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NOG gene  
NOG, another otosclerosis candidate gene, is located at Chr17q24.31. Four markers (three 
of which were fully informative) surrounding the NOG gene were genotyped and four 
distinct parental haplotypes (blue, red, dark green and yellow) were constructed. 
D17S1607 was homozygous for the same allele in four of seven genotyped relatives. 
Using the rule of least number of recombinations, one recombination between D16S1607 
and D16S1606 was detected in the proband PID III-8 (Figure 2.17). Affected siblings 
with grade I otosclerosis inherited different haplotypes across this locus. For example, 
PID III-4 inherited the parental yellow and red haplotype, while PID III-5 inherited the 
parental blue and dark green haplotypes. The four affected siblings did not share a disease 
haplotype across the NOG locus and therefore, linkage of otosclerosis in Family 2081 to 
the NOG gene was ruled out. 
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Figure 2.17: Partial pedigree of Family 2081 showing NOG gene haplotypes 
No shared region across NOG among affected members. The Family proband is PID III-8. Roman 
numerials on the left side of the pedigree indicate the generation. The blue solid symbol refers to 
otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black 
and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a deceased 
subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in brackets 
are inferred. 
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2.3.2.2  Exclusion of  Family 2114 from previously mapped loci and genes 
 Genetic analysis of Family 2114 was carried out through genotyping of three 
affected siblings, PIDs III-1, III-2 and III-7, and one unaffected sibling, PID III-6, with 
polymorphic markers that spanned OTSC1, OTSC2, OTSC3, OTSC4, OTSC5, OTSC7and 
OTSC8 and three candidate genes (COL1A1, COL1A2 and NOG ). Haplotypes of the 
three affected siblings were constructed across each locus. The mode of inheritance of 
otosclerosis in this family is presumed to be AD and the mother is thought to be the 
disease carrier. However, because we have only two generations affected, a recessive 
mode of inheritance cannot be excluded. For that reason, haplotypes of affected members 
were analyzed under both modes of inheritance (AD, AR). A single disease haplotype 
shared by affected siblings but not shared by the unaffected sibling is expected under a 
dominant mode of inheritance. Two disease haplotypes co-segregating in all affected 
siblings were expected under a recessive mode of inheritance model. Assuming a 
dominant mode of inheritance and presuming the mother to be the disease carrier, 
affected siblings did not share any disease associated haplotypes across OTSC1, OTSC4, 
OTSC3, OTSC5, OTSC7, OTSC8 or the COL1A1 and NOG genes. Whereas, assuming a 
dominant mode of inheritance and presuming the father to be the disease carrier, affected 
siblings shared a haplotype across OTSC2 and COL1A2.  A summary of the 
genotype/haplotype data is given below (Figures 2.18-2.27).  Haplotypes for Family 2114 
were created using the same microsatellite markers used for Family 2081. 
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OTSC1  
Four distinct parental haplotypes (blue, light green, red and yellow) were created 
using five microsatellite markers. Parental haplotypes were inferred and no 
recombinations were invoked (Figure 2.18). The three affected siblings (PIDs III-1, III-2 
and III-7) inherited different haplotypes across this region.  For example, the proband PID 
III-1 inherited the parental light green and yellow haplotypes, whereas, the proband’s 
sibling, PID III-2 inherited the blue and red haplotype. As affected siblings did not share 
a disease haplotype across this locus it was excluded from linkage to OTSC1. 
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 Figure 2.18: Partial pedigree of Family 2114 showing OTSC1 haplotype. 
No shared allele between affected siblings across OTSC1. The family proband is PID III-1. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates 
decessed subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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OTSC2 
 Eight microsatellite markers were used for genotyping this locus and four distinct 
parental haplotypes (dark green, red, blue and yellow) were created (Figure 2.19). First, 
four genomic DNA samples comprising the three affected siblings, PID III-1, III-2, and 
III-7, and one unaffected sibling, PID III-6 were genotyped for the markers that covered 
OTSC2. Using the rule of least number of recombinations, a recombination between the 
two informative markers D7S2513 and D7S661 was detected in PID III-7. As a result, 
PIDs III-1, III-2, and III-7 shared one allele of the four informative markers (D7S684, 
D7S2202, D7S513, and D7S 661) that covered a 5 Mb region of the blue haplotype 
(Figure 2.19 A, blue haplotype).  
In order to phase and test segregation of the blue haplotypes within Family 2114 
DNA from two extra siblings with confirmed otosclerosis, PIDs III-4 and III-5, and two 
of the mother’s siblings, PIDs II-5 and II-6, were collected and genotypes, and haplotypes 
were constructed for the OTSC2 locus. Construction of haplotypes for PIDs III-4 and III-5 
showed that these two affected siblings inherited the full blue haplotype (Figure 2.19 B, 
blue haplotype). Construction of haplotypes for the mother’s siblings, PIDs II-5 and II-6 
helped to verify the inferred mother’s yellow haplotype and determined that the shared 
blue haplotype was inherited from the father. Assuming the father is the disease carrier 
and a dominant mode of inheritance haplotype segregation across this locus shows that 
otosclerosis in Family 2114 is linked to a 5 Mb region at OTSC2 that covers four 
microsatellite markers (D7S684, D7S2202, D7S513, and D7S 661).  
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Figure 2.19: Partial pedigrees of Family 2114 showing OTSC2 haplotypes 
The family proband is PID III-1. (a) Haplotypes across OTSC2 in four siblings. (b) OTSC2 
haplotypes fully segregate with otosclerosis in Family 2114. The dark blue haplotype is the 
presumed disease haplotype.  The Family proband is PID III-1. Roman numerials on the left side 
of the pedigree indicate the generation. The blue solid symbol refers to otosclerosis grade I. The 
half blue and white symbol refers to hearing loss grade II. The half black and white symbol refers 
to hearing loss, uncategorized. The crossed symbol indicates a deceased subject. Circle =female, 
Square =male. Allele sizes are given in base airsp and alleles in brackets are inferred. 
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OTSC3 
Nine microsatellite markers were used for genotyping at this locus and four 
distinct parental haplotypes (dark green, green, yellow and orange) were created (Figure 
2.20). Using the rule of least number of recombinations, two recombinations were 
detected between D6S1568 and D6S439 in subject III-1 and III-2. Affected siblings, as 
well as the unaffected subject, PID III-6 share a 10.7 Mb region of the yellow disease 
haplotype between D16S1568 and D16S439.   This excludes linkage of Family 2114 to 
OTSC3.  
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Figure 2.20: Partial pedigree of Family 2114 showing OTSC3 haplotypes 
Affected siblings did not share a haplotype across OTSC3. The family proband is PID III-1 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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OTSC4 
 Ten microsatellite markers were genotyped at this locus and four distinct parental 
haplotypes (dark green, red, yellow and blue) were created (Figure 2.21). Using the rule 
of least number of recombinations, a recombination was detected between D16S3139 and 
D16S3018 in PID III-6. The affected siblings did not share a disease haplotype across the 
OTSC4 locus. For example, the family proband, PID III-1, inherited the parental yellow 
and red haplotypes whereas, PID III-4 inherited the blue and the dark green haplotypes. 
This ruled out linkage of otosclerosis in Family 2114 to the OTSC4 gene.  
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Figure 2.21: Partial pedigree of Family 2114 showing OTSC4 haplotypes. 
No shared allele was detected between affected siblings. The family proband is PID III-1. Roman 
numerials on the left side of the pedigree indicate the generation. The blue solid symbol refers to 
otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black 
and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a deceased 
subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in brackets 
are inferred. 
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OTSC5 
  Nine informative microsatellite markers were used for genotyping at this locus. 
Using the rule of least number of recombinations, no recombination was detected and 
four distinct parental haplotypes (green, red, yellow and blue) were inferred (Figure 2.22). 
The 4 affected family members did not share a disease haplotype across the OTSC5 locus 
under either mode of inheritance. For example, PID-III-1 inherited the parental yellow 
and blue haplotypes whereas PID III-4 inherited the green and red haplotypes. This 
excluded OTSC5 as the causative locus for Family 2114. 
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Figure 2.22: Partial pedigree of Family 2114 showing OTSC5 haplotypes 
Affected siblings did not share a single haplotype across OTSC5. The family proband is PID III-1. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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OTSC7 
Fifteen markers were genotyped at this locus and four distinct parental haplotypes 
(dark purple, red, yellow and light green) were created. Parental haplotypes were inferred 
and no recombination was invoked (Figure 2.23). Affected siblings did not share a 
disease haplotype across this locus. For example, the proband (PID III-1) and the 
unaffected PID III-6 shared the red and purple haplotypes. PID III-6 also shared the red 
haplotype with the affected sibling, PID III-7, but did not share any haplotypes with the 
affected siblings PIDs III-2 and III-4. These results exclude linkage of Family 2114 to 
OTSC7.   
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Figure 2.23: Partial pedigree of Family 2114 showing OTSC7 haplotypes. 
No shared haplotype was detected between affected siblings. The family proband is PID III-1. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
. 
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OTSC8 
Eight microsatellite markers were genotyped at this locus, four distinct parental 
haplotypes (dark green, blue, red and yellow) were created and no recombinations were 
detected (Figure 2.24). The three affected siblings (PID III-1, III-2 and III-7) did not 
share a disease haplotype across this locus. For example (PID III-1) inherited the yellow 
and blue haplotypes. Subject PIDIII-1 shared the yellow haplotype with PID III-2 and the 
blue haplotype with PID III-7. In summary, as there was no shared haplotype detected 
between the affected siblings across OTSC8, it was excluded as a causative locus in 
Family 2114. 
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Figure 2.24 Partial pedigree of Family 2114 showing OTSC8 haplotypes 
No shared haplotype was recognized between affected siblings. The family proband is PID III-1. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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COL1A1 
Five microsatellite markers covering the region surrounding the COL1A1gene 
were genotyped. Using the rule of least number of recombinations, no recombination was 
invoked and four distinct parental haplotypes (red, blue, dark green and yellow) were 
constructed (Figure 2.25). The four affected siblings, PID III-1, III-2, III-4 and III-7 did 
not share a disease haplotype across the COL1A1 region. For example, PID III-1, III-4 
and III-7 inherited the parental green haplotype but PID III-2 did not. On the other hand, 
PID III-2 and III-4 shared the blue haplotype with the unaffected sibling PID III-6 but not 
with the affected siblings PID III-1 and III-7. This excluded linkage of otosclerosis in 
Family 2114 to COL1A1. 
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Figure 2.25: Partial pedigree of Family 2114 showing COL1A1 haplotypes 
Affected siblings did not share haplotype across COL1A1. The family proband is PID III-1. 
Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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COL1A2  
  Five microsatellite markers that covered the region surrounding COL1A2 were 
genotyped and four distinct parental haplotypes (dark green, yellow, red and light green) 
were constructed (Figure 2.26 A). The three affected siblings, PIDs III-1, III-2, and III-7, 
shared the parental dark green haplotype which was not shared by the unaffected sibling 
PID III-6. This preliminary result suggested that Family 2114 was linked to COL1A2 
under a dominant mode of inheritance.  
To confirm this, DNA from the other two affected siblings, PIDs III-4 and III-5, 
and from the proband’s mother’s siblings, PIDs II-5 and II-6, were genotyped using the 
same five microsatellite markers. Construction of haplotypes for the mother’s sibling PID 
II-5 helped to infer the mother’s light green and red haplotypes and indicated that the 
shared dark green haplotype was inherited from the father, who has no history of hearing 
loss (Figure 2.26 B). Also, constructed haplotypes for the affected siblings, PIDs III-4 and 
III-5, showed that they both inherited the dark green (disease) haplotype. Assuming the 
father was the disease carrier this result links Family 2114 to the COL1A2 region.  
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Figure 2.26: Partial pedigree of Family 2114 showing COL1A2 haplotypes 
The Family proband is PID III-1. (a) Segregation of dark green haplotype in three affected (III-1, 
III-2 and III-7). (b) Segregation of dark green haplotype across COL1A2 with otosclerosis in 
Family 2114. The family proband is PID III-1. Roman numerials on the left side of the pedigree 
indicate the generation. The blue solid symbol refers to otosclerosis grade I. The half blue and 
white symbol refers to hearing loss grade II. The half black and white symbol refers to hearing 
loss, uncategorized. Crossed symbol indicates a deceased subject. Circle =female, Square =male. 
Allele sizes are given in base pairs and alleles in brackets are inferred. 
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NOG gene  
Four markers surrounding the NOG gene were genotyped and four distinct 
parental haplotypes (blue, yellow, dark green and red) were constructed.  The four 
affected siblings, PID III-1, III-2, III-4, and III-7, inherited different haplotypes (Figure 
2.27). For example, PID III-1 inherited the parental red and yellow haplotypes, while the 
PID III-4 inherited the parental blue and dark green haplotypes. Also, the three affected 
siblings PID III-2, III-4, PID III-7 and the unaffected sibling PID III-6 shared a dark 
green haplotype which the affected proband PID III-1did not have. The four haplotyped 
affecteds did not share a disease haplotype across the NOG gene locus and this ruled out 
linkage of otosclerosis in Family 2114 to the NOG gene. 
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Figure 2.27: Partial pedigree of Family 2114 showing NOG gene haplotypes 
No shared haplotype was detected between affected siblings. The family proband is PID III-1. 
Roman numerials on the left side of the pedigree indicate thegeneration. The blue solid symbol 
refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The 
half black and white symbol refers to hearing loss, uncategorized. The crossed symbol indicates a 
deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and alleles in 
brackets are inferred. 
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2.3.3  Fine mapping of OTSC4 locus in Family 2081 
Haplotype analysis at the OTSC4 locus showed that the four affected siblings 
PIDs III-4, III-5, III-8 and III-11 shared a presumed disease (yellow) haplotype (Figure 
2.10). In order to further investigate the potential role of OTSC4 in Family 2081, an extra 
14 members of the family  PIDs III-1, III-2, III-6, III-7, III-9, III-12, III-13, III-14, III-15, 
IV-1, IV-2, IV-3, IV-6 and IV 12, including the proband’s cousin PID IV-1 (who was 
diagnosed with grade I otosclerosis), were genotyped and phased for markers that 
spanned the OTSC4 interval. Segregation analysis showed that the proband, proband’s 
affected siblings (PIDs III-4, III-5, III-11, and III-13) and affected cousin (PID IV-1) 
inherited the presumed disease (yellow) haplotype (Figure 2.28). In addition, two 
unaffected subjects in the third and fourth generation (PIDs III-7 and IV-10) and two 
members with a history of uncategorized hearing loss (PID III-14 and IV-9) inherited the 
disease (yellow) haplotype. As well, the unaffected proband’s cousin, PID IV-2, and one 
parent, PID III-1, inherited the yellow haplotype. Family member PID IV-5 who has 
grade II otosclerosis did not inherit the disease (yellow) haplotype. Segregation of the 
OTSC4 presumed disease haplotype in family 2081 raised the possibility of linkage of 
Family 2081 to OTSC4. 
At the OTSC4 locus, we only have one apparent recombination within several 
generations, which consolidates this haplotype. In addition to this, all family members 
with grade I otosclerosis in generation III and their cousin (subject IV-1) shared a 
presumed disease (yellow) haplotype. However, absence of the inheritance of the yellow 
haplotype from the grade II affected family member IV-5 did not fit the pattern. Subject 
 
 
 
 
130 
PID IV-5 was considered a phenocopy because the diagnosis of otosclerosis was based on 
the audiological profile.  At this stage, we considered OTSC4 a candidate region for 
Family 2081 and subject PID IV-5 a phenocopy. 
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Figure 2.28: Partial pedigree of NL Family 2081 segregates OTSC4 haplotype 
Affected members share a yellow haplotype across OTSC4. The subject IV-5,a phenocopy, is circled. Allele sizes are given in base pairs 
and alleles in brackets are inferred. Red arrows show boundary markers D16S3107 and D16S3097 for theOTSC4 critical region. The 
family proband is PID III-8. Roman numerials on the left side of the pedigree indicate the generation. The blue solid symbol refers to 
otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black and white symbol refers to hearing loss, 
uncategorized. The crossed symbol indicates a deceased subject. Circle =female, Square =male. Allele sizes are given in base pairs and 
alleles in brackets are inferred. 
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2.3.4     Shared haplotype across four unrelated otoslerosis probands  
The OTSC4 mapped region is 9.7 Mb and contains 129 annotated genes.  In 
addition to families 2081 and 2114, we recruited probands from seven unrelated NL 
families. Because these probands originated from NL, we hypothesized that they could 
share a founder haplotype. Therefore, six out of seven of these probands (Family # 2197, 
2203, 2066, 2126, 2103 and 2200) were checked for a founder genotype across OTSC4. It 
was found that the proband of Family 2200 shared alleles of four microsatellite markers 
(D16S3095, D16S752, D16S3106 and D16S3139) with the proband of Family 2081. The 
probands of Families 2203, 2197, and 2126 shared a portion of the presumed disease 
haplotype that spanned the three microsatellite markers D16S752, D16S3106 and 
D16S3139 (Table 2.2). The probands of Families 2200 and 2203 also shared an allele at 
D16S3115.  Probands of Families 2103 and 2066 shared an allele at the D16S3139 
marker. Of these seven probands, including proband of Family 2081, four probands 
shared alleles at D16S752, D16S3106 and D16S3139, which minimized the OTSC4 
candidate region from 9.7 Mb to 4.2 Mb.  
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Table 2.2: Shared alleles among NL otosclerosis probands across OTSC4  
Four families proband (Families 2200, 2203, 2197 and 2126) share alleles of three markers 
(D16S752, D16S3106 and D16S3139) along with the proband of  Family 2081. 
 
OTSC4 Distance 
Mb  
Family 
2081 
Family 
2200 
Family 
2203 
Family  
2197 
Family 
2126 
Family 
2103 
Family 
2066 
D16S3107 66.2 292 na na na 287 288 294 
D16S3025 67.1 108 na 92 88 102 104 106 
D16S3095 68.5 150 150 152 156 160 156 156 
D16S752 69.8 113 113 113 113 113 109 105 
D16S3106 70.7 196 196 196 196 196 194 194 
D16S3139 71.2 198 198 198 198 198 198 198 
D16S3018 72.7 253 263 263 225 265 263 259 
D16S3115 73.8 243 243 243 247 245 245 247 
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2.3.5  Gene screening of functional candidate genes 
The minimized OTSC4 (4.2 Mb) region contains 49 positional candidate genes, 
which is a large number of genes to screen using Sanger sequencing. Therefore, genes 
were prioritized according to their function and expression, as described in Appendix 11. 
In total, 12 genes were sequenced and 96 variants were identified. 
2.3.5.1 Variant analysis  
Under a dominant mode of inheritance, we are expecting to identify variants that 
are present in the affected members and absent in the controls. Variant analysis was 
carried out as shown in Figure 2.1.  
Sequencing of 12 functional candidate genes in the minimized OTSC4 identified 
96 variants in the mutation screening panel (Figure 2.29 and Appendix 12). Of these 96 
variants, only seven variants, five in the ZFHX3 and two in the IL34 gene, exclusively 
segregated with the disease haplotype. To determine the possible pathogenicity of these 
seven variants, allele frequencies were checked using the SNP/1000 genome database. As 
a result, the two variants in the IL34 gene were shown to have high frequencies; the C 
allele of c.107G>C has a frequency of 0.458/120 (45%) and the A allele of c.639 C>A 
has a frequency of 0.112/224 (11.2 %). These variants were excluded from further follow-
up due to their high frequency in the general population (Appendix 10B). 
Of the five identified variants in the ZFHX3 gene, four variants were SNPs with 
no frequencies listed in the SNP/1000 genome database and one was novel. The four 
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SNPs with no frequency data included three intronic, one missense and the novel variant 
was a 3 bp insertion. To determine the effect of each variant on the mRNA and protein 
coded by the ZFHX3 gene, the effect on the protein of the missense variants were checked 
using SIFT and Polyphen prediction programs (pg. 28). The splicing effects of the three 
intronic variants were checked using HSF, MaxEntScan, NNSPLICE, GeneSplicer, SSF 
and Known constitutive signals splice prediction tools. No splicing effects were 
predicted.  
c.10831C>T, p.H3611HY variant (Figure 2.30) was predicted to be deleterious by 
SIFT (score 0.00) and probably damaging by Polyphen (score 0.6666). The conservation 
of the histidine residue at position 3611 in the ZFHX3 gene was found to be conserved in 
four of five species (dog, mouse, rat and chicken) using Clustal W and Weblogo (Figure 
2.31).  
The ZFHX3 c.10557-10558insCCG (Figure 2.32 A) was predicted to cause an in-
frame duplication of glycine (p.Gly 3527 dup). The glycine insertion was placed within a 
string of a 14-glycine repeat (Figure 2.32 B). Conservation of the 14-glycine repeats was 
checked across five species. The examined species have fewer than 14 glycine repeats (12 
in Dog and Mouse, 13 in Rat, two in Chicken and two in Zebrafish) (Figure 2.33).  We 
further examined the conservation of this region across NL population controls and found 
that the normal population controls harbour less than 14 glycine repeat at this position. 
From the conservation study of the 14 glycine repeat sequence across species and normal 
NL population controls, it appears that the glycine sequence across this region was not 
conserved across these species and controls. These results suggested that the 14 glycine 
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repeat did not have any important function and deletion of glycine residues would not 
have a drastic effect on either the mRNA or the translated protein. In other words, the 
variability seen in the length of the glycine string repeats between species and in the NL 
population is benign and gene function is retained. 
2.3.5.2 Functional assessment of the ZFHX3. c.10557_10558ins GGC  
We hypothesized that if the deletion of glycine residue (‘s) does not have a drastic 
effect, then maybe the insertion of glycine residue (‘s) could cause toxicity and therefore 
cause degradation of the mRNA. To test this hypothesis, cDNA of the proband PID III-8 
and two siblings (PID III-4 and II-5) were prepared and sequenced. If our hypothesis was 
right and the mRNA produced by the mutated form (insGGC) of the ZFHX3 gene was 
degraded, we would expect to see a normal electropherogram (no frame shift). 
Sequencing of the cDNA that covered the 3 bp insertion in the proband and two siblings 
showed that the mutated allele was not degraded as recorded by the presence of a frame 
shift in the electropherogram (Figure 2.34). This result refuted our hypothesis that the 
mRNA would render the mRNA transcript less stable. 
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Figure 2.29  Flowchart of filtration steps applied to identifed variants at the 
minimized OTSC4  
 Missense mutation and 3 bp insertion in the ZFHX3 gene segregates with disease in Family 2081. 
Allele frequencies of identified variants were determined using publicly available SNP database 
and 1000 genomes. Pathogenicity of missense mutations was evaluated by using SIFT and 
Polyphen prediction programs.  Splicing prediction programs SSF, HSF, MaxEntScan, 
NNSPLICE, GeneSplicer were used to check for possible splice site mutations. 
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2.3.5.3 Segregation analysis 
Of the five variants identified in the ZFHX3 gene, only the missense and the 3 bp 
insertion variants were subjected to segregation analysis. In order to determine which of 
the two sequencing variants in ZFHX3, were fully segregating with the disease haplotype 
in Family 2081, all members with available DNA were genotyped for these variants and 
haplotypes were created (Figure 2.35). As a result, these four variants were seen to 
exclusively segregate with the yellow haplotype in Family 2081; every subject who 
inherited the yellow haplotype harboured these two variants. Segregation analysis in 
Family 2081 determined that these two variants resided on the presumed disease (yellow) 
haplotype.  
2.3.5.4 Allele frequencies of the ZFHX3 variants in NL controls   
Allele frequencies of the two ZFHX3 variants were determined using ethnically 
matched NL population controls. The frequencies of c.10557_10558 insGGC, and 
c.1083C>T, p.H3611Y were 1.5% and 1.13% respectively (Table 2.3).  
To test the role of the missense and insertion variants in other otosclerosis 
families, eight NL otosclerosis probands, including the four used to fine map OTSC4, 
were screened.  If our hypothesis was correct and the four probands shared a founder 
haplotype, we would expect the four probands to harbour these two variants. None of the 
four probands harboured these variants which excluded the founder haplotype based on 
the assumption that these haplotypes were not really identical.
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Figure 2.30: Electropherogram shows heterozygous missense mutation ZFHX3 c.10831C>T, p.H3611HY in PID III-8. 
The upper panel is the reference sequence of ZFHX3. The lower panel is the sequence of PID III-8 that harbours the c.10831 
C>T variant. The arrow points to the c.10831C>T mutation.  
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Figure 2.31: Multiple alignment of histidine at the  amino acid position 3611 in ZFHX3 across five species. 
  Clustal W was used to align orthologs from human (NP_008816.3), dog (XP_546849.2), mouse (NP_031522.2), rat (XP_226464.3), 
chicken  (XP_414230.2 ), and Zebrafish (XP_688934.3 ).  Histidine at position 3611 (indicated by the arrow) is conserved across human 
and four species (dog, mouse, rate and chicken).  
 
 
 
 
 
 
 
 
 
Human          NP_008816.3       3581   PSTASTSQSAAHSNDSPPPPSAAAPSSASPHASRKSWPQVVSRASA   3626 
Dog            XP_546849.2       3595   PSTASTSQSAAHSNDSPPPPSAAAPSSASPHASRKSWPQVVSRASA   3642 
Mouse          NP_031522.2       3601   PSTASTSQSAAHSNDSPPPPSAAPSSSASPHASRKSWPPVGSRASA   3646 
Rat            XP_226464.3       3608   PSTASTSQSAAHSNDSPPPPSAAPSSSASPHASRKSWPPVGSRASA   3653 
Chicken        XP_414230.2       3539   PSTASTSQSAAHSNDSPPPPRPPPA---SPHASRKPWPPAAPRAPP   3581 
Zebrafish      XP_688934.3       2473   PNTASTSQSATHSNNTSPPPTTSATTPSSSTTASSCKSWSQPFSRALA 2522 
 
 
 
 
 
141 
 
 
 
Figure 2.32  Electropherogram shows hetozygous ZFHX3 c.10557_10558insGGC in PID III-8  
A. The upper panel is the reference sequence of ZFHX3. The lower panel is the reference sequence from PID III-8 showing the 3 bp 
insertion and resultant frameshift (indicated by the arrow).   
A 
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B. Reference sequence of NM_006885 (ZFHX3). 
Capture of the ZFHX3 cDNA from Genome browser
141
.  At block nine (Exon 9) of the ZFHX3, a 
string of 14 glycine codons is shown (highlighted green). Insertion of the 3 bp led to insertion of an 
extra glycine in the highlighted string.  
 
 
acaaggttgt ccagccctga gcctggtggg atacttctgt tggaaatgtt  72822875 
cgttttgaga ggatccttca agccttgaca tctcaaactg tgtgccagtg  72822825 
acaccggtaa aacgtcttga gcttcagccc tacccctgcc cagactgacc  72822775 
ggtgatttct gtctccattc ctttcagCTT TAACGTCTCC TAAGCCGAAC  72822725 
TTGATGGGTC TGCCCAGCAC AACTGTTCCT TCCCCTGGCC TCCCCACTTC  72822675 
TGGATTACCA AATAAACCGT CCTCAGCGTC GCTGAGCTCC CCAACCCCAG  72822625 
CACAAGCCAC GATGGCGATG GGCCCTCAGC AACCCCCCCA GCAGCAGCAG  72822575 
CAGCAGCAGC AACCACAGGT GCAGCAGCCT CCCCCGCCGC CAGCAGCCCA  72822525 
GCCGCCACCC ACACCACAGC TCCCACTGCA ACAGCAGCAG CAACGCAAGG  72822475 
ACAAAGACAG TGAGAAAGTA AAGGAGAAGG AAAAGGCACA CAAAGGGAAA  72822425 
GGGGAACCCC TGCCTGTCCC CAAGAAGGAG AAAGGAGAGG CCCCCACGGC  72822375 
AACTGCAGCC ACGATCTCAG CCCCGCTGCC CACCATGGAG TATGCGGTAG  72822325 
ACCCTGCACA GCTGCAGGCC CTGCAGGCCG CGTTGACTTC GGACCCCACA  72822275 
GCATTGCTCA CAAGCCAGTT CCTTCCTTAC TTTGTACCAG GCTTTTCTCC  72822225 
TTATTATGCT CCCCAGATCC CTGGCGCCCT GCAGAGCGGG TACCTGCAGC  72822175 
CTATGTATGG CATGGAAGGC CTGTTCCCCT ACAGCCCTGC ACTGTCGCAG  72822125 
GCCCTGATGG GGCTGTCCCC AGGCTCCCTA CTGCAGCAGT ACCAGCAATA  72822075 
CCAGCAGAGT CTGCAGGAGG CAATTCAGCA GCAGCAGCAG CGGCAACTAC  72822025 
AGCAGCAGCA GCAGCAAAAA GTGCAGCAGC AGCAGCCCAA AGCAAGCCAA  72821975 
ACCCCAGTCC CCCCCGGGGC TCCTTCCCCA GACAAAGACC CTGCCAAAGA  72821925 
ATCCCCCAAA CCAGAAGAAC AGAAAAACAC CCCCCGTGAG GTGTCCCCCC  72821875 
TCCTGCCGAA ACTCCCTGAA GAGCCAGAAG CAGAAAGCAA AAGTGCGGAC  72821825 
TCCCTCTACG ACCCCTTCAT TGTTCCAAAG GTGCAGTACA AGTTGGTCTG  72821775 
CCGCAAGTGC CAGGCGGGCT TCAGCGACGA GGAGGCAGCG AGGAGCCACC  72821725 
TGAAGTCCCT CTGCTTCTTC GGCCAGTCTG TGGTGAACCT GCAAGAGATG  72821675 
GTGCTTCACG TCCCCACCGG CGGCGGCGGC GGTGGCAGTG GCGGCGGCGG  72821625 
CGGCGGTGGC GGCGGCGGCG GCGGCGGCGG CTCGTACCAC TGCCTGGCGT  72821575 
GCGAGAGCGC GCTCTGTGGG GAGGAAGCTC TGAGTCAACA TCTCGAGTCG  72821525 
GCCTTGCACA AACACAGAAC AATCACGAGA GCAGCAAGAA ACGCCAAAGA  72821475 
GCACCCTAGT TTATTACCTC ACTCTGCCTG CTTCCCCGAT CCTAGCACCG  72821425 
CATCTACCTC GCAGTCTGCC GCTCACTCAA ACGACAGCCC CCCTCCCCCG  72821375 
TCGGCCGCCG CCCCCTCCTC CGCTTCCCCC CACGCCTCCA GGAAGTCTTG  72821325 
GCCGCAAGTG GTCTCCCGGG CTTCGGCAGC GAAGCCCCCT TCTTTTCCTC  72821275 
CTCTCTCCTC ATCTTCAACG GTTACCTCAA GTTCATGCAG CACCTCAGGG  72821225 
GTTCAGCCCT CGATGCCAAC AGACGACTAT TCGGAGGAGT CTGACACGGA  72821175 
TCTCAGCCAA AAGTCCGACG GACCGGCGAG CCCGGTGGAG GGTCCCAAAG  72821125 
ACCCCAGCTG CCCCAAGGAC AGTGGTCTGA CCAGTGTAGG AACGGACACC  72821075 
TTCAGATTGT AAGCTTTGAA GATGAACAAT ACAAACAAAT GAATTTAAAT  72821025 
ACAAAAATTA ATAACAAACC AATTTCAAAA ATAGACTAAC TGCAATTCCA  72820975 
AAGCTTCTAA CCAAAAAACA AAAAAAAAAA AAAAAAGAAA AAAAAGAAAA  72820925 
AGCGTGGGTT GTTTTCCCAT ATACCTATCT ATGCCGGTGA TTTTACATTC  72820875 
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Figure 2.33: Conserved domain of the ZFHX3 gene identified in Family 2081 
Clustal W was used to align orthologs from human (NP_008816.3), dog (XP_546849.2), mouse (NP_031522.2), rat 
(XP_226464.3), chicken  (XP_414230.2 ), and zebrafish (XP_688934.3 ).  The string of 14 glycine residues is not conserved 
across five species (A) or the NL population controls (B). C shows a trace of the ZFHX3 protein showing 15 glycine residues. 
A: Evolutionary evidence of expanding glycine-rich region 
 
 
Human     NP_008816.3   3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGSGGGGGGGGGGGGGGSYHCL 3532 
Dog       XP_546849.2   3499   HLKSLCFFGQSVVNLQEMVLHVPTGGGGG--GGGVGGGGGGGGGGSYHCL 3546 
Mouse     NP_031522.2   3507   HLKSLCCFGQSVVNLQEMVLHVPTGSG----GSGGGGGGSGGGGGSYHCL 3552 
Rate      XP_226464.3   3514   HLKSLCFFGQSVVNLQEMVLHVPTGSG----GGGGGGGSGGGGGGSYHCL 3559 
Chicken   XP_414230.2   3455   HLKSLCFFGQSVANLQEMVLHVPTGSG--------------QGSGSYQCV 3490 
Zebrafish XP_688934.3   2387   HLKSICFFGQSVANLQEMLLRVPNSGN-------------AAEGGLYDCL 2423                        
 
B: Alleles identified in population controls at the expanding glycine- rich region  
Human     NP_008816.3    3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGSGGGGGGGGGGGGGGSYHCL   3532 
NL Pop Control              (del 1 Gly)    3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS--GGGGGGGGGGGGGSYHCL   3532 
NL Pop Control              (del 3 Gly)    3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS-------GGGGGGGGGGGSYHCL   3532 
NL Pop Control              (del 5 Gly)    3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS------------GGGGGGGGGSYHCL   3532 
NL Pop Control              (del 6 Gly)    3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS--------------GGGGGGGGSYHCL   3532 
NL Pop Control              (del 1 Gly)     3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS---GGGGGGGGGGGGGSYHCL   3532 
NL Pop Control       (del 1 Gly)     3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS---GGGGGGGGGGGGGSYHCL   3532 
NL Pop Control              (del 3 Gly)     3483   HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGS-------GGGGGGGGGGGSYHCL   3532 
 
C: Alleles identified in patients with otosclerosis show insertion of a glycine residue  
NL OTSC proband (ins 1 Gly) 3483 HLKSLCFFGQSVVNLQEMVLHVPTGGGGGGSGGGGGGGGGGGGGGGSYHCL  3532 
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Figure 2.34 : Electropherogram shows no degradation of the ZFHX3 c.10557_10558insGGC allele  
The upper panel is the reference sequence of ZFHX3. The lower panel is the cDNA sequence trace from PID III-8 showing the 3 bp 
insertion and resultant frameshift (shown by the arrow).  The allele with the 3 bp insertion has been transcribed and therefore, did not 
undergo degradation. 
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Figure 2.35: Family 2081 shows segregation of five variants detected in   ZFHX3 on the OTSC4 yellow haplotype 
The five variants (c.3216+28C>T, c.3216+153G>A, c.10831C>T, p. H3611HY and c.10557-10558insGGC) found in the ZFHX3 gene 
reside on the yellow disease haplotype. Roman numerials on the side of the pedigree indicate the generation. The blue solid symbole refers 
to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black and white symbole refers to hearing 
loss, uncategorized. Circle =female, square = male. Alleles sizes are given in base pairs and alleles in brackets are inferred. 
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Table 2.3: Summary of allele frequency for variants identified in ZFHX3 that segregate with otosclerosis in Family 2081 
Frequencies of these variants were determined in 314 and 176 NL population controls for c.10557_10558het insGGc and c.10831C>T 
respectively. 
 
 
 
 
 
 
 
 
Genomic Change 
 
(NM_006885) 
Protein 
Level 
SNP database  
Update Feb2/2010 
Freq in NL controls 
Ratio (%) 
SIFT Prediction  Polyphen 
Prediction 
c.10557_10558insGGC p.Gly3527_ser3528insGly Novel  5/314  (1.5) n/a n/a 
c.10831C>T 
 
p.H3611Y rs200992486  
 
2/176  (1.13) Deleterious Probably damaging  
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2.3.6  Recruitment of a new family member and excluding linkage of Family 2081 
to OTSC4 
In the process of the study, PID III-16 with surgically confirmed otosclerosis was 
recruited and screened for the segregation of the presumed disease haplotype (yellow 
haplotype) across OTSC4 and for the presence of the two candidate variants. The family 
member PIDIII-16 did not inherit the presumed disease (yellow) haplotype or the two 
candidate variants. In addition, PID III-16 did not inherit a complete set of paternal 
haplotypes and thus has been assigned as a case of non-paternity (Figure 2.36). At this 
stage, we also received a confirmation of otosclerosis in PID IV-5, who had been 
diagnosed as grade II, but based on visualization of stapes fixation during surgery. This 
report has changed the diagnosis of PID IV-5 from grade II to grade I.  At this stage, two 
affected family members with grade I otosclerosis (PIDs III-16 and IV-5) did not inherit 
the previously assigned disease (yellow) haplotype, which decreases the possibility that 
OTSC4 was the disease locus for Family 2081.  
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Figure 2.36: Partial pedigree of Family 2081 showing absence of segregation of the yellow haplotype in two affected 
subjects 
Two subjects IV-5 and III-16 (circled) did not inherit the yellow haplotype. Roman numerials on the side indicate the generation. The blue 
solid symbol refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss grade II. The half black and white 
symbole refers to hearing loss, uncategorized. Circle =female, square = male. Allele sizes are given in base pairs) and alleles in brackets 
are inferred. 
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2.3.7  Two point linkage analysis 
The exclusion of the previously mapped loci and the region spanning the three 
candidate genes was based on haplotypes. To determine the statistical significance of our 
exclusion data, two point linkage analyses were carried out for the otosclerosis loci 
(OTSC1, OTSC2, OTSC3, OTSC4 OTSC5, OTSC7, OTSC8, OTSC10) and for the three 
genes (COL1A1, COL1A2 and NOG) using three microsatellite markers for each locus for 
Family 2081. At each locus, a negative LOD score was obtained at all recombination 
fractions (ranging from 0.000 to 0.5000). Statistically significant linkage exclusion of 
OTSC1, OTSC2, OTSC3, OTSC4, OTSC5, OTSC7, OTSC8 and OTSC10 loci and three 
genes was demonstrated in Family 2081 because the LOD scores were negative at almost 
all examined loci (Table 2.4). 
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Table 2.4: Two point LOD score in Family 2081 
Two point LOD scores generated by the MLINK program between otosclerosis and three markers 
within each of the published OTSC loci and three otosclerosis associated genes.  
Locus Markers                                           Recombination fraction  
   0.000                0.100              0.200               0.300             0.400                 0.500  
OTSC1 
 
D15S127 
D15S649 
D15S657 
-4.096936        -0.887153        -0.387585        -0.151425      -0.035454        0.000000 
-4.096936        -0.264114        -0.108875        -0.048774      -0.014267        0.000000 
-0.300990        -0.099513        -0.029093        -0.005594     -0.000348         0.000000 
OTSC2 
 
D7S495 
D7S1798 
D7S1827 
 0.301029          0.212668          0.130215        0.062729      0.016819          0.000000 
-4.096936        -0.887153         -0.387585       -0.151425     -0.035454         0.000000 
-13.494847       -1.33082          -0.581401       -0.227145     -0.053183         0.000000 
OTSC3 
 
GAAT3A06 
D6S273 
D6S1680 
-3.795907         -0.887043         -0.387574      -0.151424      -0.035454         0.000000 
-3.795907         -0.887043         -0.387574      -0.151424      -0.035454         0.000000 
-3.795907        -0.653891          -0.226226      -0.062029      -0.007427         0.000000 
OTSC4 
 
D16S3107 
D16S3106 
D16S3097 
-4342935         -0.766770        -0.300033       -0.086144      0.002510          0.000000 
-4342935         -0.636432        -0.200119       -0.038453      0.003295          0.000000 
-4342935         -0.598769        -0.218146      -0.063158       0.001094          0.000000 
OTSC5 
 
D3S3548 
D3S1593 
D3S1744 
0.301025         0.210206          0.118188        0.044152        0.006429         0.000000 
-4.096936       -0.755097         -0.299465      -0.104434      -0.021215           0.000000 
-3.795907       -0.653881         -0.226224      -0.062028      -0.007427           0.000000 
OTSC7 
 
D6S1619 
D6S1595  
D6S268 
-3.795906      -0.638142        -0.218710      -0.059726       -0.007201           0.000000 
-4.096936      -0.264114        -0.108875      -0.048774       -0.014267           0.000000 
-3.795906      -0.638142         -0.218710      -0.059726      -0.007201           0.000000 
OTSC8 
 
D9S2148 
D9S1862 
D9S1799 
-4.045783      -0.199700        -0.047532      -0.007852       -0.000417           0.000000 
-13.494847    -0.672523         -0.254094      -0.086982      -0.018424           0.000000 
-0.300990      -0.099513         -0.029093      -0.005594      -0.000348           0.000000 
OTSC10 
 
D1S2621 
D1S2800 
-4.096936      -0.264114         -0.108875      -0.048774       -0.014267          0.000000 
0.000000        0.000000           0.000000        0.000000        0.000000           0.000000 
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D1S2811 -4.096936     -0.264114          -0.108875     -0.048774       -0.014267           0.000000 
COL1A1 
 
D17S797 
D17S809 
D17S788 
-0.300990     -0.248075         -0.151917      -0.069146      -0.017365            0.000000 
-4.096936     -0.443629         -0.193798      -0.075713      -0.017727            0.000000 
-4.096936      -0.443629         -0.193798     -0.075713       -0.017727           0.000000 
COL1A2 
 
 
D7S644 
D7S821 
D7S651 
-3.795907     -0.013984          0.073263        0.053196       0.016338            0.000000 
-3.795902      0.025915           0.139021       0.118035        0.047724           0.000000 
0.602028       0.465356          0.318042          0.170249       0.049214          0.000000 
NOG  
 
D17S790 
D17S1606 
D17S1161 
-4.698990     -0.691749          -0.345732       -0.144865      -0.035094           0.000000 
-4.096936     -0.755097          -0.299465        -0.104434     -0.021215           0.000000 
-4.096936      -0.755097         -0.299465        -0.104434     -0.021215           0.000000 
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2.4 Discussion 
  Eight otosclerosis loci have been published and no causative genes have yet been 
identified. Large multigenerational Families (2081 and 2114) with apparent AD 
otosclerosis, and seven unrelated otosclerosis probands from NL, were investigated for 
linkage to the eight previously mapped otosclerosis loci and to three candidate genes 
(COL1A1, COL1A2 and NOG genes).  
 Otosclerosis segregating in Family 2081 was excluded from linkage to OTSC1, 
OTSC2, OTSC3, OTSC5, OTSC6, OTSC7, OTSC8, OTSC10, COL1A1, COL1A2 and the 
NOG gene through haplotype analysis and two-point linkage analysis. In the initial phase 
of the genetic study of Family 2081, individuals diagnosed with otosclerosis showed 
apparent segregation of a presumed disease (yellow) haplotype inherited from the parent 
II-3. Assuming that this was a single founder disease haplotype, six unrelated otosclerosis 
probands were genotyped across OTSC4, which minimized the region from 
approximately 9 Mb to 4.2 Mb. Twelve genes in this region were sequenced and a 
missense and a 3 bp insertion variant in the ZFHX3 gene were considered candidate 
variants for otosclerosis in Family 2081 based on the allele frequencies and pathogenicity 
prediction.  Further investigation on the effect of the glycine insertion in the ZFHX3 gene 
did not suggest any drastic effect at the mRNA level. Of these two variants, the missense 
mutation seems to be the candidate variant over the 3 bp insertion. To investigate the role 
of candidate variants in NL families with otosclerosis, nine probands with otosclerosis 
were screened and none of them harboured either the missense mutation or the insertion. 
The four otosclerosis probands used to narrow down the OTSC4 region did not harbour 
any of the two variants which suggested that these probands did not share a founder 
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haplotype with Family 2081 and the shared haplotype was explained as a common 
haplotype in the NL population. 
Recruitment of a new member of Family 2081 (PID III-6) with grade I 
otosclerosis who, along with subject IV-5, did not inherit the disease haplotype, combined 
with the negative LOD score across OTSC4, excluded linkage of Family 2081 to OTSC4.   
Additionally, subject III-16 did not inherit a complete paternal haplotype, which 
suggested a case of non-paternity and served to exclud linkage of family 2081 to the 
originally mapped OTSC4. The identified variant in ZFHX3 could cause unrelated 
disease. The ZFHX3 gene was chosen for sequencing based on its role as a transcription 
factor and involvement in in cytoskeleton organization. Variants in this gene have also 
been associated with atrial fibrillation and may be causative in families with cardiac 
arrhythmia149 150.  
Family 2114 is a large family from NL with a presumed dominant mode of 
inheritance. Haplotype studies of Family 2114 excluded linkage of this family to seven 
previously mapped loci and to the loci of three associated genes, presuming the mother 
was the disease carrier. In the process of the study, we noticed that individuals with a 
confirmed diagnosis of otosclerosis in Family 2114 shared a region from 86 Mb to143 
Mb of (57.3 Mb) (86Mb-143 Mb) at Chr 7q21.11-q35, which overlappsing with the two 
loci OTSC2 and COL1A2, inherited from the father’s side. The father of this family (PID 
II-1) had no history of hearing loss. If this clinical finding for this subject was true, this 
would exclude linkage of this family to the seven mapped loci and 3the three associated 
genes from both sides.  On the other hand, the absence of a history of hearing loss would 
not exclude non-penetrance, or a de novo mutation in the father’s germline cells. These 
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findings suggested the presence of at least one novel otosclerosis locus for this family if 
the mother was the disease carrier. Alternately, the otosclerosis gene could be in the 57.3 
Mb region at Chr7 (q21.11-q35) which overlapps OTSC2 and COL1A2.  
The presence of phenocopies in a pedigree affects linkage analysis. In the present 
study we faced a diagnostic problem with subject IV-5 of Family 2081. This subject was 
diagnosed with otosclerosis based on their audiological profile. Lack of a definitive 
diagnosis (actual visualization of stapes fixation) of otosclerosis in subject IV-5 allows us 
to exclude the genetic analysis of this subject in our final exclusion/Inclusion decision. 
Only subjects with otosclerosis confirmed by a stapedectomy were considered for the 
analysis. By doing so, OTSC4 appears to be the disease locus for Family 2081, when 
subject IV-5 is considered a phenocopy. This decision was subsequently reversed after 
later confirmation that subject IV-5 has grade 1 otosclerosis.  
 Otosclerosis has been characterized by reduced penetrance in previously mapped 
families, which complicates diagnosis
86,115,151
. Reduced penetrance can be attributed to 
age-dependent expression, environmental and/or genetic modifiers.  Otosclerosis usually 
develops between the third and sixth decade (late onset hearing loss). The severity of 
hearing loss in otosclerosis depends on the progression of the otosclerosis foci.  
To determine the frequency of possible otosclerosis disease alleles in the NL 
population we used population samples from a colorectal cancer study cohort. People 
who are recruited for colorectal cancer studies are not evaluated for hearing loss 
(otosclerosis) and the main drawback of using this cohort is under/over estimation of the 
allele frequency of a variant. The most acceptable cohort for determining the allele 
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frequency of possible otosclerosis variants would include people who were assessed 
audiologically and had no hearing loss. 
2.5 Conclusion  
In this chapter, linkage of both Family 2081 and 2114 to previously linked loci and 
three candidate genes was performed using a positional mapping technique. We are 
reporting exclusion of linkage of Family 2081 to any of the previously mapped loci. Also, 
Family 2114 was excluded from linkage to the seven previously mapped loci and three 
candidate genes presuming the mother is the disease carrier. This result raises the 
possibility of identifying a novel locus for both families. We also have illustrated the 
obstacles that complicate the study of otosclerosis and how this study has dealt with these 
obstacles. 
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3 Chapter 3 
 
 
 
 
 
 
 
A fifteen bp deletion in the FOXL1 gene causes familial otosclerosis 
in one family from NL and one from ON 
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3.1 Introduction  
In Chapter 2, Family 2081was excluded from linkage to previously published loci and 
three candidate genes using haplotype and two point linkage analyses. The key 
recombination that minimized the OTSC4 loci in the original publication was detected in 
a family member with mild conductive hearing loss which was not surgically confirmed. 
This raised the possibility of incorrect boundaries for OTSC4. In this Chapter, the distal 
boundary of OTSC4 was extended by 21.1 Mb through genotyping and haplotype 
analysis. Twelve functional candidate genes were sequenced and five samples were sent 
for whole exome sequencing. Targeted analysis of variants identified in the candidate 
region at Chr16q24 was carried out. Functional analysis was also done on the 15 bp 
deletion in the FOXL1 gene (Appendix 17). 
3.2  Subjects and methods 
3.2.1 Study population and clinical analysis 
Family 2081 is a multiplex family with seven confirmed cases of otosclerosis segregating 
in an AD mode of inheritance. Twenty-one DNA samples from Family 2081and 81 
Canadian otosclerosis probands (41 probands from NL and 40 probands from Western 
ON, contributed by Dr. Stanton) were available for the study. Otosclerosis in family 2081 
is classified according to the grading system (Chapter 2; pages 56-57). 
3.2.2  Genotype and haplotype analysis of Family 2081 
  Genomic DNA was extracted from peripheral leukocytes of all participants 
according to a standard method (Appendix 2). The OTSC4 haplotype was expanded by 
genotyping 21 members of Family 2081with nine polymorphic markers (D16S518, 
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D16S3094, D16S3098, D16S2625, D16S520, D16S422, D16S413, D16S3023 and 
D16S3026) that span 12.1 Mb, downstream of the lower boundary of the originally 
mapped OTSC4 locus. The proband from the ON family (IV-3) was genotyped with the 
nine polymorphic markers. All markers were labelled with blue fluorescent dye (6-FAM). 
DNA amplification and genotyping were carried out as described in Chapter 2 (page 58-
59).   
3.2.3 Sequencing genes within the candidate region  
The UCSC Genome Browser homepage
141
 and the March 2006 assembly (NCBI 
build 36.1) were used to define the genomic interval of each candidate region and to 
identify functional candidate genes. For primer design and PCR reaction, please refer to 
Chapter 2 (pages 60 and 61). Primer sequences for the 12 genes are outlined in Appendix 
13. 
3.2.3.1  Mutation screening 
The mutation screening panel for this locus was comprised of three affected 
siblings who carried the presumed disease haplotype (PID III-5, III-11, IV-5), one non-
disease carrier spouse (PID III-6), and one water control. This panel screened for the 
following genes PLCG2, IRF8, SCL38A8, ZDHHC7, SLC7A5, HSD17B2, COTL1, 
FOXF1, FOXL1, FOXC1, CA5A and OSGIN1. For segregation analysis, variant allele 
frequency and bioinformatics analysis please refer to Chapter 2 (pages 62). 
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3.2.4 Whole exome sequencing of five family members of Family 2081 
After Sanger sequencing of candidate genes in the linked region, five samples from 
family 2081 were sent for whole exome sequencing to validate the result and to fully 
cover the linked region at Chr16q24. Whole exome sequencing was chosen as the most 
cost-effective approach.   
3.2.4.1  Mutation screening panel 
Whole exome sequencing was carried out for five affected siblings of Family 2081 
(PIDs III-4, III-8, III-11, III-13, III-16) and two unaffected population controls Which 
were  assigned as unaffected, based on audiogram reports of normal hearing (at ages 55 
and 60). The Illumina platform was chosen due to higher coverage of the coding region. 
Samples were sent to Genome Quebec for library preparation, enrichment and whole 
exome sequencing.. DNA libraries were prepared using the TrueSeq DNA Sample Prep 
Kit. Exome enrichment was carried on prepared libraries. Paired end reads of 100 bp were 
sequenced on an Illumina Hiseq following standard manufacturer’s protocol. 
Approximately 50 to 150 million 100 bp paired-end reads from the Illumina HiSeq 2000 
sequencer were generated. All reads were required to have a length of at least 32 bp. The 
filtered reads were then aligned to the 1000 genome project reference sequence, which is 
currently used by Genome Quebec. Variants were annotated for dbSNP and for the 
variants effect on the gene (amino acid change). Finally the sample files were integrated 
into global files. The full pipeline report for NGS is attached in Appendix 14. Primers 
used for validating variants of interest are listed in Appendix 24.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
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3.3 Results 
3.3.1 Pedigree structure and clinical analysis 
Family 2081 is a multiplex family with seven members affected across two generations. 
Otosclerosis in Family 2081 appears to be inherited in an autosomal dominant mode. For 
further information on the pedigree structure and clinical analysis, refer to Chapter 2 
(pages 68-69 and 71-73). 
3.3.2 Genetic analysis 
3.3.2.1 Family 2081 is linked to a 9.7 Mb region downstream of OTSC4 
 Family 2081was excluded from linkage to the eight previously mapped loci 
(OTSC1, OTSC2, OTSC3, OTSC4, OTSC5, OTSC7, OTSC8 and OTSC10) and three 
candidate genes (COL1A1, COL1A2 and NOG) through haplotype and linkage analyses 
(Chapter 2). Initially, haplotype analysis in Family 2081 across the OTSC4 locus 
suggested linkage to OTSC4 but haplotype analysis of an extra Family member (PID III-
16) and a negative LOD score excluded this possibility. In the previous Chapter, we 
tested the linkage of Family 2081 to the fine mapped region of OTSC4, not to the entire 
reported OTSC4 locus. In the original study by Brownstein et al, distal recombination in 
one subject with mild conductive hearing loss changed the boundary of OTSC4 from 
D16S3091 (82.7 Mb) to D16S3097 (77.1 Mb), which excluded 5.6 Mb from analysis 
87
. 
As the distal recombination was identified in a person with mild conductive hearing loss 
and not confirmed surgically, I decided to expand the lower boundary of OTSC4. To do 
that, in addition to the 10 microsatellite markers used to genotype the OTSC4 locus, all 
available family members of Family 2081were genotyped with nine markers that covered 
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12.1 Mb downstream of the distal boundary (D16S3097) of the minimized OTSC4 locus. 
Four distinct parental haplotypes were created (purple, yellow, red and light green) and 
the parental haplotypes of II-3 and II-4 were inferred (Figure 3.1).   
All affected members shared a 9.7 Mb region of the light green haplotype between 
D16S518, at position 78.1Mb and D16S413, at position 87.8 Mb (Figure 3.1 and Table 
3.1). Two Family members (PIDIII-14 with uncategorized hearing loss and PID IV-12 
with no history of hearing loss) inherited the upper portion of the green haplotype 
between D16S518 and D16S2625. PID III-14 shared a 5.1Mb region of the 9.7 Mb linked 
green haplotype that covered 3 markers D16S3049, D16S3098 and D16S422 (Table 3.1). 
If we presume that PIDIII-14 and IV-12 are non disease carriers, the size of the 9.7 Mb 
linked region would reduce to 4.6 Mb. Otosclerosis is characterized by a wide range of 
clinical expression (SNHL, conductive, mixed hearing loss) and reduced penetrance.  For 
that reason, we did not designate PIDIII-14 and IV-12 as non-disease carriers and 
therefore, the 9.7 Mb region was fully examined. 
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Figure 3.1: Family 2081 co-segregating a 9.7 Mb haplotype telomeric to OTSC4 mapped locus 
All affected members share a 9.7 Mb region of the light green haplotype. A critical recombination between D16S413 and D16S520 in PID 
IV-5 minimized the linked region from 11.35 to 9.7 Mb.  Alleles sizes are given in base pairs and alleles in brackets were inferred. The 
gender of family members is hidden for confidentiality. Roman numerials on the side of the pedigree represent the generation number. 
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Table 3.1: Family 2081 affected members co-segregate a 9.7 Mb haplotype  
Bolded markers are the markers shared by all grade1 affected members of Family 2081. 
Surgically confirmed affected individuals are shaded black. All shaded black subjects share a 
region between markers D16S518 and D16S413. 
 
Markers Position 
Mb 
III-4 III-5 III-8 III-11 III-16 IV-3 IV-5 IV-10 III-16 III-14 IV-12 
D16S3107 66.2  294 294 275 275 275 294 294 292 275 275 275 
D16S3025 67.12  102 102 104 104 104 102 102 108 104 104 104 
D16S3095 68.50  150 150 156 156 156 150 150 150 156 156 156 
D16S752 70.74  105 105 117 117 117 105 105 113 117 117 117 
D16S2624 71.73 133 133 137 137 137 133 133 137 137 137 137 
D16S3106 71.26  190 190 200 200 200 190 190 196 200 200 200 
D16S3139 72.7  200 200 198 198 198 200 200 198 198 198 198 
D16S3018 73.08 259 259 263 263 263 259 259 253 263 263 263 
D16S3115 74.4  243 243 247 247 247 243 243 243 247 247 247 
D16S3097 77.3 202 202 208 208 208 202 202 200 208 208 208 
D16S518 78.3  273 273 288 288 288 273 273 287 288 288 288 
D16S3049 78.9  251 251 251 251 251 251 251 251 251 251 251 
D16S3098 81.4 155 155 155 155 155 155 155 155 155 155 155 
D16S422 82.9 205 205 205 205 205 205 205 205 205 205 205 
D16S2625 83.2 171 171 171 171 171 171 171 171 171 179 179 
D16S520 85.0 158 158 158 158 158 158 158 158 158 158 158 
D16S413 87.7  130 130 130 130 130 130 126 130 130 124 124 
D16S3023 88.4  82 82 82 82 82 82 82 82 82 82 82 
D16S3026 89.3 201 201 201 201 201 201 201 201 201 201 201 
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3.3.2.2  Mutation screening of functional candidate genes by Sanger 
sequencing 
According to UCSC genome browser (Feb2009 /hg19), the new locus located at 
Chr16q23.1-q24.2 contains 79 annotated genes. Due to the large number of positional 
candidate genes in the linked region, genes were prioritized for sequencing according to 
their expression and function related to bone remodelling. Genes that are expressed in the 
bone or immune system were prioritized for screening. In total, 12 candidate genes were 
sequenced. The function of each gene is described in Appendix 15. All twelve genes were 
screened using the following mutation panel: three affected siblings (PIDs III-5, III-11, 
and IV-5) and a spouse with no history of hearing loss (PID III-6). 
3.3.2.2.1  Variant analysis 
  Variant analysis of Family 2081 at this region was done under a dominant mode 
of inheritance. Under this mode of inheritance we would expect affected siblings (PIDs 
III-5, III-11, and IV-5) to carry a heterozygous mutation that is inherited from the parent 
PID II-4 and absent from the unaffected spouse PID III-6. 
Sequencing of the 12 genes using these four samples revealed 92 variants (Figure 
3.2 and appendix 16A). Of these ninety-two variants, 53 variants were present in the three 
affected siblings (PIDs III-5, III-11 and IV-5) as well as the unaffected spouse control 
(PID III-6).  For example, c.26C>T in the CA5A gene was detected in the three affected 
siblings PIDs III-5, III-11 and IV-5 as well as the unaffected spouse (PID III6) of Family 
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2081. Ten variants were present in only two out of three affected siblings. For example, 
c.770+125G>A in SLC7A5 was detected in two affected siblings PID III-5 and III-11 but 
it was not detected in the third affected sibling PID IV-5. Eleven variants were identified 
in one( PID IV-5), of 3 affected members and in one unaffected member (PID III-6). For 
example, c.218-104C>T in OSGIN1 exon 3 was found in the affected member PIDIV-5 
and in the unaffected member PID III-6 of Family 2081. Ten variants were found in the 
unaffected member PID III-6.  For example, c.1332C>A in exon 7 of OSGIN1 was found 
in the unaffected control member PIDIII-6.  In total, eight variants were found in the three 
affected siblings (PIDs III-5, III-11 and IV-5) but not in the unaffected control PID III-6. 
To determine candidate variants, allele frequencies of the eight variants were 
checked using SNP/1000 genomes project database. Two variants; c.2054+7G>A in the 
PLCG2 gene and c.432C>T, p. D144 in the IRF8 gene had frequencies of 2.1 and 1.5 % 
respectively (Table 3.2). Five were SNPs with frequencies ranging between 11 and 86 %. 
Only FOXL1 c.976-990del in FOXL1 was novel (Figure 3.3). The variants c.2054+7G>A 
in PLCG2, c.432C>T in IRF8, and c.976-990 het del in FOXL1were subjected to further 
analysis. 
 The novel FOXL1 c.976-990del, p. p.G327_L331del was predicted to cause an 
in-frame loss of five amino acid residues (glycine, isoleucine, proline, phenylalanine and 
leucine), which were highly conserved across five species (Figure 3.4). The silent and 
intronic variants were not predicted to effect splice sites. Only the 15 bp deletion in the 
FOXL1 gene was subjected to segregation analysis.  
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All members of Family 2081 with available DNA were tested for segregation of 
the 15 bp deletion in FOXL1.  This showed that the 15 bp deletion in the FOXL1 gene 
was segregating with the lower portion of the light green haplotype between D16S 520 
and D16S413 (Figure 3.5) in the seven grade I otosclerosis members, PID IV-10 and IV-
3. Two family members (PID III-14 and IV-12), who did not inherit the lower part of the 
green haplotype, did not harbour the FOXL1 15 bp deletion. To check the frequency of 
the 15 bp deletion in the NL population, 116 ethnically matched population controls were 
screened and all were wild type for the deletion.  
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Figure 3.2: Flowchart showing the steps used to analyse variants identified in Family 
2081, using Sanger sequencing 
Only the 15 bp deletion in the FOXL1 gene fully segregated with otosclerosis in Family 2081. 
Allele frequencies of identified variants were determined by using the publicly available SNP 
database and 1000 genomes project. Pathogenicity of missense mutations was evaluated by using 
SIFT and Polyphen prediction programs. Five prediction programs (SSF, HSF, MaxEntScan, 
NNSPLICE, and GeneSplicer) were used to predict any splicing effect.  
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Table 3.2:  Allele frequency of variants residing on the light green haplotype 
Frequencies of the identified variants within the linked region were estimated by SNP/1000 
genomes databases. The novel variant in the FOXL1 gene is bolded. 
 
 
 
 
 
 
 
Variant information  Allele frequencies using SNP 
database 
Gene 
name  
Position Variants  SNP status Allele 
frequency  
Sample 
size 
Frequency 
PLCG2 Int 20 c.2054+7G>A rs138158454 A=0.021 46 2.1 % 
PLCG2 Ex10 802C>T, p.R28RW rs1143687 T=0.11 184 11% 
PLCG2 Ex12 987-97G>C rs4889430 C=0.113 2184 11.3% 
FOXL1 Ex1 976_990del,  
p. G327_L331del 
Novel Novel 0 0 
IRF8 Ex4 432C>T, p.D144 rs16939945 T=0.015 33 1.5% 
ZDHHC7 Ex3 315+55G>A rs93173 A=0.545 22 54.5% 
ZDHHC7 Ex7 538-11C>T rs66772728 T=0.867 120 86% 
HSD17B2 Ex1 -133T>C rs4445895 C=0.472 286 47.2% 
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Figure 3.3: Electropherogram showing the heterozygous deletion of 15 bp in the 
FOXL1 gene in PID III-8 
The upper panel represents the reference sequence of the FOXL1 gene. The lower panel shows a 
trace sequence in subject III-8 with the deletion underlined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
170 
 
 
 
Figure 3.4: Multiple alignment of FOXL1 p.G327_L331del across five species   
Upper panel; Clustal W was used to align orthologos from human; NP_005241.1, Gallus; 
XP_001231599.2, M.musculus; NP_032050.2, B.taurus; XP_002694802.1, C.lupus; 
XP_851625.1, p.troglodytes; XP_511154.2. Lower panel; Weblogo image shows conservation of 
the five deleted amino acid across human and five species. Vertical axis represents the 
conservation scale; horizontal axis represents the amino acids positions.  
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Figure 3.5: Partial pedigree of Family 2081 segregates FOXL1 c. 976-990 het del 
FOXL1 c. 976-990del resides on the disease haplotype (light green) and segregates with otosclerosis in Family 2081. Roman numerials on 
the side indicate the generation. The blue solid symbol refers to otosclerosis grade I. The half blue and white symbol refers to hearing loss 
grade II. The half black and white symbole refers to hearing loss, uncategorized. The gender of family members in this pedigree is hidden for 
confidentiality. Allele sizes are given in base pairs and alleles in brackets were inferred. 
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3.3.2.3 Mutation screening of functional candidate genes by whole exome 
sequencing  
Sequencing of 12 genes in the Ch16 candidate region identified the15 bp deletion 
in the FOXL1 gene as the most promising causative mutation. To validate this result, full 
sequencing of the remaining annotated positional candidate genes (79 genes) in the Chr16 
linked region was carried out through whole exome sequencing and targeted analysis of 
the Chr16 linked region. Whole exome sequencing was carried out for five affected 
siblings of Family 2081 (PID III-4, III-8, III-11, III-13, III-16) and two unaffected 
controls.   
3.3.2.3.1  Variant analysis 
Variant analysis of this region was carried for Family 2081 under an AD mode of 
inheritance. We would expect affected exomes (PID III-4, III-8, III-11, III-13, III-16) to 
carry a heterozygous mutation that is absent from the two unaffected control samples. 
Results from Genome Quebec were received as an excel file output. Variants identified in 
genes within the newly linked region at Chr16q23.1-q24.2 were analyzed.The mean 
coverage of the sequenced variants was 65 %.   
Sequencing the coding region of the 79 annotated positional candidate genes 
revealed a total of 40 variants in the five affected exomes of Family 2081 (Figure 3.6 and 
Appendix 16B). Variants that were not exclusively found in the five affected exomes 
(present in 1, 2, 3 or 4 out of 5) were removed. For example, the M200V variant in the 
USP10 gene was found in two affected exomes (PID III-13 and III-11) but not in the 
remaining 3 affected (PID III-8, III-4 and III-16) exomes (Appendix 16B). Removing 
these variants decreases the number of variants from forty to nine. These nine variants 
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were exclusively found in the affected exome of Family 2081 and of these nine variants, 
three in PLCG2, FOXL1 and IRF8 were previously identified through Sanger sequencing.  
Allele frequencies of these nine variants were checked using SNP/1000 genome 
database. One synonymous variant c.432C>T, p.D144 in the IRF4 gene has a frequency 
of 1.5 % (Table 3.3). Five variants have allele frequencies ranging between 5.8 % and 11 
%.  Two variants (c.749A>G, p. Q250R and c.658 C>T, p. Q220* in the PKD1L2 gene) 
were SNPs with no frequency reported in the SNP/1000 genome database and one variant 
(FOXL1 c.976_990del) was novel. Of the nine variants, four were subjected to further 
analysis.  
The novel FOXL1 15 bp deletion was predicted to cause an in-frame loss of five 
amino acid residues (glycine, isoleucine, proline, phenylalanine and leucine). The 
missense mutation (c.749A>G, p. Q250R in the PKD1L2 gene) was predicted to be 
benign by SIFT (score 0.57) and Polyphen (score 0.004), but it was predicted to create a 
new donor site. No splicing effect was detected for the silent variant c.432C>T in 
PLCG2. The c.658 C>T, p. Q220* in the PKD1L2 gene was predicted to create a 
premature stop codon at position 220. Of the four variants, three (c.749A>G, p. Q250R, 
c.658 C>T, p. Q220* and c.976_990hetdel) were subjected to segregation analysis. 
As shown previously, the 15 bp deletion was fully segregating with the lower part 
of the light green haplotype between markers D16S520 and D16S413. The c.658 C>T, p. 
Q220* and c.749A>G, p. Q250R were segregating with the upper part of the light green 
haplotype between markers D16S3049 and D16S3098 (Figure 3.7).  In addition, the c.658 
C>T, p. Q220* variant was also detected in an unaffected spouse (PID III-10) and two 
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subjects (PID III-2 and IV-2) from the left side of the family who did not inherit the light 
green haplotype. This showed that the c.658 C>T, p. Q220* did not segregate with 
otosclerosis in Family 2081 and excluded it from further analysis.  
Of the three variants, two (c.749A>G, p. Q250R and c.976_990hetdel) were 
segregating with the light green haplotype; c.749A>G, p. Q250R segregates with upper 
part and c.976_990hetdel segregates with the lower part. The c.976_990del was absent 
from the SNP/1000 genomes database and from 116 NL population controls. The 
c.749A>G had no frequency data reported in the SNP/1000 genome databases. To 
determine the frequency of this variant in the NL population, 80 population control 
samples were screened and 10 samples of the 80 had this variant which  gives a frequency 
estimate of  (0.125/80) 12.5% in the NL population. Since the estimated frequency of this 
variant was high in NL population, this variant was excluded from further analysis. Only 
the FOXL1 deletion passed all the filtration criteria. A combination of Sanger and exome 
sequencing of the annotated positional candidate genes in the Chr16 linked region 
identified the 15 bp deletion in the FOXL1 as the causative mutation for otosclerosis in 
Family 2081.  
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Figure 3.6: Flowchart showing the filtration steps of variants identifed in sequenced 
exomes of Family 2081 at the chr16q linked region. 
Of three variants, FOXL1 c.976_990hetdel was novel and fully segregates with otosclerosis in 
Family 2018. Allele frequencies of identified variants were determined by using publicly 
available SNP database and 1000 genomes. Pathogenicity of missense mutations was evaluated 
by using SIFT and Polyphen prediction programs. Five splicing prediction programs were used to 
check possible splice site effects: SSF, HSF, MaxEntScan, NNSPLICE, GeneSplicer. 
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Table 3.3: Allele frequencies of NGS variants preserved on the disease haplotype  
Allele frequency represented by percentage. No frequency means no data was available in 
SNP/1000 genomes database. Bolded variants were subjected to segregation analysis.
Gene 
name  
Genomic 
Position 
Variants  SNP ID SNP status  Allele frequency in 
SNP/1000 genomes 
DYNLRB2 
 
80583497 c.196C>T,    
p.L66   
rs11866734 Silent  T=0.27 224 27% 
PKD1L2 81242107 
 
c.749A/G, 
p.Q250R 
rs143480612 Missense No frequency 
PKD1L2 81242198 c.658 C>T, 
p.Q220* 
 
rs7499011 
 
Non-sense No frequency 
PLCG2 81922813 802C>T, 
p.R268RW 
rs1143687 Missense T=0.11 184 11% 
ATP2C2 84474484
  
c.1231G>A, 
p.G411S 
rs2303853 Missense A=0.067 120 6.7% 
KLHL36 84691433 c.1020C>T,         
p. V340 
rs72797514 Silent T=0.058 120 5.8% 
IRF8  432C>T,    
p.D144 
rs16939945 Synonymous T=0.015 33 1.5% 
MTHFSD 86565826 c.940G>C, 
p.G152R 
rs3751803 Missense C=0.078 116 7.8% 
FOXL1 86613301 c.976_990hetdel Novel In frame 
deletion  
Novel 0 0 
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Figure 3.7: Partial pedigree of Family 2081 segregates a15 bp del in FOXL1 and two variants in the PKD1L2 gene. 
Figure shows segregation of FOXL1 c. 976_990del, PKDIL2 c.749A>G, p. Q250R and c.658 C>T, p. Q220* in Family 2081. Roman 
numerials on the side indicate  the generation. The blue solid symbol refers to otosclerosis grade I. The half blue and white symbol refers to 
hearing loss grade II. The half black and white symbol refers to hearing loss, uncategorized. Allele sizes are given inbase pairs) and alleles in 
brackets were inferred. The gender of family members in this pedigree is hidden for confidentiality.
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3.3.2.4 Identify the effect of the FOXL1 in NL and ON families 
To identify the role of FOXL1 15 bp deletion in other otosclerosis families, newly 
recruited otosclerosis probands from NL (41) and from western ON (40) were screened 
for the 15 bp deletion in FOXL1. As a result, one unrelated family from ON was 
identified with the 15 bp deletion. In order to determine the possible founder effect 
between the NL family and ON family, haplotypes across the extended OTSC4 were 
created for the ON proband using intragenic SNPs and five microsatellite markers and 
compared with the NL proband. Comparing haplotypes between the NL and ON probands 
showed that both probands shared the intragenic SNP genotyped alleles and alleles of two 
microsatellite markers downstream of the FOXL1 gene (Table 3.4). 
To examine the role of other mutations in FOXL1 in the recruited NL families 
with otosclerosis, DNA of 17 NL probands were bidirectional sequenced for the whole 
exon and the flanking exonic- intronic region of FOXL1. Full sequencing of the FOXL1 
gene in the 17 probands resulted in seven variants (Table 3.5). Of these, two (*1216C>T 
and *1902C>T) were SNPs with frequencies of 3.7 % and 6.5 % respectively. Four 
variants (c.47C>A, *352C>A, *925A>T and *1326G>T) were novel and one (c.814G>A) 
was a SNP with a frequency of 0.9 %. Of these five, one was a missense and four were 
located in the 3UTR. The missense mutation (c.814G>A) was predicted to be benign by 
SIFT and polyphen. No splicing prediction for the c.814G>A variant was discovered.  
Segregation analysis and functional assessment of the 3UTR variants will help to 
determine the actual role of these variants in otosclerosis development. 
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Table 3.4: Shared ancestral haplotype between affected probands from NL and ON 
Shared alleles of 37 SNPs and two markers between NL and ON probands are highlighted green. 
SNP ID Genomic position Nucleotide 
change  
Amino acid change  Family 2081 
proband 
III-8 
Family O1 
Proband  
IV-3 
D16S3098 8148388 - - 155 155 162 167 
D16S422 82911347 - - 205 208 205 208 
D16S520 86516112 - - 158 160 154 160 
rs374262221  86612362 c.33C>T p. A11 C C C C 
rs142168655  86612378 c.49A>T p.  M17L A A A A 
rs151159060  86612388 c.59T>C p.L20 T T T T 
rs377725521  86612424 c.95T>C p.  F 32S  T T T T 
rs370331025  86612461 c.132C>G p. A44 C C C C 
rs145237316  86612467 c.138C>A p. T46 C C C C 
rs200593453  86612469 c.140C>T p. P47L C C C C 
rs367924573  86612473 c.144G>A p.Q48 Q G G G 
rs199982325  86612539 c.210C>T p. V70 C C C C 
rs113108019  86612644 c.315C>G p. D105E C C C C 
rs371951781  86612674 c.345G>T p. E115 G G G G 
rs201070716  86612678 349C>A p. P117T C C C C 
rs374419803  86612702 c.373C>T p. L125 C C C C 
rs141410677  86612708 c.379C>T p. P127S C C C C 
rs200323545  86612744 c.415C>A p. R139 C C C C 
rs374413539  86612780 c.451G>A p. A151T G G G G 
rs201954519  86612784 c.455C>T p. P152T C C C C 
rs112864402  86612872 c.543C>G p. P181 C C C C 
rs202031875  86613074 745C>T p. R249C C C C C 
rs372247336  86613102 c.773C>T p. S258F C C C C 
rs62051072  86613143 c.814G>A p. G272S G G G G 
rs374181632  86613160 c.831A>T p. S277 A A A A 
 
 
 
180 
 
 
 
 
 
 
 
 
 
 
 
 
rs200642220  86613171 c.842T>C p. L281P T T T T 
rs188450396  86613173 c.844C>A p. L281I C C C C 
rs181086974  86613179 c.850G>A p. G284S G G G G 
rs368421556  86613204 c.875G>A p. R292H G G G G 
rs376672255  86613206 c.877C>T p. L293 C C C C 
rs138954668  86613221 c.892C>T p. L298 C C C C 
rs372235566  86613226 c.897C>T p. A299 C C C C 
rs369054293  86613242 c.913C>T p. RC C C C C 
rs371495333  86613273 c.944A>G p. D315G A A A A 
rs376500241  86613274 c.945C>T p. D315 C C C C 
rs185528186  86613283 c.954C>T p. V318 C C C C 
rs143767765  86613292 c.963C>T p. G321 C C C C 
Novel 86613301 c.976_990hetdel p. G325_L329del del wt Del Wt 
rs200555965  86613324 c.995A>T p. Y332F A A A A 
rs138392858  86613328 c.999C>T p. F333 C C C C 
D16S413 87893836 - - 130 132 130 142 
D16S3023 88521327 - - 82 82 82 79 
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Table 3.5: Variants identified in FOXL1 in NL otosclerosis probands  
Seven variants were identified as result of full sequencing of the FOXL1 gene in 17 NL 
probands with otosclerosis.  
 
 
3.3.3 Functional studies for the 15 bp FOXL1 deletion  
Functional studies to test the effect of the FOXL1 15 bp deletion at the RNA and protein 
level were carried out by a post-doctoral fellow (Ahmed Mostafa) as described in 
Appendix 17. This work showed that the 15 bp deletion did not affect the RNA 
expression; however, it did result in up regulation of the FOXL1 protein expression. A 
microarray study which was done to investigate the effect of the 15 bp deletion on 
downstream genes showed deregulation of many genes, especially those involved in 
inflammation and immunity. 
 
Variants  SNP ID SNP/ 1000 genomes 
database frequency 
Prediction 
SIFT/ Polyphen 
c.814G>A, p.G272S rs62051072 0.009  (0.9%) Benign 
c.47C>A, p.P16H - Novel Benign 
*352C>A - Novel Not predicted  
*925A>T - Novel Not predicted 
*1216C>T rs2288016 0.065  (6.5%) Not predicted 
*1326G>T - Novel Not predicted 
*1902C>T rs4843173 0.037  (3.7%) Not predicted 
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3.4 Discussion 
I used a positional mapping approach on a large extended NL family (2081) to 
identify a 15 bp deletion in the FOXL1 gene that was then shown to segregate with 
otosclerosis in this family. Family 2081 is a large, multiplex, five generation family 
which was excluded from linkage to previously mapped loci by our previous study 
(Chapter 2) . In this Chapter, extension of the OTSC4 haplotype suggested linkage of 
Family 2081 to a 9.7 Mb region at Chr16q23.1-q24.2. This 9.7 Mb region contains 
approximately 79 positional candidate genes. Bidirectional Sanger sequencing of 12 
candidate genes, exome sequencing and targeted analysis of the linked region identified a 
15 bp deletion (c.976_990hetdel) in FOXL1 that segregated with the disease haplotype 
and was absent from the SNP/1000 genomes project database and 116 NL population 
control chromosomes. This 15 bp deletion results in an inframe deletion of five highly 
conserved amino acid residues located at the C-terminus end of the FOXL1 protein.  
This Chapter describes the mapping of a new locus at Chr16q23.1-q24.2 in Family 
2081. The FOXL1 gene is located 9 Mb downstream of the lower boundary of the 
previously linked locus OTSC4.  Affected members of Family 2081 shared a single 
haplotype across the new locus at Chr16q23.1-q24.2. This haplotype was shown to be 
inherited from the parent PIDII-4. A high rate of recombination events was evident across 
the studied region at Chr16. This region is located toward the telomere of chromosome 
16.It has been reported that the rate of meiotic recombination is higher at telomeric 
regions 
40,152,153
.  
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To examine the role of the 15 bp in FOXL1 in other families with otosclerosis, 
otosclerosis probands (representing 81 families) from NL and ON were screened; one of 
the families from ON had the deletion. Haplotyping of the ON proband using genotyped 
microsatellite markers spanning the Chr16q23.1-q24.2 region and FOXL1 intragenic 
SNPs indicated a common ancestor.  Interestingly, sequencing of FOXL1 by OTSC4 
group didn’t reveal any deleterious mutations which suggest that the locus identified in 
this study is a new one (personal communication). 
The Human Forkhead (FKH) box (FOX) gene   consists of 43 members. They 
were named after the discovery of the Drosophila FKH gene in 1989. FOX proteins act as 
transcription factors and are characterized by the sharing of common elements that are 
formed from approximately 110 amino acid DNA binding sites, called the fork head 
domain (FHD). The FOX gene transcription factor family has been shown to be important 
in embryogenesis and cell differentiation
154,155
. FOX proteins also play an important role 
in the regulation of other genes in different species, from yeast to human, and are 
involved in different biological processes such as tumorigenesis and speech acquisition in 
humans 
156
 
157
 
158
. 
 The FOXL1 gene (Accession number; NM_005250) consists of one coding exon, 
a small 3UTR and a huge 5UTR. The FOXL1 protein, like other members of the FOX 
family, contains the conserved sequence domain FHD DNA binding site. FOXL1 is 
highly expressed in otic vesicles in vertebrates and is important in their development by 
acting as a negative regulator to Sonic hedgehog (SHH) signalling and in embryonic 
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transcriptional regulation
159
. Previous in vivo studies in mice have shown that Foxf1 
(Forkhead transcription factor f1) and Foxl1 (Forkhead transcription factor l1) genes are 
the targets of the Hedgehog (HHL) signalling pathway in stomach development as their 
expression is controlled by Gli2 and Gli3 transcription factors, which are components of 
the HHL pathway. Their mutant forms show reduced expression of BMP4 in the gut.  
BMP4 and BMP2 genes have been previously associated with otosclerosis in human
125,160
. 
The HHL signalling pathway is important in regulating many cell processes, including 
cell proliferation, differentiation, angiogenesis, cellular matrix remodelling, and stem cell 
homeostasis, and deregulation of this pathway leads to the development of different forms 
of tumours 
161
. Another study carried out in mice has shown that mutant Foxl1 causes up 
regulation of syndecan1 adhesion molecules, which suggests that Foxl1 has a role in 
decreasing bone formation and increasing bone reabsorption by increasing expression of 
IL11 and RANKL genes 
162,163
.  
FOXL1 and FOXC2 (Forkhead Transcription Factor C 2) genes are mapped to 
Chr16q24 and both have conserved GLi binding, which suggests they have a common 
regulatory mechanism. It has been found (Appendix 17) that the FOXL1 15 bp deletion 
did not cause any change at the RNA level but resulted in an up regulation of the FOXL1 
mutant protein. Up regulation of the mutant protein could be caused by accumulation of 
the misfolded protein, which would cause a gain of function. Deletion of an amino acid, 
or an incorrect amino acid could cause destabilization of the protein, resulting in incorrect 
folding of the protein. It has been reported that an  incomplete or incorrectly folded 
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protein may be degraded resulting ina loss of function or may accumulate and cause a 
gain of function 
165
. 
 The microarray expression analysis in appendix 17 was done to identify genes 
deregulated by the FOXL1 deletion. The expression of 31000 genes in mutant and wild 
cell lines was compared and numerous deregulated genes were identified. Interestingly, 
we noticed that there are many cytokines including: IL1A 
166
, IL8, CCXL10 
167
 
168
 
169
 
170
, 
IFNB1 
171
, IL29
172
 and IFIT1
173
 that have a role in inflammation and osteoclastogensis 
were deregulated by the mutant FOXL1. A previous study that used prediction algorithms  
to construct a gene regulatory network of systemic inflammation predicted that FOXL1 
regulates many cytokines including IL1A, IL6, IL1B, CXCL12, CXCL14, CCL18, IL22 
and IL8 but because of a lack of information about the expression of the FOXL1 gene, the 
authors of the study weren’t able to verify their findings 174. Another study of gene 
expression between normal and otosclerotic human stapedial footplates identified many 
genes that were differentially expressed in otosclerosis These genes were predicted to be 
involved in cytokine signaling and inflammation pathways as well as others
173
and it was 
hypothesized that the deregulation of the cytokine signaling pathway has a role in 
abnormal bone remodeling. Our finding agrees with these studies and suggests that 
cytokine pathways have a role in the of development otosclerosis.  
The study outlined in appendix 17 validate the change in expression of IL29 and 
CXCL10 as a result of the FOXL1 15 bp deletion in mutant compared to wild type cell 
lines. IL29 levels show a 2.52 fold increase in the FOXL1
-Mut
 as compared to FOXL1
-WT
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transcription factors. IL29, known also as interferon lambda, has a role in modulating the 
immune response. IL29 has a role in inhibition of T-helper 2 cells (Th2) and changes the 
Th1/Th2 cell response through down-regulation of Interleukin 13 (IL13)
175
.  Its been 
shown that IL29 up-regulates the level of IL6, and IL10 
176
  and that IL29 induces 
secretion of IP-10, MIG and IL8 cytokines in the peripheral blood cells, which have a role 
in systemic lupus erythromatosis pathogenicity 
177
.  Recently, it was shown that IL29 was 
deregulated in a patient with rheumatoid arthritis which would indicate a role in 
inflammation, one of the signs of otosclerosis
172
.   
We have shown that CCXL10 expression decreases by 2.85 fold in FOXL1
-Mut
 
compared to FOXL1
-WT
. CCXL10 is an interferon inducing protein and is expressed in 
osteoblasts at different levels during osteoclast differentiation
178
. A previous study has 
shown the importance of CCXL10 and CCXL13 in osteoblastic activity by examining the 
expression of chemokine receptors in isolated human osteoblasts.  During bone 
inflammation, mononuclear cells invade bone stroma and secrete chemokines and 
cytokines that interact with specific receptors on the osteoblast. Analysis of expression of 
chemokine receptors in osteoblasts showed CXCR3 and CXCR5 receptors to be highly 
expressed in the osteoblast and also identified CCXL10 and CCXL13 as ligands for these 
receptors. Binding of CCXL10 and CCXL13 to their receptors on the osteoblast stimulates 
and increases the b-N-acetylhexosaminidase (Hex) and alkaline phosphatase (ALP) 
activity. Hex is an enzyme known to have a role in endochondral ossification and bone 
remodeling. ALP is an important enzyme for bone calcification 
179
.  Bone specific ALP is 
reported to be increased in cases of bone loss (osteoporosis) 
180
. Changing levels of the 
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expression of CCXL10 at any stage of osteoblast differentiation could affect secretion of 
ALP and Hex enzymes, which would affect bone remodeling.  
We have identified a novel founder deletion in the FOXL1 gene that causes 
otosclerosis in a family from NL and a family from ON. We believe that the study in 
appendix 17 identified two possible downstream genes (IL29 and CCXL10) that possibly 
have a role in otosclerosis development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
188 
 
3.5 Conclusion 
This study has identified a novel founder 15 bp deletion in the FOXL1 gene which 
segregated with the otosclerosis phenotype in a NL family in a dominant mode of 
inheritance.  The mutation was also found in an ON family. Functional studies have 
shown that the c.976_990hetdel in FOXL1 upregulates the FOXL1 protein. A microarray 
study of four FOXL1 transfected cell lines has identified numerous differentially 
expressed genes and a number of pathways that potentially have a role in otosclerosis 
pathogenicity. This study is the first to identify a mutation in a transcription factor 
causing otosclerosis, and identifies the downstream effects of the mutation. This result 
provides an opening to understanding the mechanism underlying the development of 
otosclerosis. The differentially expressed genes identified can be considered as candidates 
for screening otosclerosis patients with no genetic etiology. 
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4 Chapter 4  
 
 
 
Family 2114: Genome-wide linkage analysis and exome 
sequencing  
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4.1 Introduction  
 
In Chapter 2, otosclerosis segregating in Family 2114 was excluded from linkage to 
the six reported OTSC loci (OTSC1, OTSC3, OTSC4, OTSC5, OTSC7, and OTSC8) and 
the two associated candidate genes (COL1A1 and NOG) through haplotype analysis. 
Interestingly, affected members of Family 2114 shared a region that covered 57 Mb (86 
Mb-143 Mb) at Chr 7q21.11-q35, overlapping with both the OTSC2 locus and COL1A2 
gene.  However, absence of DNA from the proband’s parents interfered with phasing the 
haplotypes across these two loci. Subsequent recruitment of maternal relatives helped to 
resolve the proband’s maternal haplotype and subsequently excluded linkage of Family 
2114 to both OTSC2 and COL1A2 from the mother’s side, suggesting that it may be 
possible to identify a new otosclerosis locus by conducting further studies on this family. 
In this Chapter, I use both SNP genotyping and exome sequencing to look for a novel 
otosclerosis locus/gene.  
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4.2 Subjects and methods 
4.2.1  Study population and clinical analysis 
To recap, Family 2114 is a multiplex family with five confirmed cases of otosclerosis, 
apparently segregating as an AD trait. Genomic DNA from eight relatives across two 
generations was available and a grading system was used to categorize otosclerosis in 
Family 2114 (refer to Chapter 2, pages 55-57 for details).   
4.2.2 Genome-wide linkage analysis 
4.2.2.1  Genome wide SNP genotyping  
To identify a new locus, genomic DNA from the five siblings confirmed to have 
otosclerosis (PIDs III-1, III-2, III-4, III-5 and III-7), one unaffected sibling (PID III-6), a 
maternal aunt with a history of hearing loss (PID II-6), and a maternal uncle with no 
history of hearing loss (PID II-5) was sent to the Genome Centre at McGill University for 
genotyping 610,000 SNPs on a 610K Illumina SNP array. Nine genomic DNA samples 
from unrelated NL subjects with normal hearing were included in the analysis as 
population controls. The genotyping data obtained from the Illumina SNP array was 
analyzed by Dr. Pingzhao Hu at The Center for Applied Genomics, University of 
Toronto.  
4.2.2.2  Genome wide linkage analysis  
4.2.2.2.1 Theoretical Maximum LOD Scores 
Dr. Hu performed simulated analysis in order to obtain the theoretical maximum 
LOD score for Family 2114 using a two-point comparison under both dominant and 
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recessive models. The LOD score calculated from this simulation indicated the maximum 
possible score that the pedigree structure can achieve.    
4.2.2.2.2 SNP filtration  
 Genotype results from Genome Quebec were sent to The Center for Applied 
Genomics (TCAG) in Toronto for this analysis. First, the genotype calls in the family 
were exported from Genome Studio software (V2010.3). Minor allele frequencies were 
estimated from the genotypes of nine unrelated hearing loss NL samples and the genetic 
distance of the SNPs was obtained from the TCAG report.   
4.2.2.2.3 Multipoint linkage analysis  
Linkage analysis was carried out on the Family 2114 pedigree with Merlin 1.12 
181
 
using the observed genotypes. Multipoint linkage analysis requires estimation of the 
disease allele frequency and penetrance. The disease allele frequency is usually estimated 
from the prevalence of the disease in the population. The prevalence of clinical 
otosclerosis was estimated to be 0.3-0.5 % in the Caucasian population 
71
. I assumed that 
the NL population had the same prevalence and the multipoint linkage analysis with 
disease allele frequencies of 0.07 and 0.1, corresponding to disease prevalence of 0.5 % 
and 1 % for the AR model was carried out. For the AD disease, the disease allele 
frequencies used were 0.0025 and 0.005, corresponding to prevalence of 0.5 % and 1 %.  
For both dominant and recessive models, multipoint linkage analysis was performed 
assuming otosclerosis is 100% penetrant (Appendix 21). 
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4.2.3 Genotyping and haplotypes analysis 
Four microsatellite markers (D17S1829, D17S1807, D17S1839 and D17S1822) 
that span the newly linked region at Chr17q25.1-q25.3 and five markers (D16S422, 
D16S2625, D16S520, D16S413 and D16S3023) at Chr16q24 were used for genotyping 
members of Family 2114. Genomic DNA from members of Family 2081 was also 
genotyped with markers at Chr17q25.1-q25.3 and used as controls for NGS analysis. PCR 
amplification and genotyping were carried out as mentioned in Chapter 2 (pages 57-58).   
4.2.4  Sequencing of positional candidate genes within the linked regions  
4.2.4.1 Candidate genes sequencing by Sanger sequencing 
The UCSC Genome Browser homepage
141
 and the March 2006 assembly (NCBI 
build 36.1) were used to define the genomic interval of each critical disease region and to 
identify candidate genes. From these, a subset of genes was chosen for sequencing based 
on knowledge of gene function and gene expression. For example, otosclerosis is a bone 
disease and it is hypothesized that otosclerosis develops as a result of abnormal bone 
remodeling in the otic capsule. For that reason, genes involved in bone metabolism and 
bone remodelling, and genes that are expressed in bone cells, connective tissue or the 
immune system, would make excellent functional candidate genes to be prioritized for 
sequencing. Primer design, amplification and sequencing were carried out as given in 
Chapter 2 (pages 60-61). Primers for all functional candidate genes are listed in Appendix 
22. 
The proband of Family 2114 was primarily sequenced for the following 11 
physical candidate genes: BIRC5, CTDNEP1, TIMP2, RPL38, SLC9A3R1, USH1G, 
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OTOP2, KCTD2, RNF157, ITGB4, and FOXJ1.  Details regarding the function of these 
genes are provided in Appendix 23. 
4.2.4.2    Whole exome sequencing of Family 2114   
Whole exome sequencing was carried out on four affected siblings (PID III-1, III-
2, III-4 and III-7). Two control exomes from the NL population with no hearing loss 
(based on late audiograms at ages 55 and 60) were also sequenced. Whole exome 
sequencing was carried out as described in Chapter 3 (pages 158-159). Primers used to 
validate variants of interest are listed in Appendix 23. The data received from Genome 
Quebec provided us with the nucleotide change, genomic position, and variant MAF from 
SNP/1000 genome database. The full pipeline report for NGS is attached in Appendix 14. 
4.2.4.3 Variant analysis 
An allele frequency of 2 % was used as the cut-off limit for heterozygous variant 
analysis under the dominant mode of inheritance. Variants with population frequencies of 
2 % or less were subjected to further analysis. For detailed information about the variant 
analysis, please refer to Chapter 2 (page 51-53).  As I could not rule out recessive 
inheritance, I needed to estimate the frequency of heterozygous variants in the general 
population. In this case, the frequency of the heterozygous carrier would be higher than 
that of the homozygous affected patients.  To determine the frequency of the 
heterozygous carrier under the recessive mode of inheritance, Hardy-Weinberg (H-W) 
equilibrium
182
 was carried out, considering the disease allele (q) and the normal allele (p) 
and using the following equation p
2 
+2pq + q
2  
=1.   
 
 
 
195 
 
                           
                                                       
                       
        
       
             
       
                     
                     
                          
           
                                                            
                                                           
                                                
 
About 0.13 (13 %) of the population will be carriers of the otosclerosis allele and 
approximately 0.5 % will be homozygous affected. Heterozygous variants with 
frequencies of 13 % or less in the SNP/1000 genomes database were included in the 
analysis under recessive inheritance. The allele frequency of homozygous variants was 
expanded to 2 %, similar to dominant heterozygous variant allele frequency. 
Homozygous variants with frequencies of 2 % or less were subjected to further analysis. 
Homozygous variants under the recessive mode of inheritance and heterozygous variants 
under the dominant mode of inheritance were analyzed as shown in Figure 2.1. The allele 
frequency of identified variants was checked first using the SNP/1000 genome database. 
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Variants with an allele frequency of 2 % or less were subjected to further analysis. 
Variants with an allele frequency of more than 2% were excluded from further analysis. 
4.3 Results 
4.3.1  Pedigree structure and clinical analysis  
Family 2114 is a multigenerational family with five cases of otosclerosis. 
Otosclerosis in Family 2114 appears to have a dominant mode of inheritance. Although 
the proband’s mother was presumed to be the disease carrier (because she has a history of 
hearing loss), a recessive mode of inheritance could not be ruled out because of the lack 
of clinical information on the paternal side of the proband’s family. For further 
information on pedigree structure and clinical analysis of Family 2114, please refer to 
Chapter 2 (pages 63-66).  
4.3.2 Genome wide linkage analysis 
Although it appears from the pedigree structure that otosclerosis is inherited as an 
AD trait, genotype analysis was carried out under both the dominant and recessive modes 
of inheritance for reasons listed above. However, linkage simulation yielded a max LOD 
of 2.5 under a recessive model and the results from the multipoint analysis yielded the 
theoretical maximum at Chr17q25.1-q25 under a recessive model. For the dominant 
model, the maximum theoretical LOD score was 1.73 and linkage analysis yielded a 
maximum observed LOD score of 1.4 at each of five distinct genomic loci (Table 4.1), 
including the same Chr17 locus identified under a recessive model.  
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It was important to first see if any of the five loci (7q, 10p, 10q, 16q, and 17q) 
overlapped with previously mapped or associated otosclerosis genes/loci. For both 10p 
and 10q, there were no mapped OTSC loci or associated genes. Chr 7q, 16q and 17q, 
however, harboured otosclerosis loci. Comparing the linked regions giving positive LOD 
scores with critical otosclerosis boundaries (Table 4.1) revealed that the Chr7 critical 
region overlapped with both OTSC2 and COL1A2 (as identified in Chapter 2) and the 
Chr16q locus overlapped with the new otosclerosis locus identified in Chapter 3.  
 
 
Table 4.1 Regions with an observed LOD score >1 under a dominant model  
All regions have a maximum LOD score of 1.4.  Boundaries SNPs are reported from 
TCAG. 
 
 Regions with LOD>1 Known OTSC loci 
Chr  Position (Mb) Size  
(Mb) 
Name Position (Mb) 
7q 73.8-143.03 69.7 OTSC2  
COL1A2 
85.05-152.05 
94.02 -94.06 
10p 0.19-3.1 2.91 - - 
10q 50.04-54.12 4.08 - - 
16q 82.6-89.02 6.3 OTSC4 67.6-77.3 
  New locus  
(Family 2081) 
78.1-87.8 
17q 71.9-77.7 5.79 NOG  54.6-54.6 
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4.3.3 Genetic analysis of Family 2114 under a recessive mode of inheritance 
Because Chr17q gave the highest LOD score under a recessive model, genetic 
analysis for this region was carried out first, which involved examining the segregation of 
haplotypes across this region and identifying paternal and maternal chromosomes. This 
was followed by Sanger sequencing of functional candidate genes and targeted analysis of 
the exome variants.  
4.3.3.1 Haplotype segregation across Chr17 linked region        
Under the assumption of a recessive mode of inheritance, we would expect that 
affected members of Family 2114 would inherit two disease haplotypes, one from each 
carrier parent. If parents were related (in the case of consanguinity) the two disease 
haplotypes would be identical by descent and all affected offspring would harbour a 
homozygous mutation. On the other hand, if parents were not related, the two disease 
haplotypes would likely not be identical and all affected offspring would harbour two 
different mutations in the same otosclerosis gene (compound heterozygotes). Also, if 
parents were not related and the recessive allele was common in the NL population, the 
two disease haplotypes might not be identical and the affected offspring would harbour 
two identical mutations on different disease haplotypes (IBS).  
Haplotypes were constructed using 23 SNPs, including the reported boundary 
SNPs rs9909316 and rs2587507 (Table 4.2), and three microsatellite markers. Although 
parental haplotypes were inferred, four distinct parental haplotypes (brown, green, red 
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and yellow) (Figure 4.1) were identified. Constructing haplotypes across Chr17q revealed 
that four out of the five affected members (PID III-1, III-2, III-5 and III-7) inherited the 
same parental haplotypes (yellow and brown). The other affected sibling (PID III-4) 
inherited the yellow haplotype, and a portion of the brown haplotype as a recombinant 
haplotype from his father. The only unaffected sibling (PID III-6) inherited the red and 
green haplotypes. Construction of the haplotype contributed by the proband’s uncle (PID 
II-5) helped to infer the mother’s yellow haplotype and led to the conclusion that the 
brown haplotype was inherited from the proband’s father. 
 
Table 4.2: Boundaries, size and gene numbers of the five linked regions 
Start and end SNPs were taken from TCAG statistical report. 
 
 Family 2114 linked regions 
Chr  Start 
SNP 
End  
SNP 
Boundaries 
position  
Size   
Mb 
Gene 
numbers  
7q rs2158797 rs2103193 73.8-143.03 69.7 284 
10p rs10903451 rs3829916 0.19-3.1 2.91 12 
10q rs7922169 rs1194683 50.04-54.12 4.08 41 
16q rs11646011 rs13329773 82.6-89.02 6.3 64 
17q rs9909316 rs2587507 71.9-77.7 5.79 141 
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Figure 4.1 Partial pedigree of Family 2114 showing segregation of Chr17q25.1-q25.3 
haplotypes.  
 The yellow haplotype and a portion of the brown haplotype are segregating in Family 2114. 
Roman numerals on the side indicate the generation level. The black solid symbol refers to 
otosclerosis grade I. The half black and white symbol refers to hearing loss, uncategorized. 
Arrows point to boundaries SNPs. ( ) refers to inferred alleles. Circle =female, square = male. 
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4.3.3.2 Positional candidate genes sequencing by Sanger sequencing  
From linkage analysis, the boundaries of Chr17 critical region were reported 
between rs9909316 and rs2587507. These boundaries cover a region spanning 5.79Mb 
with 141 annotated genes according to Genome Browser (March 2006 assembly, NCBI 
build 36.1). In total, 11 positional candidate genes were chosen and sequenced using 
genomic DNA from the proband (PID III-1). 
To determine the possible outcome of the sequencing analysis, haplotypes were 
constructed using provided genotyped SNPs. Haplotype analysis showed that affected 
members of Family 2114 inherited the same haplotypes (yellow and a portion of the 
brown haplotypes) from their parents. If the yellow and brown parental haplotypes are 
assumed to be the disease haplotypes, we would expect that the proband’s parents are 
heterozygous for two disease alleles and the proband inherits two different mutations in 
the putative disease gene (compound heterozygote). Conversely, both parents may be 
heterozygous for the same mutation, and in that case the proband inherits 2 copies of the 
same disease mutation. The full length of the linked region at Chr17 was analyzed under a 
recessive mode of inheritance primarily and then under a dominant mode. To cover both 
modes of inheritance and to detect any common variants, the region was not decreased in 
size using the recombination in subject III-4.  
Direct sequencing of the 11 genes yielded high quality sequences (Figure 4.2). In 
total, eight variants were identified in the six positional candidate genes (TIMP2, BIRC5, 
FOXJ1, ITGB4, OTOP2 and RNF157) in the proband PID III-1 (Table 4.3). No variants 
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were identified in the remaining five genes (CTDNEP1, SLC9A3R1, USH1G, RPL38 and 
KCTD2).  
Of these eight variants, no homozygous variants were identified.  Three 
heterozygous variants (missense, intronic and synonymous) were identified in the ITGB4 
gene and the remaining five variants were identified in five different genes. Under 
recessive inheritance, it is conceivable that two of the three variants identified in ITGB4 
could be pathogenic and cause otosclerosis. The first step in analyzing these three variants 
was to determine their allele frequencies. We estimated the frequency of otosclerosis 
heterozygous carriers to be 13 % under a recessive model using the Hary-Weinberg 
Equilibrium principle. Taking this number into consideration, allele frequencies of these 
variants were checked, and as result, these three variants (c.4311C>G, c.4844-25C>G and 
c.5126T>C) were excluded from further analyses because their frequencies were higher 
than 13 % (48%, 79% and 25%, respectively).  
Because Chr17q11.23-q34 gave a positive LOD score under the dominant model, 
allele frequencies of the remaining five heterozygous variants were determined, four of 
which had frequencies of greater than 10 %. Interestingly, we identified a silent variant in 
the FOXJ1 gene with a frequency of 4 %. Because FOXJ1 is a member of the FOX 
family of transcription factors, and otosclerosis in Family 2081 was caused by a deletion 
in FOXL1, I thought it was important to follow-up on this particular variant. This variant 
is not predicted to affect splicing and was further analyzed using NGS sequencing data.   
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The selection of functional candidate genes in the critical region on Chr17 did not 
yield a putative otosclerosis gene under recessive or dominant models. Of the 141 
annotated genes, we only looked at 11/141. Therefore, to provide a complete examination 
of the 5.79 Mb critical region, whole exome sequencing and target analysis of the entire 
critical region was carried out.
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Table 4.3: Sequencing variants identified in six out of 11 candidate genes examined in the Chr17 linked region. 
Frequencies of the six identified variants are higher than 2%. 
 
 
 
Gene 
Name  
NM number  Exon 
number  
Variants  SNP status SNP ID Allele 
frequency 
Sample 
size 
Frequency 
% 
Splice 
prediction 
TIMP2 NM_003255.4 Ex3 c.303G>A, p. S101 Silent  rs2277698 A=0.100 184 10% - 
BIRC5 NM_001012271.1 Ex 5 c.454G>A,p. E152K Missense rs2071214 A=0.776 1094 77% - 
FOXJ1 NM_001454 Ex3 c.726G>A,p. T242 Silent rs894542 A=0.043 1482 4% No splicing 
prediction 
ITGB4 NM_001005619 Ex32 c.4311C>G,p. p.P1437 Silent rs8669 G=0.483 120 48% - 
ITGB4 NM_001005619 Int34 c.4844-25C>G Intronic rs2249613 G=0.792 120 79% - 
ITGB4 NM_001005619 Ex38 c.5126T>C, p.L1779P Missense rs871443 C=0.258 120 25% - 
OTOP2 NM_178160.2 EX6 c.1393G>T,p. G465W Missense rs6501741 T=0.667 120 66% - 
RNF157 NM_052916 EX14 c.1450T>C,p. L484 Silent rs881502 C=0.342 120 34% - 
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Figure 4.2: Electropherogram showing an example of a high quality sequence  
The c.1450T>C, p. L484LL variant identified in the RNF157 gene. Upper panel represents 
reference sequence of the forward strand of the RNF157 gene and a trace sequence with the 
missense mutation c.1450 T>C in PID III-1. Lower panel represents reference sequence of the 
reverse strand of the RNF157 gene and a trace sequence with the missense mutation c.1450 T>C 
in PID III-1. 
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4.3.3.3 Exome sequencing and targeted analysis of Chr17  under  a recessive mode   
In order to complete sequencing of the 141 positional candidate genes at Chr17 
linked region, four exomes of Family 2114 (PID III-1, III-2, III-4 and III-7), along with 
two unaffected controls were sent for whole exome sequencing.  Results from Genome 
Quebec were received in an excel file output. Variants identified in genes within the new 
linked region at Chr17q25.1-q25.3 were fully analyzed under a recessive mode of 
inheritance. To help reduce the number of variants under consideration, extra negative 
controls were chosen. 
4.3.3.3.1  Selection of negative controls for filtering NGS data at Chr17 
In Chapter 3, DNA samples from Family 2081 were also sent for whole exome 
sequencing and targeted analysis of Chr16 was carried out. Because family 2081 was 
solved (as described in Chapter 3) by identifying a 15 bp deletion in the FOXL1 at Chr16 
and both families originated from NL, NGS from family 2081 could be used as a negative 
control.  
As Family 2081 was mapped to a new locus on Chr16, it was important to rule out 
linkage of Family 2081 to this new 17q locus. To do this, genotyping and haplotype 
analysis using four fully informative microsatellite markers that span the critical region 
(D17S1829, D17S1807, D17S1839 and D17S1822) was carried out. Although the 
proband’s maternal and paternal haplotypes were inferred, four distinct parental 
haplotypes (red, yellow, dark green and orange) were created (Figure 4.3). Using the rule 
of least recombination, two recombinations were detected between D17S1829 and 
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D17S1807 (PID III-7) and between D17S1839 and D17S1822 (PID IV-5). Affected 
siblings of Family 2081 did not share a disease haplotype across this locus. For example, 
the proband (PID III-8) inherited the yellow and the orange parental haplotypes. On the 
other hand, the proband’s affected sibling (PID III-13) inherited the dark green and the 
red parental haplotypes. Because two other affected siblings inherited two different 
parental haplotypes (and thus did not share any region on Chr17q25.1-q25.3), I concluded 
that otosclerosis in Family 2081 was excluded from linkage to Chr17q25.1-q25.3. Family 
2081 could then be confidently used as population-based controls for analyzing NGS at 
Chr17. 
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Figure 4.3: Partial pedigree of Family 2081 showing segregation of Chr17 
haplotypes in Family 2081 
No shared haplotype was detected between affected members of Family 2081 across Chr17q. 
Roman numerals on the side indicate the generation level. Blue solid symbol refers to otosclerosis 
grade I. Half blue and white symbol refers to hearing loss grade II. Half black and white symbol 
refers to hearing loss, uncategorized. Arrows point to boundaries SNPs. ( ) refers to inferred 
alleles. 
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4.3.3.3.2 Variants analysis of Family 2114 under a recessive mode of inheritance 
Sequencing of the coding regions of 141 positional candidate genes revealed a 
total of 49 heterozygous variants in Family 2114 affected exomes (Figure 4.4).  Seven 
variants were removed because they were also identified in affected members of Family 
2081. Furthermore, variants that were not inherited by all affected siblings of Family 
2114 were also removed. For example, the Q1133K variant in RNF213 was detected in 
the proband and two of her affected siblings (PID III-2 and III-1) but not in her other 
affected siblings (PID III-4 and III-7). Removing all of these variants reduced the number 
to 17, which were distributed across 11 genes. However, none of these variants were 
found to be homozygous in the affected siblings. Of these 17 variants, two were identified 
in TEN1 and six were identified in EVPL. The remaining nine were heterozygous variants 
in nine separate genes. Interestingly, the silent variant identified in FOXJ1 was found in 
three of the proband’s four affected siblings, and was also detected in two affected 
members of Family 2081 (Appendix 22).   
To examine the possibility of compound heterozygous mutations in the TEN1 and 
EVPL genes, these eight variants were analyzed under a recessive mode of inheritance. 
The frequencies of the eight variants were checked using SNP/1000 genome database and 
as a result, one was found to be a known SNP (rs10852767) with a frequency of 15.6 % 
(Figure 4.5A and Table 4.4). The seven remaining variants (five silent and one missense 
variant in EVPL; one intronic variant in TEN1) were subjected to further analysis. 
Splicing and pathogenicity effects of the silent, intronic and missense variants were 
checked and as a result the missense variant was predicted to be benign. No splicing 
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effect was predicted for the five silent, intronic and benign missense variants. Therefore, 
these seven variants were excluded from further analysis. In conclusion, the possibility of 
compound heterozygosity of the variants identified in TEN1 and EVPL could be 
excluded.  
 Complete analysis of the exome of 141 genes in the Ch17 critical region under a 
recessive mode of inheritance did not identify any homozygous or pathogenic compound 
heterozygous mutations. Therefore, I decided to analyze this region and the other four 
regions identified by linkage under a dominant mode of inheritance. 
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Figure 4.4 : Flowchart showing fitration steps of  NGS data at Chr17q  under 
recessive mode of inheritance 
 No pathogenic heterozygous variants were detected. Allele frequencies of identified variants 
were determined by using a publicly available SNP database and 1000 genomes. Pathogenicity of 
missense mutations was evaluated using SIFT and Polyphen prediction programs. Five splicing 
prediction programs were used to check splice site prediction: SSF, HSF, MaxEntScan, 
NNSPLICE, and GeneSplicer. 
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4.3.3.4 Genetic analysis of Family 2114 under dominant inheritance 
Pedigree simulation gave a maximum theoretical LOD score of 1.7 under a 
dominant mode of inheritance. The experimental result yielded a positive LOD score of 
1.4 for each of five distinct loci (Table 4.1). Under dominant inheritance, we would 
expect affected siblings to carry one copy of the disease allele (heterozygous mutation) 
that is inherited from the mother (PID II-2) and unaffected siblings to not carry the 
disease allele.  
The five distinct loci were distributed across four chromosomes (Table 4.3). All 
together, this adds up to 542 positional candidate genes. Across the five regions, exome 
sequencing revealed a total of 301 variants after removing variants from two unaffected 
NL controls (Figure 4.5). Family 2081 could be used as a negative control for both Chr7 
and Chr17 because it had been previously excluded from linkage to these regions. The 
benefit of using exome data from Family 2081 was that it resulted in a reduction of 
variants from 301 to 264 (in other words, 37 variants were also identified in exomes of 
Family 2081, the family with a causative FOXL1 deletion). Moreover, 153 variants could 
be removed because they were not found in all affected siblings, further reducing the 
number to 111 variants (Tables 4.4, 4.5, 4.6, and 4.7). Of these, 68 variants had a 
frequency of greater than 2 %, reducing the number to 43 (24 silent; 15 missense; one 
intronic; one nonsense; one deletion; and one 3 UTR).   
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 The 14 missense mutations were predicted to be benign by SIFT and Polyphen, 
and were not predicted to cause any splicing effects by HSF, MaxEntScan, GeneSplicer 
and known constitutive signals prediction programs. The c.1706 C>T, p. P569L variant in 
TNRC6C (Figure 4.6) was predicted to be deleterious by SIFT and damaging by 
Polyphen. As well, conservation of the 569 proline residue in the TNRC6C gene is highly 
conserved (Figure 4.7). The majority (23/24) of the silent variants were predicted to have 
no effect on splicing. However, the c.1143C>T, p. R381R variant in CSTF2T was 
predicted to cause the loss of a splice acceptor site. In addition, the deletion (c.1578 het 
delC) in C17orf80 was predicted to create a premature stop codon 10 codons upstream of 
the normal stop codon. The intronic c.69+11C>G variant in CDK14 (Figure 4.8) was 
predicted to create a new splice donor site.  As well, the nonsense variant c.49C>T in 
KNAP7 (Figure 4.9) was predicted to interrupt the reading frame and create a premature 
stop codon. Although mutations in the non-coding region of genes are difficult to 
interpret, it is possible that the 3’ UTR, *709 variant in SEPT has a deleterious effect on 
gene expression. In summary, variants in six genes (TNRC6C, C17orf80, SEPT, CSTF2T, 
CDK14 and KPNA7) were potentially pathogenic and therefore subjected to segregation 
analysis.  
Segregation analysis was done on a chromosome by chromosome basis. For example, 
in order to test segregation of c.69+11C>G in CDK14 and c.49C>T in KPNA7, Chr7 
haplotypes were constructed using 13 microsatellite markers and 19 genotyped SNPs, 
including the boundary SNPs. Although the haplotypes of the proband’s parents were 
inferred, four distinct parental haplotypes (red, light green, dark green and orange) could 
 
 
 
214 
 
be created (Figure 4.10). Haplotype construction of the proband’s aunt (PID II-6) and 
uncle (PID II-5) helped to infer the proband’s maternal haplotypes (light green and a 
portion of the red haplotypes in Figure 4.10). We observed that affected siblings shared a 
haplotype (dark green) that covered the region between rs2158797 and rs2103193, 
apparently inherited from their father (PID II-1).  Two variants in CDK14 and KPNA7 
were tested for segregation and as result both variants segregated with otosclerosis in 
Family 2114 and resided on the dark green paternal haplotype. 
For Chr17, haplotypes were constructed as mentioned on page 200 and three variants 
were tested. Segregation analysis of the heterozygous frameshift deletion in C17orf80 
showed that it was not present in the affected sibling PID III-5 (Figure 4.11). Segregation 
analysis of c.1706 C>T, p. P569L in TNRC6C gene and *709 in the SEPT9 gene revealed 
that these variants segregate with otosclerosis in family 2114.  
For Chr10q, haplotypes were created using nine SNPs. Four distinct parental 
haplotypes (red, yellow, dark green and blue) were created (Figure 4.12). Haplotype 
construction of the proband’s aunt (PID II-6) and uncle (PID II-5) helped to reconstruct 
the maternal contribution (PID II-2). Affected members all shared the dark green 
haplotype that appears to be inherited from their mother.  One variant was tested for 
segregation, and absence of segregation of p. R381R (CSTF2T) was noted, as one of the 
affected siblings (PID III-5) was wild type.   
Of the six tested variants, only four segregated with otosclerosis. The allele frequency 
of these variants in NL population controls was tested and as a result, c.1706 C>T in 
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TNRC6C, C.69+11C>G in CDK14, and c.49C>T in KPNA7 were not detected in 125, 64 
and 67 NL population controls, respectively. The c. *709 C>T in the SEPT9 gene has a 
frequency of 10.3 % in the NL controls.  
To summarize, exome sequencing and genetic analysis, under a recessive model 
and looking at the Chr17 region, did not yield any likely pathogenic mutations (either in 
the homozygous or compound heterozygous state). On the other hand, targeted analysis 
under a dominant model revealed three relatively rare, functionally significant variants in 
KPNA7, CDK14 and TNRC6C at Chr7, and Chr17 co-segregated with otosclerosis in 
Family 2114. Interestingly, none of the deregulated cytokines (IL29 and CCXL10) 
identified in Chapter 3 were located in the linked regions and, therefore, were not 
screened.  
Of the three variants, the KPNA7 (IPOA8) is the most promising candidate. This 
gene belongs to the importin alpha family, and although there was not much information 
about the function of this gene, it is known to act as a nuclear protein transporter and has 
been predicted to be involved in cytokine signalling in the immune system.  The non-
sense mutation in KPNA7 is predicted to be highly deleterious causing a prematurely 
truncated protein due to a frameshift within the coding region of the gene.  
The second most promising candidate is the splicing variant in the CDK14 gene. 
Cycline-Dependent Kinase 14 (CDK14) is a member of the CDC-related protein kinase 
family. A previous study reported abundant expression of CDK14 protein in the bone 
through examining osteoclast cell line
183
 and it has a role in the regulation of cell cycle 
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progression and proliferation through interaction with CCDN3 
184
. It is also involved in 
activation of the Wnt signalling pathway through phosphorylation of LRP6 
185
 and  it has 
been reported by previous studies that osteoclastogenesis is regulated by the Wnt pathway 
186
. CDK14 has been reported to interact with genes involved in cytokinesis
187
  and in 
negative regulation of osteogenesis 
188
.  
The third variant identified was in the TNRC6C gene. TNRC6C is one component 
of the TNRC6 complex, a protein family involved in silencing mRNA 
189
. Specifically, 
the TNRC6 complex is involved in miRNA induced silencing complexes (miRISCs). The 
TNRC6C interacts with other genes (AGO2, DICER, and DGCR8) involved in miRNA 
homeostasis. Previous studies have shown that gene silencing of Dicer or Argo2 by small 
interfering RNAs prevents the expression of osteoclast transcription factors (PU.1, MITF, 
c-Fos, and NFATc1) and therefore, decreases osteoclastogenesis and decreases bone 
resorption
190
. The missense mutation identified in TNRC6C was located in a highly 
conserved region and was predicted to be deleterious.  
In summary, the three genes that harboured three variants were considered good 
candidate genes for otosclerosis development. Of these three, the nonsense variant in 
KNAP7 appeared to be the most deleterious as it created a stop codon at c.49 position in 
exon 1, which probably would lead to nonsense mediated decay for the truncated gene 
product. Further functional and segregation analysis is required to validate this 
assumption and confirm the pathogenic gene/mutation causing otosclerosis in family 
2114. 
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Figure 4.5: Fowchart showing the steps of NGS analysis at five regions under the dominant model 
Three heterozygous variants in KPNA7, TNRC6C and CDK14 passed all filtration steps and segregate with otosclerosis in Family 2114. 
Allele frequencies of identified variants were determined by using a publicly available SNP database and 1000 genomes. Pathogenicity of 
missense mutations was evaluated by using SIFT and Polyphen prediction programs.Five splicing prediction programs were used to check 
splice site prediction: SSF, HSF, MaxEntScan, NNSPLICE, and GeneSplicer. 
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Table 4.4: Sequencing variants detected in exomes of four affected siblings in Family 2114 across Chr17 under both 
recessive and dominate mode of inheritance.  
Under the recessive model, variants with MAF of higher than 13 % were excluded. Bolded variants represent compound heterozygotes. 
Under the dominant model, variants with MAF of >2 % were excluded. SIFT and Polyphen were used for prediction of the missense 
mutations. Human Splicing Finder (HSF), MaxEntScan, GeneSplicer and known constitutive signals prediction programs were used for 
splice site prediction. (-) indicates no prediction was carried out. 
 
 
 
 
 
 
 
Gene 
name  
Variants  SNP ID SNP status Allele 
frequency 
  
Sample 
size 
 
Frequency 
% 
Splice 
prediction 
SIFT Polyphen 
C17orf
80 
c.1578 het delC - Frame shift No frequency - - - 
CD300
E 
c.472G>A. p.G158R rs1878061 Missense No frequency No splice 
prediction 
Benign Benign 
NUP85 c.186T>C, p.D62 rs34126097 Silent  C=0.59 128 5.9% No splice 
prediction 
- - 
ACOX
1 
c.301G>A, p.G101S rs3744032   Missense No frequency  No splice 
prediction 
Benign Benign 
TEN1 c. -128C>T rs3760132     Intronic T=0.074 162 7.4% No splice 
prediction 
- - 
TEN1 c.5823C>T, p.H65      rs10852767   Silent  T=0.156 340 15.6% No splice 
prediction 
- - 
EVPL c.5481C>T, p.T1941 rs17886642    Silent  No frequency No splice 
prediction 
- - 
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  * No frequency means no data were available in SNP/1000 genome databa
Gene 
name  
Variants  SNP ID SNP 
status 
Allele 
frequency 
 
Sample 
size 
Frequency 
% 
Splice 
prediction 
SIFT Polyphen 
EVPL  c.548C>T, p.I1827   rs7342882      Silent  No frequency No splice 
prediction  
- - 
EVPL c.5440C>T, p.P1814S rs7342883    Missense No frequency No splice 
prediction 
Benign Benign 
EVPL c.3810C>T, p.I1270 rs7225323     Silent  No frequency No splice 
prediction  
- - 
EVPL c.3675 C>T, p. S1225   rs75019874   Silent  No frequency No splice 
prediction  
- - 
EVPL  c.1347 C>T, p.V449  . Silent  No frequency No splice 
prediction 
- - 
RNF157 c.186T>C, p.F62 rs61760884 Silent  No frequency No splice 
prediction  
- - 
QRICH2 c.1808 A>G, p.H603R rs143901735 Missense No frequency No splice 
prediction 
Benign Benign  
PRPSAP1 c.1044A>G, p.Q245 rs10459 Silent G=0.148                       188    14.8% - - - 
SEPT9 c.*709C>T rs146084702 3UTR 0.0045 3974 0.45% - - - 
TNRC6C c.1706 C>T, p.P569L 
 
rs200406635 Missense 0.0028 8356 0.28% - Deleterious Probably 
damaging 
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Table 4.5: Sequencing variants detected in exomes of four affected siblings in Family 2114 across Chr7: 73,862,412-
142,344,569.  
Under the dominant model, variants with MAF of > 2 % were removed from further analysis. Bolded variants have  MAF of ≤ 2 % or  no 
frequency estimated and (-) indicates no prediction was carried out.  
Gene name  Variants  SNP ID SNP status Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice 
prediction 
SIFT Polyphen 
ZNF804B c.1614G>A,  
p.T538 
rs148827448 Silent 
 
A=0.15 8596 15% - - - 
CDK14 c.69+11C>G - Splice site No frequency   creates a 
new donor 
site 
- - 
PEX1 
 
c. 2088A>G,  
p.Iqq3M 
rs35996821   Missense G=0.038 78 3.8% - - 
 
-  
 
RBM48 
 
c.588G>A, 
 p.P196 
rs79531673 Slent A=0.023 51 3%  - - 
TRRAP 
 
c.10731C>T, 
p.I3606 
rs56290902 Silent T=0.009 20 .09% No splice 
prediction 
- - 
KPNA7 
 
c.49C>T, 
p.R17* 
- Stop_gain 
(non sense 
mutation) 
Novel - - - 
ZNF3 
 
c.55+56G>A rs34312198 Intronic A=0.05 109 5% - - - 
ZNF3 
 
c.-231G>A rs113683483   Intronic A=0.023 51 3% - - - 
MCM7 
 
c.1083C>T, 
p.I361 
rs12267 Silent T=0.446 166 44% - - - 
C7orf59 
 
c.202+141G>T 
 
rs3736590   Intronic T=0.625 176 6.25% - - - 
MUC12 
 
c.512G>A, 
p.R171Q 
rs61746936 Missense A=0.0669 3182 6.6% - - - 
MUC17 
 
c.4669A>G, 
p. T1557A 
rs74209688   Missense G=0.24 537 24% - 
 
- - 
LRWD1 
 
c.1778C>T,  
p.P593L 
rs148981077 Missense T=0.446 13004 44% - - - 
FAM185A 
 
c.56A>T,  
p.Q19L 
rs147397718 Missense T=0.088 193 8.8% - - - 
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Gene name  Variants  SNP ID SNP status Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice 
prediction 
SIFT Polyphen 
LRRC17 
 
c.560 G>A,  
p.G187A 
rs1057066 Missense A=0.173 376 17% - - - 
NAPEPLD 
 
c.454G>T, 
p.S152A 
rs12540583   Missense T=0.933 120 93% - - - 
SPAM1 
 
c.1352 A>T,  
p.D451V 
rs75168651 Missense T=.008 17 0.8% - Benign Benign 
SLC13A4 
 
c.1351C>T, 
p.P451S 
rs36004833 Missense No frequency - Benign Benign 
MGAM c.3822T>C, 
p.D1151 
rs2960758 Silent No frequency No splice 
prediction 
- - 
FAM115A c.2220G>A, 
p. G740 
rs3735380 Silent No frequency  No splice 
prediction 
- - 
GIMAP7 c.247C>T, 
p.R83C 
rs3735080 Missense T=0.169 2184 16.9% - - - 
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Table 4.6: Sequencing variants detected in exomes of four affected siblings in Family 2114 across Chr10: 49715462-
69.77254365.  
Under the dominant mode of inheritance, variants with MAF of > 2 % were excluded. Bolded variants have MAF of ≤ 2 % or no 
frequency estimated. SIFT and Polyphen were used for prediction of missense mutations. Human Splicing Finder (HSF), MaxEntScan, 
GeneSplicer and known constitutive signals prediction programs were used for splice site prediction. (-) indicates no prediction was 
carried out. 
Gene name  Variants  SNP ID SNP 
status 
Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice 
prediction 
SIFT Polyphen 
GTPBP4 
 
c. -8 C>T 
 
rs12772979   Intronic T=0.1769 8600 17.6% - - - 
C10orf71 
 
c.1998C>G, 
p.H666Q  
 
rs10857469   Missense G=0.097 211 9.7% - - - 
CSTF2T 
 
c.1263 C>T, 
p.R421 
- Silent No frequency - - No splice 
prediction 
- - 
CSTF2T 
 
c.1143C>T, 
p.R381 
- Silent No frequency - - Predicted to 
loss acceptor 
site 
- - 
CSTF2T c.312T>C, 
p. L104 
rs2292828 Silent  C=0.075 168 0.75% No splice 
prediction  
- - 
TUBB8 -48T>A rs6560829 Intronic G=0.97  224     9.7% - - - 
ZMYND11 c.1356A>G, 
p.G537 
rs1017361 Silent  A=.334  224              3.3% - - - 
DIP2C c.1866C>T, 
p.G622 
rs10904083 Silent  A=.339             224 3.35% - - - 
DIP2C c.1248 G>A,  
p.P416 
rs6560837 Silent  No frequency - - No splice 
prediction 
- - 
DIP2C c.970C>T, 
p.L324 
rs4881274 Silent  No frequency - - No splice 
prediction 
- - 
GTPBP4 c.750G>A, 
p.A250 
rs2306409 
 
Silent  No frequency - - No splice 
prediction 
- - 
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Gene name  Variants  SNP ID SNP 
status 
Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice 
prediction 
SIFT Polyphen 
WDR37 c.726+22T>C rs10794716 Intronic C=0.89 118 89% - - - 
ADARB2 c.1876G>A, 
p.A626T 
rs2271275 Missense A=0.665 226 66.5% - - - 
PFKP 1281A>G,  
p.A419 
rs1052309 Silent  G=0.625 112 62% - - - 
PFKP c.1359C>T 
p.F453 
rs4881086 Silent  T=0.252 226 25% - - - 
PITRM1 c.3021A>G, 
p.R909S 
rs11414 Missense G=0.606 226 60% - - - 
FRMPD2 c.2735G>A 
p.G912E 
rs200503523 Missense No frequency - Benign Benign 
FRMPD2 c.2720A>G, 
p.L534E 
. Missense No frequency - Benign Benign 
FRMPD2 1600A>G, 
p.L534E 
rs1864345 Missense No frequency - Benign Benign 
ARHGAP22 c.591A>G, 
p.197 
rs3853761 Silent  No frequency No splice  
prediction 
- - 
ARHGAP22 c.330C>T, 
p. A110 
rs4080665 Silent T=0.850 226 85% - - - 
WDFY4 c.4582T>C, 
p.458P 
rs2170132 Missense C=0.274 226 27% - - - 
WDFY4 c.5447G>A, 
p.R1816E 
rs7097397 Missense A=0.375 120 37% - - - 
WDFY4 c.6396A>G, 
p.Q2132 
rs3747874 Silent No frequency No splice 
prediction 
- - 
WDFY4 c.7580G>A, 
p.S2527N 
rs2663046 Missense No frequency - Benign Benign 
WDFY4 c.9216C>T,  
p.C3072 
rs2271565 Silent T=0.334 728 33.4% - - - 
WDFY4 c.9353C>T, 
p.p3118L 
rs2292584 Missense T=0.339 870 33.9% - - - 
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Gene name  Variants  SNP ID SNP 
status 
Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice 
prediction 
SIFT Polyphen 
VSTM4 c.873A>G,  
p.E291 
rs1913525 Silent G=0.89 116 89% - - - 
VSTM4 c.203T>C,  
p.F68S 
rs13088 Missense C=0.397 224 39% - - - 
C10orf71 c.1014T>C, 
p.L338 
rs7093235 Silent C=0.89 112 89% - - - 
C10orf71 2093T>C, 
p.F698S 
rs7921186 Missense  C=0.89 116 89% - - - 
PGBD3 c.1477C>T,  
p.L961 
rs4253073 Silent T=0.902 224 90% - - - 
PGBD3 c.1145G>A, 
p.R850L 
rs4253072 Missense  A=0.983 116 98% - - - 
ERCC6 c.135C>G, 
p.L45 
rs2228524 Silent G=0.617 180 61% - - - 
SLC18A3 c.1559C>A, 
p.A520E 
rs8187730 Missense A=0.899 120 89% - - - 
CHAT c.1027G>A, 
p.M343V 
rs4838544 Missense  A=0.989 118 98% - - - 
CHAT c.1287T>C, 
p.H429 
rs8178992 Silent C=0.885 226 88% - - - 
C10orf53 c.216C>T,  
p.F72 
rs1133837 Silent T=0.483 120 48% - - - 
OGDHL c.564C>T, 
p.L131 
rs1258184 Silent No frequency No splice 
effect 
  
AGAP7 c.904T>A,  
p.Y302N 
rs76363375 Missense  No frequency - Benign Benign 
NCOA4 c.22T>G,       
p.F8V 
rs10761581 Missense  0.492 
 
120 
 
48% - - 
 
- 
TIMM23 c.25A>G, 
p.N8D 
 rs4935253 Missense  No frequency - Benign Benign 
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Table 4.7: Sequencing variants detected in the exomes of four affected siblings in Family 2114 across Chr16: 
73,862,412-142,344,56.  
 
Variants with a frequency of higher than 2 % were excluded and did not predicted for pathogenicity effect and replace by (-). Bolded 
variants are analyzed under a recessive mode of inheritance. SIFT and Polyphen were used for prediction of the missense mutations. 
Human Splicing Finder (HSF), MaxEntScan, GeneSplicer and known constitutive signals prediction programs were used for splice site 
prediction. 
Gene 
name  
Variants  SNP ID SNP 
status 
Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice prediction SIFT  Polyphen 
BCMO1 c.678A>G, 
p.P226 
rs7202895 Silent G=0.124 270 12.4% - - - 
MBTPS1 c.1407C>T, 
p.L469 
rs12933523 Silent T=0.135 74 13.5% - - - 
DNAAF1 c.1898T>C, 
p.L633S 
rs2288020 Missense C=0.303 660 30% - - - 
DNAAF1 c.1976T>A, 
p.L659P 
rs2288022 Missense C=0.302 658 30% - - - 
DNAAF1 c.2024G>C, 
p.S675T 
rs2288023 Missense C=0.303 659 30% - - - 
TAF1C c.1590G>T. 
p.R768 
rs1804500 Silent T=0.196 46 19.6% - - - 
TAF1C c.1047G>A, 
p.V349 
rs2230130 Silent A=0.396 164 39.6% - - - 
TAF1C c.727T>A, 
p.L243M 
rs2230129 Missense A=0.393 1488 39.6% - - - 
TAF1C c.545A>G, 
p.A332 
rs2230127 Silent G=0.403 62 40% - - - 
ADAD2 
 
c.348C>T, 
p.A116 
rs79224535 Silent 0.029 64 2.9% - - - 
ADAD2 c.1212C>T, 
p.A404 
rs2303239 Silent 0.296 645 29% - - - 
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Gene 
name  
Variants  SNP ID SNP 
status 
Allele 
frequency  
Sample 
size 
Frequency 
% 
 
Splice prediction SIFT Polyphen 
ADAD2 c.1688C>T,
p.T563TI 
. Missense - - - - Benign Benign 
KCNG4 c.973G>A, 
p.G325R 
rs7196482 Missense G=0.795 78 79% - - - 
KIAA160
9 
 
c.107C>T, 
p.N357 
rs62640938 Silent 
 
No frequency No splice effect   
CA5A 
 
c.807A>T, 
p.A269 
rs72816311 
 
Silent 
 
0.826 4550 82% - - - 
CA5A c.453C>T, 
p.P151 
rs7186698 Silent 
 
No frequency No splice effect   
SPG7 c.1507A>G,
p.T503A 
rs2292954 Missense G=0.119 259 11% - - - 
SPG7 c.2063G>A,
p.R688Q 
rs12960 Missense A=0.118 257 11% - - - 
SPG7 c.2292C>T,
p.I764 
rs61747711 Silent T=0.016 35 0.16% No splice effect - - 
RPL13 c.141C>T, 
A47 
rs174035 Silent T=0.154 335 15% - - - 
MC1R c.178G>T, 
p. V60L 
rs1805005 Missense 
 
T=0,.051 111 6% - - - 
CTU2 C.994G>A, 
 
p.V332I 
rs4782321 Missense A=0.178 118 17% - - - 
CTU2 c.1280G>A, 
p.R427Q 
rs11549835 Missense A=0.066 144 0.6% - Benign  Benign 
PIEZO1 c.2159G>C,
p.R720P 
rs35265318 Missense A=0.178 118 17% - - - 
PIEZO1 c.2130C>G, 
p.D710E 
rs35353288 Silent T=0.074 68 7.4% - - - 
PIEZO1 c.2031C>A, 
p.V677 
rs34908386 Silent A=0.138 58 13% - - - 
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Gene 
name  
Variants  SNP ID SNP 
status 
Allele frequency  Sample size Frequency 
% 
 
Splice 
prediction 
PIEZO1 c.1540C>T, 
p.L514 
rs78905828 Silent No frequency No splice effect   
PIEZO1 c.1365G>A, 
T455 
rs61742623 Silent No frequency No splice effect   
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Figure 4.6: Electropherogram shows heterozygous missense mutation c.1706 C> T, 
p. P569L in the TNRC6C gene. Arrow pointed to the missense mutation.   
Upper panel shows a trace sequence with the missense mutation c.1706 C>T in PID III-1, 
indicated by an arrow. Lower panel represents the reference sequence of the TNRC6C gene.  
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Figure 4.7: Conservation of TNRC6C c.1706 C> T, p. P569L using 13 species 
  Upper panel, orthologous from Homo sapien, Pan troglodytes, Macaca mulatta , Rattus 
norvegicus, Mus musculus, Canis familiaris, Felis catus, Bos Taurus, Dasypus novemcinctus, 
Monodelphis domestica , Ornithorhynchus anatinus, Gallus gallus, Xenopus tropicalis and 
Tetraodon nigroviridis aligned and conserved at p. P569L, as indicated by the arrow. Highlighted 
amino acids are highly conserved.  Lower panel, Weblogo image shows conservation of the 
proline at amino acid position 569 across human and 13 otherspecies. Vertical axis represents the 
conservation scale; horizontal axis represents the amino acid position. 
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 Figure 4.8: Electropherogram shows predicted splice site mutation c.69+11C>G in 
the CDK14 gene.  
Upper panel represents the reference sequence of the CDK14 gene. Lower panel shows a trace 
sequence with the splice site c.69+11 C>G in PID III-1, indicated by the arrow.  
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Figure 4.9: Electropherogram shows nonsense mutation c.49 C>T, p.R17* in the 
KPNA7 gene.  
Upper panel represents the reference sequence of forward strand of the KPNA7 gene and a trace 
sequence with the nonsense mutation c.49 C>T in subject III-1. Lower panel represents reference 
sequence of the reverse strand of the KPNA7 gene and a trace sequence with the nonsense 
mutation cc.49 C>T in subject III-1. Arrow points to the nonsense mutation. Amino acids are 
listed at the top of the caption. 
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Figure 4.10: Partial pedigree of Family 2114 shows segregation of KPNA7 c.49 C>T 
and CDK14 c.69+11C>G at Chr7:73,862,412-142,344,569. 
c.49C>T and c.69+11C>G mutations reside on the dark green haplotype that segregates with 
otosclerosis in Family 2114. Roman numberals on the side indicate  generation level. Black solid 
symbol refers to otosclerosis grade I. Half black and white symbol refers to hearing loss, 
uncategorized. ( ) refers to inferred alleles. Circle =female, square = male. Cross symbol means 
deceased.  
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Figure 4.11: Partial pedigree of Family 2114 showing segregation of three candidate 
variants identifed in Family 2114 at Chr17.  
C17orF80 c.1578, SEPT9 c. *709C>T and TNRC6C c.1706 C>T, p. P569L reside on the brown 
haplotype that segregates with otosclerosis in Family 2114. Roman numberals on the side indicate 
generation level. Black solid symbol refers to otosclerosis grade I. Half black and white symbol 
refers to hearing loss, uncategorized. ( ) refers to inferred alleles. Circle =female, square = male 
Cross symbol means deceased. 
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Figure 4.12: Partial pedigree of Family 2114 showing segregation of  CSTF2T c.1143 
G>A at Ch10q11.23-q21. 
c.1143G>A did not segregate with otosclerosis in Family 2114. Recombination in PID III-5 is 
detected between rs1937683 and rs1194491. Roman numberals on the side indicate generation 
level. Black solid symbol refers to otosclerosis grade I. Half black and white symbol refers to 
hearing loss, uncategorized. Arrows point at boundaries SNPs. ( ) refers to inferred alleles.  
Circle =female, square = male. Cross symbol means deceased. 
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4.4 Discussion 
Otosclerosis is a complex disease with evidence of Mendelian inheritance 
191
. The 
mode of inheritance in otosclerosis is not clear, however previous studies have reported 
AD inheritance as the most common mode of inheritance 
84,86-90,114
. In Family 2114, the 
proband’s mother was presumed to be the disease carrier under a dominant inheritance 
model.  The disease allele was expected to be inherited from the mother (PID II-2), was 
found in the 5 affected siblings, and was absent in the unaffected sibling. The DNA of the 
proband’s parents was unavailable, but creating haplotypes for the mother’s siblings 
helped in inferring the mother’s haplotypes across the identified regions. Inferring the 
mother’s haplotype helped to identify three excellent candidate pathogenic mutations (in 
KPNA7, CDK14 and TNRC6C) passed down through the father. Two variants located in 
KPNA7 and CDK14, respectively, reside on the same putative otosclerosis-associated 
haplotype. The nonsense mutation is located at the first exon of KPNA7, which consists of 
a total of 10 exons. The position of the nonsense mutation was predicted to interrupt the 
reading frame and create a premature stop codon at the beginning of the gene, which may 
result in nonsense- mediated decay (NMD) of the gene. NMD is one of the protective 
mechanisms that selectively degrade the mRNA harbouring nonsense mutations. Without 
this mechanism, these mRNA would produce a truncated protein which would have a 
dominant negative effect on the normal allele 
192
.   Furthermore, KPNA7 has been 
predicted to be involved in cytokine signalling in the immune system 
193-195
.  I had 
suggested in Chapter 3 that the cytokine-signalling pathway was one that may be 
deregulated as a result of the FOXL1 deletion, as this pathway is involved in otosclerosis 
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pathology. Degradation of the KPNA7 mRNA by NMD would interfere with its function 
as a component in the cytokine signalling pathway.  The mechanism underlying 
development of otosclerosis as a result of the nonsense mutation in KPNA7 is not 
understood. Further exploration of the role of KPNA7 in bone remodeling, whether it acts 
as an activator or inhibitor, will help to identify the possible mechanism acting on the 
development of otosclerosis. 
  Cycline-Dependent Kinase 14 (CDK14) gene has only one isoform, NM_012395, 
and contains one protein kinase domain.  CDK14 interacts with many interesting proteins, 
such as CCDN3, which regulates cell cycle progression and proliferation
184
.  It also 
interacts with Septin (SEPT8), a protein predicted to have a role in cytokinesis, and the 
YWHAB protein, which has a role in negative regulation of osteogenesis
187,188
.   
TNRC6C (trinucleotide repeat containing 6C) is a large gene with two isoforms 
(NM_018996.3 and NM_001142640.1). NM_018996.3 consists of 21 exons and encodes 
1690 amino acids, while NM_001142640.1 consists of 22 exons and encodes 1726 amino 
acids. The TNRC6C protein consists of an N-terminal rich with glycine and tryptophan 
and contains an ago-hook domain that is responsible for binding to Argonaut protein. The 
c-terminal consists of a GW rich region that is referred to as the silencing domain. The 
function of TNRC6C is not fully understood. The TNRC6 group of proteins is involved in 
miRNA induced silencing complexes (miRISCs) through interaction between their N- 
terminal and Argonate protein
196
. Disease causing mutations in these genes have not been 
previously reported. The possible function of the KPNA7 in cytokine regulation and the 
high impact of the non-sense mutation make this variant the most promising candidate 
 
 
 
 237 
mutation. The other variants could have a modifier role in the disease phenotype. Further 
functional work may be needed to assign causation to one of these three mutations. Also, 
the ability to test for segregation of these variants in subsequent generations (fourth and 
fifth generations) may help determine the causative variant. On the other hand, 
sequencing genomic DNA from other otosclerosis families may also be informative. 
The linkage analysis of otosclerosis in Family 2114 identified five regions under 
both dominant and recessive inheritance. Targeted exome analysis of these regions 
identified three variants that were inherited from the father and no variants inherited from 
the mother (presumed disease carrier). This finding suggested that perhaps otosclerosis 
was inherited from the father’s side of the pedigree. As low penetrance is one of 
characteristics of otosclerosis, the father may be a case of non-penetrance.  In another 
scenario, this variant could have arisen de novo in the father’s germline and then been 
passed down to his offspring.  Further exploration of the father’s side of the pedigree may 
help in testing segregation of the other variants. In this study, we were able to infer both 
parental haplotypes but absence of their DNA samples makes it difficult to rule out de 
novo mutations.  
Previous linkage analysis (Chapter 2) excluded linkage of this family to the seven 
previously mapped otosclerosis loci and to the loci of three associated genes (assuming 
dominant inheritance and transmission from the maternal side of the pedigree).  However, 
there was evidence of possible linkage to a 57.3 Mb region on Chr7q21.11-q35 that 
overlapped OTSC2 and COL1A2 under the assumption of transmission from the paternal 
side of the pedigree. In order to identify a new otosclerosis locus, genome wide SNP 
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genotyping, linkage and targeted analyses of the linked regions were carried out. The 
highest LOD score achieved overall for the pedigree was 2.5 at Chr17q25.1-q25.3 under a 
recessive model. Conversely, under a dominant mode, linkage analysis gave a LOD score 
of 1.4 at each of five regions on different chromosomes. Further genotyping of extended 
family members could decrease the number of the linked regions. However, we were not 
able to recruit any new family members and therefore, these five regions were fully 
analyzed, with priority given to the Chr17q25.1-q25.3 region.  
In spite of the fact that the otosclerosis trait in Family 2114 appears to be inherited 
in a dominant pattern, the highest LOD score was achieved at Chr17q under a recessive 
mode of inheritance (compared to a LOD score of 1.4 under dominant mode of 
inheritance). This region is 5.79 Mb long and contains 141 genes. Targeted analysis of 
this region identified a heterozygous variant in the TNRC6C. No homozygous or 
pathogenic compound heterozygous mutations were identified under a recessive mode of 
inheritance. These findings could indicate that: 1) otosclerosis in Family 2114 is 
following a recessive mode of inheritance, but also has a second mutation located in a 
non-coding (intronic or promoter) region not covered by Sanger or exome sequencing;  2) 
the mode of inheritance in this family is dominant and the high LOD score (2.5) was 
detected by chance.  
Under a dominant mode of inheritance, Family 2114 showed suggestive linkage to 
five regions. Out of these five regions, one was overlapping with previously mapped 
OTSC2 and COL1A2 regions at Chr7.  Mutations in COL1A2 have been reported to cause 
OI (a syndromic form of otosclerosis).  COL1A2 is a huge gene, making it impractical to 
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Sanger sequence. Availability of the exome sequencing data allows us to check for 
mutations in this gene that could play a role in otosclerosis development. Analyzing 
exome data for COL1A2 did not identify any variant that segregated with the affected 
exomes of Family 2114. 
Also, another region at Chr16 was overlapping with the new locus identified in 
Family 2081 at Chr16. The haplotype inherited by Family 2114 affecting siblings at 
Chr16-linked locus was different than the linked haplotype of Family 2081. We 
hypothesized that if Family 2114 was linked to the new locus identified in Family 2081, 
both families would harbour mutations in the same gene. Because Family 2114 inherited 
a different haplotype than 2081, we would expect that Family 2114 would have a 
different mutation than Family 2081 in the same gene or it could have the same mutation 
in case of a recurrent mutation. Targeted analysis of the exome sequencing at the Chr16 
linked region did not identify any variant in Family 2114 that was shared by affected 
members of Family 2081 or a different variant in the genes of identified variants in 
Family 2081.This finding could be explained by non-linkage of Family 2114 into the new 
locus at Chr16q23.1-q24.2. The exome sequencing data of Family 2081 helped exclude 
variants across Chr7 and Chr17 regions, which significantly decreased the number of the 
candidate variants. 
 
 
 
 
 
 240 
4.5 Conclusion 
This study has identified three likely pathogenic mutations that co-segregate with 
otosclerosis in Family 2114. According to our previous finding on the role of the cytokine 
pathways in otosclerosis development and the deleterious effect of the non-sense variant 
in KPNA7, it is probable that KPNA7 will be disease causing in Family 2114. Further 
functional and segregation studies of these variants are required to determine if this is the 
case.  
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5 Chapter 5 
 
 
 
 
 
                              General discussion 
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5.1 Implication of identifying the first gene for familial otosclerosis 
              Since 1998, 10 otosclerosis loci have been mapped, but despite recent advances 
in genomic technologies such as NGS, no OTSC gene has been identified. The most 
recent locus, OTSC10, was mapped 4 years ago
84
. This thesis reports the first gene 
(FOXL1) identified as causing familial otosclerosis. To accomplish this, we applied the 
following guideline: 1) we employed strict diagnostic criteria for otosclerosis, based on 
the visual inspection of sclerotic foci during surgery; 2) we recruited extended family 
members and population controls from the homogeneous NL founder population which 
greatly helped in filtering the NGS variant data; 3) we completed a thorough and careful 
interpretation of Family 2081 pedigree, taking into account the possibility of both 
dominant and pseudodominant models, especially in the context of the NL founder 
population; and 4) we ensured close communication between researchers and clinician 
which allowed timely access to recruited probands in NL and ON.   
           The identification of FOXL1 provides the first opportunity to better understand the 
pathways that may be involved in the pathogenicity of otosclerosis. For example, our 
microarray study showed that many cytokines were deregulated by the effect of the 
FOXL1 deletion.  Cytokines have a major role in many processes that are involved in 
inflammation, the immune system, and  many cytokines are involved in osteoclastogensis 
as well as play a role in osteoclast efficiency
197
. From the known histology and pathology 
of otosclerosis, it appears that the bone cells are important players in bone remodelling 
and therefore otosclerosis development
198
 .      
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          From both literature review and our microarray findings, we speculate that the 
otosclerosis in Family 2081 developed as a result of cytokine deregulation as an indirect 
effect of the FOXL1 deletion. We can now postulate that the causative gene(s) for the 
previously mapped otosclerosis loci could be a member of the FOX gene family or in fact 
any gene that is involved in cytokine regulation. Reviews of positional candidate genes in 
the previously mapped OTSC loci have revealed several possible candidates. For 
example, the mitogen-activated protein kinase 13 (MAPK-13) gene, which is found in the 
OTSC3 locus encodes protein p38 and is activated by pro-inflammatory cytokines. 
Similarly, the Mitogen-activated protein 3 kinase 7 (MAP3K7) gene located in the OTSC7 
locus has a role in transcriptional regulation activity and apoptosis. In response to 
interleukin (IL1), the MAP3K7 gene forms a kinase complex that is required for the 
activation of nuclear factor kappa B, a proinflammatory transcriptional factor
199
. In 
OTSC5, there are two possible candidate genes: Intelukin-2 (IL2), a cytokine and 
Forkhead Box protein L2 (FOXL2), a transcriptional factor. In OTSC8, there are four 
forkhead Box protein D4 genes (FOXD4L2, FOXD4L4, FOXD4L5, FOXD4L6) while in 
OTSC10, Transforming growth factor, beta 2 gene (TGFB2) that encodes members of the 
transforming growth factor beta (TGFB) family of cytokines is located. Based on their 
related functions, we recommend screening the above genes in families linked to 
previously mapped loci. 
Clinical reports for FOXL1 family members (Family 2081) indicated variability in 
the onset of hearing loss and in the degree of severity. The onset of hearing loss in the 
proband and proband’s generation occurred in their early twenties and the progression of 
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hearing loss was consistent in most of the affected siblings in the proband’s generation. In 
six out of seven sibs, hearing loss was conductive, bilateral and progressive while a 
seventh sib suffered from a sensorineural loss.  In contrast, hearing loss in one of the 
proband’s niece presented by mid-teens and in addition to otosclerosis had a 
cholesteatoma. Interestingly, two family members, a 40 year old relative with noise-
induced hearing loss and a 28 year old with no hearing loss, harbour the FOXL1 deletion.  
It is probable these two members may be too young to express the clinical phenotype (an 
example of age-related penetrance). Recruitment of family members who carry the 
FOXL1 deletion from both the right side in Family 2081 pedigree and from the ON 
family will allow us to conduct a detailed study of the phenotype within each family.  
5.2 A possible second gene for familial otosclerosis  
In addition to the FOXL1 mutation, we identified three mutations segregating with 
otosclerosis in Family 2114. Of these three, the nonsense mutation in the KNAP7 gene 
appears to be the most plausible cause of otosclerosis. KPNA7 gene is a member of the 
importin family of nuclear importin receptors. A recent study indicates that the bovine 
KPNA7 is expressed specifically in the embryo, which indicates  a role for KPNA7 in  
early development similar to FOXL1
195
. KPNA7 binds to importin α and importin β and 
enhances import of the nuclear localization signal (NLS).  It has been proposed that 
changes in the amino acid sequence of KPNA7 could affect its  binding to importin α and 
importin β which then could interfere with transport of the NLS out of the nucleus200. 
Like FOXL1, KPNA7 protein is predicted to be involved in the interferon and cytokine 
signalling pathways
195
. Thus, the role of KPNA7 in cytokine regulation makes it a good 
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candidate gene and in conjunction with the FOXL1 transcription factor will provide an 
opportunity to study the mechanism(s) underlying the development of otosclerosis and 
the pathway(s) involved (Figure 5.1). Further recruitment and genotyping of additional 
members of Family 2114 along with probands from ON otosclerosis families may help us 
find the gene causing this disease. Confirmation of the identity of the actual variant 
responsible for otosclerosis in Family 2114 will allow us to conduct a detailed phenotype 
study of otosclerosis caused by this variant across families and also help in differentiating 
the phenotype of families with otosclerosis caused by FOXL1 mutations versus families 
with otosclerosis caused by other mutations.  
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Figure 5.1: Hypothetical figure shows the predicted role of FOXL1 and KPNA7 in 
osteoclastogenesis and bone remodeling. 
Osteoblast secretes RANKL and M-csf. RANKL interacts with the RANK receptor on 
osteoclasts. This process leads to maturation of the osteoclast and initiates bone resorption process 
and stimulate osteoblasts. Cytokines have roles in bone resorption and bone formation. FOXL1 is 
suggested as having a role in the regulation of cytokines. KPNA7 has a predicted role in cytokine 
regulation. Both genes could be components of the same pathway that are involved in cytokine 
regulation.  +/- = Activation/suppression. 
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5.3 Overcoming challenges identifying the genes associated with 
otosclerosis  
5.3.1 Issues with clinical diagnosis  
           The most accurate diagnosis of otosclerosis is surgical confirmation of 
otosclerosis. Conductive hearing loss is common and it is caused by several causes other 
than otosclerosis. Therefore, when designing a study, it is prudent to include only 
otosclerosis patients who have otosclerosis confirmed through surgery. Otherwise, 
linkage analysis may be hindered which may lead to misinterpretation of data. For 
example, in the first stage of this study, subject IV-5 of Family 2081 (see Chapter 2) was 
thought to be a phenocopy primarily because the patient had a cholesteatoma in one ear 
and the surgical report confirming or refuting otosclerosis was unavailable. With the 
availability of the surgical report, subject IV-5 was re-considered to have grade I 
otosclerosis. Concluding that subject IV-5 in Family 2081 was a phenocopy resulted in a 
suggestive linkage to OTSC4. Fortunately, confirmation of otosclerosis in subject IV-5 
along with subsequent recruitment of other family members in the last year of the study 
changed the study direction and led to the identification of the FOXL1 gene. Thus, the use 
of strict diagnostic criteria for otosclerosis helped us confirm a diagnosis of otosclerosis 
and further refine the critical disease region. In our study, only members who were 
diagnosed with otosclerosis through surgery were used. The two unaffected adult 
members that were originally used as controls were audiologically assessed to have no 
hearing loss.  
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5.3.2 Recruitment limitations  
       Large, extended families with monogenic otosclerosis are rare and this rarity is 
reflected in the low number of published studies.There are eleven previously reported 
families with otosclerosis (Table 1.3, Chapter 1.1). Collaboration with Dr. Sue Stanton 
provided access to 40 otosclerosis probands from ON which helped us in identifying a 
second otosclerosis family harbouring the FOXL1 gene mutation. This underscores the 
positively huge impact that participation rate has in the success of any gene discovery 
study. The majority of members of the FOXL1 families were open to participation in the 
study. Although initially, we were not able to recruit members from the father’s side of 
Family 2114, the family has recently become more co-operative and additional 
recruitment is in progress.   
5.3.3  Comprehensive traditional and new technologies 
           In early otosclerosis papers, the reported critical disease regions spanned 10-34.16 
Mb containing hundreds of genes. The advent of NGS, has helped in the rapid acquisition 
of data allowing analysis of exomes and whole genomes.  The limitations faced by using 
NGS have primarily been the lack of good depth of coverage and the huge numbers of 
variants detected
201
. The depth of coverage has improved with the introduction of each 
new version of advanced chemistry, protocols and instruments resulting in increased 
sensitivity and higher rate of coverage up to 100 and more. To illustrate, theTrueseq Nano 
DNA and Trueseq DNA PCR-free Kits used in the Illumina NGS platform exhibits 150 % 
coverage improvement compared to the original Trueseq DNA Kit
202. Hundreds of 
thousands of variants can be identified by NGS, but the filtering and annotation involved 
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in the process is time consuming. Hundreds of variants which are of interest must then be 
validated, for example by Sanger sequencing before testing for segregation in families. 
Fortunately, in cases of Mendelian inheritance, the decreasing cost of NGS is providing 
an opportunity to sequence a greater number of affected and unaffected family members 
thereby significantly decreasing the number of variants to be filtered and annotated. By 
carefully selecting and eliminating variants common to both affecteds and unaffecteds, 
the number of putative disease-causing variants is reduced which leads to a smaller 
number of candidate variants for validation and segregation analysis. In our study, the 
exomes of five out of seven affected members of Family 2081 and four out of five 
affected members of Family 2114 were sequenced, thus aiding in the elimination of 
sequencing variants. The NGS data of Family 2081 was also used to reduce the number of 
variants identified in Family 2114 across linked regions. Consequently, the number of 
variants to be genotyped in order to test for segregation in extended family members was 
reduced. In summary, we recognized that sequencing large number of family members 
has aid to filter out variants and significantly reduce the number of candidate variants. 
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5.4 Future direction 
Identification of the first gene for otosclerosis will have a great impact  in the area 
of otosclerosis. 
5.4.1 Benefits to patients and their families 
Otosclerosis is a disease of the middle ear but is fortunately a treatable condition. 
Surgical therapy for otosclerosis has been an established procedure for a few decades. 
The surgical treatment of otosclerosis is based on either the removal of the stapes 
footplate (stapedectomy) or the creation of a hole in the stapes footplate (stapedotomy), 
which helps the circulation of the fluid from the middle ear into the inner ear.  However, 
despite the general availability of treatment for otosclerosis, there are some cases which 
are not treatable. Furthermore, in many cases, complications may develope as a result of 
the stapedectomy. Stapedectomy can cause unexplained unilateral SNHL in about 1-2% 
of the cases
203
 and perforation of the eardrum and injury of the facial nerve occurs in 
about 1 in 1,000. For a minority of the cases, vestibular symptoms may increase or 
develope
203
.  
Identification of the otosclerosis gene can result in early diagnosis of otosclerosis 
thus allowing early intervention which may prevent or slow the progression of the disease 
while minimizing the need for surgery which may have undesirable side affects 
Otosclerosis is a disease of the middle-aged and the first sign is a loss in low frequency 
hearing, which may not be noticeable by those affected. Identification of the otosclerosis 
gene will have many positive benefits with respect to the establishment of screening 
protocols for otosclerosis. Otosclerosis screening may be extended to newborns in 
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families with a history of otosclerosis thus helping with early diagnosis. Early diagnosis 
of otosclerosis by gene screening followed by early treatment of patients based on their 
mutation results will have huge impact on patients and their families.   
 It has been reported by many studies that treatment with sodium fluoride (used as 
a dietary supplement) in early stages of otosclerosis has a beneficial effect in slowing the 
progression of the disease
204,205
. The main aim of using sodium fluoride is to stop the 
osteospongiosis phase of otosclerosis. The idea of using sodium fluoride was not 
acceptable since many side effects were reported. Side effects include stomach upset, 
allergic itching, and joint pain that can leads to arthritis.   
5.4.2 Benefit to biomedical science  
Identification of a gene causaitve for otosclerosis “opens the gate” for studying the 
mechanisms underlying the disease. The human fetal osteoblast (hFOB 1.19) cell line is 
the most acceptable and available for in vitro study.  Obtaining a stapes footplate 
specimen from surgery is the most powerful target for studying mechanism underlying 
otosclerosis. Many models have been used to study the effect of gene mutation in vivo. 
Using a mouse model to study the effect of a mutation on hearing organs was a great 
success. For example, the tectorin alpha (Tecta) mutant mouse helped researchers to 
better understand the function of the tectorial membrane and its important role in 
transforming sound waves into a mechanical stimulus. These mechanical stimuli then 
stimulate sensory hair cells converting the mechanical signal into an electrical signal that 
is sent to the brain through the cochlear nerve
206
. 
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A previous study created a mouse model to investigate the role of the FOXl1 gene 
in the gastrointestinal tract. Homozygous knock out mice showed epithelial cell 
hyperplasia with distortion of the architectures of the stomach and small intestine 
207
. 
FOXl1 is one of the targeted genes that will be studied by the International Mouse 
Phenotypic Consortium (IMPC) which is composed of 17 research institutions and their 
aim is to, by using the embryoinc stem cell (ES) of the mouse, develop targeted knockout 
mice for the 20,000 known or predicted mouse genes. In otosclerosis, conditional deletion 
is the most acceptable way to test the effect of the mutation on the otic capsule of the 
mouse model from day zero. This procedure starts by creating target vectors which carry 
the mutated FOXL1 gene, inserting this vector into mouse (ES) cells, growing these cells 
in culture, and then injecting these cells into a developing mouse embryo. The developing 
embryo will carry the cells that harbour the FOXL1 deletion. Collection of histological 
specimens of the temporal bone of the transgenic mice from day zero and across wide 
range of time will help to determine the onset of the sclerotic foci development and to   
study of the disease progression, which can eventually help in treating otosclerosis.  
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5.4.3 Gene and drug therapies  
Gene therapy has been used experimentally in the treatment of hearing loss in 
mice
208
. The concept involving gene therapy is to provide mutant cells with the required 
normal protein by inserting the normal copy of the gene into the disease specific tissue 
through the use of a specialized vector. Introduction of the normal gene copy allows the 
diseased tissue to recover and subsequently, to have its normal function restored.  As an 
example, the introduction of normal Atoh1 gene into the cochlea of young mice 
stimulates the generation of new sensory hair cells, resulting in the improved production 
of electrical signals.  
 It is believed that the development of otosclerosis is a result of abnormal bone 
remodeling in the otic capsule, which in turn leads to the formation of otosclerotic foci. 
Fixation of the stapes by the formed sclerotic foci is one of the common events which 
cause conductive hearing loss. Otosclerotic foci can also affect the cochlea and cause 
SNHL. In this study, a 15 bp deletion in the FOXL1 gene has been proposed to cause 
otosclerosis. Deletion of the FOXL1 gene results in up-regulation of the FOXL1 protein 
in the cell nucleus. The mechanism responsible for the development of otosclerosis by 
FOXL1 deletion is unknown. We speculate that up-regulation in the FOXL1 protein is a 
result of accumulation of non-functioning misfolded protein. Consequently, gene therapy 
can benefit patients with otosclerosis with the introduction of the normal copy of the 
FOXL1 gene into the otic capsule. If the therapy is successful, the normal FOXL1 allele 
will provide the diseased cells with the required FOXL1 protein, thereby restoring the 
function of the otic capsule and subsequently improving the hearing function. 
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In addition to gene therapy, drug therapy has been considered and used in treating 
genetic diseases. Therapies using anti-cytokines (anti-TNF) have been approved in the 
United States for the treatment of rheumatoid arthritis (RA)
209
.  Rheumatoid arthritis is 
characterized by ankylosis of the joints, which results from abnormal bone remodeling. 
The similarity between otosclerosis and rheumatoid arthritis regarding pathogenicity 
suggests that both diseases might share a common pathway. The results of the microarray 
study reported in Chapter 3 of this thesis suggest that the cytokine pathway is one of the 
pathways controlled by FOXL1 and may therefore play a role in regulation of bone 
remodeling. Anti-cytokines have been approved as treatment for rheumatoid arthritis. The 
association between cytokines and FOXL1 shown in this study warrants further 
investigation into the possibility of using anti–cytokines in the treatment of otosclerosis. 
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7 Appendcies  
Appendix 1: Hearing loss medical questionnaire 
 
 
 
 
 
                              
 
267 
 
 
 
 
                              
 
268 
 
 
 
 
 
 
 
                              
 
269 
 
 
 
 
 
 
 
                              
 
270 
 
 
 
 
 
 
                              
 
271 
 
 
 
 
 
 
                              
 
272 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 
273 
Appendix 2: DNA extraction from whole blood 
 
Purpose: To provide a method for the extraction, precipitation, and resuspension of DNA 
from (EDTA) whole blood. 
 
Responsibilities: Lab personnel who have been trained in this procedure. 
 
Definitions: 
 hr. = hour 
 ppt = precipitate 
 WBC = white blood cell 
 
Equipment and Supplies:   
Equipment: 
 centrifuge 
 Biological safety cabinet 
 37º or 55 ºC water bath or heat block 
 Pipette aid 
  
Supplies: 
 50 ml &15ml centrifuge tubes 
 1 & 10ml pipettes 
 2 ml micrewtube with o-ring seal screw cap 
 “hooked” Pasteur pipettes 
 500ml plastic beaker  
 
Reagents: 
 RBC lysis solution (NH4CL/Tris) 
 0.85% NaCl 
 Nuclei lysis buffer (10mM Tris-HCl, 400mM NaCl, 2.0 mM EDTA, pH 8.0).   
 10%SDS 
 Protease solution (3mg/ml protease, 1% SDS, 2mM EDTA)  
 Saturated NaCl 
 Absolute ethanol 
 TE buffer  
 70% ethanol 
 TE buffer (10mM Tris, 1mM EDTA, pH 8.0) 
 Bleach (for disinfection). 
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Procedure:  
 
Note: place a 1.0 litre plastic beaker containing ~100ml of bleach in the safety 
cabinet for waste discard/disinfection. Decant all supernatants etc. into this 
container. 
1. Pre-warm RBC lysis solution to 37ºC. 
2. In a 50ml centrifuge tube mix 5 vols. of RBC lysis solution with 1 vol. of whole blood 
(to avoid aerosols add the lysis solution first then the blood).  Mix by inverting and 
then incubate at 37ºC
 
for 5min to 1 hr. 
3. Centrifuge at 1000 x g (2500 rpm) for 5min. 
4. Decant the supernatant and add 10 ml of 0.85% NaCl.  Vortex (vigorously) to 
resuspend the WBC pellet then centrifuge (as previous). 
5. Decant the supernatant and add 3ml of nuclei lysis buffer  
6. Vortex (vigorously) to resuspend the WBC pellet then and add 0.2 ml of 10% SDS 
and 0.5ml of Protease solution. 
7. Incubate at 55ºC for 2 hr. or 37ºC for 12 to 60 hr. 
8. Add 1.0ml of saturated NaCl, shake/vortex vigorously for ~15sec. then centrifuge at 
1000 x g (~2500 rpm) for 15min’s. 
9. Carefully (so as not to disturb the pellet) decant the supernatant into a clean 15ml 
centrifuge tube containing 2 volumes of absolute ethanol and gently mix by inversion 
until a DNA ppt. is visible. If the ppt. is not visible check the underside of the tube 
cap – sometimes the DNA lodges there!  
10. “Hook” the DNA ppt. with a (“hooked”) Pasteur pipette, decant the waste from the 
tube, and then place the inverted pipette back into the tube. 
11. Wash the DNA with a stream of (~ 2-5ml) of 70% ethanol (the ethanol will flow 
down the pipette and into the tube). 
12. Break off the hooked end (containing the DNA) of the pipette into a 2 ml micrewtube 
with o-ring seal screw cap. Add 1.0ml of TE buffer and store at 4ºC. 
13. DNA can be quantitated (UV 260/280nm) after 24 hr storage at 4ºC or >2hr. at 37ºC. 
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Appendix 3: PCR setup protocol 
1x Polymerase Chain Reaction (PCR) Protocol w/ 25% Betaine 
Reagent   Volume (uL) 
dH2O    9.92 
KapaTaq Buffer  2  
25mM Betaine  5 
KapaTaq dNTPs  0.4 
Forward Primer (10uM) 0.8 
Reverse Primer  0.8 
KapaTaq Taq Pol.  0.08 
10 ng/uL DNA Sample  1______ 
Total Volume   20 
1x Polymerase Chain Reaction (PCR) Protocol w/ 25% Betaine and 5% 
Dimethylsulfoxide (DMSO) 
Reagent  Volume (uL) 
dH2O    8.92 
DMSO    1 
KapaTaq Buffer  2  
25mM Betaine  5 
KapaTaq dNTPs  0.4 
Forward Primer  0.8 
Reverse Primer  0.8 
KapaTaq Taq Pol.  0.08 
10 ng/uL DNA Sample  1______ 
Total Volume   20 
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Appendix 4: TD54 Thermocycling Program 
 
94°C for 5 mins 
5 cycles of:  
94°C Denaturation for 30s 
64°C Annealing minus 2°C per cycle for 30s 
72°C Extenstion for 30s 
30 cycles of: 
94°C Denaturation for 30s 
54°C Annealing for 30s 
72°C Extenstion for 30s 
72°C Final Extension for 7 mins 
Hold at 4° 
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Appendix 5: Genotyping protocol 
Procedure: 
1. The Rx mix consists of 0.5 ul of template*, 0.5 ul of LIZ standard**, and 9.0 ul of 
Hi-Di formamide.  
2. Centrifuge for a few seconds at ~ 1250 rpm. 
3. Denature  at 95°C for 3min before loading on the analyzer. 
 
For an “average” PCR dilute the products 1/20 (in PCR grade water). 
Mix well before use. 
 
 
Appendix 6: Microsatillete markers sequence and PCR conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 
278 
Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D15S652 FAM F 
R 
GCAGCACTTGGCAAATACTC 
CATCACTCAAGGCTCAAGGT 
 
 
90,3 
284-309 Yes TD54 2.00 
D15S1004 FAM F 
R 
GGCAAGACTCCATCTCAAAA 
GAATAAAAAGCCTGTAAACCACC 
 
 
92.1 
247-271 Yes TD54 1.50 
D15S657 FAM F 
R 
TCTACATTGGACAGAAATGGG 
GATACACATTCTGATTCATGCG 
 
 
94.5 
330-360 Yes TD54 1.50 
D15S649 FAM F 
R 
GGAACAGGTCCAACATCTTG 
CCTCATATCCCCAACTCCTT 
 
 
92.05 
285-297 Yes TD54 2.00 
D15S157 FAM F 
R 
AGTGCATGGTGTTGCC 
GTGAAGTTCCACAGTATCTGAC 
 
 
93.63 
114-125 Yes TD54 2.00 
D15S127 FAM F 
R 
CCAACCACACTGGGAA 
AACAGTTGCCCACGGT 
 
 
89.1 
137 Yes TD54 1.50 
D7S684 FAM F 
R 
GCTTGCAGTGAGCCGAC 
GATGTTGATGTAAGACTTTCCAGCC 
 
 
138.1 
169-187 Yes TD54 1.50 
D7S2513 FAM F 
R 
GCAGCATTATCCTCAACAGC 
CACAAATGGCAGCCTTTC 
 
 
141.05 
157-181 Yes TD54 1.50 
D7S661 FAM F 
R 
TTGGCTGGCCCAGAAC 
TGGAGCATGACCTTGGAA 
 
 
143.2 
252-282 Yes TD54 1.50 
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Markers Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D7S2430 FAM F 
R 
TGCAATGAGCCATGTCC 
GAGTGCAGTTTAATCCCCATAG 
 
 
93.0 
139-151 No TD54 1.50 
D7S651 FAM F 
R 
GGCTGCCTTCAAAAACTC 
AGCCTGGCATGTGGAT 
 
 
98.3 
173-191 Yes TD54 2.00 
D7S644 FAM F 
R 
AGGTGAGAGACCCTCAGCAATAGTG 
CCTCCAAAGTTAGGGGTGGAAG 
 
 
86.122 
194-206 No TD54 1.50 
D7S2202 FAM F 
R 
TCTCTTACCCTTTGGGACCT 
CTTGCAGATGGCCTAATTGT 
 
 
139.4 
149-169 Yes TD54 2.00 
D7S676 FAM F 
R 
TGANTCTAAGCAGCCACCT 
GCAACATGATCCAGAAAACA 
 
 
143.71 
149-166 Yes TD54 2.00 
D7S1827 FAM F 
R 
CATCCATCTATCTCTGTAATCTCTC 
TATTTAACACACCTGTCTCAATCC 
 
 
150.25 
142-162 Yes TD54 2.00 
D7S657 FAM F 
R 
GTCACAGCACAGTTTTTGG 
GTCAAGTAGAGATTGAGATTCC 
 
 
92.64 
245-264 Yes TD54 2.00 
D7S821 FAM F 
R 
ACAAAACCCCAAGTACGTGA 
TATGACAGGCATCTGGGAGT 
 
 
95.89 
238-270 Yes TD54 2.00 
D7S2442 FAM F 
R 
TGAGCCAAGATCACAGCACT 
CTGGAAGCAACAGATGTCACTA 
 
 
147.97 
226-236 No TD54 2.00 
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Markers 
 
Label 
Dye 
Primer Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D7S1798 
 
FAM F 
R 
AGGTGAGTAGTATGTAAAAACACCG 
CACCTAGATCTAATTTGTGCTCC 
 
 
145.0 
 
251 Yes TD54 1.50 
D7S495 FAM F 
R 
TGGCATTCATTTACAATAGCC 
AGCACCTGGTCCAATTTTCT 
 
 
137.65 
150-168 Yes TD54 1.50 
D6S1660 FAM F 
R 
GAGTCTTGAGTAACTCCCACG 
GACAATGAGTATCCCCCAC 
 
 
23.42 
198-210 Yes TD54 1.50 
D6S291 FAM F 
R 
CTCAGAGGATGCCATGTCTAAAATA 
GGGGATGACGAATTATTCACTAACT 
 
 
36.37 
203-217 Yes TD54 1.50 
D6S1680 FAM F 
R 
AAAATTCCACCCCCGC 
CCATCTCCCCAGCAGAC 
 
 
39.30 
176-198 Yes TD54 1.50 
D6S1619 FAM F 
R 
GGCCTTGCTCTAACTTGTCT 
GTCTCCTCNTCAAAGTGCTG 
 
 
69.77 
189-211 Yes TD54 1.50 
D6S280 FAM F 
R 
CCGGAACTGTCCAATATCTT 
TCTCATTCAGATTTCTCNAGTTTTA 
 
 
73.80 
150-164 Yes TD54 2.00 
D6S406 FAM F 
R 
CCTGGGTGACAGAGTGAGAC 
CACCATAGATTCTGAAGCACC 
 
 
74.52 
186-206 Yes TD54 2.00 
D6S268 FAM F 
R 
CTAGGTGGCAGAGCAACATA  
107.86 
86-100 Yes TD54 2.00 
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AAAAGGAGGTCATTTTAATCG 
 
Markers 
 
Label 
Dye 
Primer Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D6S1568 FAM F 
R 
ACATGACCAGAACTTCCCAG 
AGCTAGGCCAGGCCGT 
 
 
34.16 
84-110 Yes TD54 2.00 
D6S1602 FAM F 
R 
GATTACAGGCGTGAGCACC 
ACCTGAGTGGGAAATTCTGG 
 
 
37.54 
194-208 Yes TD54 2.00 
D6S467 FAM F 
R 
CCGAAGTCTTTGAAATGTCT 
TGACAAAATGAACAGAAACG 
 
 
69.98 
246-250 Yes TD54 2.00 
D6S1596 FAM F 
R 
GACCTCCCCAGTCACA 
CCATCACCTTACAGTTACCA 
 
 
74.44 
175-225 Yes TD54 2.00 
D6S1682 FAM F 
R 
CTCTTCAAAACCCTAAGGA 
CTGACATTTCATACAATGGA 
 
 
96.95 
231-237 Yes TD54 2.00 
D16S313
9 
FAM F 
R 
TCCTGAGCAATTAGGTAAGACA 
CCCGTGACTGTAAAACTGAC 
 
96.95 
201-209 Yes TD54 2.00 
D6S273 FAM F 
R 
GCAACTTTTCTGTCAATCCA 
ACCAAACTTCAAATTTTCGG 
 
 
31.79 
120-140 Yes TD54 2.00 
D6S464 FAM F 
R 
TGCTCCATTGCACTCC 
CTGATCACCCTCGATATTTTAC 
 
 
69.98 
202-226 Yes TD54 2.00 
D6S1576 FAM F 
R 
AGAATTATTAAGGGGCAAGA 
CCAAAGTAGTGGAATTACAGGT 
 
 
27.83 
186-222 Yes TD54 2.00 
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Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D6S439 FAM F 
R 
GATGATTTAAGTTTCCTGTGGACC 
TTCAAGGACAGCCTCAGGG 
 
35.26 
272-292 Yes TD54 2.00 
D6S1613 FAM F 
R 
AGGAAGACTCCACCTCATTT 
AGGTAACACCNACAGCAAAT 
 
 
90.65 
92-119 Yes TD54 2.00 
D6S1645 FAM F 
R 
CAGGAGAACCACTTGAACC 
CCCACTTAGCAGACAGAGAG 
 
149.64 
226-252 Yes TD54 2.00 
D6S456 FAM F 
R 
GCATAGTTTGATTACTTCAGAACAC 
TAAATGGGTCTGCCCTG 
 
 
76.16 
232-248  TD54 1.50 
D6S1589 FAM F 
R 
CCCTCCACATACAGTGAAAG 
ATGCTTGCTTCAGCCAAT 
 
 
78.51 
170-188 No TD54 1.50 
D6S460 FAM F 
R 
AATTCCCATTTGAAGAAACC 
CAGTGGGCTCTCACCC 
 
 
80.40 
144-166 No TD54 1.50 
D6S1652 FAM F 
R 
GAAATCCCTGGTCGGTC 
ATTTATGGTAGCCGAGCC 
 
 
86.01 
213-231 No TD54 1.50 
D6S1595 FAM F 
R 
ATATTACACCANTCCTCCCAAAGTA 
ACCTCTAGTTTTGCCTGCTTTTA 
 
 
88.5 
125-131 Yes TD54 1.50 
D6S450 FAM F 
R 
ACACATTCACCCGTTTATTTT 
GGAAATGAAGCACAACAATG 
 
 
92.07 
227-239 Yes TD54 1.50 
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Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D6S456 FAM F 
R 
GCATAGTTTGATTACTTCAGAACAC 
TAAATGGGTCTGCCCTG 
 
76.16 
232-248 Yes TD54 1.50 
D6S1589 FAM F 
R 
CCCTCCACATACAGTGAAAG 
ATGCTTGCTTCAGCCAAT 
 
78.51 
170-188 No TD54 1.50 
D6S460 FAM F 
R 
AATTCCCATTTGAAGAAACC 
CAGTGGGCTCTCACCC 
 
80.40 
144-166 No TD54 1.50 
GAAT3A
06 
FAM F 
R 
CCCATGAATGCTGAGACTTT 
TTGCAGTCCTTTTCAGTAAGG 
 
 
21.32 
177-189 No TD54 1.50 
D6S1016 FAM F 
R 
GCTTAAAATTTAAAAGTGAGTTTCC 
CCTGTCAGCTAGAGAGGCAG 
 
 
26.81 
231-256 Yes TD54 1.50 
D6S306 FAM F 
R 
TTTACTTCTGTTGCCTTAATG 
TGAGAGTTTCAGTGAGCC 
 
 
28.03 
230-248 Yes TD54 2.00 
D6S1545 FAM F 
R 
AATCTATGCTCCTGGGTTG 
GAAGTTCTGGAAATACAGCCTC 
 
 
25.09 
223-231 Yes TD54 2.00 
D6S299 FAM F 
R 
AGGTCATTGTGCCAGG 
TGTCTATGTATACTCCTGAATGTCT 
 
 
24.03 
206-226 Yes TD54 1.50 
D6S2439 FAM F 
R 
CATTTCAAACCCCTGAGTG 
TGGAGACAGCATGTGAATTG 
 
24.41 218-258 Yes TD54 1.50 
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Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D6S1558 FAM F 
R 
GCTACTTGGGAGGCTGGAC 
CTGGCAGGAGGGCTAGTG 
 
 
27.13 
245-259 Yes TD54 1.50 
D6S394 FAM F 
R 
GGCCAACATCTGAAACTCC 
GTGGTAATGGAACCTCCCA 
 
 
26.24 
108-338 Yes TD54 1.50 
D16S310
7 
FAM F 
R 
CCAGAGTGATGGGGAATA 
TGAGCACTGTCTCAAAAAA 
 
 
66.21 
286-296 Yes TD54 1.50 
D16S302
5 
FAM F 
R 
TCCATTGGACTTATAACCATG 
AGCTGAGAGACATCTGGG 
 
 
67.12 
90-110 Yes TD54 1.50 
D16S309
5 
FAM F 
R 
TCAGTTGGAAGATGAGTTGG 
TATAGTTTGTGTCCCCCGAC 
 
 
68.50 
134-162 Yes TD54 1.50 
D16S752 FAM F 
R 
AATTGACGGTATATCTATCTGTCTG 
GATTGGAGGAGGGTGATTCT 
 
 
69.89 
101-129 Yes TD54 1.50 
D16S262
4 
FAM F 
R 
GAGACCTACAGTCTTTTGCATTTAC 
TTTTGAAGCTGAGCAGAAGG 
 
 
70.29 
143 Yes TD54 1.50 
D16S310
6 
FAM F 
R 
GAGACCTACAGTCTTTTGCATTTAC 
TTTTGAAGCTGAGCAGAAGG 
 
70.74 
156-206 Yes TD54 1.50 
D16S311
5 
FAM F 
R 
GGAGAATGGCTTTCTTGC 
CAACTCTATGATGGGGTTTTATTAC 
 
 
73.08 
242-252 Yes TD54 1.50 
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Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D16S301
8 
FAM F 
R 
GGATAAACATAGAGCGACAGTTC 
AGACAGAGTCCCAGGCATT 
 
 
72.73 
244-270 Yes TD54 2.00 
D16S313
9 
FAM F 
R 
TCCTGAGCAATTAGGTAAGACA 
CCCGTGACTGTAAAACTGAC 
 
 
71.26 
201-209 Yes TD54 2.00 
D16S309
7 
FAM F 
R 
TGATAGCCAAAGAAGTTGGT 
CTTGTGGGTCAATATAGATTAAAAA 
 
 
75.94 
194-214 Yes TD54 1.50 
D16S422 FAM F 
R 
CAGTGTAACCTGGGGGC 
CTTTCGATTAGTTTAGCAGAATGAG 
 
 
81.46 
188-212 Yes TD54 1.50 
D16S262
5 
FAM F 
R 
TACGCAAGTCAAAGAGCCTC 
GGACACATGAGACCCTGTCT 
 
 
83.27 
183 Yes TD50 1.50 
D16S520 FAM F 
R 
GCTTAGTCATACGAGCGG 
TCCACAGCCATGTAAACC 
 
85.07 
181-197 Yes TD54 1.50 
D16S518 FAM F 
R 
GGCCTTTTGGCAGTCA 
ACCTTGGCCTCCCACC 
 
 
76.69 
271-290 Yes TD54 1.50 
D16S413 FAM F 
R 
ACTCCAGCCCGAGTAA 
GGTCACAGGTGGGTTC 
 
 
86.45 
131-149 Yes TD54 1.50 
D16S302
3 
FAM F 
R 
CTGCATTTCTCATCACAGTG 
GAGCGCCTATGTTCGG 
 
 
87.03 
77-97 Yes TD54 1.50 
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Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D16S302
6 
FAM F 
R 
CTCCCTGAGCAACAAACACC 
GGTCATCTATATGCGCCTGA 
 
 
88.02 
178-210 Yes TD54 1.50 
D16S304
9 
FAM F 
R 
GCAATGAAGGCAACAAAGT 
TTAAAAGACCTGGGGGAAT 
 
 
77.47 
233-255 Yes TD54 1.50 
D16S309
8 
FAM F 
R 
TTCCACACATAAGGTGAGTTT 
TTGTCTGCTTCTTTACGGA 
 
 
80.00 
151-165 Yes TD54 1.50 
D16S304
0 
FAM F 
R 
TACTCCGGCAAGGACG 
GCTGCCTAGCACATGG 
 
 
78.20 
109-129 Yes TD50 1.50 
D3S3641 FAM F 
R 
TCTTTTGTCTATTAAACCTCCGTTC 
CCCCCATGCTCTCTTG 
 
 
136.25 
220-228 Yes TD54 1.50 
D3S1593 FAM F 
R 
TCAATATGGCTGGTAGCAGA 
ACAGTATTCTTGGTTGAAAGGTATG 
 
 
146.81 
137-153 Yes TD54 1.50 
D3S1744 FAM F 
R 
TTTAAGCGGAAGGAAGTGTG 
CTGGCCCCATCTCTCTCTAT 
 
 
148.57 
131-163 Yes TD54 1.50 
D3S3694 FAM F 
R 
AGTGTCCATCAACATGGG 
TCGCACAAATAACAGGATTC 
 
 
143.67 
124-162 Yes TD54 2.00 
D3S3627 FAM F 
R 
AAGCTAATATCAATAAACAAGGC 
TTAAATGTAGCNTCAGATGTTAAAG 
 
 
147.82 
205-232 Yes TD54 2.00 
 
 
 
                              
 
287 
Markers 
 
Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D3S1576 FAM F 
R 
AAGCTAATATCAATAAACAAGGC 
TTAAATGTAGCNTCAGATGTTAAAG 
138.90 189-203 Yes TD54 1.50 
D3S3586 FAM F 
R 
TGGATAAATAACTGCCCACC 
CTACACATAAGTCTGGATGAATAGG 
 
 
140.47 
102-114 Yes TD54 1.50 
D3S1576 FAM F 
R 
AGCTTTGGACGCAGGAAG 
GGCTTTTATTCATGTAGTCCTCATA 
 
 
138.90 
189-203 Yes TD54 1.50 
D3S1292 FAM F 
R 
TGGCTTCATCACCAGACC 
CAGATTCAAGAGGCACTCCA 
 
 
133.11 
142-166 Yes TD54 1.50 
D3S3548 FAM F 
R 
CTTCCAGGTCCAAGAGTG 
CAAAGGCAGCAGAATATG 
 
 
132.67 
217-223 Yes TD54 1.50 
D9S970 FAM F 
R 
GTCCAAGAACTCATGAATCTC 
GCCCACCTATAAAGGCATA 
 
 
38.40 
130 Yes TD54 2.00 
D9S1879 FAM F 
R 
TCAAAGAAACCCTCAGC 
CTAAATCAGCAACAACAGC 
 
 
70.65 
140-160 Yes TD54 2.00 
D9S1799 FAM F 
R 
TTGCCAACTATTTTAGCCC 
TGCAGTTTCAATCCACATC 
 
 
72.55 
139-178 Yes TD54 2.00 
D9S1844 FAM F 
R 
CATGCGAAAAACCGCTT 
TCCGCAGCCTCAGAGA 
 
 
45.61 
139-178 Yes TD54 2.00 
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Markers Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D9S166 FAM F 
R 
AAATCATGCAATTCATTTCA 
TCCTAATTCACTGGGAAAAC 
 
 
72.37 
139-178 Yes TD54 2.00 
D9S301 FAM F 
R 
AGTTTTCATAACACAAAAGAGAACA 
ACCTAAATGTTCATCAAAAGAGG 
 
 
72.99 
235 Yes TD54 2.00 
D9S2148 FAM F 
R 
TCAATCAACATCTGTCTATTCATC 
ACATCTGGCACTCTGGAGAG 
 
 
38.28 
148-172 Yes TD54 2.00 
D9S1862 FAM F 
R 
CATGAGAGCACTGTATGAGGAC 
ACATCAGGATTGTGGGTTC 
 
 
70.33 
167-207 Yes TD54 2.00 
D17S179
5 
FAM F 
R 
AGTGCCAGAGATATACCGTG 
GTCTGCAAGGCAAGTTGTC 
 
 
45.27 
167-177 Yes TD54 2.00 
D17S809 FAM F 
R 
CAAAAAGGCAGAATGCAGTA 
TCCAGAGTCAAAAACACAGG 
 
 
47.27 
229-247 Yes TD54 2.00 
D17S160
7 
FAM F 
R 
CAGATAAAAAACACAAGTTTCTGAC 
GCTCCACCCCAGACCTA 
 
 
51.16 
103-123 Yes TD54 2.00 
D17S790 FAM F 
R 
AAAATGAGTGGACCATACGAAGA 
GGGTTATTGTTTTTCCTGTGTGA 
 
 
50.15 
187-201 Yes TD54 2.00 
         
D17S797 FAM F ACCTTACAGGTTGNAAAGTGC  
44.90 
198-204 Yes TD54 1.50 
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R CTTCTGAGCAGTGGAGGTGG 
 
Markers Label 
Dye 
Primers Genomic sequence Genomic 
position 
Mb 
Allele 
Size 
 
Betaine 
(3.75M) 
 
Thermo 
cycling File 
 
MgCl2 (mM) 
 
D17S941 FAM F 
R 
CCAAACATTGTTCAGGTGC 
TATGCCAGCCGAAATCA 
 
 
47.19 
268-277 Yes TD54 2.00 
D17S788 FAM F 
R 
CTAGGCAGCCACTACCAAAT 
CAGCATCTTTGCTATAAGCATC 
 
 
47.64 
186-198 Yes TD54 2.00 
D17S160
6 
FAM F 
R 
TGGTATTCAATCCTGGAGC 
TGATGAGTCTTCATAGCCCC 
 
 
52.68 
175 No TD54 1.50 
D17S116
1 
FAM F 
R 
GCCAAGATAATGCCATTGCA 
TTCTCCCTGTGCCCTCTAA 
 
 
53.68 
133-175 No TD54 1.50 
D1S2621 FAM F 
R 
AAGCCTTAGTTTTACCCTATGGGAC 
GTCTGGCACACCTAGCAGAATG 
216.41 139-163 No TD54 1.50 
D1S2800 FAM F 
R 
AACCTCTCTGGTATGAAGCC 
TTGTTCAAGGGTCAAATGC 
232.5 178-190 No TD54 1.50 
D1S2811 FAM F 
R 
CCACTGCACTCCAACCTG 
GTAGTTTCTGACTGAAGG 
241.175 120-164 No TD54 1.50 
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Appendix 7: List of primer sequences of genes sequenced in OTSC4 critical region 
WWP2, CALB2 and SF3B3 were sent for sequencing in Genome Quebec center 
 
 
 
 
 
  COG4 
  
 
  
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E1 NM_015386  -F ccattagagttcattgggcact 362 TD 54 yes (0.75) 1.5 
  NM_015386   -R tttttgtatcccccagcaag         
E2 NM_015386  -F cataagtgcaaaatgaagcattg 391 TD 54 yes (0.75) 1.5 
  NM_015386   -R cccttaggtgttcactttatcttga         
E3 NM_015386  -F tcaaacgttcttgagaaaaagc 384 TD 54 yes (0.75) 1.5 
  NM_015386   -R gagttggggctgtagtgagc         
E4 NM_015386  -F ggtggtgtttgtgagattgc 384 TD 54 yes (0.75) 1.5 
  NM_015386   -R tgtgtttttattggtcgagtctg         
E5 NM_015386  -F cacagcatcttgcacatgg 498 TD 54 yes (0.75) 1.5 
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Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
  NM_015386   -R ggcaacaggtgtgttgaatg         
E6 NM_015386  -F tcaatgggaggatttttgga 281 TD 54 yes (0.75) 1.5 
  NM_015386   -R catcaggctagaagggtgaga         
E7 NM_015386  -F aagcagccaaaaggattgag 400 TD 54 yes (0.75) 1.5 
  NM_015386   -R ccagtgtgcgcttagcatt         
E8 NM_015386  -F atctttggcctgtcatcctg 375 TD 54 yes (0.75) 1.5 
  NM_015386   -R ttcatatgatacattgcactgaaaa         
E9 NM_015386  -F gggactctctttgccctgta 300 TD 54 yes (0.75) 1.5 
  NM_015386   -R tccttaataagagatttgtggctta         
E10 NM_015386  -F aggtaggtgaaaacatggaaaa 394 TD 54 yes (0.75) 1.5 
  NM_015386   -R cctcagccatttccctcag         
E11 NM_015386  -F aaaagggagcagagctaggg 346 TD 54 yes (0.75) 1.5 
  NM_015386   -R ggacaaagggcagaaacaaa         
E12 NM_015386  -F ttccccctaaaagagcacct 389 TD 54 yes (0.75) 1.5 
  NM_015386   -R gacactggaggaaaagtctctagc         
E13 NM_015386  -F tagcgcaagtctgaactcca 291 TD 54 yes (0.75) 1.5 
  NM_015386   -R caccaagataagtgtcttcacca         
E14 NM_015386  -F agctggctggaggagtagaa 286 TD 54 yes (0.75) 1.5 
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  NM_015386   -R cacgatgagccagctaacaa         
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E15 NM_015386  -F agagggaagggatgagtcgt 237 TD 54 yes (0.75) 1.5 
  NM_015386   -R tctgttcagatggctctgct         
E16 NM_015386  -F aggcacagggaaggaagaat 290 TD 54 yes (0.75) 1.5 
  NM_015386   -R tccccagaaggaatgtgatg         
E17 NM_015386  -F accctcacctgtagaaactcc 300 TD 54 yes (0.75) 1.5 
  NM_015386   -R caagtcctgggggtggtg         
E18 NM_015386  -F agtcctgctctggcttctga 375 TD 54 yes (0.75) 1.5 
  NM_015386   -R tgctggcagacatggtttag         
E19a NM_015386  -F ataggacaccttccccttcc 478 TD 54 yes (0.75) 1.5 
  NM_015386   -R ATTAGGAGCCCGCTTCTCTC         
E19b NM_015386  -F GTCTGGCTTGGGGGAGAT 458 TD 54 yes (0.75) 1.5 
  NM_015386   -R aggctgaggtcttgggtttt         
  DDX19A   
 
  
  
E1 NM_018332 -F gcgcagaatgatgatgtcg 373 TD 54 yes (0.75) 1.5 
  NM_018332 -R aagagcaaatcaagggcaag         
E2 NM_018332 -F gaacaaaccgactccctgaa 300 TD 54 yes (0.75) 1.5 
  NM_018332 -R tggcttgtaaacagctgaagtt         
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Exon Primer I.D. Sequence 
Amplico
n Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E3 NM_018332 -F ccttgggctacaagaggaaa 299 TD 54 yes (0.75) 1.5 
  NM_018332 -R tctctgattcctctcatctcctg         
E4 NM_018332 -F agggagaaagagtggcttca 299 TD 54 yes (0.75) 1.5 
  NM_018332 -R gtaaaattctcacaagaatctctcag         
E5 NM_018332 -F tgacagaggtaggaggcatca 282 TD 54 yes (0.75) 1.5 
  NM_018332 -R tgttctcaggcacaaaaacg         
E6 NM_018332 -F gggggaaatatgcctttcat 265 TD 54 yes (0.75) 1.5 
  NM_018332 -R actcctcaccagatggcact         
E7 NM_018332 -F tgggtgccttcaggtctgt 250 TD 54 yes (0.75) 1.5 
  NM_018332 -R cgcatcttcaaaattcaaacg         
E8 NM_018332 -F gaccaagactgaggggaaca 399 TD 54 yes (0.75) 1.5 
  NM_018332 -R aggaggcgtctgaagtgaag         
E9 NM_018332 -F ctagggactcttccccaacc 489 TD 54 yes (0.75) 1.5 
  NM_018332 -R ggcatccagtcctcctga         
E10 NM_018332 -F tgacttgagcccaggacttt 371 TD 54 yes (0.75) 1.5 
  NM_018332 -R gaccatccgacttccctgta         
E11 NM_018332 -F ttgcctgcctatatgtgtgc 499 TD 54 yes (0.75) 1.5 
  NM_018332 -R gctccctgagaactgccata         
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Exon Primer I.D. Sequence 
Amplico
n Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E12a NM_018332 -F ctgggcgatagagtgagacc 538 TD 54 yes (0.75) 1.5 
  NM_018332 -R tgccaataacttaaaatgaaccaa         
E12b NM_018332 -F aaatgcaatgcctgtttggt 495 TD 54 yes (0.75) 1.5 
  NM_018332 -R tatgggaaaatgctggcttc         
E12c NM_018332 -F attcccccatagtcgtgtga 599 TD 54 yes (0.75) 1.5 
  NM_018332 -R GAGCACTGGCTAGCGACAT         
E12d NM_018332 -F ACAGCATCTTCCTCCCTCCT 499 TD 54 yes (0.75) 1.5 
  NM_018332 -R TCTCCCTCTCTGTGGACCTG         
E12e NM_018332 -F GCATGAGGACAGACCACAGA 397 TD 54 yes (0.75) 1.5 
  NM_018332 -R AACAAACAGCGTGAATGTGC         
 DDX19B  
 
 
 
  
E1 NM_007242  -F ggtctgagggcaacagaatc 365 TD 54 yes (0.75) 1.5 
  NM_007242   -R cccatccagcctctaatcaa         
E2 NM_007242  -F ggaggctctgttgattccaa 230 TD 54 yes (0.75) 1.5 
  NM_007242   -R gccctgcctggtacaaatac         
E3 NM_007242  -F ccccaggcctttacaaaaac 249 TD 54 yes (0.75) 1.5 
  NM_007242   -R gccaaactgggtataaaaatgaa         
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Exon Primer I.D. Sequence 
Amplico
n Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E4 NM_007242  -F tggcagttgaattagagtaaacg 363 TD 54 yes (0.75) 1.5 
  NM_007242   -R cctgggcaacagagtgagac         
E5 NM_007242  -F tcctccagatattttgctgct 240 TD 54 yes (0.75) 1.5 
  NM_007242   -R ttgctggcctgtgaaaataa         
E6 NM_007242  -F tgctacataatccaaggtctcc 299 TD 54 yes (0.75) 1.5 
  NM_007242   -R gcccatagcttgtcttttaatcc         
E7 NM_007242  -F cagctggaggagtggctaag 285 TD 54 yes (0.75) 1.5 
  NM_007242   -R caactattgggtgggttttga         
E8 NM_007242  -F gagtcgagatcatgccattg 378 TD 54 yes (0.75) 1.5 
  NM_007242   -R ggaggcatctgaagtgaagg         
E9 NM_007242  -F agctgggaaggctgtgct 391 TD 54 yes (0.75) 1.5 
  NM_007242   -R caggggcatccagtcctc         
E10 NM_007242  -F Ggatttagcagggccttcat 567 TD 54 yes (0.75) 1.5 
  NM_007242   -R agcctctgggagacacaatg         
E11 NM_007242  -F Gactgatttgcctcctgtcc 440 TD 54 yes (0.75) 1.5 
  NM_007242   -R aggggagctgttcttggagt         
E12 NM_007242  -F Tttggggctgaatgaatgat 470 TD 54 yes (0.75) 1.5 
  NM_007242   -R caggagatcctgggcaagta         
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 DHX38    
 
  
Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E1 NM_014003 -F aacggaagagcttctagtcacc 637 TD 54 yes (0.75) 1.5 
  NM_014003 -R ggatttgaccagagcaagga         
E2 NM_014003 -F tcttggagagagggagcaaa 579 TD 54 yes (0.75) 1.5 
  NM_014003 -R tctccaacaggaaaactgagaga         
E3 NM_014003 -F agaaatgccttgggttgttg 438 TD 54 yes (0.75) 1.5 
  NM_014003 -R ccctaacaaatgggtgttgc         
E4 NM_014003 -F atcacattcgagcagtgcag 384 TD 54 yes (0.75) 1.5 
  NM_014003 -R gtgcccacctgactcagaac         
E5 NM_014003 -F tttggggaattgacttttgg 334 TD 54 yes (0.75) 1.5 
  NM_014003 -R ctgagctaagccacgtcctc         
E6 NM_014003 -F CGAGATCGAGACAGgtgatg 418 TD 54 yes (0.75) 1.5 
  NM_014003 -R agcacaggaagcaggtcagt         
E7 NM_014003 -F GGCCGATGACAGAAGACACT 379 TD 54 yes (0.75) 1.5 
  NM_014003 -R taccctcatcaaagcccagt         
E8 NM_014003 -F ccttcttctgttggccatgt 385 TD 54 yes (0.75) 1.5 
  NM_014003 -R tcatcacccactcctcttcc         
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Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E9 NM_014003 -F tgacatctttgcagctaccag 400 TD 54 yes (0.75) 1.5 
  NM_014003 -R caatgatccaccctcctcag         
E10 NM_014003 -F aaggcctgatgtggagacag 382 TD 54 yes (0.75) 1.5 
  NM_014003 -R tcgggcctaaggacttgata         
E11 NM_014003 -F gaggcttgaggattggaatg 353 TD 54 yes (0.75) 1.5 
  NM_014003 -R ccacaaagtcgatgggttct         
E12 NM_014003 -F tcctgaggtcgatgagaacc 376 TD 54 yes (0.75) 1.5 
  NM_014003 -R gagctcctgggtaaacatgg         
E13 NM_014003 -F ggctgttgtcccagtgaaat 518 TD 54 yes (0.75) 1.5 
  NM_014003 -R CTTCAAAGCGGATGGCATAG         
E14 NM_014003 -F gcttccacccatttttgcta 473 TD 54 yes (0.75) 1.5 
  NM_014003 -R cagcagagcaagaacagcat         
E15 NM_014003 -F tttgtcagctttggcttgtg 366 TD 54 yes (0.75) 1.5 
  NM_014003 -R ggtccccaggaaatcttctc         
E16 NM_014003 -F tcttgtagaggcctcgcagt 390 TD 54 yes (0.75) 1.5 
  NM_014003 -R TGCTCCACAATCTGGTCTGA         
E17 NM_014003 -F ccttggtcacgactgtgatg 378 TD 54 yes (0.75) 1.5 
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  NM_014003 -R TGGAGCctagagcaggacat         
Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E18 NM_014003 -F tgggctaggaggtaggcttt 362 TD 54 yes (0.75) 1.5 
  NM_014003 -R gggttaaacaaaccaagcaca         
E19 NM_014003 -F ctgccatgtgtagcaaccag 393 TD 54 yes (0.75) 1.5 
  NM_014003 -R gaaagccactccttccttcc         
E20 NM_014003 -F gggtggggagaagaaatgag 400 TD 54 yes (0.75) 1.5 
  NM_014003 -R agcaaacccggatatttgac         
E21 NM_014003 -F CGGAGGACAACATGCTCAAC 395 TD 54 yes (0.75) 1.5 
  NM_014003 -R cagtaatacagagagaagccattcc         
E22 NM_014003 -F atgtgtgggtaggtggtagtg 384 TD 54 yes (0.75) 1.5 
  NM_014003 -R CTGCACCATGATGTCCTTGA         
E23 NM_014003 -F gagtggtggatgagcaggat 300 TD 54 yes (0.75) 1.5 
  NM_014003 -R ccacaccaggacaaaggaag         
E24 NM_014003 -F gttctgcagatctgggcttc 388 TD 54 yes (0.75) 1.5 
  NM_014003 -R tgaaaaccaacctcacatgc         
E25 NM_014003 -F cccatgtggctcctaattgt 268 TD 54 yes (0.75) 1.5 
  NM_014003 -R ggatgaccgcaagtcttcaa         
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Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E26 NM_014003 -F gagaaggcggctttggtact 399 TD 54 yes (0.75) 1.5 
  NM_014003 -R ctgtcaccagtttgccttca         
E27 NM_014003 -F ccaccatgggttaggaacag 694 TD 54 yes (0.75) 1.5 
  NM_014003 -R acccatgcaaaggaagtcag         
E1 NM_014500 -F tttacacatgcacacacaaaaa 486 TD 54 yes (0.75) 1.5 
  NM_014500  -R AAGCCCATATAAGCGCTCTC         
E1b NM_014500 -F GGGCTGGCTTACACATGCT 398 TD 54 yes (0.75) 1.5 
  NM_014500  -R ggaggggtcaaatagcaaaa         
E2 NM_014500 -F cttcgggcccttgttttct 298 TD 54 yes (0.75) 1.5 
  NM_014500  -R ctttgcaacccaaacacgat         
E3 NM_014500 -F agtctggcagatgcagaacc 479 TD 54 yes (0.75) 1.5 
  NM_014500  -R gccctaaaattcattttcttttcc         
  IL34  
 
 
  
E1 NM_001172772  -F tgggttgaagactccctcct 483 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
ttgaaacccagagcagacag         
E2a NM_001172772  -F ttcggacatcctgaagtcatt 386 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
CAGCAGCTGCCCTTATCTG         
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Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E2b NM_001172772  -F GCTCCTTGGAAAGGAAGACC 479 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
tgggaatctcagagggtgtc         
E3 NM_001172772  -F gcaaatggatgatggttgtg 370 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
ttcggagaaaggcagagaaa         
E4 NM_001172772  -F gcactccatactgggtgaca 370 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
gctgtggacagtggacaaac         
E5 NM_001172772  -F caggcacatgtttgtccact 425 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
ctctgcttgtgcccatcttt         
E6 NM_001172772  -F tcacaggaagtctggtccttc 397 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
atcctggcttccagaaatgg         
E7a NM_001172772  -F ggctacaagccatttctgga 470 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
AGAATCCCCCTCAAAGGAAA         
E7b NM_001172772  -F TTTCCTTTGAGGGGGATTCT 441 TD 54 yes (0.75) 1.5 
  
NM_001172772   -
R 
ccctccacttcctgcactt         
  PMFBP1  
  
E1 NM_001160213  -F atgcacctctgtgcatgaag 296 TD 54 yes (0.75) 1.5 
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NM_001160213   -
R 
caggatgatgcatttgaggtc         
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E2 NM_001160213  -F cttgctgagggcatagatcc 247 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
tggaattttgaatcataaaacatga         
E3 NM_001160213  -F gatggacaaatttccagcaa 364 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
tcctgaatgaacagtggaagaa         
E4 NM_001160213  -F tggatgtgaatgactgaacaaa 426 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
ctgctttctagtgggcttgg         
E5 NM_001160213  -F ttacaaccgcatcctttcct 395 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
gggtaaaggtttgggtttcc         
E6 NM_001160213  -F ccatgttcatggaattctgaagta 316 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
ttttcccctcctttctctcc         
E7 NM_001160213  -F tgctgcagaaaggaacactc 280 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
aaaaataagtaggaaagcccagaa         
E8&9 NM_001160213  -F gtggatgctgggcattttag 543 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
gcaataatggtgggtgaagg         
E10 NM_001160213  -F ggcttgagacaacctctcatt 400 TD 54 yes (0.75) 1.5 
  NM_001160213   - ggagagagaaggtggctgct         
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R 
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E11 NM_001160213  -F gggcacaaaatgaaaggaaa 393 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
atgggaaatccttgctctcc         
E12 NM_001160213  -F ctcccctccagagagaggtt 391 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
ttacaggtgtgagccactgc         
E13 NM_001160213  -F ccctgtgtgcaattgtctgt 369 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
gtccctcccgtctttcctaa         
E14 NM_001160213  -F ggtggagtggggcttttatag 297 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
gtgtggaggagaggtgggta         
E15 NM_001160213  -F gcagacaggagagagcttgg 397 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
cccacacaagggtttgagat         
E16 NM_001160213  -F cagaggacaggaagggactg 368 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
cagcccaagggaatgactta         
E17 NM_001160213  -F gctggccactgagaagaaaa 368 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
tggcatttgggtggtcatag         
E18 NM_001160213  -F ttcccagggagatagaagagg 291 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
gcaggggtgtgtgtgactaa         
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Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E19 NM_001160213  -F cagcagcagtcttgctgaga 272 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
ccccctatcaagggctaaag         
E20 NM_001160213  -F tctgtgctgtcttccctgtg 471 TD 54 yes (0.75) 1.5 
  
NM_001160213   -
R 
tggtccaaagtcgctaagaaa         
E21 NM_001160213  -F cctttcctgccacctgtaaa 490 TD 54 yes (0.75) 1.5 
  NM_001160213 –R ttcagagaaaacaggatgaaca         
  ZFHX3  
 
 
  
E0 NM_006885  -F tgctttgcatcccaattaca 630 TD 54 yes (0.75) 1.5 
  NM_006885   -R aagagaaagtttggcgtaggg         
E1a NM_006885  -F tttcttctcgcccgattcta 470 TD 54 yes (0.75) 1.5 
  NM_006885   -R TGTAAATGAAGCCCAACTCG         
E1b NM_006885  -F CGGCACGACTGTAGATGTCA 627 TD 54 yes (0.75) 1.5 
  NM_006885   -R ggaagttcagccaagactcg         
E2a NM_006885  -F gccctcctaacctctttcctt 562 TD 54 yes (0.75) 1.5 
  NM_006885   -R AGGCTCTCCACAATGTACGC         
E2b NM_006885  -F AGGTCACCTGCAACGAATGT 583 TD 54 yes (0.75) 1.5 
  NM_006885   -R AAGCCATCGAATTTGGACAG         
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Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E2c NM_006885  -F GGCTTTCCCGAATACCTCAG 597 TD 54 yes (0.75) 1.5 
  NM_006885   -R TTCAGTACCGAGCTGGTGAG         
E2d NM_006885  -F ATTCGAATGGAAGGGGAGGA 584 TD 54 yes (0.75) 1.5 
  NM_006885   -R TTCGCACCATCAAAGACAAC         
E2e NM_006885  -F CAGCAAAAAGGACCTTGCTC 567 TD 54 yes (0.75) 1.5 
  NM_006885   -R CCGCTTTTGCAGTAGACACA         
E2f NM_006885  -F GACACTCAAGTGCCCCAAGT 599 TD 54 yes (0.75) 1.5 
  NM_006885   -R TCTGGGCCAGGTAGTATTGG         
E2g NM_006885  -F 
GAGAAGCACATGCATAACATG
A 
595 TD 54 yes (0.75) 1.5 
  NM_006885   -R ttcgatgaaaccccaaagtt         
E3a NM_006885  -F aatgtccgcaggaaagattg 466 TD 54 yes (0.75) 1.5 
  NM_006885   -R GTGTTGTAGCGGCAGAGCTT         
E3b NM_006885  -F AAGTTCACGACGGACAACCT 596 TD 54 yes (0.75) 1.5 
  NM_006885   -R ggcacccagaaagagaacct         
E4 NM_006885  -F gactgtcctgtttggctgtg 473 TD 54 yes (0.75) 1.5 
  NM_006885   -R ccagctggatcagtaacgtct         
E5 NM_006885  -F agagaagggggacgagtcat 581 TD 54 yes (0.75) 1.5 
  NM_006885   -R cagcgactggaccttcaatag         
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Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E6/7 NM_006885  -F tcacccaacacaaaccctct 600 TD 54 yes (0.75) 1.5 
  NM_006885   -R cccatgttactgcatcacctt         
E8 NM_006885  -F ctggtgaaggctaattttgct 284 TD 54 yes (0.75) 1.5 
  NM_006885   -R gaattcctgaaaacctttctcc         
E9a NM_006885  -F gcacttccctcatcatcaga 597 TD 54 yes (0.75) 1.5 
  NM_006885   -R AGAGTGGGGTCTCCCATTG         
E9b NM_006885  -F GGCTCTGAAGAAGCACCTTG 587 TD 54 yes (0.75) 1.5 
  NM_006885   -R CATTGCTGCTGCCACTTG         
E9c NM_006885  -F CAGCCCAGACAACAAACCTT 564 TD 54 yes (0.75) 1.5 
  NM_006885   -R AGGAGGGTGGGGTTAAACAG         
E9d NM_006885  -F CAACAACAACAAGCACAAACG 585 TD 54 yes (0.75) 1.5 
  NM_006885   -R GAGCATGGAAGGCTCAGAAC         
E9e NM_006885  -F AAGCCAGAGAGAGAGGGACA 570 TD 54 yes (0.75) 1.5 
  NM_006885   -R GGTGCAATTGTAGGTGAGGTG         
E9f NM_006885  -F CAGAGCCACCACCACCTC 551 TD 54 yes (0.75) 1.5 
  NM_006885   -R CTCCAGGCTGGTGATAGGAG         
E9g NM_006885  -F CCCCCAGTGAAGAGCAAATA 597 TD 54 yes (0.75) 1.5 
  NM_006885   -R AATCCTCATTTTGGCTGTCG         
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Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E9h NM_006885  -F ATCAGGGAGAGGGCAAAGAT 577 TD 54 yes (0.75) 1.5 
  NM_006885   -R GGTAAGGGGCACTGTGGAG         
E9i NM_006885  -F CCGAGCAGAAGACCAACACT 554 TD 54 yes (0.75) 1.5 
  NM_006885   -R CAAACGCTTGTCTCTCTGAGG         
E9j NM_006885  -F TCCAACCTCCACAATGAACA 596 TD 54 yes (0.75) 1.5 
  NM_006885   -R TGGAGGAAGGGCTTAGAAGA         
E9k NM_006885  -F TGCGATGCTCTTAGACTGTGA 584 TD 54 yes (0.75) 1.5 
  NM_006885   -R GATCTCCGCTGTCACCAGAT         
E9l NM_006885  -F GCCCCGAGCTTTTATAGCA 592 TD 54 yes (0.75) 1.5 
  NM_006885   -R CTGCCAGTCCAAGGACCTC         
E9m NM_006885  -F CCAGCTGGACAAGGAGAAAG 341 TD 54 yes (0.75) 1.5 
  NM_006885   -R ctcagagggtttgggtggta         
E10a NM_006885  -F tctcaaactgtgtgccagtg 595 TD 54 yes (0.75) 1.5 
  NM_006885   -R GAAGGAACTGGCTTGTGAGC         
E10b NM_006885  -F CACCATGGAGTATGCGGTAG 555 TD 54 yes (0.75) 1.5 
  NM_006885   -R TGCACCTTTGGAACAATGAA         
E10c NM_006885  -F CCCCAAACCAGAAGAACAGA 536 TD 54 yes (0.75) 1.5 
  NM_006885   -R GGCTGTCGTTTGAGTGAGC         
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Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E10d NM_006885  -F GAACAATCACGAGAGCAGCA 595 TD 54 yes (0.75) 1.5 
  NM_006885   -R CAACCCACGCTTTTTCTTTT         
E10e NM_006885  -F CCAGTGTAGGAACGGACACC 550 TD 54 yes (0.75) 1.5 
  NM_006885   -R TGTGAGCGATTGACCTGAGA         
E10c/d NM_006885  -F CACCTGAAGTCCCTCTGCTT 500 TD 54 yes (0.75) 1.5 
  NM_006885   -R GAGGTGCTGCATGAACTTGA         
  ZNF19             
E1 NM_006961  -F aagaggatgtctcccaatcg 282 TD 54 yes (0.75) 1.5 
  NM_006961   -R cgtccccttctttgagctg         
E2 NM_006961  -F tgccaacatagaagaaaatgc 315 TD 54 yes (0.75) 1.5 
  NM_006961   -R acgaagccgacagccttct         
E3 NM_006961  -F tgaatgctgcttgctattgg 246 TD 54 yes (0.75) 1.5 
  NM_006961   -R tggctctaagacttgccagaa         
E4 NM_006961  -F cctcacaggactttccctca 324 TD 54 yes (0.75) 1.5 
  NM_006961   -R tcctctccactccacactcc         
E5 NM_006961  -F tcgagaaccctcttctgtgg 282 TD 54 yes (0.75) 1.5 
  NM_006961   -R tgcccagcatgattcattt         
E6a NM_006961  -F ccttatcattttcaatgctctattatt 373 TD 54 yes (0.75) 1.5 
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  NM_006961   -R CAAAAGGTTTCTCCCCAGTG         
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E6b NM_006961  -F GTGGAAAAGCACCAGGACAT 477 TD 54 yes (0.75) 1.5 
  NM_006961   -R TTTCTGATGCCGAAGTAGGG         
E6c NM_006961  -F 
CAGTGGGGACAGACCCTATTA
C 
477 TD 54 yes (0.75) 1.5 
  NM_006961   -R TTGCTAGTCAAGGCTTTTCCA         
E6d NM_006961  -F CAAAACTAACTCGGCACCAGA 453 TD 54 yes (0.75) 1.5 
  NM_006961   -R GCTTGAGGGATGGATCAGAG         
E6e NM_006961  -F AGAAGCCTGTGCTGGACATT 499 TD 54 yes (0.75) 1.5 
  NM_006961   -R AAGCCAAAACCAACCAAACA         
E6f NM_006961  -F GGTGAGAATGAAGTCCACACA 495 TD 54 yes (0.75) 1.5 
  NM_006961   -R AATGGATTCACTGGTGCAGA         
E6g NM_006961  -F CTCCTCAACCCCATGATTGT 399 TD 54 yes (0.75) 1.5 
  NM_006961   -R GAAGGACACGTGGGAGAAAA         
E6h NM_006961  -F 
TGGAATGGATGCTACTCTAGG
C 
343 TD 54 yes (0.75) 1.5 
  NM_006961   -R tgctcattcatctgctgaca         
 ZNF23  
  
  
 
  
E1a  NM_145911 -F cagcgaccttgctcctaga 455 TD 54 yes (0.75) 1.5 
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   NM_145911  -R CCAGACCTCAGCATGTCAAA         
Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E1b  NM_145911 -F TTTGTGGCTCAATAGCTTGC 500 TD 54 yes (0.75) 1.5 
   NM_145911  -R ttgcttttcatgggggtatg         
E2  NM_145911 -F gtgaggggctatgttgctct 250 TD 54 yes (0.75) 1.5 
   NM_145911  -R aagttccagtccagcaggtg         
E3  NM_145911 -F agagctttccaccctgtcct 240 TD 54 yes (0.75) 1.5 
   NM_145911  -R caggaccaaacgaccataca         
E4  NM_145911 -F tctgagatcttccccttgttg 389 TD 54 yes (0.75) 1.5 
   NM_145911  -R cagctctggggttctcactc         
E5  NM_145911 -F ctccccattgctgagacag 300 TD 54 yes (0.75) 1.5 
   NM_145911  -R gactggccaataaacacagtatg         
E6a  NM_145911 -F ttttaaggagccccctgatt 400 TD 54 yes (0.75) 1.5 
   NM_145911  -R CCCAATCCTGTACACCCAGA         
E6b  NM_145911 -F AGGAAGTCCACTCAGCAGGA 316 TD 54 yes (0.75) 1.5 
   NM_145911  -R GGCTTTTCCTCAGTGTTGTTCT         
E6c  NM_145911 -F GGGAAATCCATCAGCTTTGA 346 TD 54 yes (0.75) 1.5 
   NM_145911  -R AGGCCTTCCCACACATCTT         
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Exon Primer I.D. Sequence 
Ampl
icon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E6d  NM_145911 -F TGTTCGGAGTGTGGCAAA 454 TD 54 yes (0.75) 1.5 
   NM_145911  -R AGCTGCACCTGAAGCCTTT         
E6e  NM_145911 -F TCAGTGTTAATGGAAGCCTAAGT 462 TD 54 yes (0.75) 1.5 
   NM_145911  -R TGTGAATTCTCTGGTGTTGG         
E6f  NM_145911 -F AGGTGCAGCTCCCAGCTTAG 361 TD 54 yes (0.75) 1.5 
   NM_145911  -R GCCGCATTAGTTTCCCATTA         
E6g  NM_145911 -F CCTTCAGTGTCAAAGGGAAGTT 367 TD 54 yes (0.75) 1.5 
   NM_145911  -R TGCCTAGTTAGTTTGGCATTG         
E6h  NM_145911 -F CAATTTCGGCAGCATCTGAG 489 TD 54 yes (0.75) 1.5 
   NM_145911  -R GCCTTTGCCACATTCCAC         
E6i  NM_145911 -F GCCTTCAGTATCAATGCCAAA 499 TD 54 yes (0.75) 1.5 
   NM_145911  -R CCATATTCATGCCCTCTTGG         
E6j  NM_145911 -F GCATTCAGGTTTAGCTTCCAG 398 TD 54 yes (0.75) 1.5 
   NM_145911  -R CCTTTGTAAAGTGGCCCTCA         
E6K  NM_145911 -F CCTCCAAGAGGGCATGAATA 500 TD 54 yes (0.75) 1.5 
   NM_145911  -R ccctgtggatagtttctagctttc         
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Appendix 8:  Cycle Sequencing protocol 
Reagent   Volume (uL) 
dH2O    15.68 
BDT 5x Buffer  2  
BDT Sequencing Mix  0.5   
Primer (10uM)  0.32 
Purified PCR Sample   1      
Total Volume   20 
 
Appendix 9: Thermocycling Protocols for Cycle Sequencing  
94°C for 1 min 
25 cycles of:  
96°C Denaturation for 10s 
50°C Annealing for 5s 
60°C Extension for 4 mins 
Hold at 4° 
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Appendix 10: Cycle Sequencing DNA Precipitation Protocol 
This step was performed after Cycle sequencing was completed, as a second purification 
step before being placed on the ABI 3130xl of ABI 3730.  
Step 1) DNA precipitation 
 Add 65uL of 95% Ethanol (EtOH) to each well 
 Add 5uL of 125mM Ethylenediaminetetraacetic acid to each well 
 Let precipitate for 15 mins to overnight in dark  
o Can place at -20°C if preferred or if not using plate for a few days. 
Step 2) Ethanol mixture Removal 
 Place plate in centrifuge, spin at 3000 RPM for 30 mins 
 Remove plate from centrifuge and decant ethanol mixture onto a dry paper towel 
by inverting the plate. 
 Leave plate inverted on paper towel and place back in centrifuge. Spin up to 200 
RPM, and then immediately stop the spinning. 
 Remove and discard paper towel. 
Step 3) Rinse step 
 Add 150uL of  70% EtOH to each well, and place in centrifuge. 
 Spin plate at 3000 RPM for 5 mins. 
 Remove plate from centrifuge and decant EtOH mixture onto a paper towel 
 Leave plate inverted on paper towel and place back in centrifuge. Spin up to 200 
RPM, and then immediately stop the spinning. 
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 Remove and discard paper towel. Let plate dry in dark and uncovered for 20 mins 
 
Step 4) Sample Resuspension 
 Add 15 uL of Hi-Dye Formamide (HDF) to each well 
 Place plate in thermocycler on ‘denat’ program 
o 95°C for 2 mins 
o Hold at 4° 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 
314 
Appendix 11: Sequenced functional candidate genes at the minimized 
4.2Mb of OTSC4  
 
Genes  Accession 
number 
Strand  Genomic position 
Start            End  
Function or expression 
ZNF19 NM_006961 - 71507976     71523254 ZNF19 gene is one of zinc fingers 
genes that encoded zinc finger 
proteins. The zinc finger protein 
has a nucleic acid binding domain 
property that present in many of 
the transcription factor. ZNF19 
protein has a transcriptional and 
post-transcriptional function and it  
is highly expressed different tissue 
including temporal bone 
(http://embl-
ebi.org/gxa/gene/ENSG000002616
11?ef=organism_part). 
ZNF23 NM_145911 - 71481503   71496117 ZNF23 is located near ZNF19 and 
has the same function as ZNF19. 
COG4 NM_015386 - 70514472-70557457 COG4 is one of the multi-protein 
complexes. COG4 protein is highly 
expressed in different tissue 
including the primary osteoblast 
(http://www.ebi.ac.uk/gxa/gene/M
GI:2142808). 
DDX19B NM_001257175 + 70333062-70367735 This gene encoded protein that is 
involved in many cellular 
processes including cellular growth 
and division. Dead box protein 
reported to be expressed in the 
immune system, cartilage and 
fibrous tissue. 
PMFBP1 NM_001160213 - 72152996-72206349 This gene involved in the general 
organization of cellular 
cytoskeleton. 
DDX19A NM_018332 + 70380824-70407281 DDX19A is another DEAD gene. 
This gene encoded protein that is 
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involved in many cellular 
processes including cellular growth 
and division. Dead box protein 
reported to be expressed in the 
immune system, cartilage and 
fibrous tissue 
DHX38 NM_014003 + 72127615-72146811 DHX38 is one of the DEAD box 
gene. This gene encoded protein 
that is involved in many cellular 
processes including cellular growth 
and division. Dead box protein 
reported to be expressed in the 
immune system, cartilage and 
fibrous tissue. 
ZFHX3 NM_006885 - 72816786-73082274 ZFXH3 is one of zinc finger 
protein. This gene encoded 
transcription factor. Transcription 
factors are important for 
transcription of many down stream 
genes. Genes that act as 
transcription factor or encoded a 
transcription factor considered 
candidate in this study. It also 
involved in cytoskeleton 
organization. 
CALB2 NM_001740 + 71392616-71424342 This gene involved in the matrix 
formation during bone formation 
stage. 
IL34 NM_001172771 + 70613798-70694585 This gene plays an important role 
in inflammatory process. It also 
involved in the regulation of 
osteoclast proliferation and 
differentiation. 
SF3B3 NM_012426 + 70557691-70611571 This gene has a splicing function 
and has function in cell –cycle 
progression. 
WWP2 NM_001270455 + 69796187-69944308 This gene involved in multiple 
processes including chondrogensis 
 
 
 
                              
 
316 
Appendix 12: Sequencing variants in 12 genes across OTSC4 
A) Sequencing variants detected in ZNF19, ZNF23, COG4, DDX19B, DHX38, DDX19A, and ZNFHX3. Colours represents corresponding 
colour of haplotype in figure 2.28. The disease-associated haplotype on chromosome 16 (OTSC4) is coloured yellow. Bolded variants 
were variants subjected for further analysis. 
 
    Affected  Controls 
Gene  Location of Variant Variant location SNP PID 
 III-4 
PID  
III-8 
PID 
IV-12 
PID 
III-9 
ZNF19 c.654G>C, p. Q218QH 
c.765G>C, p. T255TT 
 *844A>T 
Coding (EX6) 
Coding (EX6) 
Coding (EX6) 
 
Rs8050872 
Rs2288489 
Rs34015581 
 
 
G 
G 
A 
 
C 
C 
T 
 
G 
G 
A 
 
G 
G 
A 
 
G 
G 
A 
 
G 
G 
A 
 
G 
G 
A 
 
C 
C 
T 
 
ZNF23 c. -756G>A 
c.82A>G, p. S28SG 
Coding (EX1) 
Coding (Ex5) 
Not Listed 
rs2070832 
G 
A 
A 
G 
G 
A 
G 
A 
G 
A 
G 
A 
G 
A 
A 
G 
COG4 c.369+38het_delT 
c.485C>T 
544+19T>A 
c.646C>T, p. L216LL 
c.1061+76T>G 
c.1482-25T>C 
Intron 3 
Coding (EX4) 
Intron 4 
Coding (EX5) 
Intron 8 
Coding (Ex12) 
Not listed 
rs3931036  
rs74324138 
rs3762171 
not Listed 
rs2303793 
Wt 
T 
T 
C 
T 
T 
Del 
T 
T 
T 
T 
C 
DEL 
T 
A 
T 
G 
C 
Wt 
T 
T 
C 
T 
T 
Wt 
T 
T 
C 
T 
T 
DEL 
T 
A 
T 
G 
C 
Wt 
T 
T 
T 
T 
C 
DEL 
T 
T 
T 
T 
C 
DDX19B c.296+122delT het 
c.607-69delA het 
Intron 4 
Intron 7 
Rs35388962 
Not listed 
Del 
Del 
WT 
WT 
WT 
WT 
Del 
Del 
Del
Del 
WT 
WT 
Del 
Del 
WT 
WT 
 
PMFBP1 c.165+21C>T 
c.2145G>A  
c.1949C>A 
c.2422-87G>T 
c.2693+61A>C 
Intron 3 
Coding (EX5) 
Coding (Ex13) 
Intron 16 
Intron 18 
rs3852785 
Not listed 
rs34832584 
rs3812987 
rs4788606 
C 
G 
C 
G 
C 
 
C 
G 
C 
T 
A 
C 
G 
C 
G 
A 
C 
G 
C 
G 
C 
T 
A 
A 
G 
A 
C 
G 
C 
G 
A 
C 
A 
A 
G 
C 
T 
G 
C 
T 
A 
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DHX38 c.754C>G 
c.456G>GT 
c.147C>G 
c.418C>A 
c.616+64_616+65delTC 
c.1308T>C 
c.1387-80T>C 
c.1698G>A 
c.10999G>T 
c.12071C>A 
c.2487+14T>C 
c.2380-20T>C 
c.*45C>G 
c.*174TC>T 
Coding (EX1) 
Coding (EX1) 
Coding (Ex2) 
Coding (EX3) 
Intron 3 
Coding ( Ex10) 
Coding (Ex11) 
Coding (EX13) 
Coding (EX14) 
Coding (Ex16) 
Coding (Ex18) 
Coding (EX18) 
Coding (EX27) 
3UTR 
 
Not listed 
Not listed 
rs105036 G=0.473 
rs1050362 A=0.432 
rs10537374  del=0.5 
Not listed 
rs8043606 
rs2240243   A=0.42 
rs12325142 T=0.49 
rs2074626   A=0.49 
rs42544 
rs150617 
rs7940 
rs6680       T=0.441 
 
C 
G 
G 
A 
Del 
T 
T 
A 
T 
A 
C 
T 
C 
T 
 
 
 
 
 
 
C 
G 
G 
A 
Del 
C 
C 
A 
T 
A 
C 
C 
C 
T 
G 
G 
G 
A 
Del 
C 
T 
A 
T 
A 
C 
C 
C 
T 
C 
G 
G 
A 
Del 
T 
T 
A 
T 
A 
C 
T 
C 
T 
 
C 
T 
C 
C 
Wt 
T 
T 
G 
G 
C 
C 
T 
G 
C 
C 
G 
G 
A 
del 
C 
T 
A 
T 
A 
C 
C 
C 
T 
 
G 
G 
C 
C 
Wt 
T 
C 
G 
G 
C 
C 
T 
G 
C 
C 
G 
G 
A 
Del 
C 
C 
A 
T 
A 
C 
C 
C 
T 
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DDX19A 
 
 
 
 
 
 
 
c.360C>T  het 
c.783-152T>C het 
c.783-113T>C  het 
c.783-105C>T het 
c.783-64G>A het 
c.783-51C>T het 
c.783-48T>C het 
c.783-40A>G het 
c.783-23T>C het 
c.783-17C>A het 
c.876T>C  het 
c.912T>C het 
c.876T>C  het 
c.1020+12C>T 
c.1020+33C>T 
c.*92G>A 
c.*265T>A 
Coding (Ex5) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Intron 9 
Intron 9 
Intron 12 
Intron 12 
 
Rs1134074 
Not Listed 
Not Listed 
Rs188463504 
Not Listed 
Not Listed 
Not Listed 
Not Listed 
Not Listed 
Not Listed 
Rs1065167 
Rs1065168 
Rs1065167 
Rs200086133 
Not Listed 
Rs111798739 
Rs114589283 
 
C 
T 
T 
T 
G 
C 
T 
A 
T 
C 
T 
T 
T 
C 
C 
G 
T 
 
T 
T 
T 
T 
G 
C 
T 
A 
T 
C 
T 
T 
T 
C 
C 
A 
T 
 
T 
C 
C 
C 
A 
T 
C 
G 
C 
A 
C 
C 
C 
T 
T 
G 
A 
C 
T 
T 
T 
G 
C 
T 
A 
T 
C 
T 
T 
T 
C 
C 
G 
T 
C 
T 
T 
T 
G 
C 
T 
A 
T 
C 
T 
T 
T 
C 
C 
G 
T 
T 
C 
C 
C 
A 
T 
C 
G 
C 
A 
C 
C 
C 
T 
T 
G 
A 
C 
C 
C 
C 
A 
T 
C 
G 
C 
A 
C 
C 
C 
T 
T 
G 
T 
T 
T 
T 
T 
G 
C 
T 
A 
T 
C 
T 
T 
T 
C 
C 
A 
T 
ZFHX3 c.185C>T, p.A62AV 
c.214T>G, p.S72SA 
c.3663+55A>C 
c.1282A>C, p.T428TP 
c.1602C>T,p.P534PP 
c.1753G>A. p.G585GS 
c.1776C>T, p.D592DD 
c.2330T>C, p.V777VA 
c.2385G>C, p.795PP 
c.2577C>A,p.A859AA 
c.2719+40G>A 
c.2719+229G>A 
c.2916G>A 
c. 3216+28G>A 
c.3216+153G>A 
c.3216+28C>T 
Coding (EX2) 
Coding (Ex2) 
Coding (EX2) 
Coding (EX2) 
Coding (Ex2) 
Coding (EX2) 
Coding (EX2) 
Coding (EX2) 
Coding (EX2) 
Coding (EX2) 
Coding (EX2) 
Coding (EX2) 
Coding (EX3) 
Coding (EX3) 
Intron 3 
Intron 3 
Not 1602listed 
Not listed 
rs9972835 
not listed 
rs62640008 
rs140602496 
rs11075951 
rs4788682 
rs10852515 
not listed 
rs2157786 
rs73592725 
rs2228200 
not Listed 
Rs12149928 
rs12149946 
C 
G 
A 
A 
C 
G 
C 
C 
C 
C 
A 
G 
G 
G 
G 
T 
T 
G 
C 
C 
T 
A 
C 
C 
C 
A 
A 
A 
G 
G 
G 
C 
C 
T 
C 
C 
C 
G 
C 
T 
G 
A 
G 
G 
G 
G 
G 
C 
C 
G 
A 
A 
C 
G 
C 
C 
C 
C 
A 
G 
G 
G 
G 
T 
C 
G 
C 
A 
C 
G 
C 
C 
C 
A 
A 
G 
G 
G 
G 
C 
C 
T 
C 
C 
C 
G 
C 
T 
G 
C 
G 
G 
G 
G 
G 
C 
C 
G 
C 
A 
C 
G 
T 
C 
C 
C 
A 
G 
A 
A 
A 
C 
T 
G 
C 
C 
T 
A 
C 
C 
C 
A 
A 
A 
G 
G 
G 
C 
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c.3216+153G>A 
c.4446A>T, p.A1482A 
c.6819G>A, p.E2273EE 
c.8823A>G, p.G2941G 
c.10831C>T, 
p.H3611HY 
c.10557-10558 het 
ins GGC 
Intron 6 
Coding (EX9) 
Coding (EX9) 
Coding (EX9) 
Coding (EX10) 
Coding (EX10 
rs12149928 
Rs740178 
Not Listed 
Rs699444 
rs200992486  
Not listed 
 
A 
C 
T 
G 
T 
Ins 
 
 
 
 
 
G 
A 
A 
G 
C 
WT 
 
G 
A 
T 
A 
C 
WT 
 
A 
C 
T 
G 
T 
Ins 
G 
A 
T 
G 
C 
Wt 
G 
A 
T 
A 
C 
WT 
A 
A 
T 
G 
C 
WT 
G 
A 
A 
G 
C 
Wt 
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B) Sequencing variants detected in sequencing CALB2, IL34, SF383 and WWP2 .  
Colours represents corresponding colour of haplotype in figure 2.28. The disease-associated haplotype on chromosome 16 (OTSC4) is 
coloured yellow. Bolded variants were variants subjected for further analysis. 
 
    Affected  Control 
Gene  Location of Variant Variant location SNP III-5 III-11 IV-1 IV-5 
CALB2 c.95-32C>T 
c.699+44A>G 
c.540+5214T>C 
Intron 1 
Intron 10 
Intron 9 
rs7203012 
rs43270 
C 
G 
C 
T 
G 
C 
 
C 
G 
C 
C 
G 
C 
 
C 
G 
C 
T 
G 
C 
 
C 
G 
C 
T 
G 
C 
IL34 c.-107G>C 
c.-1C>G 
c.367G>C 
c.639C>A 
Intron 2 
Intron 2 
Coding (EX5) 
Coding (EX8) 
rs3813904 
rs3813905 
rs8046424 0.458/120 
rs4985556 0.112/224 
C 
G 
C 
A 
 
G 
C 
G 
C 
 
C 
G 
C 
A 
G 
C 
C 
C 
 
C 
G 
C 
A 
C 
G 
G 
C 
 
G 
C 
G 
C 
G 
C 
G 
C 
SF3B3 c.717A>T, 
c.2827-60G>A 
Coding (EX6) 
Intron 21 
rs33910368 
rs7197262 
A 
G 
T 
A 
 
A 
G 
T 
A 
 
A 
G 
T 
A 
A 
G 
T 
A 
WWP2 c.219-165T>G 
c.341-37T>G 
c.478+32C>T 
c.575+62T>G 
c.575+63T>G 
c.915-52delG 
c.1179+62_1179+63insTC 
c.1239G>A 
c.1522-131T>G 
c.1522-132C>T 
Intron 4 
Intron 5 
Intron 6 
Intron 7 
Intron 7 
Intron  
Intron 11 
Coding (Ex13) 
Intron 14 
Intron 14 
Not listed 
rs2291959 
rs2291960 
Not listed 
Not listed 
Not listed 
Not listed 
Not listed 
rs8052727 
rs78727023 
T 
T 
C 
T 
T 
Del 
InS 
A 
G 
C 
G 
G 
C 
T 
G 
WT 
WT 
A 
G 
C 
T 
T 
C 
T 
T 
Del 
ins 
A 
G 
C 
T 
T 
C 
T 
T 
WT 
WT 
G 
T 
C 
T 
T 
C 
T 
T 
Del 
Ins 
A 
G 
C 
G 
G 
T 
G 
G 
WT 
WT 
A 
G 
T 
G 
G 
C 
T 
G 
DEL 
INS 
A 
T 
C 
G 
G 
C 
T 
T 
WT 
WT 
A 
T 
C 
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c.1593+109A>G 
c.1707T>C 
c.1976+111T>G 
c.2091A>G 
c.2440+101A>G 
c.1008+31068G>A 
Intron 16 
Coding (EX18) 
Intron 19 
Coding (EX19) 
Intron 23 
Intron 24 
rs2291961 
rs2270841 
rs2270842 
rs1983016 
rs2270843 
- 
G 
C 
G 
G 
G 
G 
G 
C 
G 
G 
A 
A 
G 
C 
G 
G 
G 
G 
A 
T 
T 
A 
A 
G 
 
 
 
G 
C 
G 
G 
G 
G 
G 
C 
G 
G 
A 
A 
G 
C 
G 
G 
G 
G 
 
G 
C 
G 
G 
A 
A 
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Appendix 13:  List of primers sequences used for genes sequenced in the critical region on 
chromosome Chr16q24 
PLCG2,IRF, SLC38A8, ZDHHC7 and SLC7A5 were sent for sequencing at Genome Quebec sequencing center. 
 
CA5A    
Exon Primer I.D. Sequence Amplicon Size Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
E1 NM_001739  -F atcaaagcccagtgacctga 466 TD 54 yes (0.75) 1.5 
  NM_001739   -R ggctcgggatggtctctact         
E2 NM_001739 -F gtttcccgtgggtcagttt 397 TD 54 yes (0.75) 1.5 
  NM_001739 -R cgaagctcttgaccctgct         
E3 NM_001739 -F ggcagagtgaatgggacaga 499 TD 54 yes (0.75) 1.5 
  NM_001739 -R ttacagcgccttcctcgtag         
E4 NM_001739 -F ccattcagaaggggaagtga 465 TD 54 yes (0.75) 1.5 
  NM_001739 -R gcggatcatctaaggtcagg         
E5 NM_001739 -F cttagatgatccgcccacct 381 TD 54 yes (0.75) 1.5 
  NM_001739 -R cgcacccagctagttttgta         
E6 NM_001739 -F gccttatctgggggaaag 400 TD 54 yes (0.75) 1.5 
 
 
 
                              
 
323 
  NM_001739 -R ccccaaatgcatgaaagaat         
E7 NM_001739 -F attgatcatttcgggccatc 463 TD 54 yes (0.75) 1.5 
  NM_001739 -R ctccatcccagcgttatgtt         
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COTL1              
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
1 
NM_021149-
Ex1F Gccgccagagaatcaagac 498 TD 54 yes (0.75) 1.5 
  
NM_021149-
Ex1R GGAATAAGGCGAGGAAGACA         
2 
NM_021149-
Ex2F Tgtcttcctcgccttattcc 393 TD 54 yes (0.75) 1.5 
  
NM_021149-
Ex2R Gaggccttaaaacgctcaca         
3 
NM_021149-
Ex3F Aactgcaccggtctcctg 398 TD 54 yes (0.75) 1.5 
  
NM_021149-
Ex3R Gcttgtcccaagtcacagcta         
4a 
NM_021149-
Ex4aF Tcccagtgtgttgcctga 592 TD 54 yes (0.75) 1.5 
  
NM_021149-
Ex4aR GGGCTCTGGAAAGCAACG         
4b 
NM_021149-
Ex4bF CTCCTGCAGTGACCCCTTT 587 TD 54 yes (0.75) 1.5 
  
NM_021149-
Ex4bR CGTTCCCAGCTCTCCTTAAA         
4c 
NM_021149-
Ex4cF GACGGAGGGAGTATTTCAGG 545 TD 54 yes (0.75) 1.5 
  
NM_021149-
Ex4cR Tctgaaggcgatgatgactg         
FOXF1 (NM_001451)             
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
1a 
NM_001451-
Ex1aF atgacggcagaggTGCAG 560 TD 54 yes (0.75) 1.5 
  
NM_001451-
Ex1aR CCCTCCTCGAACATGAACTC         
1b 
NM_001451-
Ex1bF CTCTCGCTCAACGAGTGCTT 385 TD 54 yes (0.75) 1.5 
  
NM_001451-
Ex1bR AGCCGCCCATGTACGAGT         
1c 
NM_001451-
Ex1cF CATGATGAACGGCCACTTG 571 TD 54 yes (0.75) 1.5 
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NM_001451-
Ex1cR cactcttcgaagggggagag         
2 
NM_001451-
Ex2F tgctcctctgcctgaactct 575 TD 54 yes (0.75) 1.5 
  
NM_001451-
Ex2R TCAGCAGAATTCCTGTGTGG         
FOXL1              
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
1a 
NM_005250-
Ex1aF ggagggaaaagcttggagtt 579 TD 54 yes (0.75) 1.5 
  
NM_005250-
Ex1aR TGTCGTGGTAGAAGGGGAAG         
1b 
NM_005250-
Ex1bF GCCTCCCTACAGCTACATCG 514 TD 54 yes (0.75) 1.5 
  
NM_005250-
Ex1bR GTCACCAGCGTCCTCGTT         
1c 
NM_005250-
Ex1cF GGAAGAGGAAGCCCAAGC 585 TD 54 yes (0.75) 1.5 
  
NM_005250-
Ex1cR GCAGGGGGAAATAAGAGAGG         
              1d   
NM_005250-
Ex1dF 
AACGAGGACGCTGGTGAC 
585 TD 54 yes (0.75) 1.5 
 
NM_005250-
Ex1dR 
CCCAGGCAAAGATCATTTTA 
    
HSD17B2               
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
1 
NM_002153-
Ex1F CGAGAGCGGTCAAATAGGAA 578 TD 54 yes (0.75) 1.5 
  
NM_002153-
Ex1R CCAGATTTGACAAAGTCCTGCT         
2 
NM_002153-
Ex2F cctcaggaacccctctcttc 481 TD 54 yes (0.75) 1.5 
  
NM_002153-
Ex2R acacatggtaggggttcagc         
3 
NM_002153-
Ex3F ctctaatcccccaggagacc 386 TD 54 yes (0.75) 1.5 
  
NM_002153-
Ex3R ttgttcgcccacatagaatg         
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4 
NM_002153-
Ex4F tttgtctgcccaagtcactg 374 TD 54 yes (0.75) 1.5 
  
NM_002153-
Ex4R tggctgtgctcatctttgac         
5 
NM_002153-
Ex5F ccttcccaacagagacaagc 618 TD 54 yes (0.75) 1.5 
  
NM_002153-
Ex5R attctccatgaggctgttgc         
OSGIN1  
             
Exon Primer I.D. Sequence 
Amplicon 
Size 
Annealing 
temp. 
Betaine (final conc. 
(M)) 
MgCl (final conc 
(mM)) 
1 
NM_182981-
Ex1F CTCTCTGCAGCCCCTCTAAC 599 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex1R aatgtgcagctccaacacac         
2 
NM_182981-
Ex2F gcacatacatactggcacacg 371 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex2R gatgtgtaagaacactgcatgg         
3 
NM_182981-
Ex3F gtttggagcagaggctgtgt 495 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex3R ttgcagtgaaccaagattgc         
4 
NM_182981-
Ex4F cagtgtctggcacaggctaa 389 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex4R tccagcaaacacacacttttg         
5 
NM_182981-
Ex5F cctccagtgccagggaaat 395 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex5R aaagggagatgccagagtcc         
6 
NM_182981-
Ex6F ggcatctccctttcctcatt 353 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex6R cgtcctcaaccttggaaaaa         
7a 
NM_182981-
Ex7aF ctgacactgccctggacat 596 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex7aR CATCTTGGGCAGCTGGTT         
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7b 
NM_182981-
Ex7bF CTACAACATCCCGGTGATCC 497 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex7bR CCTTCCTTAGCAGGGAGCTG         
7c 
NM_182981-
Ex7cF AAGAGGAACCCCATTGACG 580 TD 54 yes (0.75) 1.5 
  
NM_182981-
Ex7cR Aatcccctttcctcccttc         
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Appendix 14: pipeline report of NGS  
 
 
Exome Sequencing Pipeline 
 
Genome Quebec and McGill Innovation Center 
September 2012 
bioinformatics.genome@mail.mcgill.ca 
 
 
 
 
This document contains the description of the current exome-seq analysis pipeline. The 
information presented here reflects the current state of the pipeline as of September 2012.  
 
 
 
Program Version Reference 
Genome Analysis 
Toolkit 
  http://www.broadinstitute.org/gsa/wiki/index.php/
The_Genome_Analysis_Toolkit 
BWA   http://bio-bwa.sourceforge.net/ 
igvtools   http://www.broadinstitute.org/igv/igvtools 
samtools   http://samtools.sourceforge.net/ 
fastX   http://hannonlab.cshl.edu/fastx_toolkit/ 
picard   http://picard.sourceforge.net/ 
snpSift/snpEff   http://snpeff.sourceforge.net/SnpSift.html 
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Deliverables 
The following files are delivered to the client: 
1. A sample statistics file containing the metrics enumerated in Step 6. 
2. A .csv file containing all the variants found in at least one sample, often classified by 
chromosome because of large file sizes 
3. A .csv file containing all the high impact coding variants found in at least one sample, 
based on the Step 9 annotations 
Sequencing 
Reads 
Around 50 to 150 million 100 b.p. paired-end reads from the Illumina HiSeq 2000 sequencer. 
Base quality is encoded in phred 33. 
Pipeline steps 
The pipeline is executed on Compute Canada clusters via unix bash commands, perl scripts and 
open source software. 
Step 1: Read trimming and clipping of adapters 
Reads are trimmed from the 3' end to have a phred score of at least 30. Illumina sequencing 
adapters are removed from the reads, and all reads are required to have a length of at least 32 b.p. 
Trimming and clipping are done with the fastx software [1]. 
Step 2: Aligning the reads to the genome reference 
The filtered reads are aligned to a reference genome. The 1000 genome reference is currently used 
for human samples, and the mm9 reference is currently used for the mouse samples. The 1000 
genome reference is similar to the hg19 reference, except that it uses the newer mitochondrial 
build (NC_012920). Also chromosome nomenclature is slightly different ('1' vs 'chr1', non-
chromosomal supercontigs are named differently e.g. GL000207 ). The alignment is done per lane 
of sequencing, and then merged for a complete Binary Alignment Map file (.bam). The alignment 
software used is bwa [2], and the merging is done with the picard software 
210
. 
Step 3: Realigning insertions and deletions (INDELs) 
Insertion and deletion realignment is performed on regions where multiple base mismatches are 
preferred over indels by the aligner since it can appear to be less costly by the algorithm. Such 
regions will introduce false positive variant calls which may be filtered out by realigning those 
regions properly. Realignment is done with the GATK software 
19
. 
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Step 4: Fixing the read mates 
Once local regions are realigned, the read mate coordinates of the aligned reads need to be 
recalculated since the reads are realigned at positions that differ from their original alignment. 
Fixing the read mate positions is done with picard software 
210
. 
 
Step 5: Marking duplicates 
Aligned reads are duplicates if they have the same 5' alignment positions (for both mates in the 
case of paired-end reads). All but the best pair (based on alignment score) will be marked as a 
duplicate in the .bam file. Marking duplicates is done with picard software 
210
. 
 
Step 6: Compute metrics and generating coverage track 
Multiple metrics are computed at this stage and given in the statistics file: 
 Number of raw reads 
 Number of filtered reads (after Step 1) 
 Number of aligned reads (after Step 2) 
 Number of duplicate reads (after Step 5) 
 Duplicate rate (number of duplicate reads / number of raw reads. Good run max of 25%) 
 Median, mean and standard deviation of insert sizes of reads after alignment 
 Mean coverage over exons (mean number of reads per base position) 
 Percentage of bases covered at X reads (%_bases_above_50 means the % of exons bases 
which have at least 50 reads. A good run is typically around 50%) 
A TDF (.tdf) coverage track is also generated at this step for easy visualization of coverage in the 
IGV browser 
19
. 
Step 7: Variant calling 
Variants (SNPs and INDELs) are called using samtools mpileup and bcftools varfilter 
19
. The 
following options are given to mpileup to filter for low quality variants which could introduce 
false positive calls: -L 1000 -E -q 1 -u -D -S, where: 
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-L INT  max per-sample depth for INDEL calling [250] 
-E  extended BAQ for higher sensitivity but lower specificity 
-q INT  skip alignments with mapQ smaller than INT 
210
 
-u  generate uncompress BCF output 
-D  output per-sample DP in BCF (require -g/-u) 
-S  output per-sample strand bias P-value in BCF (require -g/-u) 
The output of mpileup is then fed to varfilter, which does an additional filtering of the variants 
and transforms the output into the VCF (.vcf) format. The arguments used are: -d 2 -D 1200 -Q 15 
-1 0.0, where: 
-d INT  minimum read depth [2] 
-D INT maximum read depth [10000000] 
-Q INT minimum RMS mapping quality for SNPs 
19
 
-1 FLOAT min P-value for strand bias (given PV4) [0.0001] 
The final .vcf files are filtered for long 'N' INDELs which are sometimes introduced and causing 
excessive memory usage by downstream tools. 
 
Step 8: Mappablility annotation 
An in-house database identifies regions in which reads are confidently mapped to the reference 
genome.  Generally, low mappability corresponds nicely to RepeatMasker regions and increases 
substantially with read length.  A region is identified as HC = coverage too high (>400), LC = 
low coverage (<50), MQ = to low mean mapQ (<20) and ND = no data at the position 
 
Step 9: dbSNP annotation 
The .vcf files are annotated for dbSNP using the software SnpSift [7]
211
. 
 
Step 10: Variant effect annotation 
The .vcf files are annotated for variant effects using the SnpEff software [7]. SnpEff annotates 
and predicts the effects of variants on genes (such as amino acid changes).  
Step 11: Additional SVN annotations 
Provides extra information about SVN by using numerous published databases. 
1. Biomart : adds GO annotations based on gene information 
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2. dbNSFP: an integrated database of functional annotations from multiple sources for 
the comprehensive collection of human non-synonymous SNPs. It compiles 
prediction scores from four prediction algorithms (SIFT, Polyphen2, LRT and 
Mutation Taster), three conservation scores (PhyloP, GERP++ and SiPhy) and other 
function annotations. 
3. Cosmic (Catalogue of Somatic Mutations in Cancer): Annotates SVNs which are 
known somatic mutations   
 
Step 10: Merging the .vcf files 
This step merges the sample .vcf files into a global .csv file. The following columns are reported: 
Column Description 
chromosome chromosome number 
position position on chromosome 
ref_allele reference allele 
alt_alleles alternativ allele 
mappability Mappability flag from simulated dataset (LC = low 
coverage, HC = high coverage, NODATA = no data, 
empty = normal mappability) 
gene_name gene name 
Nb_Samples number of samples with this variant 
Frac_of_Samples number of samples with this variant / total number of 
samples 
Avg._Depth mean coverage of variant over all samples that have the 
variant 
Frac_of_Alt mean fraction of reads which have the alternate allele 
over all samples 
1000_genome_global_maf minor allele frequency score (-1 = no sample in the 1000 
genome database has this variant, 1=all samples in the 
1000 genome database has this variant) 
gene_description gene description generated by biomart. Derived from 
Ensembl 
go_ids all GO ids associated with gene 
go_terms all GO terms associated with gene 
impact severity of the change 
effect description of change 
effect_type type of change 
codon_change exact nucleotide change 
amino_acid_change exact amino acid change 
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gene_type type of transcript from annotation file 
transcript ENSEMBL transcript ID 
db_snp_id snp id in the db_snp database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) 
1000genome_population_mafs 1000 genome MAF divided by population 
CosmicID cosmic ID and cancer type information from control 
database of somatic mutations  
InterPro_Domain description of domain 
Uniprot Uniprot gene ID 
GERP++_neutral_rate Neutral rates of evolution (sum of branch lengths) 
GERP++_RS_score RS score, the larger the score, the more conserved the 
site. 
29way_SiPhy_score SiPhy score based on 29 mammals genomes. The larger 
the score, the more conserved the site. 
Polyphen2 Prediction based on HumVar, 'D' ('probably damaging'), 
'P' ('possibly damaging') and 'B' ('benign') (separated by 
',') 
SIFT_score If a score is smaller than 0.05 the corresponding NS is 
predicted as 'D(amaging)' otherwise it is predicted as 
'T(olerated)' 
Normal HomRef Number of samples homozygous for reference allele 
Normal HomAlt Number of samples homozygous for alternative allele 
Normal Het Number of samples heterozygous  
"SampleName" Depth Depth of Coverage from sample from DP field 
"SampleName"  INFO field from vcf file (GT:PL:DP:SP:GQ) GT: 
Genotype, PL:  Genotype likelihood (RR, RA, AA), DP: 
Depth of Coverage, SP: Strand bias, GQ: Genotype 
Quality 
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Appendix 15: Sequenced functional candidate genes at the extended 
newly linked 9.6 Mb region 
   Genomic 
position  
  
Genes Accession 
Number  
St Start                 
End  
Exons  Function or expression 
PLCG2  NM_002661  +  81812930  
81991899  
 
 
 
 
33  This gene encodes by protein 
which is responsible for 
conversion of  1-phosphatidyl-1D-
myo-inositol 4,5-bisphosphate to 
1D-myo-inositol 1,4,5-
trisphosphate (IP3) and 
diacylglycerol (DAG) which is 
important for transmitting signals 
from growth factors receptors and 
immune system receptors a cross 
the cell membranes  
HSD17B2  NM_002153  +  82660339     
82132139  
5  It is a single -pass type membrane 
protein and it is expressed in the 
bone and bone marrow. 
OSGIN1  NM_182980  +  83982672     
83999937  
7  It regulates the differentiation and 
proliferation of normal cells 
through apoptosis. Also it regulate 
inflammatory and anti-
inflammatory molecules. Absence 
of this gene and it is protein leads 
to uncontrolled proliferation and 
growth.  
SLC38A8  NM_001080442  -  84043389     
84075762  
10  It is a multi-pass membrane 
protein and is widely expressed in 
tissue including immune system, 
connective tissue and ear.  
COTL1  NM_021149  +  84599204     
84651609  
4  This gene encodes one of the 
numerous actin-binding proteins 
which regulate actin cytoskeleton.  
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IRF8  NM_002163  +  85932774     
85956211  
9  It plays a negative regulatory role 
in cells of the immune system, and 
is expressed in connective tissue.  
ZDHHC7  NM_001145548  -   85008067     
85045141  
9  It is one of the zinc finger protein . 
it is expressed in connective tissue 
and bone. 
FOXF1  NM_001451  +  86544133     
86548070  
1  This gene belongs to the forkhead 
family of transcription factors. 
Function of this gene has not been 
determined yet. it is abundantly 
expressed in the connective tissue.  
FOXC2  NM_001453 + 81610681       
81614129 
This gene belongs to the forkhead 
family of transcription factors. 
Function of this gene has not been 
determined and it has been shown 
a role in regulation of embryonic 
and ocular development. Mutation 
in this gene has been identified in 
various glaucoma phenotypes.  it is 
abundantly expressed in the 
connective tissue 
FOXL1  NM_005250  +  86612115     
86615304  
1  This gene belongs to the forkhead 
family of transcription factors. 
Function of this gene has not been 
determined yet. it is abundantly 
expressed in the connective tissue. 
SLC7A5  NM_003486  -   87863629    
87903100   
10  It is a multi-pass membrane 
protein which is abundantly 
expressed in bone marrow and 
inflammatory immune systeme. 
CA5A  NM_001739  +  87921625     
87970112  
7  Carbonic anhydrases are a large 
family of zinc metalloenzyme. 
They have an important role in a 
variety of biological processes 
including calcification and bone 
resorption . 
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Appendix 16: Variants detected from exome / Sanger sequencing of 
genes in 9.7 Mb  
A. Variants detected from the sequencing of genes in the newly linked 9.7Mb region. 
Variants present in the three affected and the control subject are bolded. Variants present 
in only two affected are highlighted yellow. Variants present in one affected and one 
unaffected subject are highlighted brown. Variants present in only unaffected are 
highlighted blue. Variants that were exclusively in affected are highlighted light blue. 
Green haplotype was constructed among the three affected siblings (highlighted green).  
 
  Affected  Unaffected  
Gene name  Variants   III-5 III-11 IV-5 III-6 
CA5A 
 EX1 
c. -26C>T T     T T  T T   T T   T 
c.-4C>T    T     T T  T T   T T   T 
c.(11G>A  A    A A  A A  A A  A 
c.41-43 
delTCT 
Del  del Del del Del del Del  del 
c.44T>G   G    G G  G G  G G G 
c.120A>G  G    G G  G G  G G G 
c.121T>C C    C C  C C  C C C 
c.125A>G G    G G  G G   G G G 
c.134A>G  G    G G  G G   G G G 
c.142+23 
T>C 
C    C C  C C   C C  C 
142+26delG Del  del Del del Del  del Del del 
142+31G>A A    A A  A A   A A A 
142+65G>A A    A A  A A  A A A 
142+69G>T T   T T  T T  T T  T 
142+77G>T T  T T/T T/T T/T 
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142+85G>A A/A A/A A/A A/A 
EX2  143-9T>A A/A A/A A/A A/T 
EX4 c. 555+61 het 
delT 
Del/wt Del/wt Del/wt Del/wt 
COTL1 
Ex1 
c.-136T>C  C/C C/C C/C C/C 
Ex3 c.*108T>G G/G G/G G/G G/G 
c.*109T>G G/G G/G G/G T/G 
EX4 c.*104A>G A/G A/G A/G A/G 
FOXL1  976_990Het 
delGGGATC
CCCTTCCT
C 
Del/wt Del/wt Del/wt Wt/wt 
HSD17B2 
Ex1 
-133T>C T/C T/C T/T T/T 
IRF8 
Ex4 
c.432C>T,p.
D144DD 
C/T C/T C/T C/C 
OSGIN1  
Ex1 
 
c.-95C>T T/T T/T T/T T/T 
c.17C>T,p.P6
L 
T/T T/T T/T T/T 
Ex2 C.101A>C,p.
N34T 
C/C C/C C/C C/C 
c.169A>C,p.
M67L 
C/C C/C C/C C/C 
c.175C>G,p.
L59V 
G/G G/G G/G G/G 
Ex3 c.218-
104C>T 
C/C C/C C/T C/T 
c.316+115T>
C 
T/T T/T T/C T/C 
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316+116T>G T/T T/T T/G T/G 
Ex4 c.317-80G>A A/A A/A A/A A/A 
EX5 c.454-48C>A C/C C/C C/A C/A 
c.454-21C>T C/C C/C C/T C/T 
Ex6 c.646-38G>A G/G G/G G/A G/A 
c.646-17G>T T/T T/T T/T T/T 
Ex7 c.1332C>A, 
p.L444L 
C/C C/C C/C C/A 
c.*205T>C C/T C/T C/T T/C 
c.*41A>G A/A A/A A/G A/G 
PLCG2 
Ex2 
 
EX3 
-109C>G C/C C/C C/C C/G 
c.174T>C, 
p.A58AA 
C/C C/C C/C C/C 
c.194-92A>C A/A A/A A/C A/C 
c.[297A>G,p.
L9 
A/A A/A A/G A/G 
c.337+45G>C G/G G/G G/C G/C 
c.3314-23C/A  C/A C/A C/C C/C 
EX4 c.431+37G>
C 
C/C C/C C/C C/C 
EX6 c.480-56A>G A/G A/G A/A A/A 
c.480-22A>G G/G G/G G/G G/G 
c.564+87G>A A/G A/G A/A A/A 
c.648+134C>
T 
C/C C/C C/C C/T 
c.648+171T>
A 
T/T T/T T/T T/A 
c.648+237A> T/T T/T T/T T/A 
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T 
c.648+242C>
T 
T/T T/T T/T T/C 
c.648+319T>
C 
C/C C/C C/C C/T 
Ex8 c.692+25C>T C/T C/T C/T C/T 
c.692+61A>C A/A A/A A/A A/C 
Ex10 802C>T,p.R2
68RW 
C/T C/T C/T C/C 
Ex12 987-97G>C C/G C/G C/G G/G 
 c.1149C>T,p.
D383D 
C/T C/T C/T C/T 
c.1188C>G,p.
T396TT 
C/C C/C C/C C/G 
Ex15 c.1467+38G>
C 
C/C C/C C/C G/C 
 c.147+45G>T G/G G/G G/G G/T 
Ex16 c.1497C>T],p
.A499A 
T/T T/T T/T T/T 
Ex19 c.2054+7G>
A 
A/G A/G A/G G/G 
c.[2054+47A
>C 
A/A A/A A/A A/C 
Ex20 c.[2055-8T>C C/C C/C C/C C/C 
Ex21 c.[2236-
14C>G 
G/G G/G G/G G/G 
Ex28 c.[3093T>C,p
.N1031NN 
C/C C/C C/C T/C 
Ex30 c.[3314-
23C>A 
A/A A/A A/A A/A 
SLC7A5 c.345C>A,p. C/A C/A C/A C/A 
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Ex1b G115GG 
 c.770+125G>
A 
G/A G/A G/G G/G 
c.770+127C>
A 
C/A C/A C/A C/A 
Ex5 c.939+61T>G G/T G/T G/G G/G 
 c.1140+85C>
G 
C/G C/G C/C C/C 
SLC38A8 
Ex1 
c.89+11G>T T/ G T/G T/T T/T 
 c.[388+128A
>T 
A/A A/A A/A A/T 
Ex4 c.[531-
137T>C 
C/T C/T C/C C/C 
Ex6 c.805+53_805
+54het_delA
A 
Wt/del Wt/del Wt/del Wt/del 
Ex8 c.[1162+87C
>G 
G/C G/C G/G G/C 
Ex9 c.[1214+107G
>A 
G/A G/A G/G G/G 
c.[1214+116C
>T 
C/T C/T C/C C/C 
c.[1214+174T
>C 
T/C T/C T/T T/T 
c.[1214+194A
>G 
A/G A/G A/A A/A 
ZDHHC7 
Ex3 
c.[315+55G>
A 
A/A A/A A/G G/G 
Ex5 c.316-
366het_delT 
Wt/wt Wt/wt Wt/del del/wt 
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Ex7 c.538-11C>T T/T T/T T/C C/C 
Ex9 c.[906T>C],p
.G302G 
C/C C/C C/T T/C 
HSD17B2 
Ex1 
c.[-133T>C C/T C/T C/T T/T 
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B: Variants detected from exome sequencing of 79 genes in the newly linked 9.7 Mb region.  
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Appendix 17: Functional studies to identify the effect of the FOXL1 
deletion on the RNA and protein levels 
 
6.1 Aim of the study: To identify the downstream effect of the 15 bp deletion in FOXL1 
gene.  
6.2 Material and Methods   
6.2.1 Test expression of wild (normal) and mutant forms of FOXL1 gene from 
patients lymphoblastoid cell lines  
To measure the effect of the FOXL1 deletion on the mRNA. First, total RNA was 
extracted from Epstein-Barr virus-transformed lymphocytes cell line from four deletion 
carriers (PID III-4, III-5, III-8 and III-11), and two non-deletion NL control subjects 
(EC09, TA09). Lymphoblastoid cell lines were maintained  in a 37 C , 5% CO2, 
humidified chamber, with growth media consisting of Roswell Park Memorial Institute 
media (RPMI), 10% heat inactivated fetal calf serum (FCS) , 2 mM L-glutamine and 
antibiotic-antimycotic mixture (100 units/ml penicillin G sodium, 100 µg/ml 
streptomycin sulfate, and 0.25 µg/ml amphotericin B).   
RNA was isolated using Trizol reagent (Invitrogen by Life Techonologies, 
Carlsbad, CA) and was followed by treatment with TURBO DNA-free DNase treatment 
(Ambion, Austin, TX). RNA(s) were evaluated and quantified using a 2100 Bioanalyzer 
(Agilent Technologies; Waldbronn, Germany) and  samples with a RNA value greater 
than 8.5 were used.  Complementary DNA (cDNA) synthesis was performed using High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and Reverse 
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transcriptase PCR was carried using primers surrounding the c. 976_990 deletion  in the 
FOXL1 gene. Amplification reaction was carried out for all the reactions by the ABI PCR 
GeneAmp 9700 thermocycler. Primers were amplified using a touchdown 54 program 
(Appendix 3 and 4) and the size fragmented on 1% agarose gel stained with SYBER safe 
to confirm amplification. 
6.2.2 FOXL1 deletion generation and transfection 
6.2.2.1   Generation of FOXL1c.976_990het_delGGGATCCCCTTCCTC deletion 
construct 
The FOXL1 gene was not expressed in the lymphoblastoid cell line, the wild and 
mutant forms of the FOXL1 gene were overexpressed. Two FOXL1 expression vector 
construct (ORF; NM_005250) (Catalogue number: EX-E0843-M02), (Catalogue number: 
EX-E0843-M29) containing wild type full-length FOXL1 and two empty (mock) 
plasmids (Catalogue number: EX-NEG-M02), (Catalogue number: EX-NEG-M29) were 
purchased from GeneCopoeia company, USA.  Two of the purchased plasmid (EX-
E0843-M29) and (EX-NEG-M29) were tagged with the green fluorescent protein (GFP).  
Mutant constructs of FOXL1 (FOXL1 c.976_990het_delGGGATCCCCTTCCTC) were 
generated by site directed mutagenesis using the FOXL1 expression vectors (EX-E0843-
M02), (EX-E0843-M29-GFP) as a template. FOXL1 deletion construction was generated 
and sequenced by Noroclone Company (biotech laboratory, Canada). 
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6.2.2.2 Cell Culture and treatment  
Human fetal osteoblast (hFOB 1.19) cell lines were used for transfection and 
human embryonic kidney cell lines (HEK293A) were used as a positive control. Both cell 
lines were purchased from American Type Culture Collection (ATCC, Biocompare, 
Canada). HEK293A cells were maintained in a 37 C, 5% CO2, humidified chamber, with 
growth media consisting of Modified Dulbecco’s Media (IMDM), 10% heat inactivated 
fetal calf serum (FCS, Hyclone,), 2 mM L-glutamine and antibiotic-antimycotic mixture 
(100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, and 0.25 µg/ml 
amphotericin B). hFOB 1.19 cells maintained in a 37 C, 5% CO2, humidified chamber, 
with growth media consisting of Modified Dulbecco’s Media (IMDM) without phenol 
red, 10% heat inactivated fetal calf serum (FCS), 2 mM L-glutamine, antibiotic-
antimycotic mixture (100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, 
and 0.25 µg/ml amphotericin B) and geneticin antibiotic (G418) was added to a final 
concentration of 0.3 mg/ml.  
 6.2.2.3 Transient Transfection 
hFOB1.19 cells were transfected each time with one of the following six plasmids 
FOXL1
-WT
 (wild type), FOXL1
-WT-GFP, 
(wild type- tagged with GFP), FOXL1
-Mut
 (mutant 
type), FOXL1
-Mut-GFP
 (mutant type- tagged with GFP), FOXL1
-Mock
 (empty plasmid), and 
FOXL1
-Mock-GFP 
 (empty plasmid-tagged with GFP (MOCK-GFP) vectors. Transfection of 
hFO1.19 cells was performed using FuGENE ® HD transfection reagent (Roche, Applied 
Science, USA) according to the manufacturer’s instruction. Plasmids harbouring the wild 
and mutant forms of FOXL1 were diluted with Opti-MEM® /Reduced serum media 
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(Invitrogen by Life technology) to a concentration of 0.02µg /µl.  Fugene HD transfection 
reagent was added to the diluted plasmids in the ratio of 7:2 (Fugene HD in µl: Plasmid 
DNA in µg) and left for 20 minutes incubation at room temperature. Following 
incubation, 100ul of this mixture was used to transfect the cells in a 6-well plate and 
incubated for a further 48 hours at 37C.  
6.2.3 Test RNA expression of wild and mutant forms of FOXL1 transfected 
hFOB1.19 cell lines and FOXL1 downstream genes 
6.2.3.1 Real-time PCR (Q-PCR) 
To test the expression of the transfected FOXL1 genes (wild type versus mutant 
type), total RNA(s) were extracted and cDNA(s) were prepared as mentioned above.  
Primers for the real time PCR were designed using primer3 as follows: left primer: 
CCTCCCTACAGCTACATCGC, right primer: TGTCGTGGTAGAAGGGGAA and 
hybrid probe: GGTCACGCTCAACGGCATCTA.  
In order to test expression of the FOXL1 downstream genes, primers for the 
following genes; IL1A (Catalogue number: Hs00174092_m1), CXCL8 (Catalogue 
number: Hs00174103_m1), CXCL10 (Catalogue number: Hs01124251_g1), IL29 
(Catalogue number: Hs00601677_g1), IFNB1 (Catalogue number: Hs01077958_s1), 
IFIT1 (Catalogue number: Hs01911452_s1), FEN1 (Catalogue number: Hs00748727_s1) 
and SP4 (Catalogue number: Hs00162095_m1) were designed and purchased from 
Applied Biosystem. Housekeeping gene (GAPDH) (Catalogue number: Hs03929097_g1) 
was used as endogenous control. RNA negative control sample and reference sample 
(HEK293A cell line) were included in each experiment. Amplification reactions and 
 
 
 
                              
 
347 
calculation were carried out for all the reactions as described in Appendix18. Each 
experiment was repeated three times for validation and the mean of the three experiments 
was calculated.  
6.2.4 Testing protein expression of wild and mutant forms of FOXL1 transfected 
hFOB1.19 cell lines 
 6.2.4.1 Antibodies 
FOXL1 protein expression was determined using Anti-FOXL1 rabbit polyclonal 
IgG (Catalogue number: clone ab83000, Abcam). α tubulin housekeeping proteins were 
detected with α tubulin antibody of 200 μg/ml concentration (Catalogue number: clone 
DM1A+DM1B, Abcam) and anti-nuclear matrix protein p84 antibody of 1µg/ml 
concentration (Catalogue number: clone 5E10, Abcam). Secondary antibodies used in this 
experiment were horseradish peroxidase conjugated mice and rabbit IgG antibodies. 
Secondary antibodies were purchased from Jackson Immunoresearch.  
6.2.4.2 Western blot (Immunoblotting) 
 Nuclear and cytoplasmic proteins were extracted from four hFOB1 cell lines 
(three hFOB1 cell lines were transfected with FOXL1
-WT
, FOXL1
-Mut
, and an FOXL1
-Mock
 
plasmids respectively and one hFOB1 cell line was left non-transfected as a negative 
control) by nuclear extract kit (ActiveMotif, USA) according to the manufacturer’s 
protocol. Protein concentration was quantified using a Bradford protein assay kit 
(BioRad, USA). 0.2M of mercaptoethanol was added to the protein samples and then 
samples were boiled for 5 minutes. Ten micrograms of protein were loaded per lane of 
8% Sodium Dodecyl Sulfate polyacrylamide (SDS-PAG) gel. Following electrophoresis, 
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proteins were transferred onto nitrocellulose membranes and blocked with 5% milk 
powder prepared in TBS-Tween solution (5M NaCl, 1M Tris pH 7.4, 0.5% Tween 20) for 
1 hour. Optimally diluted primary antibodies were added and incubated at 4 C overnight. 
Membranes were washed, and horseradish peroxidase conjugated secondary antibodies 
were used to detect primary α tubulin antibody binding and rabbit IgG antibody was used 
to detect primary FOXL1 rabbit polyclonal IgG antibody. Signals were amplified using 
chemoluminescence detection agent (Millipore). Immunoreactivity was visualized and 
quantified by scanning densitometry using Image Quant LAS 4000 and Image GE 
software respectively (GE Healthcare, USA). 
6.2.4.3 Immunofluorescence  
To visualize the protein fluorescent intensity of the living hFOB1.19 cells 
transfected by, FOXL1
-WT-GFP
, FOXL1
-Mut-GFP
, and FOXL1
-Mock-GFP
, transfected living 
hFOB1.19 cells were grown in 6-well plates and visualized by a fluorescent microscope 
(Carl Zeiss AxioObserver A.1) with settings at X20 magnification objective. Images were 
captured using a Zeiss AxioCam MRM3 camera with Zeiss AxioVision 4.8 software.To 
measure the fluorescent intensity, flow-cytometry was carried out.  In flow-cytometry, 
GFP-transfected cells were harvested by trypsin, followed by fixation in 1.0% 
formaldehyde (Sigma). 10,000 cells were analyzed using a FACS Calibur flow cytometer 
(Becton-Dickinson, Franklin Lakes, NJ). 
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6.2.5 Testing the effect of the FOXL1 deletion on the downstream genes 
 6.2.5.1 Microarray Analysis 
Microarray analysis was carried out by Genome Quebec using Illumina platform. 
Total RNA (s) were extracted from four hFOB1 cell lines (three hFOB1 cell lines were 
transfected with FOXL1
-WT
, FOXL1
-Mut
, and FOXL1
-Mock
 plasmids respectively and one 
hFOB1 cell line was left non-transfected as a negative control) and quantified using a 
NanoDrop Spectrophotometer ND-1000 (NanoDrop Technologies, Inc.). RNA(s) 
integrity was assessed using a 2100 Bioanalyzer (Agilent Technologies). Double stranded 
cDNA was synthesized from 250 ng of total RNA, and in-vitro transcription was 
performed to produce biotin-labelled cRNA using Illumina® TotalPrep RNA 
Amplification Kit, according to manufacturer’s instructions (Life Technologies). The 
biotin-labeled cRNA was hybridized on Human HT-12 v4 Expression Bead Chip and 
incubated in an Illumina Hybridization oven at 580C for 14 to 20 hours at a rocking speed 
of 5 according to Illumina’s Whole-Genome Gene Expression Direct Hybridization Assay 
Guide. All four samples were hybridized in triplicate. Chemoluminescence detection and 
image acquisition were performed using Illumina iScan Reader. Human HT-12 v4 
Expression BeadChip covers greater than 31,000 annotated genes with more than 47,000 
probes derived from the National Center for Biotechnology information Reference 
Sequence (NCBI). 
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6.2.5.2 Microarray Statistical analysis  
Microarray results were analyzed by Genome Quebec using LIMMA package 
212
 
from the Bioconductor project. The expression data of two color microarrays were 
compared using LIMMA package and expressed in a log ratio. The neqc 
213
 method was 
applied to the raw intensity values, which performs background adjustments using 
negative control probes, and performs quantile normalization followed by a log2 
transformation. Normalization was carried out to adjust microarray data for any effects 
that could be arise from variation in the technology rather than from biological 
differences between the RNA samples or between the printed probes. In Log2 
transformed data, Value of 2 equal to ratio of 4. A log2 transformation helps in 
identifying doubling or halfing in ratios.  
The statistical significance of the fold change of each transcript between the four 
cell lines was determined by Student’s t-test using log2 transformed data. Storey’s q-
value false discovery rate (FDR) method was used to detect expected proportions of false 
positives. Significantly differentially expressed genes were determined using false 
discovery rate FDR of <0.05% and a fold change equal or greater than 2 fold. Genes 
reaching statistical significance were submitted to Panther for functional analysis.   
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6.3 Result  
6.3.1 RNA expression by real time PCR 
In order to test the effect of the FOXL1 deletion on the RNA expression, levels of 
FOXL1 mRNA expression were tested in four-deletion carriers (PID III-4, III-5, III-8 and 
III-11) and two non-deletion carriers (EC09 and TA09), using RNA extracted from 
lymphoblastoid cells of the tested subjects and RNA from HEK293A, as a positive 
control. Comparing the level of the FOXL1 expression between the samples and the 
positive control showed that level of the RNA expression in the samples was less than the 
cut of value (0.2) (Figure 6.1). This data implied that FOXL1 is not normally expressed in 
lymphocytes.  
 Because of the lack of FOXL1 expression in the lymphoblastoid cells, an artificial 
bone cell line model system was created: FOXL1
-WT
 (hFOB1.19 cells transiently 
transfected with the wild type FOXL1 expression plasmid), FOXL1
-Mut
 (hFOB1.19 cells 
transiently transfected with the FOXL1 harboring the 15bp deletion expression plasmid), 
FOXL1
-Mock
 (hFOB1.19 cells transiently transfected with the empty expression plasmid). 
FOXL1 mRNA was relatively quantified by Q-PCR from the three-bone cell line models 
and untransfected hFOB1.19 cell line and compared. The hFOB1.19 cells normally 
expressed FOXL1 as shown in figure 3.9 and transfection of the empty vector cause slight 
increase in the expression but it was not significant. Transfection of the  hFOB1.19 cell 
line with the wild type FOXL1 showed significant increase in the expression of the 
FOXL1 and no significant difference was detected between FOXL1
-WT
 and FOXL1
-Mut
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(Figure 6.2), suggesting that the FOXL1 deletion did not alter the FOXL1 mRNA 
expression.  
Figure 6.1: FOXL1 is not normally expressed in the lymphoblast 
FOXL1 mRNA was relatively quantified by real time PCR using Taqman gene expression 
assay. GAPDH was used as an endogenous control and the data were expressed relative 
to a control HEK293A cell line. Bar graphs represent the mean ± SD of three replicate 
assays 
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FIGURE 6.2: FOXL1 MRNA EXPRESSION WAS NOT AFFECTED BY THE 15BP 
DELETION 
hFOB 1.19 cell line was either non-transfected or transiently transfected with mock, wild, 
or mutant types FOXL1 expression plasmids. FOXL1 mRNA was relatively quantified by 
real time PCR using Taqman gene expression assay. GAPDH was used as an endogenous 
control and the data was expressed relative to a HEK293A cell line. Bar graphs represent 
the mean ± SD of three independent experiments. (***=p value <0.001). Note that 
FOXL1 was originally expressed in the hFOB 1.19 cells and transient transfection of the 
FOXL1 resulted in 1000-fold increase in mRNA expression of FOXL1. 
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6.3.2 Protein expression by Western blot and immunofluorescent 
Creating FOXL1 cell line models and measuring the FOXL1 expression did not 
show any difference in the gene expression between the wild and mutant form of the 
FOXL1 transfected cell line. Mutations in other members of the FOX family of 
transcription factors have been reported to be associated with cellular mislocalization and 
protein aggregation 
214,215
. Thus, we hypothesized that the identified FOXL1 deletion may 
affect the folding of the FOXL1 protein and subsequently hide the nuclear localization 
signals (NLS). To test this hypothesis, localization and protein level expression of 
FOXL1
-WT
 and FOXL1
-Mut
 were tested and we found that both FOXL1
-Mut  
and FOXL1
-WT
  
have the same diffuse nuclear localization, but the staining intensity was higher in 
FOXL1
-Mut
 (Figure 6.3 A). This finding was further confirmed by flow-cytometry through 
quantification of the mean fluorescence intensity (Figure 6.3 B-C).  To overcome the 
argument that protein function can be modified by GFP-fusion 
216,217
 
218
, nuclear and 
cytoplasmic protein extracts were prepared from the artificial bone cell lines model 
system (discussed above), followed by immunoblotting and probing with anti-FOXL1 
antibody. Expression of the FOXL1 protein was mainly in the nuclear extract (Figure 6.3 
D) and the FOXL1 deletion resulted in a significant increase of FOXL1 protein 
expression (Figure 6.3 D-E). These findings suggest that mutation in FOXL1 may result 
in a gain of protein function.  
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Figure 6.3:  mutant FOXL1 localized appropriately  
hFOB 1.19 cell line was either transiently transfected with mock, wild, or mutant type of 
FOXL1-GFP fusion proteins expression plasmids. A) Living cells were examined by 
direct fluorescence microscope using equal exposure time. B) Cells were harvested by 
trypsinization and fluorescence intensity was measured by flow cytometry. 40% of 
hFOB1.19 cell line transfected by the mutant FOXL1 were shifted to the left comparing 
to the hFOB transfected by the wild FOXL1. C) bar graphs represents mean florescence 
intensity (MFI) + SD of three independent experiments. D) hFOB 1.19 cell line was either 
non transfected or transiently transfected with mock, wild, or mutant types FOXL1 
expression plasmids followed by cytoplasmic and nuclear extract preparation and 
immunoblotted using FOXL1 antibody (ab83000). Α Tubulin (DM1A+DM1B) and P84 
(5E10) were used as cytoplasmic and nuclear loading control respectively. E) FOXL1 
levels were normalized to P84 and the average band intensity after normalization is 
presented in the bar graph. Error bars represent the ± SD of three independent 
experiments. (**=p value <0.01). 
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6.3.3 Test expression of the downstream genes using microarray analysis 
Protein expression measurement showed that the FOXL1 protein expression was 
increased in the hFOB1.19 cells transfected by the mutant form of FOXL1 gene which 
could be as result of cellular misfolding of the FOXL1 protein and protein aggregation. If 
our hypothesis that the 15 bp deletion in FOXL1 gene causes misfolding of the FOXL1 
protein is correct, then that means that FOXL1 mutant could fail in binding and regulation 
of the downstream genes as transcription factor and that lead to deregulation of the gene 
expression of these genes.   
 To test this hypothesis, microarray analysis was carried out to identify genes 
deregulated by this FOXL1 deletion through testing the difference in the expression level 
of 31,000 annotated genes, between FOXL1
-WT
 and FOXL1
-Mut
 hFOB1.19 transfected 
cells and FOXL1
-Mock
 cells was used as a negative control. Twelve RNA samples were 
analyzed: three paired RNA samples from each of FOXL1
-WT
, FOXL1
-Mut 
and FOXL1
-Mock 
transfected hFOB1.19 cells and untransfected hFOB1.19. Comparison of gene expression 
between FOXL1
-WT
 and FOXL1
-Mut  
 cells was carried out using the false discovery rate 
(FDR) <0.05 and two fold increase as a significant cutoff.  Using this cutoff, seventeen 
genes were up regulated in the FOXL1
-Mut 
cells and 33 genes were down regulated in the 
FOXL1
-Mut
 cells (Figure 6.4 A and 6.4 B and appendices 19 and 20). These genes were 
only deregulated in FOXL1
-Mut
 cells and not in FOXL1
-WT 
or FOXL1
-MOCK   
which reflects 
the actual effect of the deletion. These results demonstrated that FOXL1-induced genes 
are differentially expressed between FOXL1
-WT
 and FOXL1
-Mut
 cells. The top 25 
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deregulated genes in FOXL1
-Mut 
were selected and their differential expression was 
illustrated in a heat map (Figure 6.5 A-B).  
Gene ontology (GO) analysis using the PANTHER classification system was 
performed to determine the biological process associated with these top 25 deregulated 
genes. The top 25 deregulated genes were involved in pathways related to inflammation, 
immunity, gene regulation and Eicasonoid signaling (Figure 6.5 C-D). 
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Figure 6.4: Microarray analysis showing genes induced in FOXL1-WT and FOXL1-
Mut cells. 
A) Venn diagram comparing genes up regulated by different forms of FOXL1 
transfection. First, we compared expression genes up regulated by FOXL1 in FOXL1
-WT
 
and FOXL1
-Mut
.  Ninety genes were up regulated in FOXL1
-WT
 cells while 17 genes were 
up regulated in FOXL1
-Mut
 cells. Twenty-five genes were up regulated commonly in both 
FOXL1
-WT
 and FOXL1
-Mut
 cells.  B) Venn diagram comparing genes down regulated by 
different forms of FOXL1 transfection. Shown are the numbers of genes significantly 
down regulated (FDR <0.05). Forty-nine genes were down regulated in FOXL1
-WT
 cells, 
thirty-three genes were down regulated in FOXL1
-Mut
 cells and 20 genes were commonly 
down regulated in both FOXL1
-WT
 and FOXL1
-Mut
. 
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Figure 6.5: Gene ontology analysis of genes differentially expressed in FOXL1-WT 
and FOXL1-Mut cells 
Heat map representation of the top twenty-five genes.  A) Twenty-five genes down 
regulated in FOXL1
-Mut
 cells. B) Twenty five gens up regulated in FOXL1
-Mut
 cells. The 
lowest gene expression is shown in blue and the highest are shown in orange. Cut-off 
value =0. Differentially expressed genes were analysed using PANTHER classification 
system. C) Pathways down regulated in FOXL1-Mut cells. D) Pathways up regulated in 
FOXL1-Mut cells, each number value reflects the number of genes in each pathway. Of 
25 down-regulated genes, only 22 genes were predicted to be involved in known 
pathways. The remaining three genes are of unknown function. The same was for the 25 
upregulated genes, only 19 genes were predicted and the remaning were of unknown 
function. 
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6.3.4 Validation of the microarray result by qPCR 
We have identified many cytokines deregulated in the FOXL1
-Mut 
transfected cells.  
Of these cytokines, there were cytokines reported to have a significant role in bone 
development and remodelling including, for example: IL1A 
166
, IL8, CCXL10 
167
 
168
 
169
 
170
, IFNB1 
171
, IL29
172
 and IFIT1
173
 (Appendix 17). Quantitative RT-PCR (RT-qPCR) 
was conducted to validate the results of the microarray analysis of these six cytokines 
genes and 2 regulatory genes (FEN1 and SP4) using FOXL1
-WT
, FOXL1
-Mut
 and FOXL1
-
Mock
 transfected cells (Figure 6.6). Due to the difference in sensitivity and statistical 
power of the two different techniques, we were only able to validate the microarray 
results of two genes CCXL10 and IL29. Microarray analysis indicated a 2.85 fold down-
regulation of CXCL10 in FOXL1
-Mut
 cells comparing with the FOXL1
-WT  
cells. This was 
confirmed by QPCR, which showed decrease in CXCL10 mRNA levels in FOXL1
-Mut
 
cells. Also, QPCR showed that IL29 was significantly increased in FOXL1
-Mut
 cells 
comparing with the FOXL1
-WT cells
 , which was consistent with microarray results, which 
showed a 2.52 fold up-regulation in FOXL1
-Mut
 cells.   
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Figure 6.6. Validation of microarray data by quantitative RT-PCR 
The level of gene expression in untransfected, FOXL1
-Mock
, FOXL1
-WT
 and FOLXL1
-Mut
 
cells was determined by quantitative RT-PCR. The relative expression was calculated 
compared to HEK293A positive control cells after normalisation against GAPDH. Bar 
graphs represent the mean ± SD of three independent experiments. (***=p value <0.001, 
**=p value <0.01, *=p<0.05). A. CXCL10 is slightly expressed in the hFOB1.19, 
transfection of the empty plasmid cause increase the level of CXCL10 expression. 
Transfection of the FOXL1
-WT
 plasmid cause significant increase in the expression of 
CXCL10 comparing to the FOXL1-
Mock. . 
Transfection of
 
FOXL1
-Mut
 showed significant 
decrease in the CXCL10 expression comparing with the FOXL1
-WT.
 B. the level of the 
expression of IL29 was significantly increased in the  FOXL1
-Mut
 comparing with the 
FOXL1
-WT.
 
 
 
6.4 Discussion: see pages 189-195  
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Appendix 18: Real time amplification and interpretation    
 
Real time PCR was performed using TaqMan® probe-based gene expression 
analysis kit that include pre-designed primers and probes for optimal amplification 
(Applied Biosystems) along with TaqMan® universal PCR master mix (Applied 
Biosystem). All gene expression assays have a carboxyfluorescein (FAM) reporter dye at 
the 5’ end of TaqMan minor groove binder (MGB) probe and non-fluorescent quencher at 
the 3’ end of the probe. All samples were assayed in triplicate to ensure accuracy with a 
reaction volume of 20 µl. Ten microliters of TaqMan gene expression master mix 
(Amplitaq® Gold DNA polymerase Ultra-Pure, Uracil DNA glycosylase, dNTP’s , 
ROX
TM
 which act as a passive reference) were mixed with 1 µl of specific primer, 1 µl of 
cDNA and 8 µl UltraPure™ DNase/RNase-Free distilled water. The optimal 
concentration of cDNA was predetermined using a 10-fold serial dilution to generate a 
standard curve. Ideally, 10-fold dilution increases the cycle threshold (CT) value about 
3.33 cycles. The amplification efficiency is calculated from the slope, which should lie 
between 85-100%.  The thermal cycler protocol included an initial 2 min at 50
o
C, 10 min 
at 95
o
C, followed by 40 cycles of 15 seconds at 95
o
C and 1 min at 60
o
C 
Real-time PCR amplification was performed by the comparative cycle threshold 
(CT) method and normalized to GAPDH. A control sample without RNA and a 
reference sample (RAJI, B cell line) were included in each experiment. The ΔΔCT 
method is used to determine the relative quantity (RQ) in samples. The software 
 
 
 
                              
 
365 
determines the RQ of target in each sample by subtracting normalized target quantity in 
each sample from normalized target quantity in the reference sample. Therefore, the 
formulas used to calculate RQ are: 
CTCIITA - CTGAPDH =CT (both in samples and reference control) 
CTsample- CTreference control = CT 
Relative quantity =2
-CT
 
 
After calculation of relative quantity of the samples and controls, samples and the positive 
control RNA expression were compares and the cut-off limit was placed at 0.2 ( double 
the background).  
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Appendix 19: Genes down regulated by FOXL1 mutant 
 
Gene symbol Gene Name Function  
Fold 
change 
P-Value 
ADD3 
Adducin 3 
(gamma) 
Membrane-cytoskeleton-associated protein that 
promotes the assembly of the spectrin-actin 
network. Binds to calmodulin 
1.39 1.55E-04 
 
ARHGAP11B 
Rho GTPase 
activating protein 
11B GTPase activation 
2.15 8.01E-05 
CXCL10 
Chemokine (C-X-
C motif) ligand 10 
chemotaxis, cytokine, inflammation, 
inflammatory response,  osteoclastogenesis, 
osteoblast proliferention 
2.85 1.07E-05 
 
FEN1 
Flap structure-
specific 
endonuclease 1 
Acetylation, complete proteome, direct protein 
sequencing, Endonuclease, exonuclease, 
hydrolase, magnesium, metal-binding, nuclease 
2.37 6.44E-07 
 
GRLF1 
Glucocorticoid 
receptor DNA 
binding factor 1 
Alternative splicing, complete proteome, 
cytoplasm, dna-binding, GTPase activation, 
nucleus, phosphoprotein, repeat, repressor, 
Transcription, transcription regulation, tumor 
suppressor 
1.57 
 
1.55E-04 
 
IFIT1 
Interferon-induced 
protein with 
tetratricopeptide 
repeats 1 
Proteome, polymorphism, repeat, tpr repeat, 
decreased in otosclerosis 
1.82 
 
7.11E-06 
 
IFNB1 
Interferon, beta 1, 
fibroblast 
Antiviral defense, cytokine, pharmaceutical, 
,Secreted, signal, maintain bone homeostasis  
-2.58 2.91E-06 
 
IL1A 
interleukin 1, 
alpha 
 cytokine,  immunoregulation, ‘Inflammatory  
response, osteoclast activating factor, osteoclast 
differentiation  
1.71 1.33E-04 
 
JAK2 Janus kinase 2 
kinase, ,SH2 domain, transferase, tyrosine-
protein kinase, IFNγ signaling, cytokine 
signalling 
1.654172
948 
 
1.00E-04 
LRRN3 
leucine rich repeat 
neuronal 3 Immunoglobulin domain, leucine-rich repeat, 
membrane, polymorphism, repeat, signal, 
2.21 1.94E-05 
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transmembrane, fetal development  
Gene symbol Gene Name Function  
Fold 
change 
P-Value 
MIR658 microRNA 658  Post-transcriptional regulation of gene 
1.75   
1.32E-05 
 
NBR2 
neighbor of 
BRCA1 gene 2  this gene does not appear to encode a protein 
1.94 1.00E-05 
 
NIPBL 
Nipped-B 
homolog 
(Drosophila) 
facilitates enhancer-promoter communication of 
remote enhancers 
and plays a role in developmental regulation 
associated with deafness 
1.77 5.78E-05 
 
NR2F1 
nuclear receptor 
subfamily 2, 
group F, member 
1 
transcription factor neurogenesis and neural 
crest cell differentiation associated with 
deafness 
2.15 1.34E-06 
 
PKIA 
protein kinase 
(cAMP-
dependent, 
catalytic) inhibitor 
alpha 
inhibitor of cAMP-dependent protein kinase 
activity 
 
 
 
1.49 3.75E-05 
 
PTGER4 
prostaglandin E 
receptor 4 
(subtype EP4) 
one of four receptors identified for 
prostaglandin E2 (PGE2). 
mediate PGE2 induced expression of early 
growth response 1 (EGR1), regulate the level 
and stability of cyclooxygenase-2 mRNA 
Stimulation of bone formation and prevention 
of bone loss 
PGE2 Signaling Through the EP4 Receptor on 
Fibroblasts Upregulates RANKL and 
Stimulates Osteolysis 
1.6 1.44E-04 
 
PTGFR 
Prostaglandin F 
receptor (FP) receptor forPGF2-alpha 
1.59 2.89E-05 
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Gene symbol Gene Name Function  
Fold 
change 
P-Value 
PTGS2 
prostaglandin-
endoperoxide 
synthase 2 
(prostaglandin 
G/H synthase and 
cyclooxygenase 
3d-structure,chromoprotein,complete 
proteome,dioxygenase,disulfide 
bond,endoplasmic reticulum,Fatty acid 
biosynthesis,glycoprotein,heme,iron,lipid 
synthesis,membrane,metal-
binding,metalloprotein,microsome,oxidoreduct
ase,peroxidase,phosphoprotein,polymorphism,p
rostaglandin biosynthesis,signal, 
1.76 1.31E-05 
 
SETD6 
SET domain 
containing 6 
down-regulate NF-kappa-B transcription factor 
activity by RELA6 monomethylates 'Lys-310' 
1.73 
 
9.88E-05 
 
SP4 
Sp4 transcription 
factor 
Binds to GT and GC boxes promoters elements. 
Probable transcriptional activator 
2.00 2.52E-06 
 
VTRNA1-1 
vault RNA 1-3; 
vault RNA 1-1; 
vault RNA 1-2 
 This family of RNAs are found as part of the 
enigmatic vault ribonucleoprotein complex. 
3.34 
 
1.97E-06 
 
ZNF555 
zinc finger protein 
555 May be involved in transcriptional regulation 
1.45 
 
1.32E-04 
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Appendix 20: Genes up regulated by FOXL1 mutant 
 
Gene 
symbol Gene Name Function  
Fold 
change 
P-Value 
ASNS 
asparagine 
synthetase 
Involved in the synthesis of asparagine, 
Associated with osteopenia 1.63 9.35E-05 
ATOH8 
atonal 
homolog 8 
(Drosophila) 
Putative transcription factor. implicated in 
specification and differentiation of neuronal 
cell lineages in the brain. participate in kidney 
development and involved in podocyte 
differentiation involved in TGF/BMP signaling 2.10 1.15 E-04 
CD1C 
CD1c 
molecule 
Antigen-presenting protein that binds self and 
non-self lipid and glycolipid antigens and 
presents them to 
T-cell receptors on natural killer T-cells 5.07 5.69E-05 
CD34 
CD34 
molecule 
Cluster differentiation molecule, adhesion 
molecule It also interacts with L-selectin, 
important in inflammation. 
Expressed in osteoblast precursors. 
improved osteoblast activity and concurrently 
impaired osteoclast differentiation, maturation 
and functionality 1.62 7.47E-05 
CDH24 
cadherin-like 
24 
calcium dependent cell adhesion proteins 
upregulated in osteoblast 1.52 1.35 E-04 
CRYAB 
crystallin, 
alpha B 
act as molecular chaperones 
protecting the osteoblast cytoskeleton from 
mechanical stress 1.81  1.27 E-04 
DDIT3 
DNA-
damage-
inducible 
transcript 3 
Inhibits the DNA-binding activity of C/EBP 
and LAP by forming heterodimers that cannot 
bind DNA 
induces osteoblastic cell differentiation. 
1.52019
8633 5.18E-05 
ELOVL3 elongation of 
very long 
 Condensing enzyme that elongates saturated 
and monounsaturated very long chain fatty 
2.35812
9228 8.83E-06 
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chain fatty 
acids 
(FEN1/Elo2, 
SUR4/Elo3, 
yeast)-like 3 
acids 
Gene 
symbol Gene Name Function  
Fold 
change 
P-Value 
FGD1 
FYVE, 
RhoGEF and 
PH domain 
containing 1 
Activates CDC42, a member of the Ras-like 
family of Rho- and Rac proteins, by exchanging 
bound GDP for free 
GTP. Plays a role in regulating the actin 
cytoskeleton and cell shape 
important regulator of bone development. 
 
1.59412
4735 3.81E-05 
FMO1 
flavin 
containing 
monooxygena
se 1 
This protein is involved in the oxidative 
metabolism of a variety of xenobiotics 
1.94829
9913 9.43E-05 
FOLR3 
folate receptor 
3 (gamma) 
  
Binds to folate and reduced folic acid 
derivatives and mediates delivery of 5-
methyltetrahydrofolate to the 
interior of cells. 
Foxl1 binding site 
1.59510
7187 3.44E-05 
IL29 
interleukin 29 
(interferon, 
lambda 1)  Cytokine with immunomodulatory activity 
2.52788
3612 2.66E-05 
LILRB5 
leukocyte 
immunoglobu
lin-like 
receptor, 
subfamily B 
(with TM and 
ITIM 
domains), 
member 5 
bind to MHC class I molecules on antigen-
presenting cells and inhibit stimulation of an 
immune response 
1.71075
6739 5.39E-05 
PSAT1 
chromosome 
8 open 
reading frame 
62; 
atalyzes the reversible conversion of 3-
phosphohydroxypyruvate to phosphoserine and 
of 
1.78477
6735 1.12 E-04 
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phosphoserine 
aminotransfer
ase 1 
3-hydroxy-2-oxo-4-phosphonooxybutanoate to 
phosphohydroxythreonine 
Gene 
symbol Gene Name Function  
Fold 
change 
P-Value 
STK11IP 
serine/threoni
ne kinase 11 
interacting 
protein 
regulate STK11/LKB1 function by controlling 
its subcellular localization  
 
 
1.78365
1263 5.15E-05 
SYTL4 
synaptotagmin
-like 4 
Modulates exocytosis of dense-core granules 
and secretion of hormones 
1.87031
0362  1.51E-04 
TLCD1 
TLC domain 
containing 1  
1.83063
6358 1.00E-04 
TRAPPC6A 
trafficking 
protein 
particle 
complex 6A play a role in vesicular transport 
3.04674
7925 9.79E-05 
TTLL1 
tubulin 
tyrosine 
ligase-like 
family, 
member 1 
Catalytic subunit of the neuronal tubulin 
polyglutamylase complex. 
1.64604
7548 5.65E-05 
ZNF787 
zinc finger 
protein 787 
transcription termination factor I interacting 
peptide 
1.65335
4835 
0.0001.27-
E04 
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Appendix 21:  Statistical analysis report 
 
 
 
STATISTICAL CONSULTING REPORT 
TITLE: 
 
Genome-wide linkage analysis  
SPONSOR: Dr. Terry Young 
  
REPORT PREPARED BY: Pingzhao Hu 
Statistical Analysis Core Facility 
The Center for Applied Genomics 
The Hospital for Sick Children Research Institute 
E-mail: phu@sickkids.ca 
Tel.: (416) 813-7654 ext. 6016 
  
TIME SPENT ON ANALYSIS:                    25 hours
  
  
REPORT DATE: August 15, 2011 
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Linkage Analysis 
Genotype Calls  
The 8 samples in the family have been genotyped using Illumina Human 610 chip. 
Genotype calls (forward strand) in the family were exported from GenomeStudio 
software (V2010.3). All the 8 samples have call rate larger than 95%. 
Gender and Pedigree Check 
We estimated the gender of the 8 individuals in GenomeStudio using their genotype 
information and confirmed the estimated gender of the individuals is matched to their 
clinically defined gender. We also performed pairwise IBD estimation of the individuals 
using PLINK (Purcell et al., 2007) and confirmed the below pedigree structure is correct.  
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pedigree individualID fatherID motherID sex affection 
      
F1 1 0 0 1 0 
F1 2 0 0 2 0 
F1 TF09 1 2 1 1 
F1 JP09 1 2 2 1 
F1 3 0 0 1 0 
F1 4 0 0 2 0 
F1 EM08 3 4 2 2 
F1 LC09 3 4 2 2 
F1 LF09 3 4 1 2 
F1 GW08 3 4 2 2 
F1 JF09 3 4 1 2 
F1 RB08 3 4 2 1 
      
Sex: 1-male while 2 is female 
 Affection: 1 is unaffected while 2 is affected and 0 is unknown 
For TF09, the original gender was defined as female in the pedigree plot. We identified 
he should be male based on genetic information and reconfirmed with the family, now he 
is defined as male. 
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Genetic Linkage Analysis 
Minor allele frequency estimation 
We estimated minor allele frequency of the SNPs used in linkage analysis based on the 9 
unrelated samples from the 7 families as bellows 
TF09 
BR08 
DW08 
AR07 
RA04 
EP06 
LY08 
SM08 
PL07 
Software for linkage analysis 
 
We used MERLIN software (version 1.1.2) to do the parametric linkage analysis 
(Abecasis et al. 2002). The software was downloaded from 
(http://www.sph.umich.edu/csg/abecasis/Merlin/tour/parametric.html).  
 
Selection of markers for linkage analysis 
 
To select the markers only on autosomal chromosomes used in linkage analysis, we performed the 
following filtering steps using the 16 samples (8 in the family and 9 unrelated samples mentioned 
above. Please be noted that one (TF09) of the nine unrelated samples is in the family for linkage 
analysis): 
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A: QC: Here QC cutoffs are defined as follows (SNPs meet either condition is removed for 
further analysis): 
1) Hardy Weinberg Equilibrium (Wigginton et al. 2005) p value in controls smaller than 
1*10
-5
 
2) Missing genotype rate (SNPs) larger than 0.05 
3) Minor allele frequency (MAF)  smaller than 0.05 
4) Mendel error rate larger than 0.1 
 
B: LD-based SNP pruning using PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink). 
We performed two times pruning.  In the first round pruning, the parameters used in the pruning 
are: 
  
 Consider a window of 50 SNPs,  
 Calculate LD between each pair of SNPs in the window,  
 Remove one of a pair of SNPs if the LD is greater than 0.4,  
 Shift the window 5 SNPs forward and repeat the procedure. 
 
From the pruned data, we performed the second round pruning,  
In the parameters used in the pruning are: 
  
 Consider a window of 50 SNPs,  
 Calculate LD between each pair of SNPs in the window,  
 Remove one of a pair of SNPs if the LD is greater than 0.25,  
 Shift the window 5 SNPs forward and repeat the procedure. 
 
From the second round pruned data, we selected SNPs which have minor allele frequency (MAF) 
at least 0.45 in the selected samples described above. We got total 6073 SNPs used in final 
linkage analysis.  
Genetic distance 
We obtained the genetic distance of the SNPs from 
http://compgen.rutgers.edu/RutgersMap/AffymetrixIllumina.aspx. 
 
 
Penetrances 
 
We considered two genetic models: one is recessive model and another is dominant 
model  
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For autosomal recessive model, we consider penetrances  0.0001, 0.0001, 1.0 (no mutated 
allele, one mutated allele and two mutated alleles) and disease allele frequency 0.1.  
 
For autosomal dominant model, we consider penetrances 0.0001, 1.0, 1.0 (no mutated 
allele, one mutated allele and two mutated alleles) and disease allele frequency 0.005.  
 
 
Multi-point LOD score calculation (Parametric linkage analysis) 
 
We calculate the parametric LOD score for a 1-cM grid along the chromosomes. The 
distribution of LOD scores for each chromosome is shown in files for the 4 cases:  
 
Dominant model _RB08 is Unaffected 
LODScore_DominantModel_RB08UnAff.txt  (actuall LOD scores) 
LODScore_DominantModel_RB08UnAff.pdf (LOD score plot) 
 
Recessive model _RB08 is Unaffected 
LODScore_RecessiveModel_RB08UnAff.txt  (actuall LOD scores) 
LODScore_RecessiveModel_RB08UnAff.pdf (LOD score plot) 
 
 
The potential linkage signals (LOD>1) in each case are: 
  
Dominant model _RB08 is Unaffected (maximum LOD ~1.4) 
Chr7: 85.059cM - 152.059cM 
Chr10: 0.121cM - 7.121cM and 67.121cM - 69.121cM 
Chr16: 112.252cM - 133.252cM 
Chr17: 112.044cM - 129.044cM 
 All these 5 regions are in the previous analysis with the same bound. 
 
 Recessive model _RB08 is Unaffected (maximum LOD 2.5) 
Chr17: 111.044cM - 129.044cM  
 
Steps to find genes/physical positions in these regions: 
1. Based on the start and end position (cM) in the linkage regions (see above in each case), you 
can find the start and end SNP ids in file: Nellya.map (this file has been sorted).  
2. Based on the start and end SNPs in a given region, you can find the start and end positions 
(bp) from dbSNP – remember genome build for the positions (you can use either hg18 or 
hg19) 
3. Based on the start and end position (bp), you can find genes from UCSC genome browser in 
the regions. 
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Appendix 22:  List of primers sequences used for genes sequenced in the critical region on chromosome 
in Family 2114 
BIRC              
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl  
(final conc (mM)) 
E1 NM_001012271-Ex1F gactacaactcccggcacac 344 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex1R agtcacagtggcctcgcta         
E2 NM_001012271-Ex2F ctcccctccctgctttgt 248 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex2R gttcaaaacaaagcccatcg         
E3 NM_001012271-Ex3F 
 
tgagagtgtgagctaggggg 194 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex3R tagtggagacggggtttcac         
E4 NM_001012271-Ex4F actgccgctttaatcccttc 213 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex4R cattgaacagggtttgagca         
E5 NM_001012271-Ex5F aaatatggtagggaaggggg 168 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex5R aacagaccctggcaaacatc         
E6-1 NM_001012271-Ex6-1F ctgggaagctctggtttcag 461 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex6-11R CTAGCAAAAGGGACACTGCC         
E6-2 NM_001012271-Ex6-2F GGGCTCATTTTTGCTGTTTT 465 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex6-2R CATCCACCTGAAGTTCACCC         
E6-3 NM_001012271-Ex6-3F CATGGCTTTCTTATTTTGTTTGAA 498 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex6-31R TTCCAGCGAAGCTGTAACAA         
E6-4 NM_001012271-Ex6-4F GCTGAAGTCTGGCGTAAGATG 466 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex6-41R ACAGAGGCTGGAGTGCATTT         
E6-5 NM_001012271-Ex6-5F TTTCTGCCACATCTGAGTCG 476 TD 54 yes (0.75) 1.5 
  NM_001012271-Ex6-51R CCTGAAAAATGGACATGTGG         
E6-6 NM_001012271-Ex6-6F AATAAAGCCGTAGGCCCTTG 390 TD 54 yes (0.75) 1.5 
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  NM_001012271-Ex6-61R ctgtggtcattccactgcac         
CTDNEP1     
 
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E2 NM_015343-Ex2F ctccccgttcctgcgag 407 TD 54 yes (0.75) 1.5 
  NM_015343-Ex2R ggattcccttcctaggccc         
E3-4 NM_015343-Ex3-4F ggtgcacgcctgtagtcc 280 TD 54 yes (0.75) 1.5 
  NM_015343-Ex3-4R cagaggaacaagatgggctg         
E5 NM_015343-Ex5F gtcccagagcatctgtctcc 82 TD 54 yes (0.75) 1.5 
  NM_015343-Ex5R taccattacacagcctcccc         
E6-7 NM_015343-Ex6-7F tcctcagagacatttgatgttg 345 TD 54 yes (0.75) 1.5 
  NM_015343-Ex6-7R tgcatttcgacttacagcaaac         
E8 NM_015343-Ex8F tgttgacttccggtagtggg 85 TD 54 yes (0.75) 1.5 
  NM_015343-Ex8R tttgaagtaagacgacctggg         
E9-1 NM_015343-Ex9-1F gtaggctgtgggcaaattga 329 TD 54 yes (0.75) 1.5 
  NM_015343-Ex9-1R TGTGTCCATCCAGACTCCAA         
FOXJ1      
 
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E1 NM_001454-Ex1F agaggcggaagctgtttatg 315 TD 54 yes (0.75) 1.5 
  NM_001454-Ex1R ccacttccgttaaggacgaa         
E2-1 NM_001454-Ex2-1F ccgtacacacactgtcccct 585 TD 54 yes (0.75) 1.5 
  NM_001454-Ex2-1R CGGATTGGTGGCGTAGTC         
E2-2 NM_001454-Ex2-2F ACCAGGTGCCAGGTTCAG 399 TD 54 yes (0.75) 1.5 
  NM_001454-Ex2-2R gcctgcagatttgggatatg         
E3-1 NM_001454-Ex3-1F cactgacctagcggttcctc 476 TD 54 yes (0.75) 1.5 
  NM_001454-Ex3-1R AAAGTTGCCTTTGAGGGGTT         
E3-2 NM_001454-Ex3-2F GCATAAGCGCAAACAGCC 499 TD 54 yes (0.75) 1.5 
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  NM_001454-Ex3-2R ACCCTGACTTGGGCACTGT         
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E3-3 NM_001454-Ex3-3F CTCTTTGAGGCTGGGGATG 490 TD 54 yes (0.75) 1.5 
  NM_001454-Ex3-3R CCTGGGGACTCTCTCTGGAT         
E3-4 NM_001454-Ex3-4F AACAGAACTGGGCCCTCC 495 TD 54 yes (0.75) 1.5 
  NM_001454-Ex3-4R GGTCCCAGTAGTTCCAGCAA         
E3-5 NM_001454-Ex3-5F GGGGCAGGACAGACAGACTA 331 TD 54 yes (0.75) 1.5 
  NM_001454-Ex3-5R ctctccagaacactgagccc         
ITGB4      
  
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E2  NM_000213-F gcccttggtcacattgttg 89 TD 54 yes (0.75) 1.5 
   NM_000213 -R caagttttccagccctgaag         
E3-4  NM_000213-F ccatctctccaggtgaaggt 312 TD 54 yes (0.75) 1.5 
   NM_000213 -R cagctggctagagggtcact         
E5  NM_000213-F GAGgtgcctggtgtggg 205 TD 54 yes (0.75) 1.5 
   NM_000213 -R ggggctcaaatgtccagtg         
E6  NM_000213-F acctttgtccagcatgcaa 97 TD 54 yes (0.75) 1.5 
   NM_000213 -R tctgacctcaggtgatctgc         
E7  NM_000213-F gtgagccaagatcgtgcata 172 TD 54 yes (0.75) 1.5 
   NM_000213 -R tgagcttgtctcagggtgaa         
E8  NM_000213-F cttgctgtgaatccagtggc 264 TD 54 yes (0.75) 1.5 
   NM_000213 -R ggaaggaaagggaggaaaag         
E9-10  NM_000213-F ggctaagagggcaggctc 494 TD 54 yes (0.75) 1.5 
   NM_000213 -R gctaggcccagggatctg         
E11-12  NM_000213-F gagcaggagctcatttcagg 428 TD 54 yes (0.75) 1.5 
   NM_000213 -R tagccgtttctttgattgcc         
E13  NM_000213-F agcttgcagtgagccaagat 203 TD 54 yes (0.75) 1.5 
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   NM_000213 -R cctgaacttggggattctga         
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E14-15  NM_000213-F gagatgacttctaccccaggc 336 TD 54 yes (0.75) 1.5 
   NM_000213 -R gctccccaaacctcttgc         
E16  NM_000213-F caggaggggctaagcctg 130 TD 54 yes (0.75) 1.5 
   NM_000213 -R ccagctctggagttcctgtc         
E17-18  NM_000213-F aaggacttccactcttcccc 323 TD 54 yes (0.75) 1.5 
   NM_000213 -R acccaggaaggggttgg         
E19-20  NM_000213-F gtgtctggggaggcactg 400 TD 54 yes (0.75) 1.5 
   NM_000213 -R catagcaccatcagcacagg         
E21-22  NM_000213-F ctatgaacctcatgcctcgg 494 TD 54 yes (0.75) 1.5 
   NM_000213 -R acaaagagggcgctgtgag         
E23  NM_000213-F AGACCAAGTTCCGgtgagtc 24 TD 54 yes (0.75) 1.5 
   NM_000213 -R acacatctgaccctcccttc         
E24-25  NM_000213-F gaagaccctgcacttcttgc 421 TD 54 yes (0.75) 1.5 
   NM_000213 -R acagatggagaaaccaaggc         
E26  NM_000213-F cagagggcaatgcatagagg 149 TD 54 yes (0.75) 1.5 
   NM_000213 -R gcacggccagtatccag         
E27  NM_000213-F gtactccacccagcaagcag 205 TD 54 yes (0.75) 1.5 
   NM_000213 -R tcctaccaacgtgtatgttgtttac         
E28  NM_000213-F ggtgggcaggtctgagttg 158 TD 54 yes (0.75) 1.5 
   NM_000213 -R gaccacctgtgctaggttcc         
E29-30  NM_000213-F cacatggcagatctctcagc 432 TD 54 yes (0.75) 1.5 
   NM_000213 -R gctgaccaggatgaaggc         
E31-32  NM_000213-F gctttgccttgcttccc 404 TD 54 yes (0.75) 1.5 
   NM_000213 -R attgcatttgtccaaggctg         
E33  NM_000213-F aagggtttcacctgccg 210 TD 54 yes (0.75) 1.5 
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   NM_000213 -R tgcctctgagcagctgtg         
E34  NM_000213-F gagggaaactggttgtatttaagc 240 TD 54 yes (0.75) 1.5 
   NM_000213 -R gtgtgcgtgcatgtgtgc         
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E35  NM_000213-F gggtgagtgagttgtccagc 150 TD 54 yes (0.75) 1.5 
   NM_000213 -R tctcaggctggatgggg         
E36-37  NM_000213-F aaaccacagctagtcctggg 431 TD 54 yes (0.75) 1.5 
   NM_000213 -R GGGCTGTCTCCATCCACC         
E38-39  NM_000213-F ATGGGGATATCGTCGGCTAC 368 TD 54 yes (0.75) 1.5 
   NM_000213 -R AGGGTCAGCCCATctgtg         
OTOP2      
E1  NM_178160-F ccctgtcctcctgggtataa 200 TD 54 yes (0.75) 1.5 
   NM_178160 -R tggatgggaagaaaggagaa         
E2  NM_178160-F tcagggttgacctggagttt 485 TD 54 yes (0.75) 1.5 
   NM_178160 -R gccctcgtatgtcaatctgc         
E3  NM_178160-F gccttctctcctgcctcttt 244 TD 54 yes (0.75) 1.5 
   NM_178160 -R tggccaagtgttagctcctt         
E4  NM_178160-F cgctggagttttgtccatct 193 TD 54 yes (0.75) 1.5 
   NM_178160 -R agggtggaaagcctgaatct         
E5  NM_178160-F agggtcacaggcctctttgt 266 TD 54 yes (0.75) 1.5 
   NM_178160 -R atgagggcacaggagactga         
E6-1  NM_178160-F aaaggtcacaggctaggggt 489 TD 54 yes (0.75) 1.5 
   NM_178160 -R AAACGGTAGATGATGGAGCC         
E6-2  NM_178160-F GCAGGCCCTGGTCATCTACT 492 TD 54 yes (0.75) 1.5 
   NM_178160 -R CTTCTGGGGGTTGAGACGAT         
E6-3  NM_178160-F ACCTCACCTTCACCAACCTG 231 TD 54 yes (0.75) 1.5 
   NM_178160 -R tcagtctcttctcccaagcc         
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E7  NM_178160-F agaaatgacccacaggcatc 304 TD 54 yes (0.75) 1.5 
   NM_178160 -R ttcccagagggtgtctgagt         
RNF157      
  
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E1 NM_052916 -F TGTACCGCTACCCGCCCAAGT 147 TD 54 yes (0.75) 1.5 
   NM_052916  -R TTTCGGAGCGTCCGCAACCA         
E2 NM_052916 -F tcagggttgacctggagttt 119 TD 54 yes (0.75) 1.5 
   NM_052916  -R gccctcgtatgtcaatctgc         
E3 NM_052916 -F gccttctctcctgcctcttt 89 TD 54 yes (0.75) 1.5 
   NM_052916  -R tggccaagtgttagctcctt         
E4 NM_052916 -F cgctggagttttgtccatct 147 TD 54 yes (0.75) 1.5 
   NM_052916  -R agggtggaaagcctgaatct         
E5 NM_052916 -F agggtcacaggcctctttgt 118 TD 54 yes (0.75) 1.5 
   NM_052916  -R atgagggcacaggagactga         
E6 NM_052916 -F aaaggtcacaggctaggggt 67 TD 54 yes (0.75) 1.5 
   NM_052916  -R AAACGGTAGATGATGGAGCC         
E7 NM_052916 -F GCAGGCCCTGGTCATCTACT 44 TD 54 yes (0.75) 1.5 
   NM_052916  -R CTTCTGGGGGTTGAGACGAT         
E8 NM_052916 -F ACCTCACCTTCACCAACCTG 48 TD 54 yes (0.75) 1.5 
   NM_052916  -R tcagtctcttctcccaagcc         
E9 NM_052916 -F agaaatgacccacaggcatc 72 TD 54 yes (0.75) 1.5 
   NM_052916  -R ttcccagagggtgtctgagt         
E10-11 NM_052916 -F TGTACCGCTACCCGCCCAAGT 468 TD 54 yes (0.75) 1.5 
   NM_052916  -R TTTCGGAGCGTCCGCAACCA         
E12 NM_052916 -F tcagggttgacctggagttt 239 TD 54 yes (0.75) 1.5 
   NM_052916  -R gccctcgtatgtcaatctgc         
E13 NM_052916 -F gccttctctcctgcctcttt 109 TD 54 yes (0.75) 1.5 
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   NM_052916  -R tggccaagtgttagctcctt         
E14 NM_052916 -F cgctggagttttgtccatct 112 TD 54 yes (0.75) 1.5 
   NM_052916  -R agggtggaaagcctgaatct         
E15-16 NM_052916 -F agggtcacaggcctctttgt 483 TD 54 yes (0.75) 1.5 
   NM_052916  -R atgagggcacaggagactga         
E17 NM_052916 -F aaaggtcacaggctaggggt 46 TD 54 yes (0.75) 1.5 
   NM_052916  -R AAACGGTAGATGATGGAGCC         
E18 NM_052916 -F GCAGGCCCTGGTCATCTACT 111 TD 54 yes (0.75) 1.5 
   NM_052916  -R CTTCTGGGGGTTGAGACGAT         
E19-1 NM_052916 -F ACCTCACCTTCACCAACCTG 580 TD 54 yes (0.75) 1.5 
   NM_052916  -R tcagtctcttctcccaagcc         
E19-2 NM_052916 -F agaaatgacccacaggcatc 580 TD 54 yes (0.75) 1.5 
   NM_052916  -R ttcccagagggtgtctgagt         
RPL38       
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E1 NM_001035258 -F gcgaacgcctacatgagtct 202 TD 54 yes (0.75) 1.5 
   NM_001035258  -R ggtccccagatttcacctg         
E2 NM_001035258 -F gccgatatttcgggggag 198 TD 54 yes (0.75) 1.5 
   NM_001035258  -R ggaggctctctcgccctc         
E3 NM_001035258 -F ccgggagacgtgtctcttt 154 TD 54 yes (0.75) 1.5 
   NM_001035258  -R ctaggcaccgctcttcttga         
E4 NM_001035258 -F gcttgagtgtatttgcacatgg 258 TD 54 yes (0.75) 1.5 
   NM_001035258  -R acacagcaaccttccaaacc         
E5 NM_001035258 -F agacaagcagcagcaactca 179 TD 54 yes (0.75) 1.5 
   NM_001035258  -R agcatttttccctttcccat         
  TIMP2      
E1  NM_003255-F CCCGAGACAAAGAGGAGAGA 458 TD 54 yes (0.75) 1.5 
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  NM_003255 -R acttgcaggattcgagaagg         
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E2  NM_003255-F tggacgtcttatccctctcc 288 TD 54 yes (0.75) 1.5 
  NM_003255 -R tagtccacaggtggccaga         
E3  NM_003255-F gctgtaccccagctacaggt 349 TD 54 yes (0.75) 1.5 
  NM_003255 -R taccctgcctcactgttcct         
E4  NM_003255-F acagtgcacaggattgttgc 372 TD 54 yes (0.75) 1.5 
  NM_003255 -R cttcccagagcctggtctta         
E5-1  NM_003255-F gcacatgacaggtaggcaca 481 TD 54 yes (0.75) 1.5 
  NM_003255 -R CCAGACCCACAACCATGTCT         
E5-2  NM_003255-F ctggacatgcccccagag 395 TD 54 yes (0.75) 1.5 
  KCTD2     
  
Exon Primer I.D. Sequence Amplicon Size Annealing temp. Betaine (final conc. (M)) MgCl (final conc 
(mM)) 
E1 NM_015353 -F tctccctgccgagaaatg 599 TD 54 yes (0.75) 1.5 
  NM_015353  -R atgcctcagcatggaagaag         
E2 NM_015353 -F ttgcaaattccagccagtaag 597 TD 54 yes (0.75) 1.5 
  NM_015353  -R tctcacccaggaagctgaac         
E3 NM_015353 -F ttgggagactgaggcaagag 551 TD 54 yes (0.75) 1.5 
  NM_015353  -R tggtaagcagcgacaatcttc         
E4 NM_015353 -F cacagtatgctggcttgtgg 557 TD 54 yes (0.75) 1.5 
  NM_015353  -R tggaaagtctgcgtgtgaag         
E5 NM_015353 -F aatgatgccctgatgaagaac 559 TD 54 yes (0.75) 1.5 
  NM_015353  -R attgatttggcagaggatgg         
E6 NM_015353 -F ccccgacatctctgtctttc 565 TD 54 yes (0.75) 1.5 
  NM_015353  -R acgtcttggagggtgcatag         
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USH1G      
Exon Primer I.D. Sequence Amplicon 
Size 
Annealing 
temp. 
Betaine (final 
conc. (M)) 
MgCl (final 
conc (mM)) 
E1 NM_173477-F gggtgagcgtttcagatgtcttg 483 TD 54 yes (0.75) 1.5 
  NM_173477  -R ggcagctcagaggagtggtgga         
E2 NM_173477-F ctgtgacagtggggaagctccc 1,399 TD 54 yes (0.75) 1.5 
  NM_173477  -R cctgaataggcagatctgtaccccc         
E2a NM_173477-F tctccgaggatgggcgcaag 551 TD 54 yes (0.75) 1.5 
  NM_173477  -R gaggaacatgtcccggagcgg         
E3 NM_173477-F ggtatctatggccgttatcctg 385 TD 54 yes (0.75) 1.5 
  NM_173477  -R tgcagacagactttcaaaggag         
SLC9A3R1    
Exon Primer I.D. Sequence Amplicon 
Size 
Annealing 
temp. 
Betaine (final 
conc. (M) 
MgCl 
(final conc 
(mM)) 
E1 NM_004252-F tggtctgtggtcctctctcg 810 TD 54 yes (0.75) 1.5 
  NM_004252  -R cctgcctaggatgtgtcagg         
E2 NM_004252-F ccagaaccctctcaaattgc 542 TD 54 yes (0.75) 1.5 
  NM_004252  -R caggggagtggaggtaagag         
E3 NM_004252-F atattttcgttggcccttcc 576 TD 54 yes (0.75) 1.5 
  NM_004252  -R tgccactccctacactaggc         
E4 NM_004252-F ggggctaggagtttgagacc 552 TD 54 yes (0.75) 1.5 
  NM_004252  -R tgtatggtggggagttggag         
E5 NM_004252-F gtctgttcccatcccatcc 517 TD 54 yes (0.75) 1.5 
  NM_004252  -R cattaggctccctggtcctc         
E6 NM_004252-F gttcttgtgacctggcttcc 544 TD 54 yes (0.75) 1.5 
  NM_004252  -R aggcactcagtgaggaggag         
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TNRC6C   
Exon Primer I.D. Sequence Amplicon 
Size 
Annealing 
temp. 
Betaine (final 
conc. (M) 
MgCl (final 
conc (mM)) 
E1 NM_004252-F tggtctgtggtcctctctcg 810 TD 54 yes (0.75) 1.5 
  NM_004252  -R cctgcctaggatgtgtcagg         
E2 NM_004252-F ccagaaccctctcaaattgc 542 TD 54 yes (0.75) 1.5 
  NM_004252  -R caggggagtggaggtaagag         
E3 NM_004252-F atattttcgttggcccttcc 576 TD 54 yes (0.75) 1.5 
  NM_004252  -R tgccactccctacactaggc         
E4 NM_004252-F ggggctaggagtttgagacc 552 TD 54 yes (0.75) 1.5 
  NM_004252  -R tgtatggtggggagttggag         
E5 NM_004252-F gtctgttcccatcccatcc 517 TD 54 yes (0.75) 1.5 
  NM_004252  -R cattaggctccctggtcctc         
E6 NM_004252-F gttcttgtgacctggcttcc 544 TD 54 yes (0.75) 1.5 
  NM_004252  -R aggcactcagtgaggaggag         
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Appendix 2: Positional candidate gene in the candidate region at         
Chr 17q  
 
Gene name  Gene function Accession 
number 
Strand Start End Ex 
n 
BIRC5 Encoded negative regulatory 
proteins that prevent apoptotic 
cell death 
NM_001012271 + 76210277 76221716 5 
CTDNEP1  expressed in bone cells  NM_015343 + 7146906 7155259 9 
TIMP2 The proteins encoded by this 
gene family are natural 
inhibitors of the matrix 
metalloproteinases, a group of 
peptidases involved in 
degradation of the 
extracellular matrix 
NM_003255 - 76849059 76921472 5 
RPL38 This gene encodes a 
ribosomal protein that is a 
component of the 60S subunit 
NM_000999 + 72199795 72206019 3 
SLC9A3R1 Defect in this gene causes 
osteoporosis type2  
  
NM_004252 + 72744763 72765499  
USH1G Mutations in this gene are 
associated with Usher 
syndrome type 1G ( 
NM_173477 - 70423771 70430946 3 
OTOP2  NM_178160 + 70431965 70441601 7 
KCTD2 Homo sapiens potassium 
channel tetramerisation 
domain containing 2 
NM_015353 + 70554874 70573576 6 
RNF157  NM_052916 - 71650129 71747985 19 
ITGB4 Integrins mediate cell-matrix 
or cell-cell adhesion, and 
transduced signals that 
regulate gene expression and 
cell growth. 
NM_000213 + 71229111 71265494 40 
FOXJ1 Polymorphisms in this gene 
are associated with systemic 
lupus erythematosus and 
allergic rhinitis. 
NM_001454 - 74132415 74137380 1 
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Appendix 24: Primers used to amplify three variants identified by NGS  
 
 
 
 
Gene name  Genomic 
position 
Variant  Primers  Amplicon 
size 
PCR 
program 
PKD1L2 81242107  c.749A/G, p.Q250R  
 
 
F. agcccagtacctggtcttca 
R. gtgggtggctgctgtctc 
 
370 TD54 
PKD1L2 81242198  c.658 C>T, p.Q220*  
 
KPNA7 98805041  
 
c.49C>T 
p.R17* 
F. taacccacacaatgggcact 
R. tgttgggattacaggcatga 
244  
TD54 
CDK14 90338935  
 
c.69+11C>G  -  
 
F. TTGTGAATTGCCTTGACAGC 
R. tgagaagaactcaaaggacatgc 
197  
TD54 
TNRC6C 75495449  c.1706 C>T,p.P569L  F. AGTATCTGGGTGGGTCAACG 
R. GTTCCCAGATCTCGTGGTGT 
400  
TD54 
SEPT9 75495449  *709C>T  F. GCCCTGCTCCTAAGGGTAGA 
R. ACACTTCCCTGGTCACTTGG 
459 TD54 
